"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the CR Bard Inc. Fourth Quarter 2014 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference will be recorded -- is being recorded and will be available for f",375,"Ladies and gentlemen, thank you for standing by, and welcome to the CR Bard Inc. Fourth Quarter 2014 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference will be recorded -- is being recorded and will be available for future on-demand reply to the Bard website. 
Today's presentation will be hosted by Timothy Ring, Chairman and Chief Executive Officer; along with John Weiland, President and Chief Operating Officer. Christopher Holland, Senior Vice President and Chief Financial Officer; and John DeFord, Senior Vice President, Science, technology and clinical affairs. Also in attendance today is Todd Garner, Vice President, Investor Relations. 
Today, Bard's management will discuss some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters and outcome of contingencies such as legal proceedings. The uncertainty of loss reserve estimates, share repurchases, acquisitions and other economic business competitive and/or regulatory factors. Please refer to the cautionary statement regarding forward-looking information in Bard's September 30, 2014 10-Q and information under the caption Risk Factors in the company's 2013 10-Q, including disclosure of the factors that could cause actual results to differ materially from those expected or implied. 
During the call, references will be made to certain non-GAAP measures, which measurement believes provide an additional meaningful assessment of the core operating performance of the company and its individual product categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of January 29, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to prior -- are to the prior year period. At this time, I will turn the conference over to Mr. Timothy Ring. Please go ahead."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. A lot of work there, I appreciate it. Welcome, everybody, to Bard's fourth quarter 2014 earnings call. And thank all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 35 minutes or so",1060,"Thank you. A lot of work there, I appreciate it. Welcome, everybody, to Bard's fourth quarter 2014 earnings call. And thank all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 35 minutes or so. 
The agenda today will go as follows. I'll begin with an overview of the results for the fourth quarter. John Weiland, our President and COO, will review of fourth quarter product line revenue. John DeFord, our Senior Vice President of Science, Technology and Clinical Affairs, will give you an update on our product development outline. And then Christopher Holland, our Senior VP and CFO, will review the fourth quarter income statement, balance sheet and also provide our financial guidance for 2015. And then finally, we'll wrap it up with Q&A. 
Fourth quarter 2014 net sales totaled $867.2 million, that's up 10% over Q4 last year on an as-reported basis and up 11% on a constant currency basis. The currency impact for the quarter versus the same quarter of 2013 was unfavorable by about 140 basis points. 
The core royalty revenue in the quarter was approximately $38.6 million. The impact of the divestiture of our business, which occurred in Q4 2013 net of the impact of the Rochester medical acquisition in the same quarter was unfavorable by about 20 basis points growth for the quarter. Of that, that puts our organic growth rate for Q4 2014 at approximately 6.3% with a little over 200 basis points from the early approval and launch of the Lutonix drug-coated PTA balloon in the U.S. 
Net sales for the full year 2014 were $3.3 billion, that's up 9% as reported and on a constant currency basis, which exceeded our original guidance for the year. Net income for the fourth quarter was $134.2 million and diluted earnings per share were $1.72. I will remind you that we recognized the onetime gain from the Gore litigation in the prior year quarter. Excluding this and other items that affected the comparability of results between periods, which Chris will cover later, fourth quarter 2014 net income and diluted cash earnings per share, which excludes amortization of intangibles, were $158.9 million and $2.29, that's up 39% and 40%, respectively. 
Full year 2014 net income was $294.5 million and diluted EPS was $3.76. Excluding items again that affect comparability between periods, full year 2014 net income was $586 million and diluted cash EPS were $8.40 and that's up 23% and 29%, respectively from 2013, again, well in excess of our original guidance for the year. 
Looking at the fourth quarter revenue growth geographically compared to the prior year, on a constant currency basis. Net sales in the U.S. grew 14%, internationally, we grew 5%, with Europe up 3%; Japan up 2% and our other international geographics up 8%. Excluding the Gore royalty and divestiture impact, net sales in the U.S. grew 7% and total international sales were up 10%, with Europe up 10%; Japan up 3%; and the remaining geographies up 11%. 
As anticipated in our strategic investment plan, our emerging market sales continued to increase and represented about 9% of our total revenue in Q4. Looking back at 2014, we are pleased with the progress that we've made throughout the year. 2 years ago, I will remind you, we introduced our 3-year strategic investment plan and then on that same quarter, our organic growth rate was flat. We finished 2014 with organic growth rate of the portfolio in the mid-single digits, which is what we had projected. It's difficult to know precisely what's happening in real-time in the underlying markets. But we believe the market's organic growth continues to be in the low single digits. While many in our sector had stronger growth in Q3 than expected, some of those same companies themselves sequential deceleration of growth in Q4. In contrast, we continue to see sequential improvement on our organic growth rate. And we believe that the implementation and execution of our strategic investment planning contributed to this acceleration. 
As we look to 2015, wef expect the full year organic growth rate to again improve over the full year 2014. And to be clear, that assumes no benefit from any underlying market improvement. If the market improves as some are suggesting, then we should do better than that. 
2015 is an important year of execution, once again, for us. We expect our investments in emerging markets to continue to shift the mix of the portfolio on faster growing geographies. The key to this initiative is improved productivity from the teams that we build and additional product registrations in these markets. 
In 2015, we also anticipate we'll begin to see some returns from our R&D investments. Over the past couple of years, we significantly increased the level of R&D as we pursued expanded indications of current product platforms and introductions of new technologies. We remain in investment mode. The long-term objective is to drive above market revenue growth with a lower risk profile on a sustainable basis. There obviously remains significant uncertainty in the market, including unsettled issues in Washington. FX headwinds at this magnitude, frankly, are difficult and come up as quick as we've seen in years. The market acceptance, reimbursement decisions, competitive response on through drug-coated balloons in the U.S. could have a meaningful impact in our results. And we have no way of knowing whether Gore royalty will increase, decrease or be consistent compared to 2014 levels. 
However, amidst of these uncertainties, we remain focused on the execution of our strategic plan and the things we can control. We believe our investments will improve the organic engine of the company in both revenue and profitability. And as we said, we measure success over the long-term. If 2015 brings some tailwind in the market as some suggest, we would look for opportunities to invest any short-term outperformance back into the business for longer term benefit. 
Chris will give you more detail when he lays out his financial guidance. We continue to believe that the effective execution of our strategic investment plan will allow us to continue to increase shareholder value over the long term and on a sustainable basis. 
With that, as an introduction, let me turn you over to John Weiland to review of our fourth quarter product line revenue"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, as usual, I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let me start with Vascular. Total net sales in this category fo",805,"Good afternoon, everyone. Before I start, as usual, I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let me start with Vascular. Total net sales in this category for the quarter were $244.6 million, an increase of 19% on an as-reported basis and 22% on a constant currency basis when compared to the fourth quarter of 2013. Excluding the Gore royalty and the impact of the EP divestiture, global Vascular sales were up 9%, with the United States business up 14% for the quarter and international up 3%. Sales in our Vascular graft category were down 6% in Q4. 
Excluding the Gore royalty, our Endovascular business grew 11% in the fourth quarter. Within Endovascular, our biopsy line was up 1%. 
Our peripheral PTA products were up 49% this quarter, driven by the early FDA approval of Lutonix drug-coated balloon in the United States on October 10. We're extremely pleased with how our Vascular sales, development and operations team executed the early launch of this first of the kind product in the United States. As you know, we were shipping product to customers on the day of approval with the first cases being performed the following day. 
The early market acceptance has been impressive and we look forward to expanded adoption of this technology longer-term as the market continues to develop. 
Our Stent business was down 10% in Q4, which is within the range of recent experience. As we've said, pricing headwinds continue to drive down ASPs in this category. 
And to complete the category, sales in our vena cava filter line were flat in the fourth quarter. 
Now let's move to Urology. Total net sales were $217.8 million, which is up 8% versus the Q4 of last year on an as a reported basis, and 9% on a constant currency basis. About 600 points of this global growth was related to the Rochester acquisition, which anniversary-ed in the quarter. The United States business was up 6%, while internationally, we grew 14%. 
The Targeted Temperature Management products saw strong double-digit growth this quarter. And we remain optimistic about the long-term growth prospects of this technology platform. 
Our basic drainage business was up 7% in Q4, with about 400 points of that growth coming from the acquired Rochester medical products. 
IC Foleys were down 2% globally with the United States down 4%. These results in basic drainage are fairly consistent with recent quarters. While some surveys and reports have suggested improvement in the United States hospital volumes, we haven't seen any underlying improvement reflected here so far. 
Our continence business grew 24% over the prior year quarter. Excluding the impact of the acquired products, our legacy continence products were down 6% for the quarter, within the range of recent experience. 
Sales in the urological specialties were up 11% with the emerging markets growing close to 40% organically in this category. Our brachytherapy products were down 3% globally for the quarter. 
And finally, sales from our catheter stabilization line decreased 3% in the fourth quarter. 
Now let's turn to Oncology. Total net sales in this category were $237.5 million, an increase of 8% over the fourth quarter last year on as a reported basis and 9% on a constant currency basis. Net sales in the United States were up 7%, while outside the United States, sales were up 15%. 
Our frontline was up 5% versus the fourth quarter of last year with significant growth coming from the emerging markets. 
PICC revenue growth was 11% in Q4 with strong performance again in the United States and internationally. Our Vascular Access ultrasound product line was up 8% this quarter. And our dialysis catheter business was up 11% in the fourth quarter. 
And we'll finish with Surgical Specialties. Net sales in this category were $145.0 million in the fourth quarter, up 3% on as-reported basis and 4% on a constant currency basis. United States sales increased 4%, while international sales were up 6%. As you know, we anniversary the 2013 acquisition of Medafor on the first day of the fourth quarter. Our biosurgical product portfolio grew double digits organically in the quarter and we're excited about the long-term potential here. 
Sales from our biosurgical products already exceed the combined sales of our fixation products and our natural tissue products. 
Our soft tissue repair business grew 5% overall in the fourth quarter. Our total synthetic hernia products were up double digits again this quarter, while our natural tissue products declined 15%. 
Closing out the surgical category, our fixation business was down 3% in the fourth quarter and our performance irrigation business was down 14% versus an above average quarter a year ago. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John. Good evening, everyone. 2014 was a pretty busy year at Bard. We launched over 40 new products and our pipeline of launches in 2015 is also robust. Starting with the drug-coated balloons. We're making good progress on additional sizes and i",930,"Thanks, John. Good evening, everyone. 2014 was a pretty busy year at Bard. We launched over 40 new products and our pipeline of launches in 2015 is also robust. 
Starting with the drug-coated balloons. We're making good progress on additional sizes and indications worldwide. We're in the follow-up phase of our Levant 2 Japan study and we expect to submit late this year for Japan approval. Enrollment continues in our below the knee IDE and in-stent restenosis studies and we are making good progress in our AV access IDE study with enrollment anticipated to start mid-2015. 
We're also expanding the clinical science of DCBs through our robust real world clinical experience. For example, at LINC this week, Dr.  Marcus Steen [ph] presented the first look at interim one year results from the Lutonix global SFA and popliteal registry of almost 700 patients. Lesion LINCs were over 100 millimeters and treated LINCs were almost 200 millimeters, while roughly 30% of lesions were located in the popliteal artery.  Primary patency was 81.7% and 88.5% of patients were free from the re-intervention of 1 year. 
The randomized study designs are quite different, making comparison of results very difficult across different studies, registry has provided a more balanced comparison across technologies. And we believe these results compare well to any of the competitive DCBs. 
Also in Vascular, we launched the LifeStream balloon expandable covered stent in Europe in Q4 and enrollment is going well in the IDE study to support an iliac artery disease indication in the U.S. 
Finally in Vascular, we're responding to some FDA questions and anticipate U.S. launch in Q1 of the first in the series of new Tru-Flo PTA catheters for use in valvuloplasty procedures. Tru-Flo has a unique flow-through design to allow blood to pass through a large channel in center of the balloon, promoting prolonged inflation, while potentially reducing the need for rapid pacing or other hemodynamic maneuvers used to reduce cardiac output during the time the balloon has expanded. 
Next, moving to Urology. We've just begun the rollout of our new skyline sub 2 French stone [ph] basket family. This new product in our endourology line provides the urologists with one of the smallest baskets in the industry, yet provides high strength and maneuverability along with highly visible atraumatic tip to aid in safe and accurate use. 
In our Targeted Temperature Management portfolio, we've just launched our new PAD systems for use with neonates and pediatric patients in the U.S. And we're rolling out a new software update to support enhanced functionality and additional languages. 
Moving to Oncology. We are anticipating U.S. regulatory clearance and launch about mid-year of our free hand stereotactic system for Vascular Access named Pinpoint GT. The technology will initially be offered on a new Site-Rite aid system and a planned single simultaneous launch. Pinpoint GT will also be backwards compatible to Site-Rite 6. 
In PICC we're now tracking towards submission around mid-year of our first family of thromboresistant devices. We plan to broaden the offering to our full line of PICC over the back half of 2015 and into 2016. Similarly, we anticipate submitting our first antimicrobial PICC in the second half of 2015 and launching upon regulatory clearance. This first product will be followed by a series of launches to support coated PICC in both our PowerPICC and PowerPICC solo configurations. 
Turning to midlines. We're making good progress in our next-generation POWERGLIDE family and currently anticipate our U.S. regulatory submission in Q4 with the first half of 2016 launch. 
I'll close my portion of the discussion today with surgery. We informed you on the last call that we just received U.S. regulatory clearance of the first antibiotic-coated biologic XenMatrix AB and I'm pleased to tell you that product was launched in December. XenMatrix AB utilizes our proprietary coding, which is intended to preserve the integrity of the biologic graft and abdominal wall reconstruction procedures and has demonstrated a broad spectrum of safety and efficacy against several typically encountered bacteria. 
Moving to our BioSurgery product family. In early Q3, we filed our PMA supplement for our Progel sealant, seeking expanded use in video-assisted and robot-assisted thoracic surgery. We continue to be optimistic about approval and launch in the first half of this year. 
Also, we completed a follow-up early this year in our vascular sealant pivotal IDE study. The team is working toward PMA submission in the first half of the year and we anticipate approval and launch in mid 2016. 
And finally  in mesh fixation, we remain on track to launch in the first half of the year our new spring-loaded resorbable tack device named OPTIFIX. We also anticipate launching another fixation platform later in the year. 
As Tim said, we have a very important year of execution ahead of us and we look forward to updating you on our progress throughout the year. As part of our effort for continuous improvement, we initiated a survey of investors last year. And one of the more common suggestions we received was to take a fresh look at the need to hold a formal analyst meeting every year. We've been clear about our growth drivers and the opportunities we're pursuing and our investment strategy has not changed. Because of that, we've determined that the resource and time-intensive effort, like the formal analyst meeting, is just not justified this year. We'll update you on our pipeline and growth drivers throughout the year if circumstances allow in the appropriate forum. Thanks very much for your attention. Now I will hand the discussion over to Chris"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $7.5 million pretax, mostly related to Lutonix milestone accretion and $10.1 million pretax charge for re",1630,"Thank you, John. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $7.5 million pretax, mostly related to Lutonix milestone accretion and $10.1 million pretax charge for restructuring and productivity initiatives. We also booked expense of $12.7 million, related to the judges order in the women's health litigation that we work up 500 cases simultaneously. 
And finally, we had a credit of $3.5 million pretax related to the medical device excise tax paid in 2013 after reaching an agreement with the IRS. These items are detailed in the notes to the financial statements and the reconciliation accompanying our Q4 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $547.7 million in Q4 and $547.4 million on an adjusted basis or 63.1% of sales, up 230 basis points from the prior year with 170 basis points of that improvement related to the Gore royalty and about 120 basis points coming from cost of goods sold. We also had about 50 basis points of benefit when compared to the higher integration cost and investments in Q4 of 2013. 
Some headwinds to GPC in Q4 were new amortization of about 50 basis points, foreign exchange at about 10 basis points and mix of about 20 basis points. Pricing pressure was about 100 basis points of headwind on the revenue line and about 30 basis points in GP in Q4. We continue to expect the pricing pressure going forward between 100 and 150 basis points on the revenue line. 
For the full year 2014, that brings adjusted gross profit as a percentage of sales to 62.1%, up 110 basis points from 2013, much better than our original guidance of 30 to 60 basis points of improvement. 
While the Gore royalty did exceed our expectations, the effect on GP was only 10 to 20 basis points higher than our projections from a year ago. The over achievement was primarily driven by more favorable mix than originally expected. 
SG&A expenses were $257.5 million for the quarter or 29.7% of sales. On an adjusted basis, SG&A was $261 million even or 30.1% sales, down 170 basis points from the prior year period, driven by the Gore royalty being in a denominator as well as improving leverage from our emerging markets investments and the integration of our 2013 acquisitions. 
For the full year 2014, adjusted SG&A percentage of sales was 29.6%, a decrease of 40 basis points from the prior year. R&D expenditures totaled $79.2 million for the fourth quarter or 9.1% of sales. On an adjusted basis, R&D expense was $71.5 million or 8.2% of sales, a decrease of 70 basis points from the prior year period, mostly driven by the Gore royalty now in the denominator. 
For the full year 2014 on an adjusted basis, R&D expense was 8% of sales compared to 8.5% in 2013. However, without the Gore royalty and the revenue line, R&D expense would've been 8.4% of sales in 2014. 
Interest expense was $11.2 million for the fourth quarter and $44.8 million for the full year. Other income expense was $25.1 million of expense for the fourth quarter. On an adjusted basis, it was $2.2 million of expense for the quarter and $4.7 million of income for the full year. 
The effective tax rate for the quarter was 23.2%. On an adjusted basis, it was 21.1%, taking us to 24.3% for the full year. The quarter was lower than the full year average due to the renewal of the R&D tax credit in December. 
At the beginning of the year, we had told you to expect about 100 basis points of improvement in the effective tax rate in 2014 and we came in at 90 basis points of improvement, despite significantly stronger U.S. income than we had anticipated. That all adds up to cash EPS of $2.29 for Q4, excluding items affecting comparability, which brings us in at $8.40 for the full year on a same basis. That's a full $0.10 above the high end of our original guidance for the year and above our updated guidance as well, indicative of the strong performance we saw in 2014. 
We purchased about 785,000 shares of the company's stock during the fourth quarter, taking the total buybacks in 2014 to approximately 4.5 million shares at an average price of $146.67. Between buybacks and dividends, we returned approximately $725 million to shareholders over the course of 2014. 
The balance sheet as of December 31 reflects cash, restricted cash and short-term investments of $1.01 billion versus $1.04 billion at September 30th. For the full year, AR days were down 7.3 days and inventory days were up 0.2 days. Capital expenditures totaled $36.6 million for the quarter and $126.6 million for the year. 
On the liability side, total debt was $1.5 billion as of December 31 versus $1.4 billion at September 30. Debt to total capital at the end of the fourth quarter was about 45% and total shareholder investment was $1.8 billion at December 31. 
So with a strong 2014 now in the books, let's turn to the financial guidance for 2015, excluding the impact of items that affect comparability. For revenue, we project 2015 constant currency organic revenue growth between 4% and 5%. Given the potential variability of the Gore royalty, our overall constant currency guidance is between 3% and 5%. As Tim said, this assumes no fundamental improvement in the market growth rates from where they have been the last couple of years, which we would characterize as low single digits. If the markets improve, as some suggest, then we would expect to do better. But with all of the uncertainties surrounding us, we believe it's too early to count on any improvement in the underlying markets. 
Obviously, foreign exchange rates are significant headwind for everyone as we head into 2015 and we are certainly not immune to that. We estimate that at current rates, we're looking at revenue headwind related to currency of about 3%. 
As far as constant currency revenue growth in our 4 disease state categories, in 2015, we expect Vascular revenue growth to be between 3% and 7%; urology to be between 1% and 4%; Oncology to grow between 3% and 6%; and our Surgical Specialties business to grow between 3% and 6% as well. We expect our overall gross margin percent to decline in 2015 by between 30 and 70 basis points compared to 2014. That reflects about 50 basis points of pressure from FX and about 20 basis points of incremental amortization from the U.S. approval of Lutonix in October of 2014. 
Pricing pressure continues to be a significant issue for us. And we estimate the impact on 2015 to be between 40 and 60 basis points of headwind to GP. Fortunately, our cost improvement programs are projected to once again contribute about 50 basis points of benefits to GP and we expect mix to be favorable between 20 to 40 basis points. 
So organic constant currency gross margins are expected to improve in 2014 as we projected, when we first introduced our strategic investment plan 2 years ago. And again, as we said, we expect to see improving operating leverage in 2015. While we continue to increase investments in emerging markets, we expect SG&A as a percentage of sales to decline between 50 and 100 basis points in 2015. And we expect R&D as a percentage of sales to be in the mid-7% range, both excluding items that affect the comparability. We expect interest expense in 2015 to be between $45 million and $47 million. We expect the effective tax rate to improve again, this time, between 0 and 50 basis points for the full year and this does assume the renewal of the R&D tax credit for 2015. 
All of that adds up to adjusted cash at 2015, excluding items that affect comparability between $8.95 and $9.05 per share. That includes a negative currency impact of about $0.25 based on today's rates. So without this very atypical currency situation, we would have been forecasting at or above our target of 10% GPS growth. 
While we evaluate alternatives that could increase earnings for 2015, given the expected FX magnitude and the fact that this is not a Bard specific issue, we don't think it would be wise for short-term benefits to scale back investments and possibly interrupt the momentum in organic growth that we achieved during 2014. 
In the end, we believe that maintaining our flexibility and continuing to focus on the longer-term organic growth profile of the company builds better value for our shareholders. 
In Q1, we expect constant currency sales growth between 4% and 5% and adjusted cash EPS between $2.04 and $2.08. As for capital expenditures, we expect 2015 to be similar to 2014, between $120 million and $140 million. And we expect operating cash flow to be in the $700 million range, again in 2015. 
I'd like to conclude my comments by reminding you that the objective of our strategy is to position Bard of from a portfolio standpoint to deliver above market revenue growth for years to come. The key measure of success for this transition plan will be the improvement in the organic engine. This plan was never about maximizing EPS in a given year, but the strength of the business for the long-term in a disciplined and thoughtful way. We believe that we are doing that. While we expect further improvement in our operating margins in 2015, we intend to remain in investment mode with the desired outcome of positioning the company for long-term success to enhance shareholder value. And with that, I'll turn the call back over to Tim"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. While we are pleased with our performance in 2014, we have a lot of work in front of us to position the company where we want it to be. As many of you have heard me repeat one of my favorite quotes, great strategy is more about great execut",127,"Thanks, Chris. While we are pleased with our performance in 2014, we have a lot of work in front of us to position the company where we want it to be. As many of you have heard me repeat one of my favorite quotes, great strategy is more about great execution than it is about great thinking. In 2015 is a very important year of execution for us. We are not taking anything for granted. I'm sure there will be bumps along the way it all resist. We focus on the long-term health of the business with the intention of increasing shareholder value. That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Lawrence Keusch from Raymond James.",16,"[Operator Instructions] And our first question comes from the line of Lawrence Keusch from Raymond James."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess I would just start off, Tim, with asking a little bit. You laid out nicely the expectations for 2015. But I guess I'm thinking past 2015 and kind of understand what's the ultimate game plan is here. Can you talk about, as you look out what you thi",65,"I guess I would just start off, Tim, with asking a little bit. You laid out nicely the expectations for 2015. But I guess I'm thinking past 2015 and kind of understand what's the ultimate game plan is here. Can you talk about, as you look out what you think the appropriate levels of organic growth and perhaps EPS growth would be for the company?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Larry. Obviously, the market's volatility and especially as you grow into more and varied geographies, the market growth rates can be even more complex. We, as we stated, don't anticipate any change in the external environment for this year. If this",210,"Yes, Larry. Obviously, the market's volatility and especially as you grow into more and varied geographies, the market growth rates can be even more complex. We, as we stated, don't anticipate any change in the external environment for this year. If this happens, we'll do better than that. We stated a couple of years ago that our goal was to be 200 to 300 basis points above what the market growth rate was and the competitive aspect of that within the sector. That would still be our goal. We're big believers that sustainable revenue growth drives shareholder value and that's what we're about. So we remain fixated on that as a strategic objective. We do think that there's a lot of leverage for us with the investments we made in some of the emerging markets. Just to put in perspective, that represents almost 1/3 of our total sales headcount but as we mentioned, 9% of revenue. So we think there's a lot of room to grow into that. And those markets are growing clearly above what we called out as the market average in total. So to the extent we can accelerate growth in those segments that are growing faster, we should continue the momentum that we demonstrated last year."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. The other thing that I would add, Larry, as it relates to EPS growth is we are absolutely focused on double-digit EPS growth, 10% EPS growth. And certainly, we believe the model will allow us to deliver that. And without this recent move in the dolla",118,"Yes. The other thing that I would add, Larry, as it relates to EPS growth is we are absolutely focused on double-digit EPS growth, 10% EPS growth. And certainly, we believe the model will allow us to deliver that. And without this recent move in the dollar, we would have delivered 10% to 11% growth in 2015. So the growth organically on the top line, we believe over time, will allow us to drive 10% EPS growth. Again, this unprecedented move, which cost us $0.25 now as we turn into '15, has just prevented that from happening this year. But the plan, strategy and the leveraging of the investments over time should allow us to achieve that objective."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just again on the uses of cash, you guys obviously generated a significant amount of free cash flow. No significant M&A done in 2014. You obviously bought back a bunch of stock associated with the Gore bonus payment. But can you talk about 2015",67,"Okay. And just again on the uses of cash, you guys obviously generated a significant amount of free cash flow. No significant M&A done in 2014. You obviously bought back a bunch of stock associated with the Gore bonus payment. But can you talk about 2015 perhaps what your expectations may be for M&A as well as would you be open to deploying cash for share repurchase?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll cover that kind of high level and can detail. Clearly, our use of cash has not changed for, well, 10 years or longer. It's strategic first. We want to continue to invest in businesses, technologies and platforms to grow the company. And we'll c",72,"Sure. I'll cover that kind of high level and can detail. Clearly, our use of cash has not changed for, well, 10 years or longer. It's strategic first. We want to continue to invest in businesses, technologies and platforms to grow the company. And we'll continue to do that prioritize it that way. Second would be share repurchases. And third would be dividends in that order and there's no change to that."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","So again, Larry, I think obviously it's very much transaction dependent. And as Tim said, we're looking for the right acquisitions to make for the company every day, I think the free cash flow does allow us to do both in the ordinary course continue to ma",121,"So again, Larry, I think obviously it's very much transaction dependent. And as Tim said, we're looking for the right acquisitions to make for the company every day, I think the free cash flow does allow us to do both in the ordinary course continue to make acquisitions of a certain size as well as continuing to constantly return cash to shareholders. Will generate free cash flow in the $500 million to $600 million that we can deploy in 2015. First priority is a strategic. But even in conjunction with that, I think we'll continue to have flexibility to do a bit of both, again, deal dependent. But in the ordinary course, I would expect that [indiscernible] balanced use of cash."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question comes from the line of Brooks West with Piper Jaffray.",14,"And our next question comes from the line of Brooks West with Piper Jaffray."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple on emerging markets for me. Tim, you mentioned third of sales headcount in emerging markets versus 9% of revenue. How long will it take for that ratio to normalize? And kind of can you walk us through the levers that's associated with that? That'",67,"A couple on emerging markets for me. Tim, you mentioned third of sales headcount in emerging markets versus 9% of revenue. How long will it take for that ratio to normalize? And kind of can you walk us through the levers that's associated with that? That's question 1. Question 2 is where you are with the product registrations and emerging markets versus where you want to be?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, in terms of the comparison kind of a productivity per sales wrapped across geographies, it's difficult to do a couple of different reasons. Number one, by design in the emerging markets, we didn't give every country manager the 14,000 SKU play",125,"Sure. Well, in terms of the comparison kind of a productivity per sales wrapped across geographies, it's difficult to do a couple of different reasons. Number one, by design in the emerging markets, we didn't give every country manager the 14,000 SKU playbook and tell them to go sell everything. So we're being very strategic relative to how we target within those geographies. And I'm not sure that's a good way to look at the announcements frankly. But we are pleased with the productivity that is being made in there. We do think that there's a lot of room to grow into that investment. That was really the plan. And we are pleased with the execution to date. And the second part of the question?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Registration.",1,"Registration."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the registration pipeline. I kind of view that as almost like a second R&D file. And it's something we measure our metric every month, frankly, from the divisions. So there are literally hundreds of registrations sitting as we speak at various minist",135,"Yes, the registration pipeline. I kind of view that as almost like a second R&D file. And it's something we measure our metric every month, frankly, from the divisions. So there are literally hundreds of registrations sitting as we speak at various ministries of health around the world. There is even more than that sitting within our geographic business centers, waiting to be filed, being prepared to be filed with the ministries of health. And even beyond that in the sourcing divisions, there's more than that, hundreds that are being prepared to submit to our business centers that in turn gets submitted to the ministers of health around the world. So we are pleased with the pipeline and the flow that we've got in the regulatory side of things at the moment in those markets."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next is the line of Mike Weinstein with JPMorgan.",9,"Next is the line of Mike Weinstein with JPMorgan."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","So a couple of items. First, just to clean up on the guidance. So Chris, in the 2015 guidance, what are you assuming for share repurchases?",26,"So a couple of items. First, just to clean up on the guidance. So Chris, in the 2015 guidance, what are you assuming for share repurchases?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we're assuming sort of ordinary towards number, Mike. We certainly look to offset dilution from benefit plans as well as a little bit of incremental reduction to share count. We don't want to commit to a specific number because again, the range of o",82,"Well, we're assuming sort of ordinary towards number, Mike. We certainly look to offset dilution from benefit plans as well as a little bit of incremental reduction to share count. We don't want to commit to a specific number because again, the range of opportunities we might face on the M&A front could force us into a little bit of a different place. But we would expect to continue to be able to move the share count lower to a certain degree."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. The 4% to 5% organic growth guidance kind of the board right now. It feels like it should be a little bit better than that. But this quarter, I think last few quarters kind of underlying business? Lutonix has been moving from what was 3% to moving c",136,"Okay. The 4% to 5% organic growth guidance kind of the board right now. It feels like it should be a little bit better than that. But this quarter, I think last few quarters kind of underlying business? Lutonix has been moving from what was 3% to moving closer to 4%, given your first quarter of Lutonix out there and Lutonix just over 200 basis points due to the growth this quarter. So it feels like you're being a little bit conservative, both on the base business as well as Lutonix, like in the Oncology guidance, the Oncology was up 7% constant currency in 2014, you're guiding with 3% to 6%. So could you just  give a minute on the 4% to 5% and why that doesn't -- it feels conservative. Why is that not conservative?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Mike. We're attacking this. I think first of all -- urology or oncology?",14,"Yes, Mike. We're attacking this. I think first of all -- urology or oncology?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Oncology. Oncology was up 7% in '14. You're guiding to 3% to 6%.",13,"Oncology. Oncology was up 7% in '14. You're guiding to 3% to 6%."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think with respect to -- we have large contracts and there is certainly some timing associated with large multiyear contracts that could from a pricing standpoint provide headwind in certain categories. I think bigger picture, certainly, we expect",191,"Yes. I think with respect to -- we have large contracts and there is certainly some timing associated with large multiyear contracts that could from a pricing standpoint provide headwind in certain categories. I think bigger picture, certainly, we expect a very competitive dynamic with respect to DCBs over the course of 2015. We'll see how that plays out. We certainly have the ambitions to do very well. But we also want to make sure that we're maintaining the right level of caution. I think Europe, where we had a very strong 2014, we are somewhat cautious, just given some of the macro challenges and headwinds that the continent is facing as well. And as Tim said, there's a lot of uncertainties surrounding us and the sector overall, including as it relates to the health care in the U.S. and as the Affordable Care Act continues to remain under some uncertainty longer-term. So Gore, as we said, we're going to try to do better. And if we get some tailwind, we can. But we believe 4% to 5% as we exited '14 is absolutely the right place for us to be."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And are there any other headwind that you had mentioned that we should know about?",15,"And are there any other headwind that you had mentioned that we should know about?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Nothing major.",2,"Nothing major."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next we'll go to the line of Bob Hopkinson with the Bank of America.",15,"Next we'll go to the line of Bob Hopkinson with the Bank of America."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 questions. One, first for Chris. In the 4% to 5%, can you just give us a sense as to the year-over-year change that goes into that 4% to 5% from just the Gore royalty and Lutonix revenues?",39,"Just 2 questions. One, first for Chris. In the 4% to 5%, can you just give us a sense as to the year-over-year change that goes into that 4% to 5% from just the Gore royalty and Lutonix revenues?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think -- we try to capture the range of scenarios we see with respect to Gore in a constant currency number of 3% to 5%. So there are scenarios there, Bob. They don't move the needle much on the high end than they do take it in a bit of on the low",131,"Yes, I think -- we try to capture the range of scenarios we see with respect to Gore in a constant currency number of 3% to 5%. So there are scenarios there, Bob. They don't move the needle much on the high end than they do take it in a bit of on the low end. So again we believe we are capturing what is likely within the 3% to 5% as it relates to Gore. And we're certainly not going to give specific expectation around the Lutonix as we look at '15. We're going to continue to work like to help develop the market and penetrate the market. But I assume you can respect from a competitive standpoint, we're not going to be more specific than that at this point."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Sure. But I think I gathered from Tim's comments that maybe in the fourth quarter you did high teens revenue for Lutonix?",22,"Sure. But I think I gathered from Tim's comments that maybe in the fourth quarter you did high teens revenue for Lutonix?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I think you guys will be able to do the math to a number that's in that range.",19,"I think you guys will be able to do the math to a number that's in that range."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then for John, on the launch, a couple of things. I'd love just to get your views on what you're seeing as you pioneer this new therapy. So a couple of quick things. One, what's the progress on the add-on payment? When do you expect that? Do you",91,"Okay. And then for John, on the launch, a couple of things. I'd love just to get your views on what you're seeing as you pioneer this new therapy. So a couple of quick things. One, what's the progress on the add-on payment? When do you expect that? Do you have any use of market size and what will happen to the stent market as a result of drug-coated balloons and what you're seeing in the early launch? Just would love to get some thoughts now that you're in the marketplace."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me just give you some general perspectives on the launch itself. I think first of all, our team did an excellent job preparing for this launch literally over the last year in great detail. And I'd evidence that by the comments that we made were -- we",255,"Let me just give you some general perspectives on the launch itself. I think first of all, our team did an excellent job preparing for this launch literally over the last year in great detail. And I'd evidence that by the comments that we made were -- we had approval on Friday we were shipping that Friday and our first case was done on a Saturday. And I think that the knowledge base of physicians in the United States and anticipation of the technology was a significant. And I think that our team has done an excellent job helping to continue educate physicians since the October launch. We have 2 thresholds for payment reimbursement changes, potentially in the second quarter and fourth quarter. One for inpatient and one for outpatient. All of our submissions are in the CMS at this point in time. And we'll see what develops there. We have no reason to believe that they are not looking at this very favorably at this point in time. In terms of market size, the -- we had already said that the European market was about $80 million. That's not changed substantially. And we could all take a -- have a poll on what the United States will end up that at the end of 2015. We're certainly working hard to make as large as we possibly can. But I think that will be a wildcard and we'll see how that -- how the whole market has developed now that competitors has approved as well."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And those steps, has those been approved?",7,"And those steps, has those been approved?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","In the early reviews that we've done, we have not seen that at this point in time, although I would imagine that downstream, the total stent market maybe affected slightly. But we have not seen anything at this point in time. I think the good news is that",79,"In the early reviews that we've done, we have not seen that at this point in time, although I would imagine that downstream, the total stent market maybe affected slightly. But we have not seen anything at this point in time. I think the good news is that our market basket, so to speak, our products offered into the vascular surgeons, interventional cardiologist, obviously, went up substantially. So our presence went up substantially and we stepped up accordingly."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next we'll go to the line of David Lewis with Morgan Stanley.",14,"Our next we'll go to the line of David Lewis with Morgan Stanley."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a couple of quick questions. First  for Chris. Chris, there's been a pathway or guidance to get sort of the mid-25 in terms of operating margin specific targets. But when you think about just putting that in context for the last several years, that p",95,"Just a couple of quick questions. First  for Chris. Chris, there's been a pathway or guidance to get sort of the mid-25 in terms of operating margin specific targets. But when you think about just putting that in context for the last several years, that put you halfway between peak margins before the reinvestment and then the trough margins around 22 obviously during the reinvestment. You're sort of halfway through the trough and the peak. Can you give us a sense of the amount of time it will take to get back to that peak?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think what we've essentially committed to put the guidance today is 50 to 100 basis points of operating margin improvement in 2015. And that's with this unfortunate currency headwind. That's making GPs by 50 basis points. And so when you think abou",204,"Yes. I think what we've essentially committed to put the guidance today is 50 to 100 basis points of operating margin improvement in 2015. And that's with this unfortunate currency headwind. That's making GPs by 50 basis points. And so when you think about the dilution associated with the portfolio moves we made in 2015, which cost us about 200 basis points, I think we're on our way to getting back to those mid-27% level. And the objective, as we look at the model, is to drive 50 to 100 basis points of operating margin improvement annually. So we're making a nice downpayment on the returns to those levels in '15. That will be the objective again in '16 and the objective for several years. So we feel good about the trajectory. Again, the portfolio moves. I Just lowered the jumping off point. We believe we are absolutely the right things to do for the company. And again, if you adjust for those, we'd actually be -- and without the currency headwind, we'd be right in spitting distance of those margins in '15. So we feel good about that. A lot of work to get those improvements year after year. But that's the commitment."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, very helpful. And maybe just a quick detailed question on the product side for John. There's a lot of strength in PICCs this quarter. We've seen several quarters this year where PICC strength was significant. This particular quarter ultrasound was a",60,"Okay, very helpful. And maybe just a quick detailed question on the product side for John. There's a lot of strength in PICCs this quarter. We've seen several quarters this year where PICC strength was significant. This particular quarter ultrasound was a little weak. Was there anything specific there that we should be thinking about as we head into 2015?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I wouldn't say ultrasound was weak this quarter. We had a pretty good solid quarter in ultrasound. And that varies from time to time based on product launches and things like that. But I would say that the reality is we had a very strong quarter across-th",76,"I wouldn't say ultrasound was weak this quarter. We had a pretty good solid quarter in ultrasound. And that varies from time to time based on product launches and things like that. But I would say that the reality is we had a very strong quarter across-the-board. Every product line showed a significant strength on Oncology around the world. And in the United States, we're delighted with the performance we had in Oncology the quarter."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","We had a pretty good pipeline going to 2015 with our Site-Rite 8 plan for launch around mid-year. That was another addition to that pipeline.",26,"We had a pretty good pipeline going to 2015 with our Site-Rite 8 plan for launch around mid-year. That was another addition to that pipeline."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Can I one more actually maybe for Tim or for John. I guess, what's really interesting is in the period CR Bard was decelerating, there was this commentary that utilization was one of the factors. And what's really fascinating is on the acceleration, your",136,"Can I one more actually maybe for Tim or for John. I guess, what's really interesting is in the period CR Bard was decelerating, there was this commentary that utilization was one of the factors. And what's really fascinating is on the acceleration, your underlying growth this quarter was 4.5% that puts you well above peers' underlying growth rate. And you're not doing it with contribution from Foley and some of the key utilization sensitive markets. So it looks like frankly some good old-fashioned not market driven. So market obviously is upside. So Tim as you sort of think about the underlying business performance, where you think the 2 or 3 areas that you feel most confident last 2 years have driven that underlying performance, given it doesn't appear to come from the market at all?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, as we said, if you want to grow faster, you got to invest in faster growing segments and that's frankly what we've been doing. Clearly, the underlying market growth rates in emerging markets are faster than the total average, probably closer to",139,"Yes. Well, as we said, if you want to grow faster, you got to invest in faster growing segments and that's frankly what we've been doing. Clearly, the underlying market growth rates in emerging markets are faster than the total average, probably closer to a double-digit kind of growth rate underlying underlying market growth rates. The acquisitions that we've made over the last several years were all of this platforms here for us to invest in because those were faster growing segments. And then the R&D segments that we've made across the board have also been faster growing segments. So as we execute and those things start to pay off and come to fruition, the plan called for the growth rates to be higher and that's what you're seeing. So it's really not any more complex than that, frankly."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Kristen Stewart with Deutsche Bank.",10,"We have a question from Kristen Stewart with Deutsche Bank."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I'm sorry if I missed this. But did you give a growth rate for Lutonix outside the United States and are you still seeing good growth above else of the data from a market perspective?",36,"I'm sorry if I missed this. But did you give a growth rate for Lutonix outside the United States and are you still seeing good growth above else of the data from a market perspective?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Still excellent growth outside the United States.",7,"Still excellent growth outside the United States."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Any way to quantify?",4,"Any way to quantify?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Other than -- I'll do the next one?",8,"Other than -- I'll do the next one?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes.",1,"Yes."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we were delighted where we were at the end of the quarter both in the United States and outside the United States. We could take share.",28,"I think we were delighted where we were at the end of the quarter both in the United States and outside the United States. We could take share."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we can take share every quarter ex U.S.",11,"I think we can take share every quarter ex U.S."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then I guess bigger picture, I guess, Tim. When I guess how are you thinking just sort of around M&A in terms of the size of the company? Or would you be willing to step out and do something a little bit larger?",44,"And then I guess bigger picture, I guess, Tim. When I guess how are you thinking just sort of around M&A in terms of the size of the company? Or would you be willing to step out and do something a little bit larger?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Nothing has changed in terms of our perspective on that. As we've said, we've never shied away from the doing a big deal. But we haven't seen one that's been so compelling that gets all the filters that we have set forth for all of our acquisitions.",158,"Yes. Nothing has changed in terms of our perspective on that. As we've said, we've never shied away from the doing a big deal. But we haven't seen one that's been so compelling that gets all the filters that we have set forth for all of our acquisitions. Frankly, size isn't something we have a stoplight. That probably comes into play the third and fourth round of question. So we start strategically. We look at as a platform and as the growth sustainable and is it the market leadership or does it help the market leader position that in the current portfolio. And we answered all of those first. So would we be willing to do it? Sure but we would have to be so compelling that we are convinced that it was the right thing to do for the long-term growth of the company. And frankly, we don't even think about size when we look at deals."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then for Chris, just in terms of the gross margin guidance that you provided. Mix favorable by 20% to 40 basis points. We thought that it was a little bit better just with Lutonix coming in this year and also strong growth across the BioSurgery servic",69,"And then for Chris, just in terms of the gross margin guidance that you provided. Mix favorable by 20% to 40 basis points. We thought that it was a little bit better just with Lutonix coming in this year and also strong growth across the BioSurgery services, which is a little bit higher than that as well. Maybe you could speak to this puts and takes from mix perspective?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think there are other areas that are going to be -- continue to be important contributors, but are not  our lower margin. And I think we're working on improving the margins from the Rochester portfolio. That's going to take some time. We're not the",146,"Yes. I think there are other areas that are going to be -- continue to be important contributors, but are not  our lower margin. And I think we're working on improving the margins from the Rochester portfolio. That's going to take some time. We're not there yet. That's still another year to 2 out. Those products are growing nicely. And so that's actually something that's hurting us in this intervening period. And again, as we get out 12 or 24 months from now, that will be a contributor. But I think 20 to 40 is a very nice number and if that, as we construct the portfolio, we think it's something that's a sustainable. We actually feel pretty good about that. Certainly, we would like to see the number higher. But as we look at 2015 and the puts and takes, that's how we see it."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just to go back to Lutonix, that number that you quoted at the contribution, was there any stacking or consignment basis?",22,"And just to go back to Lutonix, that number that you quoted at the contribution, was there any stacking or consignment basis?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","We're -- I think there are certainly some initial stocking orders. We've also seen a very significant levels of a reorder as well at which we're tracking closely. So it's impossible to stay perfectly. But there's a healthy portion of customers that have r",84,"We're -- I think there are certainly some initial stocking orders. We've also seen a very significant levels of a reorder as well at which we're tracking closely. So it's impossible to stay perfectly. But there's a healthy portion of customers that have reordered more than once already. And that's why -- listen, it's going to take a little bit of time to settle this out. But to John's point, we feel great about the launch and certainly great about the initial demand."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of David Roman, Goldman Sachs.",11,"Next, we'll go to the line of David Roman, Goldman Sachs."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just start with the emerging markets which has been a very successful relatively fast return for you guys. Could you maybe just talk through kind of a where you are in the evolution of that strategy and ultimately, where you can foresee that b",56,"I wanted to just start with the emerging markets which has been a very successful relatively fast return for you guys. Could you maybe just talk through kind of a where you are in the evolution of that strategy and ultimately, where you can foresee that business going in terms of mix in the overall company?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. David, the -- as Tim said earlier, we are -- we've invested ahead of the growth potential within those markets. We're delighted with how well we've done in China since we embarked down this journey. We think we have an awful lot of runway yet ahead",177,"Sure. David, the -- as Tim said earlier, we are -- we've invested ahead of the growth potential within those markets. We're delighted with how well we've done in China since we embarked down this journey. We think we have an awful lot of runway yet ahead of this in China in many different product lines, especially new products that we have not yet launched in that specific geography. Emerging markets in -- within Europe, we're delighted with our uptick there across both Europe and Russia. And I'd say that we are anticipating the investments that we've made in Latin America yet to generate the results that we're expecting. So I think that '15 and '16 will be a particularly important year for us in the Latin American marketplace. We like the traction were getting around the world in the other markets that we've invested in. And I think that you'll continue to see this be a significant contributor to Bard's growth in the years to come. We don't have an upward limit in terms of this."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's fair. That's helpful. And then in one of the prior question, you alluded to Lutonix having the potential to give you a better foothold with the interventional cardiologists and essentially the vascular surgeon. To what extent overtime can tha",71,"Okay, that's fair. That's helpful. And then in one of the prior question, you alluded to Lutonix having the potential to give you a better foothold with the interventional cardiologists and essentially the vascular surgeon. To what extent overtime can that become potential leverage point? And do you have sufficient products in your bag really to use that call point potentially more efficiently? And how much of a focus is that?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","It's certainly an opportunity for us to use that call point more efficiency -- more efficiently. I think especially as we become a bigger part of the operating suites with DCB and the other products that can be utilized within this suite. I'd say that if",152,"It's certainly an opportunity for us to use that call point more efficiency -- more efficiently. I think especially as we become a bigger part of the operating suites with DCB and the other products that can be utilized within this suite. I'd say that if you look at it long-term, though, that's only one aspect of our DCB strategy. You see the other indications that John talked about. I mean, it gives us a runway of new platforms for the next 5 years or so that we think will be very significant. And we'll have an opportunity to build large markets over the years. Below the knees and obvious examples as the other indications that John talked about. So I'd say this is as much about being a larger part of the operating suites as well as being able to take this significant technology and move it to other indications."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Dave Turkaly, JMP Securities.",11,"Next, we'll go to the line of Dave Turkaly, JMP Securities."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim, just quickly, just a follow-up. I guess, maybe to wrap up this M&A lines. Your competitor mentioned that they thought the market was getting a little bit more competitive, that it's harder to find things. Would you agree with that? Are you finding --",62,"Tim, just quickly, just a follow-up. I guess, maybe to wrap up this M&A lines. Your competitor mentioned that they thought the market was getting a little bit more competitive, that it's harder to find things. Would you agree with that? Are you finding -- are you being presented with still interesting technologies? Or is the overall M&A environment more competitive today?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We're finding things -- in fact just recently internally, done kind of technologies and companies we look at. And it's as well as I've ever seen. So we are pleased with that. I think you were really down the road about the way venture capital  has sh",141,"Yes. We're finding things -- in fact just recently internally, done kind of technologies and companies we look at. And it's as well as I've ever seen. So we are pleased with that. I think you were really down the road about the way venture capital  has shifted over the last several years within the sector. We haven't bumped into any chops in the market well because of that yet. But who knows down the road whether that happens. So and the other part of that is we're more actively, as these emerging markets and other geographies grow, our expectation is there may be more opportunities in those sectors to look there. So we put more resource into that as well. So now we weren't pleased with our execution in 2014 but it wasn't because of a slowdown of deal flow."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And would you say that it was also was not because of evaluations or your evaluation sensitivity?",17,"And would you say that it was also was not because of evaluations or your evaluation sensitivity?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think so. I saw things that frankly like everything else that you didn't like when you go to buy something it's a negotiation. You can look at it in some ways that something in that and that happens but that's not that happened 5 years ago and 3 y",99,"I don't think so. I saw things that frankly like everything else that you didn't like when you go to buy something it's a negotiation. You can look at it in some ways that something in that and that happens but that's not that happened 5 years ago and 3 years ago and that's the way like this, right? So I don't think we -- is it we haven't changed our evaluation profile that we look at nor we do see any reason to do that. So that doesn't concern me at all relative to deal flow even."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to Matthew Taylor, Barclays.",7,"Next, we'll go to Matthew Taylor, Barclays."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to ask one about I guess your philosophy behind the Gore guidance because you take your top line guidance year, obviously forecasting some kind of decline. Is it just general uncertainty? Or is that something that you're expecting will cause",46,"I just wanted to ask one about I guess your philosophy behind the Gore guidance because you take your top line guidance year, obviously forecasting some kind of decline. Is it just general uncertainty? Or is that something that you're expecting will cause it to decline?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I think Matt, it's just trying to be prudent about the range of scenarios of that could happen. Again, we don't think there is a level of upside that again moves the guidance, which is why it's still 5% rounded the high end. It could continue at the c",190,"No, I think Matt, it's just trying to be prudent about the range of scenarios of that could happen. Again, we don't think there is a level of upside that again moves the guidance, which is why it's still 5% rounded the high end. It could continue at the current level or as we've always said, it could decline out of our control. And as we have said and we repeat again now, we don't have any information that leads us to believe that it will decline. But we wait and on a quarterly basis, understand what sales were and what the royalties were. So we're trying to be prudent and make commitments to you guys that we can deliver on within a range of scenarios. And certainly, as we think about potential upside, we're giving you bottom line commitments that we're committed to delivering and we would certainly like the ability to reinvest any upside back into the business while still delivering bottom line commitments. So we're trying to kick in what we think the likely scenarios and then make commitments that we're going to hit within those scenarios."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And this kind of a probably weighted forecast for you in terms of what could happen?",16,"And this kind of a probably weighted forecast for you in terms of what could happen?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, that's a good way to think about it.",9,"Yes, that's a good way to think about it."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Operator, we are well past an hour now. We're going to take 3 more and we apologize to the rest of people in queue. But obviously, you can call us and we can catch up after. But we'll take 3 more and then we're done with the call, operator.",49,"Operator, we are well past an hour now. We're going to take 3 more and we apologize to the rest of people in queue. But obviously, you can call us and we can catch up after. But we'll take 3 more and then we're done with the call, operator."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Joanne Wuensch, BMO Capital.",4,"Joanne Wuensch, BMO Capital."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I think a lot of us are focused on what are you going to buy next. But can we shift the topic a little bit to what you might divest next?",31,"I think a lot of us are focused on what are you going to buy next. But can we shift the topic a little bit to what you might divest next?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So yes, let me deal with that. So it's always easier to divest a business than it is to divest product lines. So with 14,000 plus SKUs at any point in time, we've got a number -- a large number of SKUs that are actually declining that, frankly, if w",152,"Sure. So yes, let me deal with that. So it's always easier to divest a business than it is to divest product lines. So with 14,000 plus SKUs at any point in time, we've got a number -- a large number of SKUs that are actually declining that, frankly, if we have -- we could get rid of or sell or whatever that are needed in the marketplace by patients and clinicians, which is why we continue to manufacture those and provide those. But there are also time distraction to do that kind of thing. So we'd rather have our management's efforts and the workforce focus on growth as opposed to divesting singular product lines. And there's really not a business as such that we have in total outside of what we do with electric physiology that would be nicely packaged for divestitures. So no current plans at the moment for anything."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And the other thing that's what I'd like your catheter business is that it sort of becomes the precursor of volume trends. And yet you're not releasing that you're seeing or the pick up in volumes. Do you have an idea what you're not exper",58,"That's helpful. And the other thing that's what I'd like your catheter business is that it sort of becomes the precursor of volume trends. And yet you're not releasing that you're seeing or the pick up in volumes. Do you have an idea what you're not experiencing it while others are starting to talk about it already?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, when you look at that catheter business, I think it's an interesting aspect of it. One is that hospitals had tried to reduce catheterization because of their need to reduce urinary tract infections or hospital acquired infections. That's one aspect",96,"Well, when you look at that catheter business, I think it's an interesting aspect of it. One is that hospitals had tried to reduce catheterization because of their need to reduce urinary tract infections or hospital acquired infections. That's one aspect of it. The other aspect is oftentimes on outpatient surgery, a patient will not be catheterized also. So you'll see the trend being very, very close on inpatient surgeries, but it won't capture demand from outpatient surgeries. I think that there's a couple of aspects of Foley catheterization that are new ones in this case."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I appreciate that clarification. But do you have an idea why you're not starting to see that kind of pick up that others are talking about?",26,"I appreciate that clarification. But do you have an idea why you're not starting to see that kind of pick up that others are talking about?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I do think we're seeing inpatient surgery. We don't see inpatient surgeries increasing.",14,"I do think we're seeing inpatient surgery. We don't see inpatient surgeries increasing."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to Richard Newitter, Leerink.",7,"Next, we'll go to Richard Newitter, Leerink."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Robie in for Richard Newitter. I have 2 on Lutonix. One, maybe regarding the other indication that you're exploring. I was wondering if you were willing to put an aspirational time line on some of those approvals? And then 2, I think last fall, we",72,"This is Robie in for Richard Newitter. I have 2 on Lutonix. One, maybe regarding the other indication that you're exploring. I was wondering if you were willing to put an aspirational time line on some of those approvals? And then 2, I think last fall, we were discussing on these calls the publication that you guys were searching to put the Lutonix data in an update on that would be appreciated."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So let me just jump in the approvals side. We talked about starting the ADX study. So enrollment that's going to be -- we started mid-this year, which is the plan. We expect that to enroll a relatively quickly. But with the timing of that, that's pr",262,"Sure. So let me just jump in the approvals side. We talked about starting the ADX study. So enrollment that's going to be -- we started mid-this year, which is the plan. We expect that to enroll a relatively quickly. But with the timing of that, that's probably sort of 2018 time frame for AV. Now below the knee, enrollment has been a little bit slower. We had hoped for sort of 2017 approval. We think that's still possible probably later in the year, just based on the way enrollments are going on right now. And in-stent restenosis indication, there is another one that we -- I want to hold back a little bit on that. We talked a little bit about it in 2017, late 2017 kind of time frame in the past. But we're trying to see where we can get information and more data that could give us other opportunities. So I don't want to commit to anything at this point. But there are ways out for indications. Now as far as the publication goes, I can tell you no one is more frustrated at the timing than I am. But this is purely something that's not within our control. As we understand it, the author's investigators have the manuscript on the rent you with the journal. It's not within our control as much as I'd like it to be. And we continue to believe that's important to get it published. So as soon as we know something and we have an opportunity to let you know, we will."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","The last question will come from Mike Matson, Needham & Company.",11,"The last question will come from Mike Matson, Needham & Company."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just wondering, with the Lutonix product, obviously, you had good sales, but is a reimbursement an issue at all? And with regard to the add-on payment, I mean that's for inpatient. So how many of these are being done inpatient versus outpatient? Is there",62,"Just wondering, with the Lutonix product, obviously, you had good sales, but is a reimbursement an issue at all? And with regard to the add-on payment, I mean that's for inpatient. So how many of these are being done inpatient versus outpatient? Is there any potential to get some type of something for outpatient setting that would increase or reimbursement as well?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me just jump in the reimbursement. First, off, I think were trying to track inpatient versus outpatient use. We don't have great visibility to that, frankly. But we believe that this is primarily outpatient use, which is typical for SFA kind of pro",291,"So let me just jump in the reimbursement. First, off, I think were trying to track inpatient versus outpatient use. We don't have great visibility to that, frankly. But we believe that this is primarily outpatient use, which is typical for SFA kind of procedures. So we think that's probably sort of in the 60% range or so. On the reimbursement, we think it is an issue. There are certainly -- certain value conscious buyers that would be holding off until they hear more about reimbursement. Obviously, we're getting picked up in spite of that at this stage. But there are, as John mentioned earlier, for reimbursement. And there's the outpatient reimbursement piece, which CMS, there's really no official time line. They can work within whatever they want. We think in April time frame is a reasonable. Again, CMS is not obligated to work within that time frame. But typically, sort of a couple of cycles of review is common. And we are in that time period from when we submitted our documentation to CMS last fall. Now as far as the inpatient piece goes, I just saw today, actually on the CMS website, the agenda for a meeting next week at town hall meeting where drug-coated balloons will be reviewed and I think that's the last step, as my understanding, at least, the last public step in the review process for the inpatient piece. But remember, inpatient only receives the approval or changes one time a year, which is typically the October time frame. So John alluded to the Q4 inpatient time period, which is what we think it would be sort of the reasonable customary time frame. But again, CMS is not obligated to work with any of that."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then, just in your surgical business, can give us an update on the natural tissue products? It seems like the market sort of moved away from those? And I guess  where your antibiotic coated product would sit in?",39,"And then, just in your surgical business, can give us an update on the natural tissue products? It seems like the market sort of moved away from those? And I guess  where your antibiotic coated product would sit in?"
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that the entire market is under some significant pressure. I mean, primarily based around pricing. The ASPs of some of those grafts are very, very substantial. And I think that hospitals and clinicians are being very prudent about the use of",127,"Sure. I think that the entire market is under some significant pressure. I mean, primarily based around pricing. The ASPs of some of those grafts are very, very substantial. And I think that hospitals and clinicians are being very prudent about the use of natural tissue products and really trying to focus those only when they are absolutely necessary. The product that we recently launched is the first of its kind. It the first product of graft that is antibiotic coated we think that as significant opportunity to be utilized in those indications where patients may be compromised. We -- the excitement in the marketplace is substantial. Our launch was significant. And we're delighted as well as where we are in that initial launch in late December."
254131,281166647,751766,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. Moderator, thank you very much for all of your assistance. Let me also thank everybody for joining us today. And I'd like to also take this opportunity to thank Bard employees around the world for a very solid year of execution looking forward to an",66,"Okay. Moderator, thank you very much for all of your assistance. Let me also thank everybody for joining us today. And I'd like to also take this opportunity to thank Bard employees around the world for a very solid year of execution looking forward to an even better one this year and also for dedication and commitment and we'll talk to you after the first quarter."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the CR Bard Inc. Fourth Quarter 2014 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference will be recorded -- is being recorded and will be available for f",382,"Ladies and gentlemen, thank you for standing by, and welcome to the CR Bard Inc. Fourth Quarter 2014 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference will be recorded -- is being recorded and will be available for future on-demand reply through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters and outcome of contingencies such as legal proceedings. The uncertainty of loss reserve estimates, share repurchases, acquisitions and other economic business competitive and regulatory factors. Please refer to the cautionary statement regarding forward-looking information in Bard's September 30, 2014 10-Q and the information under the caption Risk Factors in the company's 2013 10-Q, including disclosure of the factors that could cause actual results to differ materially from those expected or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of January 29, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to prior -- are to the prior year period. At this time, I will turn the conference over to Mr. Timothy Ring. Please go ahead."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. That's a lot of work there, I appreciate it. I'd like to welcome, everybody, to Bard's Fourth Quarter 2014 Earnings Call, and thank all of you for taking the time to join us today. I would expect the presentation portion of the call to last abo",1065,"Thank you. That's a lot of work there, I appreciate it. I'd like to welcome, everybody, to Bard's Fourth Quarter 2014 Earnings Call, and thank all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 35 minutes or so.
The agenda today will go as follows. I'll begin with an overview of the results for the fourth quarter. John Weiland, our President and COO, will review our fourth quarter product line revenue. John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline. And then Chris Holland, our Senior VP and CFO, will review the fourth quarter income statement balance sheet and also provide our financial guidance for 2015. And then finally, we'll wrap it up with Q&A. 
Fourth quarter 2014 net sales totaled $867.2 million, that's up 10% over Q4 last year on an as-reported basis and up 11% on a constant currency basis. The currency impact for the quarter versus the same quarter of 2013 was unfavorable by about 140 basis points.
The Gore royalty revenue in the quarter was approximately $38.6 million. The impact of the divestiture of our EP business, which occurred in Q4 2013, net of the impact of the Rochester Medical acquisition in the same quarter, was unfavorable by about 20 basis points to growth for the quarter. That all puts our organic growth rate for Q4 2014 at approximately 6.3%, with a little over 200 basis points from the early approval and launch of the Lutonix drug-coated PTA balloon in the U.S.
Net sales for the full year 2014 were $3.3 billion, that's up 9% as reported and on a constant currency basis, which exceeded our original guidance for the year. Net income for the fourth quarter was $134.2 million and diluted earnings per share were $1.72. I will remind you that we recognized the onetime gain from the Gore litigation in the prior year quarter. Excluding this and other items that affected the comparability results between periods, which Chris will cover later, fourth quarter 2014 net income and diluted cash earnings per share, which excludes amortization of intangibles, were $158.9 million and $2.29, that's up 39% and 40%, respectively.
Full year 2014 net income was $294.5 million and diluted EPS was $3.76. Excluding items again that affect comparability between periods, full year 2014 net income was $586 million and diluted cash EPS were $8.40, and that's up 23% and 29%, respectively, from 2013. Again, well in excess of our original guidance for the year.
Looking at fourth quarter revenue growth geographically compared to the prior year, on a constant currency basis, net sales in the U.S. grew 14%. Internationally, we grew 5%, with Europe up 3%; Japan up 2% and our other international geographies up 8%. Excluding the Gore royalty and EP divestiture impact, net sales in the U.S. grew 7% and total international sales were up 10%, with Europe up 10%; Japan up 3%; and the remaining geographies up 11%.
As anticipated in our strategic investment plan, our emerging market sales continued to increase and represented about 9% of our total revenue in Q4. Looking back in 2014, we're pleased with the progress that we've made throughout the year. 2 years ago, to remind you, we introduced our 3-year strategic investment plan and then on that same quarter, our organic growth rate was flat. We finished 2014 with our organic growth rate of our other portfolio in the mid-single digits, which is what we had projected. It's difficult to know precisely what's happening in real time in the underlying markets, but we believe the market organic growth continues to be in the low single digits. While many in our sector had stronger growth in Q3 than expected, some of those same companies then saw sequential deceleration of growth in Q4. In contrast, we continue to see sequential improvement on organic growth rate. And we believe that the implementation and execution of our strategic investment planning contributed to this acceleration.
As we look to 2015, we expect the full year organic growth rate to again improve over the full year 2014. And to be clear, that assumes no benefit from any underlying market improvement. If the market improves as some are suggesting, then we should do even better than that.
2015 is an important year of execution, once again, for us. We expect our investments in emerging markets to continue to shift the mix of the portfolio of faster growing geographies. The key to this initiative is improved productivity from the teams that we've built and additional product registrations in these markets.
In 2015, we also anticipate we'll begin to see some returns from our R&D investments. Over the past couple of years, we significantly increased the level of R&D as we pursued expanded indications of current product platforms and introductions of new technologies. We remain in investment mode. The long-term objective is to drive above market revenue growth with a lower risk profile on a sustainable basis. There obviously remains significant uncertainty in the market, including unsettled issues in Washington. FX headwinds at this magnitude, frankly, are as difficult and come up as quick as we've seen in years. The market acceptance, reimbursement decisions, competitive response from drug-coated balloons in the U.S. could have a meaningful impact in our results. And we have no way of knowing whether Gore royalty will increase, decrease or be consistent compared to 2014 levels.
However, amidst these uncertainties, we remain focused on the execution of our strategic plan and the things we can control. We believe our investments will improve the organic engine of the company in both revenue and profitability. And as we said, we measure success over the long term. If 2015 brings some tailwinds in the market as some suggest, we would look for opportunities to invest any short-term out-performance back into the business for longer-term benefit.
Chris will give you more details when he lays out our financial guidance. We continue to believe that the effective execution of our strategic investment plan will allow us to continue to increase shareholder value over the long term and on a sustainable basis.
With that as an introduction, let me turn you over to John Weiland for a review of our fourth quarter product line revenue."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, as usual, I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's start with Vascular. Total net sales in this category for",801,"Good afternoon, everyone. Before I start, as usual, I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's start with Vascular. Total net sales in this category for the quarter were $244.6 million, an increase of 19% on an as-reported basis and 22% on a constant currency basis when compared to the fourth quarter of 2013. Excluding the Gore royalty and the impact of the EP divestiture, global Vascular sales were up 9%, with the United States business up 14% for the quarter and international up 3%. Sales in our Vascular graft category were down 6% in Q4.
Excluding the Gore royalty, our Endovascular business grew 11% in the fourth quarter. Within Endovascular, our biopsy line was up 1%.
Our peripheral PTA products were up 49% this quarter, driven by the early FDA approval of the Lutonix drug-coated balloon in the United States on October 10. We're extremely pleased with how our Vascular sales, development and operations team executed the early launch of this first-of-a-kind product in the United States. As you know, we were shipping product to customers on the day of approval with the first cases being performed the following day.
The early market acceptance has been impressive and we look forward to expanded adoption of this technology longer term as the market continues to develop.
Our Stent business was down 10% in Q4, which is within the range of recent experience. As we've said, pricing headwinds continue to drive down ASPs in this category.
And to complete the category, sales in our vena cava filter line were flat in the fourth quarter.
Now let's move to Urology. Total net sales were $217.8 million, which is up 8% versus the Q4 of last year on an as-reported basis, and 9% on a constant currency basis. About 600 points of this global growth was related to the Rochester acquisition, which anniversary-ed in the quarter. The United States business was up 6%, while internationally, we grew 14%.
The Targeted Temperature Management products saw strong double-digit growth this quarter, and we remain optimistic about the long-term growth prospects of this technology platform.
Our basic drainage business was up 7% in Q4, with about 400 points of that growth coming from the acquired Rochester Medical products. 
I.C. Foleys were down 2% globally, with the United States down 4%. These results in basic drainage are fairly consistent with recent quarters. While some surveys and reports have suggested improvement in the United States hospital volumes, we haven't seen any underlying improvement reflected here so far.
Our continence business grew 24% over the prior year quarter. Excluding the impact of the acquired products, our legacy continence products were down 6% for the quarter, within the range of recent experience.
Sales in urological specialties were up 11% with emerging markets growing close to 40% organically in this category. Our brachytherapy products were down 3% globally for the quarter.
And finally, sales from our StatLock catheter stabilization line decreased 3% in the fourth quarter.
Now let's turn to Oncology. Total net sales in this category were $237.5 million, an increase of 8% over the fourth quarter last year on as a reported basis and 9% on a constant currency basis. Net sales in the United States were up 7%, while outside the United States sales were up 15%.
Our port line was up 5% versus the fourth quarter of last year with significant growth coming from emerging markets.
PICC revenue growth was 11% in Q4 with strong performance again in the United States and internationally. Our vascular access ultrasound product line was up 8% this quarter. And our dialysis catheter business was up 11% in the fourth quarter.
And we'll finish with Surgical Specialties. Net sales in this category were $145.0 million in the fourth quarter, up 3% on an as-reported basis and 4% on a constant currency basis. United States sales increased 4%, while international sales were up 6%. As you know, we anniversary-ed the 2013 acquisition of Medafor on the first day of the fourth quarter. Our biosurgical product portfolio grew double digits organically in the quarter, and we're excited about the long-term potential here.
Sales from our biosurgical products already exceed the combined sales of our fixation products and our natural tissue products.
Our soft tissue repair business grew 5% overall in the fourth quarter. Our total synthetic hernia products were up double digits again this quarter, while our natural tissue products declined 15%.
Closing out the surgical category, our fixation business was down 3% in the fourth quarter and our performance irrigation business was down 14% versus an above average quarter 1 year ago.
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John. Good evening, everyone. 2014 was a pretty busy year at Bard. We launched over 40 new products and our pipeline of launches in 2015 is also robust.Starting with drug-coated balloons. We're making good progress on additional sizes and indica",924,"Thanks, John. Good evening, everyone. 2014 was a pretty busy year at Bard. We launched over 40 new products and our pipeline of launches in 2015 is also robust.
Starting with drug-coated balloons. We're making good progress on additional sizes and indications worldwide. We're in the follow-up phase of our Levant 2 Japan study and we expect to submit late this year for Japan approval. Enrollment continues in our Below the Knee IDE and in-stent restenosis studies and we are making good progress in our AV access IDE study with enrollment anticipated to start mid-2015.
We're also expanding the clinical science of DCBs through our robust real world clinical experience. For example, at LINC this week, Dr. Markus Stein presented the first look at interim 1 year results from the Lutonix global SFA and popliteal registry of almost 700 patients. Lesion lengths were over 100 millimeters and treated lengths were almost 200 millimeters, while roughly 30% of lesions were located in the popliteal artery. Primary patency was 81.7% and 88.5% of patients were free from a re-intervention at 1 year.
The randomized study designs are quite different, making comparison of results very difficult across different studies. Registry has provided a more balanced comparison across technologies, and we believe these results compare well to any of the competitive DCBs.
Also in Vascular, we launched the LifeStream Balloon Expandable Covered Stent in Europe in Q4 and enrollment is going well in the IDE study to support an iliac artery disease indication in the U.S.
Finally in Vascular, we're responding to some FDA questions and anticipate U.S. launch in Q1 of the first in the series of new Tru-Flo PTA Catheters for use in valvuloplasty procedures. Tru-Flo has a unique flow-through design to allow blood to pass through a large channel in center of the balloon, promoting prolonged inflation, while potentially reducing the need for rapid pacing or other hemodynamic maneuvers used to reduce cardiac output during the time the balloon has expanded.
Next, moving to Urology. We've just begun the rollout of our new skyline sub 2 per inch stone basket family. This new product in our endourology line provides the urologists with one of the smallest baskets in the industry that provides high strength and maneuverability, along with a highly visible atraumatic tip to aid in safe and accurate use.
In our Targeted Temperature Management portfolio, we've just launched our new PAD systems for use with neonates and pediatric patients in the U.S. And we're rolling out a new software update to support enhanced functionality and additional languages.
Moving to Oncology. We're anticipating U.S. regulatory clearance and launch about midyear of our freehand stereotactic system for Vascular Access named Pinpoint GT. The technology will initially be offered on a new Site-Rite 8 system in a planned simultaneous launch. Pinpoint GT will also be backwards compatible to Site-Rite 6.
In PICCs, we're now tracking towards submission around midyear of our first family of thromboresistant devices. We plan to broaden the offering to our full line of PICCs over the back half of 2015 and into 2016. Similarly, we anticipate submitting our first antimicrobial PICC in the second half of 2015 and launching upon regulatory clearance. This first product will be followed by a series of launches to support coated PICCs in both our PowerPICC and PowerPICC SOLO configurations.
Turning to midlines. We're making good progress in our next-generation POWERGLIDE family and currently anticipate our U.S. regulatory submission in Q4 with the first half 2016 launch.
I'll close my portion of the discussion today with surgery. We informed you on the last call that we just received U.S. regulatory clearance of the first antibiotic-coated biologic mesh, XenMatrix AB, and I'm pleased to tell you that product was launched in December. XenMatrix AB utilizes our proprietary coding, which is intended to preserve the integrity of the biologic graft in abdominal wall reconstruction procedures and has demonstrated broad spectrum safety and efficacy against several typically-encountered bacteria.
Moving to our BioSurgery product family. In early Q3, we filed our PMA supplement for our Progel sealant, seeking expanded use in video-assisted and robot-assisted thoracic surgery. We continue to be optimistic about approval and launch in the first half of this year.
Also, we completed a follow-up early this year in our TRIDYNE vascular sealant pivotal IDE study. The team is working toward PMA submission in the first half of the year and we anticipate approval and launch in mid-2016.
And finally, in mesh fixation, we remain on track to launch in the first half of the year, our new spring-loaded resorbable tack device named OPTIFIX. We also anticipate launching another fixation platform later in the year.
As Tim said, we have a very important year of execution ahead of us and we look forward to updating you on our progress throughout the year. As part of our effort for continuous improvement, we initiated a survey of investors last year. And one of the more common suggestions we received was to take a fresh look at the need to hold a formal analyst meeting every year. We've been clear about our growth drivers and the opportunities we're pursuing and our investment strategy has not changed. Because of that, we have determined that a resource and time-intensive effort, like a formal analyst meeting, is just not justified this year. We'll update you on our pipeline and growth drivers throughout the year if circumstances allow in the appropriate forum. Thanks very much for your attention. Now I will hand the discussion over to Chris."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $7.5 million pretax, mostly related to Lutonix milestone accretion and a $10.1 million pretax charge for",1632,"Thank you, John. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $7.5 million pretax, mostly related to Lutonix milestone accretion and a $10.1 million pretax charge for restructuring and productivity initiatives. We also booked expense of $12.7 million, related to the judges order in the women's health litigation that we work up 500 cases simultaneously.
And finally, we had a credit of $3.5 million pretax related to the medical device excise tax paid in 2013 after reaching an agreement with the IRS. These items are detailed in the notes to the financial statements and the reconciliation accompanying our Q4 earnings press release.
Now let's go to the statement of income for the quarter. Gross profit was $547.7 million in Q4 and $547.4 million on an adjusted basis or 63.1% of sales, up 230 basis points from the prior year, with 170 basis points of that improvement related to the Gore royalty and about 120 basis points coming from cost improvements. We also had about 50 basis points of benefit when compared to the higher integration costs and investments in Q4 of 2013.
Some headwinds to GPs in Q4 were new amortization of about 50 basis points, foreign exchange at about 10 basis points and mix of about 20 basis points. Pricing pressure was about 100 basis points of headwind on the revenue line and about 30 basis points in GP in Q4. We continue to expect the pricing pressure going forward between 100 and 150 basis points on the revenue line.
For the full year 2014, that brings adjusted gross profit as a percentage of sales to 62.1%, up 110 basis points from 2013, much better than our original guidance of 30 to 60 basis points of improvement.
While the Gore royalty did exceed our expectations, the effect on GP was only 10 to 20 basis points higher than our projections from 1 year ago. The overachievement was primarily driven by more favorable mix than originally expected.
SG&A expenses were $257.5 million for the quarter or 29.7% of sales. On an adjusted basis, SG&A was $261 million even or 30.1% of sales, down 170 basis points from the prior year period, driven by the Gore royalty being in the denominator as well as improving leverage from our emerging markets investments and the integration of our 2013 acquisitions.
For the full year 2014, adjusted SG&A as a percentage of sales was 29.6%, a decrease of 40 basis points from the prior year. R&D expenditures totaled $79.2 million for the fourth quarter or 9.1% of sales. On an adjusted basis, R&D expense was $71.5 million or 8.2% of sales, a decrease of 70 basis points from the prior year period, mostly driven by the Gore royalty now in the denominator.
For the full year of 2014 on an adjusted basis, R&D expense was 8% of sales compared to 8.5% in 2013. However, without the Gore royalty and the revenue line, R&D expense would've been 8.4% of sales in 2014.
Interest expense was $11.2 million for the fourth quarter and $44.8 million for the full year. Other income and expense was $25.1 million of expense for the fourth quarter. On an adjusted basis, it was $2.2 million of expense for the quarter and $4.7 million of income for the full year.
The effective tax rate for the quarter was 23.2%. On an adjusted basis, it was 21.1%, taking us to 24.3% for the full year. The quarter was lower than the full year average due to the renewal of the R&D tax credit in December.
At the beginning of the year, we had told you to expect about 100 basis points of improvement in the effective tax rate in 2014 and we came in at 90 basis points of improvement, despite significantly stronger U.S. income than we had anticipated. That all adds up to cash EPS of $2.29 for Q4, excluding items affecting comparability, which brings us in at $8.40 for the full year on the same basis. That's a full $0.10 above the high end of our original guidance for the year and above our updated guidance as well, indicative of the strong performance we saw in 2014.
We purchased about 785,000 shares of the company's stock during the fourth quarter, taking the total buybacks in 2014 to approximately 4.5 million shares at an average price of $146.67. Between buybacks and dividends, we returned approximately $725 million to shareholders over the course of 2014.
The balance sheet as of December 31 reflects cash, restricted cash and short-term investments of $1.01 billion versus $1.04 billion at September 30. For the full year, AR days were down 7.3 days and inventory days were up 0.2 days. Capital expenditures totaled $36.6 million for the quarter and $126.6 million for the year.
On the liability side, total debt was $1.5 billion as of December 31 versus $1.4 billion at September 30. Debt to total capital at the end of the fourth quarter was about 45% and total shareholder investment was $1.8 billion at December 31.
So with the strong 2014 now in the books, let's turn to financial guidance for 2015, excluding the impact of items that affect comparability. For revenue, we project 2015 constant currency organic revenue growth between 4% and 5%. Given the potential variability of the Gore royalty, our overall constant currency revenue guidance is between 3% and 5%. As Tim said, this assumes no fundamental improvement in the market growth rates from where they have been the last couple of years, which we would characterize as low single digits. If the markets improve as some suggest, then we would expect to do better. But with all of the uncertainties surrounding us, we think it's too early to count on any improvement in the underlying markets.
Obviously, foreign exchange rates are significant headwind for everyone as we head into 2015 and we are certainly not immune to that. We estimate that at current rates, we're looking at a revenue headwind related to currency of about 3%.
As far as constant currency revenue growth in our 4 disease state categories, in 2015, we expect Vascular revenue growth to be between 3% and 7%; Urology to be between 1% and 4%; Oncology to grow between 3% and 6%; and our Surgical Specialties business to grow between 3% and 6% as well. We expect our overall gross margin percent to decline in 2015 by between 30 and 70 basis points compared to 2014. That reflects about 50 basis points of pressure from FX and about 30 basis points of incremental amortization from the U.S. approval of Lutonix in October of 2014.
Pricing pressure continues to be a significant issue for us. And we estimate the impact on 2015 to be between 40 and 60 basis points of headwind to GP. Fortunately, our cost improvement programs are projected to once again contribute about 50 basis points of benefits to GP and we expect mix to be favorable between 20 to 40 basis points.
So organic constant currency gross margins are expected to improve in 2014 as we projected when we first introduced our strategic investment plan 2 years ago. And again, as we said, we expect to see improving operating leverage in 2015. While we continue to increase investment in emerging markets, we expect SG&A as a percentage of sales to decline between 50 and 100 basis points in 2015. And we expect R&D as a percentage of sales to be in the mid-7% range, both excluding items that affect comparability. We expect interest expense in 2015 to be between $45 million and $47 million. We expect the effective tax rate to improve again, this time, between 0 and 50 basis points for the full year and this does assume the renewal of the R&D tax credit for 2015.
All of that adds up to adjusted cash EPS for 2015, excluding items that affect comparability between $8.95 and $9.05 per share. That includes a negative currency impact of about $0.25 based on today's rates. So without this very atypical currency situation, we would have been forecasting at or above our target of 10% EPS growth.
While we evaluated alternatives that could increase earnings for 2015, given the expected FX magnitude and the fact that this is certainly not a Bard-specific issue, we don't think it would be wise for a short-term benefit to scale back investments and possibly interrupt the momentum in organic growth that we achieved during 2014.
In the end, we believe maintaining our flexibility and continuing to focus on the longer-term organic growth profile of the company builds better value for our shareholders.
In Q1, we expect constant currency sales growth between 4% and 5% and adjusted cash EPS between $2.04 and $2.08. As for capital expenditures, we expect 2015 to be similar to 2014, between $120 million and $140 million. And we expect operating cash flow to be in the $700 million range again in 2015.
I'd like to conclude my comments by reminding you that the objective of our strategy is to position Bard from a portfolio standpoint to deliver above market revenue growth for years to come. The key measure of success for this transition plan will be the improvement in the organic engine. This plan was never about maximizing EPS in a given year, but the strength in the business for the long-term in a disciplined and thoughtful way. We believe we are doing that. While we expect further improvement in our operating margins in 2015, we intend to remain in investment mode with the desired outcome of positioning the company for long-term success to enhance shareholder value. And with that, I'll turn the call back over to Tim."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. While we're pleased with our performance in 2014, we have a lot of work in front of us to position the company where we want it to be. As many of you have heard me repeat one of my favorite quotes, great strategy is more about great executi",125,"Thanks, Chris. While we're pleased with our performance in 2014, we have a lot of work in front of us to position the company where we want it to be. As many of you have heard me repeat one of my favorite quotes, great strategy is more about great execution than it is about great thinking. 2015 is a very important year of execution for us. We're not taking anything for granted. I'm sure there will be bumps along the way as there always is. We're focused on the long-term health of the business with the intention of increasing shareholder value. That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Larry Keusch with Raymond James.",16,"[Operator Instructions] And our first question comes from the line of Larry Keusch with Raymond James."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess I would just start off, Tim, with asking a little bit. You laid out nicely the expectations for 2015. But I guess I'm thinking past 2015 and really trying to understand what the ultimate game plan is here. Can you talk about, as you look out what",67,"I guess I would just start off, Tim, with asking a little bit. You laid out nicely the expectations for 2015. But I guess I'm thinking past 2015 and really trying to understand what the ultimate game plan is here. Can you talk about, as you look out what you think the appropriate levels of organic growth and perhaps EPS growth it would be for the company?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Larry. Obviously, the market's volatile and especially as you grow into more and varied geographies, the underlying market growth rates can be even more complex. We, as we stated, don't anticipate any change in the external environment for this year.",211,"Yes, Larry. Obviously, the market's volatile and especially as you grow into more and varied geographies, the underlying market growth rates can be even more complex. We, as we stated, don't anticipate any change in the external environment for this year. If it happens, we'll do better than that. We stated a couple of years ago that our goal was to be 200 to 300 basis points above what the market growth rate was and the competitive aspect of that within the sector. That would still be our goal. We're big believers that sustainable revenue growth drives shareholder value and that's what we're about. So we remain fixated on that as a strategic objective. We do think that there's a lot of leverage for us with the investments we've made in some of the emerging markets. Just to put in perspective, that represents almost 1/3 of our total sales headcount but as we mentioned, 9% of revenue. So we think there's a lot of room to grow into that. And those markets are growing clearly above what we called out as the market average in total. So to the extent we can accelerate growth in those segments that are growing faster, we should continue the momentum that we demonstrated last year."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. The only thing, I'd add, Larry, as it relates to EPS growth is we're absolutely focused on double-digit EPS growth, 10% EPS growth. And certainly, we believe the model will allow us to deliver that. And without this recent move in the dollar, we woul",117,"Yes. The only thing, I'd add, Larry, as it relates to EPS growth is we're absolutely focused on double-digit EPS growth, 10% EPS growth. And certainly, we believe the model will allow us to deliver that. And without this recent move in the dollar, we would have delivered 10% to 11% EPS growth in 2015. So the growth organically on the top line, we believe over time, will allow us to drive 10% EPS growth. Again, this unprecedented move, which cost us $0.25 now as we turn to '15, has just prevented that from happening this year. But the plan, the strategy and the leveraging on the investments over time should allow us to achieve that objective."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just again on the uses of cash, you guys obviously generated significant amount of free cash flow. No significant M&A done in 2014. You obviously bought back a bunch of stock associated with the Gore bonus payment. But can you talk about 2015 pe",66,"Okay. And just again on the uses of cash, you guys obviously generated significant amount of free cash flow. No significant M&A done in 2014. You obviously bought back a bunch of stock associated with the Gore bonus payment. But can you talk about 2015 perhaps, what your expectations may be for M&A as well as would you be open to deploying cash for share repurchase?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll cover that kind of at a high level and Chris can chime with detail. Clearly, our use of cash has not changed for, well, 10 years or longer. It's strategic, first. We want to continue to invest in businesses, technologies and platforms to grow t",77,"Sure. I'll cover that kind of at a high level and Chris can chime with detail. Clearly, our use of cash has not changed for, well, 10 years or longer. It's strategic, first. We want to continue to invest in businesses, technologies and platforms to grow the company. And we'll continue to do that, prioritize it that way. Second would be share repurchases. And third would be dividends in that order, and there's no change to that."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So again, Larry, I think obviously, it's very much transaction dependent. And as Tim says, we're looking for the right acquisitions to make for the company every day. I think the free cash flow does allow us to do both in the ordinary course, continu",121,"Yes. So again, Larry, I think obviously, it's very much transaction dependent. And as Tim says, we're looking for the right acquisitions to make for the company every day. I think the free cash flow does allow us to do both in the ordinary course, continue to make acquisitions of a certain size as well as continuing to constantly return cash to shareholders. We'll generate free cash flow in the $500 million to $600 million range that we can deploy in 2015. First priority is strategic. But even in conjunction with that, I think we'll continue to have flexibility to do a bit of both. Again, deal dependent. But in the ordinary course, I would expect a balanced use of cash."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question comes from the line of Brooks West with Piper Jaffray.",14,"And our next question comes from the line of Brooks West with Piper Jaffray."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple on emerging markets for me. Tim, you mentioned 1/3 of sales headcount in emerging markets versus 9% of revenue. How long will it take for that ratio to normalize? And kind of can you walk us through the levers that's associated with that? That's",68,"A couple on emerging markets for me. Tim, you mentioned 1/3 of sales headcount in emerging markets versus 9% of revenue. How long will it take for that ratio to normalize? And kind of can you walk us through the levers that's associated with that? That's question 1. Question 2 is where you are with the product registrations in emerging markets now versus where you want to be?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, in terms of the comparison of kind of productivity per sales rep across geographies, it's difficult to do for a couple of different reasons. Number one, by design in the emerging markets, we didn't give every country manager the 14,000 SKU pla",121,"Sure. Well, in terms of the comparison of kind of productivity per sales rep across geographies, it's difficult to do for a couple of different reasons. Number one, by design in the emerging markets, we didn't give every country manager the 14,000 SKU playbook and tell them to go sell everything. So we're being very strategic relative to how we target within those geographies. And I'm not sure that's a good way to look at the analysis, frankly. But we're pleased with the productivity that's being made there. We do think there's a lot of room to grow into that investment. That was really the plan. And we're pleased with the execution to date. And the second part of the question?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Registrations.",1,"Registrations."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Oh, yes, the registration pipeline. I kind of view that as almost like a second R&D funnel. And it's something we measure our metric every month, frankly, from the divisions. So there are literally hundreds of registrations sitting as we speak at various",134,"Oh, yes, the registration pipeline. I kind of view that as almost like a second R&D funnel. And it's something we measure our metric every month, frankly, from the divisions. So there are literally hundreds of registrations sitting as we speak at various ministries of health around the world. There's even more than that sitting within our geographic business centers waiting to be filed, being prepared to be filed with the ministries of health. And even beyond that in the sourcing divisions, there's more than that, hundreds that are being prepared to submit to our business centers that in turn gets submitted to the ministries of health around the world. So we're pleased with the pipeline and the flow that we've got in the regulatory side of things at the moment in those markets."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Mike Weinstein with JPMorgan.",11,"Next, we'll go to the line of Mike Weinstein with JPMorgan."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","So a couple of items first just to clean up on the guidance. So Chris, in the 2015 guidance, what are you assuming for share repurchases?",26,"So a couple of items first just to clean up on the guidance. So Chris, in the 2015 guidance, what are you assuming for share repurchases?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","We're assuming sort of an ordinary course number, Mike. We'd certainly look to offset dilution from benefit plans as well as a little bit of an incremental reduction in the share count. We don't want to commit to a specific number because again, the range",85,"We're assuming sort of an ordinary course number, Mike. We'd certainly look to offset dilution from benefit plans as well as a little bit of an incremental reduction in the share count. We don't want to commit to a specific number because again, the range of opportunities we might face on the M&A front could force us into a little bit of a different place. But we would expect to continue to be able to move the share count lower to a certain degree."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. The 4% to 5% organic growth guidance kind of x the Gore noise feels like it should be a little bit better than that this quarter. Or as we maybe think about the last few quarters that your kind of underlying business pre-Lutonix has been moving from",142,"Okay. The 4% to 5% organic growth guidance kind of x the Gore noise feels like it should be a little bit better than that this quarter. Or as we maybe think about the last few quarters that your kind of underlying business pre-Lutonix has been moving from what was 3% to moving closer to 4%, you had your first quarter of Lutonix out there, and Lutonix just adds over 200 basis points to the growth this quarter. So it feels like you're being a little bit conservative both on the base business as well as Lutonix. Like in the Oncology guidance, the Oncology was up 7% constant currency in 2014. You're guiding with 3% to 6%. So could you just spend a minute on the 4% to 5% and why that doesn't -- it feels conservative. Why is that not conservative?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Mike. We'll tag team this. I think first of all -- I don't know if you said Urology or Oncology?",21,"Yes, Mike. We'll tag team this. I think first of all -- I don't know if you said Urology or Oncology?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","No, Oncology. Oncology was up 7% in '14. You're guiding to 3% to 6%.",14,"No, Oncology. Oncology was up 7% in '14. You're guiding to 3% to 6%."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think with respect to ports, for example, we have a number of large contracts, and there's certainly some timing associated with large multiyear contracts that could, from a pricing standpoint, provide a headwind in certain categories. I think bigg",196,"Yes. I think with respect to ports, for example, we have a number of large contracts, and there's certainly some timing associated with large multiyear contracts that could, from a pricing standpoint, provide a headwind in certain categories. I think bigger picture, certainly, we expect a very competitive dynamic with respect to DCBs over the course of 2015. We'll see how that plays out. We certainly have ambitions to do very well, but we also want to make sure that we're maintaining the right level of caution. I think Europe, where we had a very strong 2014, we're somewhat cautious just given some of the macro challenges and headwinds that the continent is facing as well. And as Tim said, there's a lot of uncertainties surrounding us and the sector overall, including as it relates to the health care in the U.S. and as the Affordable Care Act continues to remain under some uncertainty longer term. So Gore, as we said, we're certainly going to try to do better. And if we get some tailwind, we can. But we believe 4% to 5% as we exited '14 is absolutely the right place for us to be."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And are there any other headwinds that you didn't mention that we should know about?",16,"And are there any other headwinds that you didn't mention that we should know about?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Nothing major.",2,"Nothing major."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Bob Hopkinson with Bank of America.",13,"Next, we'll go to the line of Bob Hopkinson with Bank of America."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Congrats on a great launch. Just 2 questions. One, first for Chris. In the 4% to 5%, can you just give us a sense as to the year-over-year change that goes into that 4% to 5% from just the Gore royalty and Lutonix revenues?",44,"Congrats on a great launch. Just 2 questions. One, first for Chris. In the 4% to 5%, can you just give us a sense as to the year-over-year change that goes into that 4% to 5% from just the Gore royalty and Lutonix revenues?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think with -- we try to capture the range of scenarios we see with respect to Gore in a constant currency number of 3% to 5%. So there are some scenarios there, Bob. They don't move the needle much on the high end than they do tick it down a bit on",131,"Yes, I think with -- we try to capture the range of scenarios we see with respect to Gore in a constant currency number of 3% to 5%. So there are some scenarios there, Bob. They don't move the needle much on the high end than they do tick it down a bit on the low end. So again, we believe we're capturing what is likely within the 3% to 5% as it relates to Gore. And we're certainly not going to give specific expectation around Lutonix as we look at '15. We're going to continue to work like heck to help develop the market and penetrate the market. But I assume you can respect from a competitive standpoint we're not going to be more specific than that at this point."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Sure. But I think I gathered from Tim's comments that maybe in the fourth quarter you did high teens revenue for Lutonix?",22,"Sure. But I think I gathered from Tim's comments that maybe in the fourth quarter you did high teens revenue for Lutonix?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think you guys will be able to do the math to get to a number that's in that range.",21,"Yes, I think you guys will be able to do the math to get to a number that's in that range."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then for John, on the launch, a couple of things. I'd love just to kind of get your views on what you're seeing as you pioneer this new therapy. So a couple of quick things. One, what's the progress on the add-on payment? When do you expect that",94,"Okay. And then for John, on the launch, a couple of things. I'd love just to kind of get your views on what you're seeing as you pioneer this new therapy. So a couple of quick things. One, what's the progress on the add-on payment? When do you expect that? Do you have any evolved views on market size and what will happen to the stent market as a result of drug-coated balloons and what you're seeing in the early launch? Just would love to get some thoughts now that you're in the marketplace."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me just give some general perspectives on the launch itself. I think first of all, our team did an excellent job preparing for this launch literally over the last year in great detail. And I'd evidence that by the comments that we made where we had ap",249,"Let me just give some general perspectives on the launch itself. I think first of all, our team did an excellent job preparing for this launch literally over the last year in great detail. And I'd evidence that by the comments that we made where we had approval on a Friday, we were shipping that Friday, and our first case was done on Saturday. And I think that the knowledge base of physicians in the United States and anticipation of the technology was significant. And I think that our team has done an excellent job helping to continue educate physicians since the October launch. We have 2 thresholds for payment reimbursement changes potentially in the second quarter and fourth quarter, one for inpatient and one for outpatient. All of our submissions are in the CMS at this point in time. And we'll see what develops there. We have no reason to believe that they're not looking at this very favorably at this point in time. In terms of market size, the -- we had already said that the European market was about $80 million. That's not changed substantially. And we could all take a -- have a pull on what the United States will end up at, at the end of 2015. We're certainly working hard to make it as large as we possibly can. But I think that will be a wildcard, and we'll see how the whole market develops now that a competitor is approved as well."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then on stents, are those being affected, just generally?",10,"And then on stents, are those being affected, just generally?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","In the early reviews that we've done, we have not seen that at this point in time, although I would imagine that downstream, the total stent market may be affected slightly. But we have not seen anything at this point in time. But I think the good news is",80,"In the early reviews that we've done, we have not seen that at this point in time, although I would imagine that downstream, the total stent market may be affected slightly. But we have not seen anything at this point in time. But I think the good news is that our market basket, so to speak, products offered into the vascular surgeons, interventional cardiologists, obviously, went up substantially. So our presence went up substantially and we staffed it accordingly."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","And next, we'll go to the line of David Lewis with Morgan Stanley.",13,"And next, we'll go to the line of David Lewis with Morgan Stanley."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a couple of quick questions. First for Chris. Chris, there's a pathway within guidance at least in our view to get sort of the mid-25s in terms of operating margin in hitting your specific targets. But if I think about just putting that in context ov",107,"Just a couple of quick questions. First for Chris. Chris, there's a pathway within guidance at least in our view to get sort of the mid-25s in terms of operating margin in hitting your specific targets. But if I think about just putting that in context over the last several years, that sort of puts you halfway between sort of your peak margins before the reinvestment and then the trough margins around 22, obviously, during the reinvestment. You're sort of halfway through the trough and the peak. Can you give us a sense of the amount of time it will take to get back to that peak?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think what we've essentially committed to with the guidance today is 50 to 100 basis points of operating margin improvement in 2015. And that's with this unfortunate currency headwind that's nicking GPs by 50 basis points. And so when you think abo",203,"Yes. I think what we've essentially committed to with the guidance today is 50 to 100 basis points of operating margin improvement in 2015. And that's with this unfortunate currency headwind that's nicking GPs by 50 basis points. And so when you think about the dilution associated with the portfolio moves we made in 2015, which cost us about 200 basis points, I think we're well on our way to getting back to those mid-27% level. And the objective, as we look at the model, is to drive 50 to 100 basis points of operating margin improvement annually. So we're making a nice downpayment on returning to those levels in '15. That will be the objective again in '16 and the objective for several years. So we feel good about the trajectory. Again, the portfolio moves that just lowered the jumping off point, we believe, were absolutely the right things to do for the company. And again, if you adjust for those, we'd actually be -- and without the currency headwind, we'd be right in spitting distance of those margins in '15. So we feel good about that. A lot of work to get those improvements year after year. But that's the commitment."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, very helpful. And maybe just a quick detail question on the product side for John. John, there's a lot of strength in PICCs this quarter. We've seen actually several quarters this year where PICC strength was significant. This particular quarter, ul",62,"Okay, very helpful. And maybe just a quick detail question on the product side for John. John, there's a lot of strength in PICCs this quarter. We've seen actually several quarters this year where PICC strength was significant. This particular quarter, ultrasound was a little weak. Was there anything specific there that we should be thinking about as we head into 2015?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I wouldn't say ultrasound was weak this quarter. We had a pretty good solid quarter in ultrasound. And that varies from time to time based on product launches and things like that. But I would say that the reality is we had a very strong quarter across th",78,"I wouldn't say ultrasound was weak this quarter. We had a pretty good solid quarter in ultrasound. And that varies from time to time based on product launches and things like that. But I would say that the reality is we had a very strong quarter across the board. Every product line showed significant strength on Oncology around the world. And in the United States, we're delighted with the performance we had in Oncology in the quarter."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. And we've got a pretty good pipeline going into 2015 with our Site-Rite 8 [ph] planned for launch around mid-year. That was another addition into that pipeline.",28,"Yes. And we've got a pretty good pipeline going into 2015 with our Site-Rite 8 [ph] planned for launch around mid-year. That was another addition into that pipeline."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Can I just stick one more in? Actually maybe for Tim or for John. I guess, what's really interesting is in the period where Bard was decelerating, there was this commentary that utilization was one of the factors. And what's really fascinating is on",144,"Okay. Can I just stick one more in? Actually maybe for Tim or for John. I guess, what's really interesting is in the period where Bard was decelerating, there was this commentary that utilization was one of the factors. And what's really fascinating is on the acceleration, your underlying growth this quarter was 4.5%, puts you well above peers' underlying growth rate. And you're not doing it with contribution from Foley and some of those key utilization-sensitive markets. So it looks like, frankly, it's just good old-fashioned Bard and it's not market driven. So market, obviously, is upside. So Tim, as you sort of think about the underlying business performance, where do you think the 2 or 3 areas that you feel most confident in the last 2 years have driven that underlying performance given it doesn't appear to come from market at all?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, as we said, if you want to grow faster, you've got to invest in faster-growing segments, and that's frankly what we've been doing. Clearly, the underlying market growth rates in the emerging markets are faster than the total average, probably c",139,"Yes. Well, as we said, if you want to grow faster, you've got to invest in faster-growing segments, and that's frankly what we've been doing. Clearly, the underlying market growth rates in the emerging markets are faster than the total average, probably closer to a double-digit kind of growth rate, underlying market growth rates. The acquisitions that we've made over the last several years were all thought of as platforms here for us to invest in because those were in faster-growing segments. And then the R&D investments that we've made across the board have also been in faster-growing segments. So as we execute and those things start to pay off and come to fruition, the plan called for the growth rates to be higher and that's what you're seeing. So it's really not any more complex than that, frankly."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Kristen Stewart with Deutsche Bank.",10,"We have a question from Kristen Stewart with Deutsche Bank."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I'm sorry if I missed this, but did you give a growth rate for Lutonix outside the United States? And are you still seeing good growth on the heels of all the data from a market perspective?",38,"I'm sorry if I missed this, but did you give a growth rate for Lutonix outside the United States? And are you still seeing good growth on the heels of all the data from a market perspective?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we did, we saw excellent growth outside of the United States.",12,"Yes, we did, we saw excellent growth outside of the United States."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Any way to quantify?",4,"Any way to quantify?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Other than excellent?",3,"Other than excellent?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes.",1,"Yes."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we were delighted where we were at the end of the quarter both in the United States and outside of the United States. And we continue to take share.",31,"I think we were delighted where we were at the end of the quarter both in the United States and outside of the United States. And we continue to take share."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Right. I think that was the point. We continue to take share every quarter x U.S.",16,"Right. I think that was the point. We continue to take share every quarter x U.S."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then I guess bigger picture, I guess, Tim. I guess how are you thinking just about M&A in terms of the size of the company? Or would you be willing to step out and do something a little bit larger?",41,"And then I guess bigger picture, I guess, Tim. I guess how are you thinking just about M&A in terms of the size of the company? Or would you be willing to step out and do something a little bit larger?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Nothing has changed in terms of our perspective on that. As we've said, we've never shied away from doing a big deal. But we haven't seen one that's been so compelling that hits all the filters that we have set forth for all of our acquisitions. Fran",159,"Yes. Nothing has changed in terms of our perspective on that. As we've said, we've never shied away from doing a big deal. But we haven't seen one that's been so compelling that hits all the filters that we have set forth for all of our acquisitions. Frankly, size isn't something we even start with. That probably comes into play in the third and fourth round of question. So we start strategically. We look at it as a platform and is the growth sustainable and is it a market leadership or does it help the market leadership positions that in the current portfolio. And we answered all of those first. So would we be willing to do it? Sure. But it would have to be so compelling that we were convinced that it was the right thing to do for the long-term growth of the company. And frankly, we don't even think about size when we look at deals."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then for Chris, just in terms of the gross margin guidance that you provided, mix favorable by 20 to 40 basis points. We thought that would have been maybe a little bit better just with Lutonix coming in this year and also strong growth across the Bio",78,"And then for Chris, just in terms of the gross margin guidance that you provided, mix favorable by 20 to 40 basis points. We thought that would have been maybe a little bit better just with Lutonix coming in this year and also strong growth across the BioSurgery services, which I thought was a little bit higher as well. Can you maybe just speak to us what are the, I guess, puts and takes from a mix perspective?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think there are other areas that are going to be -- continue to be important contributors but are not are lower margin. And I think we're working on improving the margins from the Rochester portfolio. That's going to take some time. We're not there",147,"Yes. I think there are other areas that are going to be -- continue to be important contributors but are not are lower margin. And I think we're working on improving the margins from the Rochester portfolio. That's going to take some time. We're not there yet. That's still another a year to 2 out. Those products are growing nicely. And so that's actually something that's hurting us in this intervening period. And again, hopefully, as we get out 12 or 24 months from now, that will be a contributor. But I think 20 to 40 is a very nice number. And if that -- as we construct the portfolio, we think it's something that's sustainable. We actually feel pretty good about that. Certainly, we'd like to see the number higher. But as we look at 2015 and the puts and takes, that's how we see it."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just to go back to Lutonix, that number that you quoted or the contribution, was there any stacking or are you on a consignment basis?",26,"And just to go back to Lutonix, that number that you quoted or the contribution, was there any stacking or are you on a consignment basis?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","We're -- I mean, there are certainly some initial stocking orders. We've also, though, seen very significant levels of reorder as well, which we're tracking closely. So it's impossible to say perfectly. But there's a healthy portion of customers that have",83,"We're -- I mean, there are certainly some initial stocking orders. We've also, though, seen very significant levels of reorder as well, which we're tracking closely. So it's impossible to say perfectly. But there's a healthy portion of customers that have reordered more than once already. And that's why -- listen, it's going to take a little bit of time for this to settle out. But to John's point, we feel great about the launch and certainly great about the initial demand."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of David Roman, Goldman Sachs.",11,"Next, we'll go to the line of David Roman, Goldman Sachs."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just start with the emerging markets, which clearly has been a very successful relatively fast return for you guys. Could you maybe just talk through kind of where you are in the -- just in the evolution of that strategy and ultimately where y",60,"I wanted to just start with the emerging markets, which clearly has been a very successful relatively fast return for you guys. Could you maybe just talk through kind of where you are in the -- just in the evolution of that strategy and ultimately where you can foresee that business going in terms of mix in the overall company?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. David, the -- as Tim said earlier, we are -- we've invested ahead of the growth potential within those markets. We're delighted with how well we've done in China since we embarked down this journey. We think we have an awful lot of runway yet ahead",178,"Sure. David, the -- as Tim said earlier, we are -- we've invested ahead of the growth potential within those markets. We're delighted with how well we've done in China since we embarked down this journey. We think we have an awful lot of runway yet ahead of this in China in many different product lines, especially new products that we have not yet launched in that specific geography. Emerging markets in -- within Europe, we're delighted with our uptick there across both Europe and Russia. And I'd say that we are anticipating the investments that we've made in Latin America yet to generate the results that we're expecting. So I think that '15 and '16 will be a particularly important year for us in the Latin American marketplace. We like the traction that we're getting around the world in the other markets that we've invested in. And I think that you'll continue to see this be a significant contributor to Bard's growth in the years to come. We don't have an upward limit in terms of this."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's helpful. And then in one of the prior questions, you alluded to Lutonix having the potential to give you a better foothold with the interventional cardiologists and potentially the vascular surgeon. To what extent over time can that become a",71,"Okay, that's helpful. And then in one of the prior questions, you alluded to Lutonix having the potential to give you a better foothold with the interventional cardiologists and potentially the vascular surgeon. To what extent over time can that become a potential leverage point? And do you have sufficient products in your bag really to use that call point potentially more efficiently? And how much of a focus is that?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","It's certainly an opportunity for us to use that call point more efficiency -- efficiently, I think, especially as we become a bigger part of the operating suites with DCB and the other products that can be utilized within this suite. I'd say that if you",154,"It's certainly an opportunity for us to use that call point more efficiency -- efficiently, I think, especially as we become a bigger part of the operating suites with DCB and the other products that can be utilized within this suite. I'd say that if you look at it long term, though, that's only one aspect of our DCB strategy. You see the other indications that John talked about. I mean, it gives us a runway of new platforms for the next 5 years or so that we think will be very significant, and we'll have an opportunity to build large markets over the years. Below the knee is an obvious example as are the other indications that John talked about. So I'd say this is as much about being a larger part of the operating suites as well as being able to take this significant technology and move it to other indications."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Dave Turkaly, JMP Securities.",11,"Next, we'll go to the line of Dave Turkaly, JMP Securities."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim, just quickly, just a follow-up, I guess, maybe to wrap up this M&A lines. Your competitor mentioned that they thought the market was getting a little more competitive or it's harder to find things. Would you agree with that? Are you finding -- are yo",61,"Tim, just quickly, just a follow-up, I guess, maybe to wrap up this M&A lines. Your competitor mentioned that they thought the market was getting a little more competitive or it's harder to find things. Would you agree with that? Are you finding -- are you being presented with still interesting technologies? Or is the overall M&A environment more competitive today?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We're finding things. In fact, I just recently internally looked at a kind of scattergram of technologies and companies we look at. And it's as full as I've ever seen. So we're pleased with that. I think you worry a little bit down the road about the",150,"Yes. We're finding things. In fact, I just recently internally looked at a kind of scattergram of technologies and companies we look at. And it's as full as I've ever seen. So we're pleased with that. I think you worry a little bit down the road about the way venture capital money has shifted over the last several years within the sector. We haven't bumped into any troughs in the market flow because of that yet. But who knows down the road whether that happens. So -- and the other part of that is we're more actively -- as these emerging markets and other geographies grow, our expectation is there may be more opportunities in those sectors to look there. So we put more resource into that as well. So now we weren't pleased with our execution in 2014, but it wasn't because of a slowdown in the deal flow."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And would you say that it also was not because of evaluations or your evaluation sensitivity?",16,"And would you say that it also was not because of evaluations or your evaluation sensitivity?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think so. I mean, there are some things that, frankly, like everything else in life, when you go to buy something, it's a negotiation. You can look at somebody and say, ""You're crazy,"" and we're not saying that. And that happens but that's not new",102,"I don't think so. I mean, there are some things that, frankly, like everything else in life, when you go to buy something, it's a negotiation. You can look at somebody and say, ""You're crazy,"" and we're not saying that. And that happens but that's not new. That happened 5 years ago and 3 years ago, and that's the way like this, right? So I don't think we -- we certainly haven't changed our evaluation profile that we look at nor we do see any reason to do that. So that doesn't concern me at all relative to deal flow either."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to Matthew Taylor, Barclays.",7,"Next, we'll go to Matthew Taylor, Barclays."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to ask one about, I guess, your philosophy behind the Gore guidance because if we take your top line guidance, you're obviously forecasting some kind of decline. Is it just general uncertainty? Or is there something that you're expecting tha",48,"I just wanted to ask one about, I guess, your philosophy behind the Gore guidance because if we take your top line guidance, you're obviously forecasting some kind of decline. Is it just general uncertainty? Or is there something that you're expecting that will cause it to decline?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I think, Matt, it's just trying to be prudent about the range of scenarios that could happen. Again, we don't think there's a level of upside that again moves the guidance, which is why it's still at 5% rounded on the high end. It certainly could cont",192,"No, I think, Matt, it's just trying to be prudent about the range of scenarios that could happen. Again, we don't think there's a level of upside that again moves the guidance, which is why it's still at 5% rounded on the high end. It certainly could continue at the current level, or as we've always said, it could decline. It's absolutely out of our control. And as we have said and we'll repeat again now, we don't have any information that leads us to believe that it will decline. But we wait, and on a quarterly basis, understand what sales were and what the royalties were. So we're trying to be prudent and make commitments to you guys that we can deliver on within a range of scenarios. And certainly, as we think about potential upside, we're giving you bottom line commitments that we're committed to delivering. We'd certainly like the ability to reinvest any upside back into the business while still delivering bottom line commitments. So we're trying to take in what we think are the likely scenarios and then make commitments that we're going to hit within those scenarios."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And it's kind of a probability weighted forecast for you in terms of what could happen?",17,"And it's kind of a probability weighted forecast for you in terms of what could happen?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, that's a good way to think about it.",9,"Yes, that's a good way to think about it."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Operator, we are well past an hour now. We're going to take 3 more, and we apologize to the rest of the people in queue. But obviously, you can call us and we can catch up after. But we'll take 3 more here on the call, operator.",47,"Operator, we are well past an hour now. We're going to take 3 more, and we apologize to the rest of the people in queue. But obviously, you can call us and we can catch up after. But we'll take 3 more here on the call, operator."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Joanne Wuensch, BMO Capital.",4,"Joanne Wuensch, BMO Capital."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I think a lot of us are focused on what are you going to buy next. But can we shift the topic a little bit to what you might divest next? How do you...",34,"I think a lot of us are focused on what are you going to buy next. But can we shift the topic a little bit to what you might divest next? How do you..."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So yes, let me deal with that. So it's always easier to divest a business than it is to divest product lines. With 14,000 plus SKUs at any point in time, we've got a number -- a large number of SKUs that are actually declining that, frankly, if we h",152,"Sure. So yes, let me deal with that. So it's always easier to divest a business than it is to divest product lines. With 14,000 plus SKUs at any point in time, we've got a number -- a large number of SKUs that are actually declining that, frankly, if we had our druthers we'd get rid of or sell or whatever. They are needed in the marketplace by patients and clinicians, which is why we continue to manufacture those and provide those. But there are also time distraction to do that kind of thing. So we'd rather have our management's efforts and the workforce focus on growth as opposed to divesting singular product lines. And there's really not a business as such that we have in total outside of what we did with electric physiology that would be nicely packaged for divestitures. So no current plans at the moment for anything there."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And then the other thing which I've always liked about your catheter business is that it sort of becomes the precursor of volume trends. And yet you're not really saying that you're seeing the pickup in volumes. Do you have an idea why you",61,"That's helpful. And then the other thing which I've always liked about your catheter business is that it sort of becomes the precursor of volume trends. And yet you're not really saying that you're seeing the pickup in volumes. Do you have an idea why you're not experiencing it while others are sort of starting to talk about it already?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, when you look at the catheter business, I think it's an interesting aspect of it. One is that hospitals have tried to reduce catheterization because of their need to reduce urinary tract infections or hospital-acquired infections. That's one aspect",96,"Well, when you look at the catheter business, I think it's an interesting aspect of it. One is that hospitals have tried to reduce catheterization because of their need to reduce urinary tract infections or hospital-acquired infections. That's one aspect of it. The other aspect is oftentimes on outpatient surgery, a patient will not be catheterized also. So you'll see the trend being very, very close on inpatient surgeries, but it won't capture demand from outpatient surgeries. I think that's -- there's a couple of the aspects of Foley catheterization that are nuanced in this case."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I appreciate that clarification. But do you have an idea why you're not starting to see that kind of pickup that others are talking about?",25,"I appreciate that clarification. But do you have an idea why you're not starting to see that kind of pickup that others are talking about?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think we're seeing an inpatient surgery. We don't see inpatient surgeries increasing.",15,"I don't think we're seeing an inpatient surgery. We don't see inpatient surgeries increasing."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to Richard Newitter, Leerink.",7,"Next, we'll go to Richard Newitter, Leerink."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Ravi Misra in for Rich Newitter. I have 2 on Lutonix. One, maybe regarding the other indications that you're exploring. I was wondering if you were willing to put any aspirational time line on some of those approvals? And then two, I think last fa",73,"This is Ravi Misra in for Rich Newitter. I have 2 on Lutonix. One, maybe regarding the other indications that you're exploring. I was wondering if you were willing to put any aspirational time line on some of those approvals? And then two, I think last fall, we were discussing on these calls the publication that you guys were searching to put the Lutonix data in. An update on that would be appreciated."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So let me just jump on the approvals side. We've talked about starting the AV access study. So enrollment that's going to be -- we started mid this year, which is the plan. We expect that to enroll relatively quickly. But with the timing of that, th",266,"Sure. So let me just jump on the approvals side. We've talked about starting the AV access study. So enrollment that's going to be -- we started mid this year, which is the plan. We expect that to enroll relatively quickly. But with the timing of that, that's probably sort of 2018 time frame for AV. Now below the knee, enrollment has been a little bit slower. We had hoped for a sort of 2017 approval. We think that's still possible probably later in the year just based on the way that enrollment is going right now. And the in-stent restenosis indication, there's another one that we -- I want to hold back a little bit on that. We talked a little bit about a 2017 -- late 2017 kind of time frame in the past. But we're trying to see where we can get information and more data that could give us other opportunities. So I don't want to commit to anything at this point. But certainly, there are ways out for U.S. indications. Now as far as the publication goes, I can tell you that no one is more frustrated at the timing than I am. But this is clearly something that's not within our control. As we understand it, the author's investigators have the manuscript under review with the journal. It's not within our control as much as I'd like it to be. And we continue to believe that it's important to get it published. So as soon as we know something and we have an opportunity to let you know, we will."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","The last question will come from Mike Matson, Needham & Company.",11,"The last question will come from Mike Matson, Needham & Company."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just wondering, with the Lutonix product, obviously, you had good sales. But is reimbursement an issue at all? And with regard to the add-on payment, I mean, I think that's for inpatient. So how many of these are being done inpatient versus outpatient? Is",65,"Just wondering, with the Lutonix product, obviously, you had good sales. But is reimbursement an issue at all? And with regard to the add-on payment, I mean, I think that's for inpatient. So how many of these are being done inpatient versus outpatient? Is there any potential to get some type of pass-through or something for the outpatient setting that would increase reimbursement as well?"
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me just jump in on reimbursement. First off, I think we're trying to track inpatient versus outpatient use. We don't have great visibility to that, frankly. But we believe that this is primarily outpatient use, which is typical for SFA popliteal ki",287,"So let me just jump in on reimbursement. First off, I think we're trying to track inpatient versus outpatient use. We don't have great visibility to that, frankly. But we believe that this is primarily outpatient use, which is typical for SFA popliteal kind of procedures. So we think that's probably sort of in the 60% range or so. On reimbursement, we think it is an issue. There are certainly certain value-conscious buyers that would be holding off until they hear more about reimbursement. Obviously, we're getting pickup in spite of that at this stage. But there are, as John mentioned earlier, 2 paths for reimbursement. And there's the outpatient reimbursement piece, which CMS, there's really no official time line. They can work within whatever they want. We think an April time frame is reasonable. Again, CMS is not obligated to work within that time frame. But typically, sort of a couple of cycles of review is common. And we're in that time period from when we submitted our documentation to CMS last fall. Now as far as the inpatient piece goes, I just saw today, actually, on the CMS website the agenda for a meeting next week, a town hall meeting where drug-coated balloons will be reviewed. And I think that's the last step, as my understanding, at least, the last public step in the review process for the inpatient piece. But remember, inpatient only receives the approval or changes one time a year, which is typically the October time frame. So John alluded to the Q4 inpatient time period, which is what we think would be sort of the reasonable customary time frame. But again, CMS is not obligated to work within any of that."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just in your surgical business, can give us an update on the natural tissue products? It seems like the market sort of had moved away from those and I guess where your antibiotic coated product would fit in.",40,"And then just in your surgical business, can give us an update on the natural tissue products? It seems like the market sort of had moved away from those and I guess where your antibiotic coated product would fit in."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that the entire market is under some significant pressure, I mean, primarily based around price. The ASPs of some of those grafts are very, very substantial. And I think that hospitals and clinicians are being very prudent about the use of n",128,"Sure. I think that the entire market is under some significant pressure, I mean, primarily based around price. The ASPs of some of those grafts are very, very substantial. And I think that hospitals and clinicians are being very prudent about the use of natural tissue products and really trying to focus those only when they're absolutely necessary. The product that we recently launched, Xen AB, is the first of its kind. It's the first product or graft that is antibiotic coated. We think that has significant opportunity to be utilized in those indications where patients may be compromised. We -- the excitement in the marketplace is substantial. Our launch was significant. And we're delighted as well as where we are in that initial launch in late December."
254131,281166647,752054,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. Moderator, thank you very much for all of your assistance. Let me also thank everybody for joining us today. And I'd like to also take this opportunity to thank Bard employees around the world for a very solid year of execution. Looking forward to a",69,"Okay. Moderator, thank you very much for all of your assistance. Let me also thank everybody for joining us today. And I'd like to also take this opportunity to thank Bard employees around the world for a very solid year of execution. Looking forward to an even better one this year. And I also them for their dedication and commitment. And we'll talk to you after the first quarter."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the CR Bard Inc. Fourth Quarter 2014 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference will be recorded -- is being recorded and will be available for f",382,"Ladies and gentlemen, thank you for standing by, and welcome to the CR Bard Inc. Fourth Quarter 2014 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference will be recorded -- is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as anticipate, estimate, expect, project, intend, forecast, plan, believe and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters and outcome of contingencies such as legal proceedings. The uncertainty of loss reserve estimates, share repurchases, acquisitions and other economic business competitive and regulatory factors. Please refer to the cautionary statement regarding forward-looking information in Bard's September 30, 2014 10-Q and the information under the caption Risk Factors in the company's 2013 10-Q, including disclosure of the factors that could cause actual results to differ materially from those expected or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of January 29, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to prior -- are to the prior year period. At this time, I will turn the conference over to Mr. Timothy Ring. Please go ahead."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. That's a lot of work there, I appreciate it. I'd like to welcome, everybody, to Bard's Fourth Quarter 2014 Earnings Call, and thank all of you for taking the time to join us today. I would expect the presentation portion of the call to last abo",1062,"Thank you. That's a lot of work there, I appreciate it. I'd like to welcome, everybody, to Bard's Fourth Quarter 2014 Earnings Call, and thank all of you for taking the time to join us today. I would expect the presentation portion of the call to last about 35 minutes or so.
The agenda today will go as follows. I'll begin with an overview of the results for the fourth quarter. John Weiland, our President and COO, will review fourth quarter product line revenue. John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline. And then Chris Holland, our Senior VP and CFO, will review the fourth quarter income statement balance sheet and also provide our financial guidance for 2015. And then finally, we'll wrap it up with Q&A. 
Fourth quarter 2014 net sales totaled $867.2 million, that's up 10% over Q4 last year on an as-reported basis and up 11% on a constant currency basis. The currency impact for the quarter versus the same quarter of 2013 was unfavorable by about 140 basis points.
The Gore royalty revenue in the quarter was approximately $38.6 million. The impact of the divestiture of our EP business, which occurred in Q4 2013, net of the impact of the Rochester Medical acquisition in the same quarter, was unfavorable by about 20 basis points to growth for the quarter. That all puts our organic growth rate for Q4 2014 at approximately 6.3%, with a little over 200 basis points from the early approval and launch of the Lutonix drug-coated PTA balloon in the U.S.
Net sales for the full year 2014 were $3.3 billion, that's up 9% as reported and on a constant currency basis, which exceeded our original guidance for the year. Net income for the fourth quarter was $134.2 million and diluted earnings per share were $1.72. I'll remind you that we recognized the onetime gain from the Gore litigation in the prior year quarter. Excluding this and other items that affected the comparability results between periods, which Chris will cover later, fourth quarter 2014 net income and diluted cash earnings per share, which excludes amortization of intangibles, were $158.9 million and $2.29, that's up 39% and 40%, respectively.
Full year 2014 net income was $294.5 million and diluted EPS were $3.76. Excluding items again that affect comparability between periods, full year 2014 net income was $586 million and diluted cash EPS were $8.40, and that's up 23% and 29%, respectively, from 2013. Again, well in excess of our original guidance for the year.
Looking at fourth quarter revenue growth geographically compared to the prior year, on a constant currency basis, net sales in the U.S. grew 14%. Internationally, we grew 5%, with Europe up 3%; Japan up 2% and our other international geographies up 8%. Excluding the Gore royalty and the EP divestiture impact, net sales in the U.S. grew 7% and total international sales were up 10%, with Europe up 10%; Japan up 3%; and the remaining geographies up 11%.
As anticipated in our strategic investment plan, our emerging market sales continued to increase and represented about 9% of our total revenue in Q4. Looking back on 2014, we're pleased with the progress that we've made throughout the year. 2 years ago, to remind you, we introduced our 3-year strategic investment plan and then that same quarter, our organic growth rate was flat. We finished 2014 with our organic growth rate of our other portfolio in the mid single digits, which is what we had projected. It's difficult to know precisely what's happening in real time in the underlying markets, but we believe the market organic growth continues to be in the low single digits. While many in our sector had stronger growth in Q3 than expected, some of those same companies then saw sequential deceleration of growth in Q4. In contrast, we continue to see sequential improvement on organic growth rate. And we believe the implementation and execution of our strategic investment planning contributed to this acceleration.
As we look to 2015, we expect the full year organic growth rate to again improve over the full year 2014. And to be clear, that assumes no benefit from any underlying market improvement. If the market improves as some are suggesting, then we should do even better than that.
2015 is an important year of execution, once again, for us. We expect our investments in emerging markets to continue to shift the mix of the portfolio of faster growing geographies. The key to this initiative is improved productivity from the teams that we've built and additional product registrations in these markets.
In 2015, we also anticipate we'll begin to see some returns from our R&D investments. Over the past couple of years, we've significantly increased the level of R&D as we pursued expanded indications of current product platforms and introductions of new technologies. We remain in investment mode. The long-term objective is to drive above market revenue growth with a lower risk profile on a sustainable basis. There obviously remains significant uncertainty in the market, including unsettled issues in Washington. FX headwinds at this magnitude, frankly, are as difficult and come up as quick as we've seen in years. The market acceptance, reimbursement decisions, competitive response around drug-coated balloons in the U.S. could have meaningful impact on our results. And we have no way of knowing whether Gore royalty will increase, decrease or be consistent compared to 2014 levels.
However, amidst these uncertainties, we remain focused on the execution of our strategic plan and the things we can control. We believe our investments will improve the organic engine of the company in both revenue and profitability. And as we said, we measure success over the long term. If 2015 brings some tailwinds to the market as some suggest, we would look for opportunities to invest any short-term out-performance back into the business for longer-term benefit.
Chris will give you more details when he lays out our financial guidance. We continue to believe that the effective execution of our strategic investment plan will allow us to continue to increase shareholder value over the long term and on a sustainable basis.
With that as an introduction, let me turn you over to John Weiland for a review of our fourth quarter product line revenue."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, as usual, I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's start with Vascular. Total net sales in this category for",802,"Good afternoon, everyone. Before I start, as usual, I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's start with Vascular. Total net sales in this category for the quarter were $244.6 million, an increase of 19% on an as-reported basis and 22% on a constant currency basis when compared to the fourth quarter of 2013. Excluding the Gore royalty and the impact of the EP divestiture, global Vascular sales were up 9%, with the United States business up 14% for the quarter and international up 3%. Sales in our Vascular graft category were down 6% in Q4.
Excluding the Gore royalty, our Endovascular business grew 11% in the fourth quarter. Within Endovascular, our biopsy line was up 1%.
Our peripheral PTA products were up 49% this quarter, driven by the early FDA approval of the Lutonix drug-coated balloon in the United States on October 10. We're extremely pleased with how our Vascular sales, development and operations team executed the early launch of this first-of-a-kind product in the United States. As you know, we were shipping product to customers on the day of approval with the first cases being performed the following day.
The early market acceptance has been impressive and we look forward to expanded adoption of this technology longer term as the market continues to develop.
Our Stent business was down 10% in Q4, which is within the range of recent experience. As we've said, pricing headwinds continue to drive down ASPs in this category.
And to complete the category, sales in our vena cava filter line were flat in the fourth quarter.
Now let's move to Urology. Total net sales were $217.8 million, which is up 8% versus the Q4 of last year on an as-reported basis, and 9% on a constant currency basis. About 600 points of this global growth was related to the Rochester acquisition, which anniversary-ed in the quarter. The United States business was up 6%, while internationally, we grew 14%.
The Targeted Temperature Management products saw strong double-digit growth this quarter, and we remain optimistic about the long-term growth prospects of this technology platform.
Our vesic [ph] drainage business was up 7% in Q4, with about 400 points of that growth coming from the acquired Rochester Medical products. 
I.C. Foleys were down 2% globally, with the United States down 4%. These results in vesic [ph] drainage are fairly consistent with recent quarters. While some surveys and reports have suggested improvement in United States hospital volumes, we haven't seen any underlying improvement reflected here so far.
Our continence business grew 24% over the prior year quarter. Excluding the impact of the acquired products, our legacy continence products were down 6% for the quarter, within the range of recent experience.
Sales in urological specialties were up 11% with emerging markets growing close to 40% organically in this category. Our brachytherapy products were down 3% globally for the quarter.
And finally, sales from our StatLock catheter stabilization line decreased 3% in the fourth quarter.
Now let's turn to Oncology. Total net sales in this category were $237.5 million, an increase of 8% over the fourth quarter last year on an as reported basis and 9% on a constant currency basis. Net sales in the United States were up 7%, while outside the United States sales were up 15%.
Our port line was up 5% versus the fourth quarter of last year with significant growth coming from emerging markets.
PICC revenue growth was 11% in Q4, but strong performance again in the United States and internationally. Our vascular access ultrasound product line was up 8% this quarter. And our dialysis catheter business was up 11% in the fourth quarter.
And we'll finish with Surgical Specialties. Net sales in this category were $145.0 million in the fourth quarter, up 3% on an as-reported basis and 4% on a constant currency basis. United States sales increased 4%, while international sales were up 6%. As you know, we anniversary-ed the 2013 acquisition of Medafor on the first day of the fourth quarter. Our biosurgical product portfolio grew double digits organically in the quarter, and we're excited about the long-term potential here.
Sales from our biosurgical products already exceed the combined sales of our fixation products and our natural tissue products.
Our soft tissue repair business grew 5% overall in the fourth quarter. Our total synthetic hernia products were up double digits again this quarter, while our natural tissue products declined 15%.
Closing out the surgical category, our fixation business was down 3% in the fourth quarter and our performance irrigation business was down 14% versus an above average quarter 1 year ago.
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John. Good evening, everyone. 2014 was a pretty busy year at Bard. We launched over 40 new products and our pipeline of launches in 2015 is also robust.Starting with drug-coated balloons. We're making good progress on additional sizes and indica",923,"Thanks, John. Good evening, everyone. 2014 was a pretty busy year at Bard. We launched over 40 new products and our pipeline of launches in 2015 is also robust.
Starting with drug-coated balloons. We're making good progress on additional sizes and indications worldwide. We're in the follow-up phase of our Levant 2 Japan study and we expect to submit late this year for Japan approval. Enrollment continues in our Below the Knee IDE and in-stent restenosis studies and we are making good progress in our AV access IDE study with enrollment anticipated to start mid-2015.
We're also expanding the clinical science of DCBs through our robust real world clinical experience. For example, at LINC this week, Dr. Markus Stein presented a first look at interim 1 year results from the Lutonix global SFA and popliteal registry of almost 700 patients. Lesion lengths were over 100 millimeters and treated lengths were almost 200 millimeters, while roughly 30% of lesions were located in the popliteal artery. Primary patency was 81.7% and 88.5% of patients were free from a re-intervention at 1 year.
Though randomized study designs are quite different, making comparison of results very difficult across different studies. Registries provide a more balanced comparison across technologies, and we believe these results compare well to any of the competitive DCBs.
Also in Vascular, we launched the LifeStream Balloon Expandable Covered Stent in Europe in Q4 and enrollment is going well in the IDE study to support an iliac artery disease indication in the U.S.
Finally in Vascular, we're responding to some FDA questions and anticipate U.S. launch in Q1 of the first in a series of new Tru-Flo PTA Catheters for use in valvuloplasty procedures. Tru-Flo has a unique flow-through design to allow blood to pass through a large channel in the center of the balloon, promoting prolonged inflation while potentially reducing the need for rapid pacing or other hemodynamic maneuvers used to reduce cardiac output during the time the balloon has expanded.
Next, moving to Urology. We've just begun the rollout of our new skyline sub 2 French stone basket family. This new product in our endourology line provides the urologists with one of the smallest baskets in the industry, yet provides high strength and maneuverability, along with a highly visible atraumatic tip to aid in safe and accurate use.
In our Targeted Temperature Management portfolio, we've just launched our new PAD systems for use with neonates and pediatric patients in the U.S. And we're rolling out a new software update to support enhanced functionality and additional languages.
Moving to Oncology. We're anticipating U.S. regulatory clearance and launch about midyear of our freehand stereotactic system for Vascular Access named Pinpoint GT. The technology will initially be offered on a new Site-Rite 8 system in a planned simultaneous launch. Pinpoint GT will also be backwards compatible to Site-Rite 6.
In PICCs, we're now tracking towards submission around midyear of our first family of thromboresistant devices. We plan to broaden the offering to our full line of PICCs over the back half of 2015 and into 2016. Similarly, we anticipate submitting our first antimicrobial PICC in the second half of 2015 and launching upon regulatory clearance. This first product will be followed by a series of launches to support coated PICCs in both our PowerPICC and PowerPICC SOLO configurations.
Turning to midlines. We're making good progress in our next-generation POWERGLIDE family and currently anticipate our U.S. regulatory submission in Q4 with a first half 2016 launch.
I'll close my portion of the discussion today with surgery. We informed you on the last call that we just received U.S. regulatory clearance of the first antibiotic-coated biologic mesh, XenMatrix AB, and I'm pleased to tell you that product was launched in December. XenMatrix AB utilizes our proprietary coding, which is intended to preserve the integrity of the biologic graft in abdominal wall reconstruction procedures and has demonstrated broad spectrum safety and efficacy against several typically-encountered bacteria.
Moving to our BioSurgery product family. In early Q3, we filed our PMA supplement for our Progel sealant, seeking expanded use in video-assisted and robot-assisted thoracic surgery. We continue to be optimistic about approval and launch in the first half of this year.
Also, we completed a follow-up early this year in our TRIDYNE vascular sealant pivotal IDE study. The team is working toward PMA submission in the first half of the year and we anticipate approval and launch in mid-2016.
And finally, in mesh fixation, we remain on track to launch in the first half of the year, our new spring-loaded resorbable tack device named OPTIFIX. We also anticipate launching another fixation platform later in the year.
As Tim said, we have a very important year of execution ahead of us and we look forward to updating you on our progress throughout the year. As part of our effort for continuous improvement, we initiated a survey of investors last year. And one of the more common suggestions we received was to take a fresh look at the need to hold a formal analyst meeting every year. We've been clear about our growth drivers and the opportunities we're pursuing and our investment strategy has not changed. Because of that, we have determined that a resource and time-intensive effort, like a formal analyst meeting, is just not justified this year. We'll update you on our pipeline and growth drivers throughout the year if circumstances allow in the appropriate forum. Thanks very much for your attention. Now I will hand the discussion over to Chris."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $7.5 million pretax, mostly related to Lutonix milestone accretion and a $10.1 million pretax charge for",1630,"Thank you, John. Let me start by covering the items that affect the comparability of our results between periods. We had acquisition-related items of $7.5 million pretax, mostly related to Lutonix milestone accretion and a $10.1 million pretax charge for restructuring and productivity initiatives. We also booked expense of $12.7 million, related to the judges order in the women's health litigation that we work up 500 cases simultaneously.
And finally, we had a credit of $3.5 million pretax related to the medical device excise tax paid in 2013 after reaching an agreement with the IRS. These items are detailed in the notes to the financial statements and the reconciliation accompanying our Q4 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $547.7 million in Q4 and $547.4 million on an adjusted basis or 63.1% of sales, up 230 basis points from the prior year, with 170 basis points of that improvement related to the Gore royalty and about 120 basis points coming from cost improvements. We also had about 50 basis points of benefit when compared to the higher integration costs and investments in Q4 of 2013.
Some headwinds to GPs in Q4 were new amortization of about 50 basis points, foreign exchange at about 10 basis points and mix of about 20 basis points. Pricing pressure was about 100 basis points of headwind on the revenue line and about 30 basis points in GP in Q4. We continue to expect pricing pressure going forward between 100 and 150 basis points on the revenue line.
For the full year 2014, that brings adjusted gross profit as a percentage of sales to 62.1%, up 110 basis points from 2013, much better than our original guidance of 30 to 60 basis points of improvement.
While the Gore royalty did exceed our expectations, the effect on GP was only 10 to 20 basis points higher than our projections from 1 year ago. The overachievement was primarily driven by more favorable mix than originally expected.
SG&A expenses were $257.5 million for the quarter or 29.7% of sales. On an adjusted basis, SG&A was $261 million even or 30.1% of sales, down 170 basis points from the prior year period, driven by the Gore royalty being in the denominator as well as improving leverage from our emerging markets investments and the integration of our 2013 acquisitions.
For the full year 2014, adjusted SG&A as a percentage of sales was 29.6%, a decrease of 40 basis points from the prior year. R&D expenditures totaled $79.2 million for the fourth quarter or 9.1% of sales. On an adjusted basis, R&D expense was $71.5 million or 8.2% of sales, a decrease of 70 basis points from the prior year period, mostly driven by the Gore royalty now in the denominator.
For the full year 2014 on an adjusted basis, R&D expense was 8% of sales compared to 8.5% in 2013. However, without the Gore royalty and the revenue line, R&D expense would've been 8.4% of sales in 2014.
Interest expense was $11.2 million for the fourth quarter and $44.8 million for the full year. Other income and expense was $25.1 million of expense for the fourth quarter. On an adjusted basis, it was $2.2 million of expense for the quarter and $4.7 million of income for the full year.
The effective tax rate for the quarter was 23.2%. On an adjusted basis, it was 21.1%, taking us to 24.3% for the full year. The quarter was lower than the full year average due to the renewal of the R&D tax credit in December.
At the beginning of the year, we had told you to expect about 100 basis points of improvement in the effective tax rate in 2014 and we came in at 90 basis points of improvement, despite significantly stronger U.S. income than we had anticipated. That all adds up to cash EPS of $2.29 for Q4, excluding items affecting comparability, which brings us in at $8.40 for the full year on the same basis. That's a full $0.10 above the high end of our original guidance for the year and above our updated guidance as well, indicative of the strong performance we saw in 2014.
We purchased about 785,000 shares of the company's stock during the fourth quarter, taking the total buybacks in 2014 to approximately 4.5 million shares at an average price of $146.67. Between buybacks and dividends, we returned approximately $725 million to shareholders over the course of 2014.
The balance sheet as of December 31 reflects cash, restricted cash and short-term investments of $1.01 billion versus $1.04 billion at September 30. For the full year, AR days were down 7.3 days and inventory days were up 0.2 days. Capital expenditures totaled $36.6 million for the quarter and $126.6 million for the year.
On the liability side, total debt was $1.5 billion as of December 31 versus $1.4 billion at September 30. Debt to total capital at the end of the fourth quarter was about 45% and total shareholder investment was $1.8 billion at December 31.
So with a strong 2014 now in the books, let's turn to financial guidance for 2015, excluding the impact of items that affect comparability. For revenue, we project 2015 constant currency organic revenue growth between 4% and 5%. Given the potential variability of the Gore royalty, our overall constant currency revenue guidance is between 3% and 5%. As Tim said, this assumes no fundamental improvement in the market growth rates from where they have been the last couple of years, which we would characterize as low single digits. If the markets improve as some suggest, then we would expect to do better. But with all of the uncertainties surrounding us, we think it's too early to count on any improvement in the underlying markets.
Obviously, foreign exchange rates are a significant headwind for everyone as we head into 2015 and we are certainly not immune to that. We estimate that at current rates, we're looking at a revenue headwind related to currency of about 3%.
As far as constant currency revenue growth in our 4 disease state categories, in 2015, we expect Vascular revenue growth to be between 3% and 7%; Urology to be between 1% and 4%; Oncology to grow between 3% and 6%; and our Surgical Specialties business to grow between 3% and 6% as well. We expect our overall gross margin percent to decline in 2015 by between 30 and 70 basis points compared to 2014. That reflects about 50 basis points of pressure from FX and about 30 basis points of incremental amortization from the U.S. approval of Lutonix in October of 2014.
Pricing pressure continues to be a significant issue for us. And we estimate the impact on 2015 to be between 40 and 60 basis points of headwind to GP. Fortunately, our cost improvement programs are projected to once again contribute about 50 basis points of benefits to GP and we expect mix to be favorable between 20 to 40 basis points.
So organic constant currency gross margins are expected to improve in 2015 as we projected when we first introduced our strategic investment plan 2 years ago. And again, as we said, we expect to see improving operating leverage in 2015. While we continue to increase investment in emerging markets, we expect SG&A as a percentage of sales to decline between 50 and 100 basis points in 2015. And we expect R&D as a percentage of sales to be in the mid-7% range, both excluding items that affect comparability. We expect interest expense in 2015 to be between $45 million and $47 million. We expect the effective tax rate to improve again, this time, between 0 and 50 basis points for the full year and this does assume the renewal of the R&D tax credit for 2015.
All of that adds up to adjusted cash EPS for 2015, excluding items that affect comparability between $8.95 and $9.05 per share. That includes a negative currency impact of about $0.25 based on today's rates. So without this very atypical currency situation, we would have been forecasting at or above our target of 10% EPS growth.
While we evaluated alternatives that could increase earnings for 2015, given the expected FX magnitude and the fact that this is certainly not a Bard-specific issue, we don't think it would be wise for short-term benefit to scale back investments and possibly interrupt the momentum in organic growth that we achieved during 2014.
In the end, we believe maintaining our flexibility and continuing to focus on the longer-term organic growth profile of the company builds better value for our shareholders.
In Q1, we expect constant currency sales growth between 4% and 5% and adjusted cash EPS between $2.04 and $2.08. As for capital expenditures, we expect 2015 to be similar to 2014, between $120 million and $140 million. And we expect operating cash flow to be in the $700 million range again in 2015.
I'd like to conclude my comments by reminding you that the objective of our strategy is to position Bard from a portfolio standpoint to deliver above market revenue growth for years to come. The key measure of success for this transition plan will be the improvement in the organic engine. This plan was never about maximizing EPS in a given year, but the strength in the business for the long-term in a disciplined and thoughtful way. We believe we are doing that. While we expect further improvement in our operating margins in 2015, we intend to remain in investment mode with the desired outcome of positioning the company for long-term success to enhance shareholder value. And with that, I'll turn the call back over to Tim."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. While we're pleased with our performance in 2014, we have a lot of work in front of us to position the company where we want it to be. As many of you have heard me repeat one of my favorite quotes, great strategy is more about great executi",125,"Thanks, Chris. While we're pleased with our performance in 2014, we have a lot of work in front of us to position the company where we want it to be. As many of you have heard me repeat one of my favorite quotes, great strategy is more about great execution than it is about great thinking. 2015 is a very important year of execution for us. We're not taking anything for granted. I'm sure there will be bumps along the way as there always is. We're focused on the long-term health of the business with the intention of increasing shareholder value. That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Larry Keusch with Raymond James.",16,"[Operator Instructions] And our first question comes from the line of Larry Keusch with Raymond James."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess I would just start off, Tim, with asking a little bit. You laid out nicely the expectations for 2015. But I guess I'm thinking past 2015 and really trying to understand what the ultimate game plan is here. Can you talk about, as you look out what",66,"I guess I would just start off, Tim, with asking a little bit. You laid out nicely the expectations for 2015. But I guess I'm thinking past 2015 and really trying to understand what the ultimate game plan is here. Can you talk about, as you look out what you think the appropriate levels of organic growth and perhaps EPS growth would be for the company?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Larry. Obviously, the market's volatile and especially as you grow into more and varied geographies, the underlying market growth rates get even more complex. We, as we stated, don't anticipate any change in the external environment for this year. If",211,"Yes, Larry. Obviously, the market's volatile and especially as you grow into more and varied geographies, the underlying market growth rates get even more complex. We, as we stated, don't anticipate any change in the external environment for this year. If it happens, we'll do better than that. We stated a couple of years ago that our goal was to be 200 to 300 basis points above what the market growth rate was and the competitive aspect of that within the sector. That would still be our goal. We're big believers that sustainable revenue growth drives shareholder value and that's what we're about. So we remain fixated on that as a strategic objective. We do think that there's a lot of leverage for us with the investments we've made in some of the emerging markets. Just to put it in perspective, that represents almost 1/3 of our total sales headcount but as we mentioned, 9% of revenue. So we think there's a lot of room to grow into that. And those markets are growing clearly above what we called out as the market average in total. So to the extent we can accelerate growth in those segments that are growing faster, we should continue the momentum that we demonstrated last year."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. The only thing, I'd add, Larry, as it relates to EPS growth is we're absolutely focused on double-digit EPS growth, 10% EPS growth. And certainly, we believe the model will allow us to deliver that. And without this recent move in the dollar, we woul",117,"Yes. The only thing, I'd add, Larry, as it relates to EPS growth is we're absolutely focused on double-digit EPS growth, 10% EPS growth. And certainly, we believe the model will allow us to deliver that. And without this recent move in the dollar, we would have delivered 10% to 11% EPS growth in 2015. So the growth organically on the top line, we believe over time, will allow us to drive 10% EPS growth. Again, this unprecedented move, which cost us $0.25 now as we turn into '15, has just prevented that from happening this year. But the plan, the strategy and the leveraging on the investments over time should allow us to achieve that objective."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just again on the uses of cash, you guys obviously generate a significant amount of free cash flow. No significant M&A done in 2014. You obviously bought back a bunch of stock associated with the Gore bolus [ph] payment. But can you talk about 2",68,"Okay. And just again on the uses of cash, you guys obviously generate a significant amount of free cash flow. No significant M&A done in 2014. You obviously bought back a bunch of stock associated with the Gore bolus [ph] payment. But can you talk about 2015 perhaps, what your expectations may be for M&A as well as would you be open to deploying cash for share repurchase?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll cover that kind of at a high level and Chris can chime in with detail. Clearly, our use of cash has not changed for, well, 10 years or longer. It's strategic, first. We want to continue to invest in businesses, technologies and platforms to gro",78,"Sure. I'll cover that kind of at a high level and Chris can chime in with detail. Clearly, our use of cash has not changed for, well, 10 years or longer. It's strategic, first. We want to continue to invest in businesses, technologies and platforms to grow the company. And we'll continue to do that, prioritize it that way. Second would be share repurchases. And third would be dividends in that order, and there's no change to that."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So again, Larry, I think obviously, it's very much transaction dependent. And as Tim says, we're looking for the right acquisitions to make for the company every day. I think the free cash flow does allow us to do both in the ordinary course, continu",121,"Yes. So again, Larry, I think obviously, it's very much transaction dependent. And as Tim says, we're looking for the right acquisitions to make for the company every day. I think the free cash flow does allow us to do both in the ordinary course, continue to make acquisitions of a certain size as well as continuing to consistently return cash to shareholders. We'll generate free cash flow in the $500 million to $600 million range that we can deploy in 2015. First priority is strategic. But even in conjunction with that, I think we'll continue to have flexibility to do a bit of both. Again, deal dependent. But in the ordinary course, I would expect a balanced use of cash."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","And our next question comes from the line of Brooks West with Piper Jaffray.",14,"And our next question comes from the line of Brooks West with Piper Jaffray."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple on emerging markets for me. Tim, you mentioned 1/3 of sales headcount in emerging markets versus 9% of revenue. How long will it take for that ratio to normalize? And kind of can you walk us through the levers that's associated with that? That's",68,"A couple on emerging markets for me. Tim, you mentioned 1/3 of sales headcount in emerging markets versus 9% of revenue. How long will it take for that ratio to normalize? And kind of can you walk us through the levers that's associated with that? That's question 1. Question 2 is where you are with the product registrations in emerging markets now versus where you want to be?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, in terms of the comparison of kind of productivity per sales rep across geographies, that's difficult to do for a couple of different reasons. Number one, by design in the emerging markets, we didn't give every country manager the 14,000 SKU p",121,"Sure. Well, in terms of the comparison of kind of productivity per sales rep across geographies, that's difficult to do for a couple of different reasons. Number one, by design in the emerging markets, we didn't give every country manager the 14,000 SKU playbook and tell them to go sell everything. So we're being very strategic relative to how we target within those geographies. And I'm not sure that's a good way to look at the analysis, frankly. But we're pleased with the productivity that's being made there. We do think there's a lot of room to grow into that investment. That was really the plan. And we're pleased with the execution to date. And the second part of the question?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Registrations.",1,"Registrations."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Oh, yes, the registration pipeline. I kind of view that as almost like a second R&D funnel. And it's something we measure and metric every month, frankly, from the divisions. So there are literally hundreds of registrations sitting as we speak at various",134,"Oh, yes, the registration pipeline. I kind of view that as almost like a second R&D funnel. And it's something we measure and metric every month, frankly, from the divisions. So there are literally hundreds of registrations sitting as we speak at various ministries of health around the world. There's even more than that sitting within our geographic business centers waiting to be filed, being prepared to be filed with the ministers of health. And even beyond that in the sourcing divisions, there's more than that, hundreds that are being prepared to submit to our business centers that in turn gets submitted to the ministers of health around the world. So we're pleased with the pipeline and the flow that we've got in the regulatory side of things at the moment in those markets."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Mike Weinstein with JPMorgan.",11,"Next, we'll go to the line of Mike Weinstein with JPMorgan."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","So a couple of items first just to clean up on the guidance. So Chris, in the 2015 guidance, what are you assuming for share repurchases?",26,"So a couple of items first just to clean up on the guidance. So Chris, in the 2015 guidance, what are you assuming for share repurchases?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","We're assuming sort of an ordinary course number, Mike. We'd certainly look to offset dilution from benefit plans as well as a little bit of an incremental reduction in the share count. We don't want to commit to a specific number because again, the range",85,"We're assuming sort of an ordinary course number, Mike. We'd certainly look to offset dilution from benefit plans as well as a little bit of an incremental reduction in the share count. We don't want to commit to a specific number because again, the range of opportunities we might face on the M&A front could force us into a little bit of a different place. But we would expect to continue to be able to move the share count lower to a certain degree."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. The 4% to 5% organic growth guidance kind of x the Gore noise feels like it should be a little bit better than that this quarter, or think about the last few quarters, the kind of underlying business pre-Lutonix has been moving from what was 3% to m",138,"Okay. The 4% to 5% organic growth guidance kind of x the Gore noise feels like it should be a little bit better than that this quarter, or think about the last few quarters, the kind of underlying business pre-Lutonix has been moving from what was 3% to moving closer to 4%, you have your first quarter of Lutonix out there, and Lutonix just adds over 200 basis points to the growth this quarter. So it feels like you're being a little bit conservative both on the base business as well as Lutonix. Like in the Oncology guidance, Oncology was up 7% constant currency in 2014 and you're guiding with 3% to 6%. So could you just spend a minute on the 4% to 5% and why that doesn't -- it feels conservative. Why is that not conservative?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Mike. We'll tag team this. I think first of all -- I don't know if you said Urology or Oncology?",21,"Yes, Mike. We'll tag team this. I think first of all -- I don't know if you said Urology or Oncology?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","No, Oncology. Oncology was up 7% in '14. You're guiding to 3% to 6%.",14,"No, Oncology. Oncology was up 7% in '14. You're guiding to 3% to 6%."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think with respect to ports, for example, we have a number of large contracts, and there's certainly some timing associated with large multiyear contracts that could, from a pricing standpoint, provide a headwind in certain categories. I think bigg",196,"Yes. I think with respect to ports, for example, we have a number of large contracts, and there's certainly some timing associated with large multiyear contracts that could, from a pricing standpoint, provide a headwind in certain categories. I think bigger picture, certainly, we expect a very competitive dynamic with respect to DCBs over the course of 2015. We'll see how that plays out. We certainly have ambitions to do very well, but we also want to make sure that we're maintaining the right level of caution. I think Europe, where we had a very strong 2014, we're somewhat cautious just given some of the macro challenges and headwinds that the continent is facing as well. And as Tim said, there's a lot of uncertainty surrounding us and the sector overall, including as it relates to the health care in the U.S. and as the Affordable Care Act continues to remain under some uncertainty longer term. So, or as we said, we're certainly going to try to do better and if we get some tailwind, we can. But we believe 4% to 5% as we exited '14 is absolutely the right place for us to be."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And are there any other headwinds that you didn't mention that we should know about?",16,"And are there any other headwinds that you didn't mention that we should know about?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Nothing major.",2,"Nothing major."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of Bob Hopkins with Bank of America.",13,"Next, we'll go to the line of Bob Hopkins with Bank of America."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 questions. One, first for Chris. In the 4% to 5%, can you just give us a sense as to the year-over-year change that goes into that 4% to 5% from just the Gore royalty and Lutonix revenues?",39,"Just 2 questions. One, first for Chris. In the 4% to 5%, can you just give us a sense as to the year-over-year change that goes into that 4% to 5% from just the Gore royalty and Lutonix revenues?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think with -- we tried to capture the range of scenarios we see with respect to Gore in the constant currency number of 3% to 5%. So there are some scenarios there, Bob. They don't move the needle much on the high end than they do tick it down a bi",131,"Yes, I think with -- we tried to capture the range of scenarios we see with respect to Gore in the constant currency number of 3% to 5%. So there are some scenarios there, Bob. They don't move the needle much on the high end than they do tick it down a bit on the low end. So again, we believe we're capturing what is likely within the 3% to 5% as it relates to Gore. And we're certainly not going to give specific expectation around Lutonix as we look at '15. We're going to continue to work like heck to help develop the market and penetrate the market. But I assume you can respect from a competitive standpoint we're not going to be more specific than that at this point."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Sure. But I think I gathered from Tim's comments that maybe in the fourth quarter you did high teens revenue for Lutonix?",22,"Sure. But I think I gathered from Tim's comments that maybe in the fourth quarter you did high teens revenue for Lutonix?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think you guys will be able to do the math to get to a number that's in that range.",21,"Yes, I think you guys will be able to do the math to get to a number that's in that range."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then for John, on the launch, a couple of things. I'd love just to kind of get your views on what you're seeing as you pioneer this new therapy. So a couple of quick things. One, what's the progress on the add-on payment? When do you expect that",94,"Okay. And then for John, on the launch, a couple of things. I'd love just to kind of get your views on what you're seeing as you pioneer this new therapy. So a couple of quick things. One, what's the progress on the add-on payment? When do you expect that? Do you have any evolved views on market size and what will happen to the stent market as a result of drug-coated balloons and what you're seeing in the early launch? Just would love to get some thoughts now that you're in the marketplace."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me just give some general perspectives on the launch itself. I think first of all, our team did an excellent job preparing for this launch literally over the last year in great detail. And I'd evidence that by the comments that we made where we had ap",249,"Let me just give some general perspectives on the launch itself. I think first of all, our team did an excellent job preparing for this launch literally over the last year in great detail. And I'd evidence that by the comments that we made where we had approval on a Friday, we were shipping that Friday, and our first case was done on Saturday. And I think that the knowledge base of physicians in the United States in anticipation of the technology was significant. And I think that our team has done an excellent job helping to continue educate physicians since the October launch. We have 2 thresholds for payment reimbursement changes potentially in the second quarter and fourth quarter, one for inpatient and one for outpatient. All of our submissions are in the CMS at this point in time. And we'll see what develops there. We have no reason to believe that they're not looking at this very favorably at this point in time. In terms of market size, the -- we had always said that the European market was about $80 million. That's not changed substantially. And we could all take a -- have a pool on what the United States will end up at, at the end of 2015. We're certainly working hard to make it as large as we possibly can. But I think that will be a wildcard, and we'll see how the whole market develops now that a competitor is approved as well."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then on stents, are those being affected, just generally?",10,"And then on stents, are those being affected, just generally?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","In the early reviews that we've done, we have not seen that at this point in time, although I would imagine that downstream, the total stent market may be affected slightly. But we have not seen anything at this point in time. But I think the good news is",81,"In the early reviews that we've done, we have not seen that at this point in time, although I would imagine that downstream, the total stent market may be affected slightly. But we have not seen anything at this point in time. But I think the good news is that our market basket, so to speak, of products offered into the vascular surgeons, interventional cardiologists, obviously, went up substantially. So our presence went up substantially and we staffed it accordingly."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","And next, we'll go to the line of David Lewis with Morgan Stanley.",13,"And next, we'll go to the line of David Lewis with Morgan Stanley."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a couple of quick questions. First for Chris. Chris, there's a pathway within guidance at least in our view to get sort of the mid-25s in terms of operating margin, noting [ph] your specific targets. But if I think about just putting that in context",109,"Just a couple of quick questions. First for Chris. Chris, there's a pathway within guidance at least in our view to get sort of the mid-25s in terms of operating margin, noting [ph] your specific targets. But if I think about just putting that in context over the last several years, that sort of puts you halfway between sort of your peak margins before the reinvestment and then the trough margins around 22, obviously, during the reinvestment. You're sort of halfway through the trough and the peak. Can you kind of give us a sense of the amount of time it will take to get back to that peak?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think what we've essentially committed to with the guidance today is 50 to 100 basis points of operating margin improvement in 2015. And that's with this unfortunate currency headwind that's nicking GPs by 50 basis points. And so when you think abo",203,"Yes. I think what we've essentially committed to with the guidance today is 50 to 100 basis points of operating margin improvement in 2015. And that's with this unfortunate currency headwind that's nicking GPs by 50 basis points. And so when you think about the dilution associated with the portfolio moves we made in 2015, which cost us about 200 basis points, I think we're well on our way to getting back to those mid-27% level. And the objective, as we look at the model, is to drive 50 to 100 basis points of operating margin improvement annually. So we're making a nice downpayment on returning to those levels in '15. That will be the objective again in '16 and the objective for several years. So we feel good about the trajectory. Again, the portfolio moves that just lowered the jumping off point, we believe, were absolutely the right things to do for the company. And again, if you adjust for those, we'd actually be -- and without the currency headwind, we'd be right in spitting distance of those margins in '15. So we feel good about that. A lot of work to get those improvements year after year. But that's the commitment."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, very helpful. And maybe just a quick detail question on the product side for John. John, there's a lot of strength in PICCs this quarter. We've seen actually several quarters this year where PICC strength was significant. This particular quarter, ul",62,"Okay, very helpful. And maybe just a quick detail question on the product side for John. John, there's a lot of strength in PICCs this quarter. We've seen actually several quarters this year where PICC strength was significant. This particular quarter, ultrasound was a little weak. Was there anything specific there that we should be thinking about as we head into 2015?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I wouldn't say ultrasound was weak this quarter. We had a pretty good solid quarter in ultrasound. And that varies from time to time based on product launches and things like that. But I would say that the reality is we had a very strong quarter across th",78,"I wouldn't say ultrasound was weak this quarter. We had a pretty good solid quarter in ultrasound. And that varies from time to time based on product launches and things like that. But I would say that the reality is we had a very strong quarter across the board. Every product line showed significant strength on Oncology around the world. And in the United States, we're delighted with the performance we had in Oncology in the quarter."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. And we've got a pretty good pipeline going into 2015 with our Site-Rite 8 [ph] planned for launch around mid-year as another addition into that pipeline.",27,"Yes. And we've got a pretty good pipeline going into 2015 with our Site-Rite 8 [ph] planned for launch around mid-year as another addition into that pipeline."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Can I just stick one more in? Actually maybe for Tim or for John. I guess, what's really interesting is in the period where Bard was decelerating, there was this commentary that utilization was one of the factors. And what's really fascinating is on",144,"Okay. Can I just stick one more in? Actually maybe for Tim or for John. I guess, what's really interesting is in the period where Bard was decelerating, there was this commentary that utilization was one of the factors. And what's really fascinating is on the acceleration, your underlying growth this quarter was 4.5%, puts you well above peers' underlying growth rate. And you're not doing it with contribution from Foley's and some of those key utilization-sensitive markets. So it looks like, frankly, it's just good old-fashioned Bard and it's not market driven. So market, obviously, is upside. So Tim, as you sort of think about the underlying business performance, where do you think the 2 or 3 areas that you feel most confident in the last 2 years have driven that underlying performance given it doesn't appear to come from market at all?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, as we said, if you want to grow faster, you've got to invest in faster-growing segments, and that's frankly what we've been doing. Clearly, the underlying market growth rates in the emerging markets are faster than the total average, probably c",139,"Yes. Well, as we said, if you want to grow faster, you've got to invest in faster-growing segments, and that's frankly what we've been doing. Clearly, the underlying market growth rates in the emerging markets are faster than the total average, probably closer to a double-digit kind of growth rate, underlying market growth rates. The acquisitions that we've made over the last several years were all thought of as platforms here for us to invest in because those were in faster-growing segments. And then the R&D investments that we've made across the board have also been in faster-growing segments. So as we execute and those things start to pay off and come to fruition, the plan called for the growth rates to be higher and that's what you're seeing. So it's really not any more complex than that, frankly."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","We have a question from Kristen Stewart with Deutsche Bank.",10,"We have a question from Kristen Stewart with Deutsche Bank."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I'm sorry if I missed this, but did you give a growth rate for Lutonix outside the United States? And are you still seeing good growth on the heels of all the data from a market perspective?",38,"I'm sorry if I missed this, but did you give a growth rate for Lutonix outside the United States? And are you still seeing good growth on the heels of all the data from a market perspective?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we did, we saw excellent growth outside of the United States.",12,"Yes, we did, we saw excellent growth outside of the United States."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Any way to quantify?",4,"Any way to quantify?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Other than excellent?",3,"Other than excellent?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes.",1,"Yes."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we were delighted where we were at the end of the quarter both in the United States and outside of the United States. We continue to take share.",30,"I think we were delighted where we were at the end of the quarter both in the United States and outside of the United States. We continue to take share."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Right. I think that was the point. We continue to take share every quarter x U.S.",16,"Right. I think that was the point. We continue to take share every quarter x U.S."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then I guess bigger picture, I guess, Tim. I guess how are you thinking just about M&A in terms of the size of a company? Or would you be willing to step out and do something a little bit larger?",41,"And then I guess bigger picture, I guess, Tim. I guess how are you thinking just about M&A in terms of the size of a company? Or would you be willing to step out and do something a little bit larger?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Nothing has changed in terms of our perspective on that. As we've said, we've never shied away from doing a big deal. But we haven't seen one that's been so compelling that hits all the filters that we have set forth for all of our acquisitions. Fran",161,"Yes. Nothing has changed in terms of our perspective on that. As we've said, we've never shied away from doing a big deal. But we haven't seen one that's been so compelling that hits all the filters that we have set forth for all of our acquisitions. Frankly, size isn't something we even start with. That probably comes into play in the third or fourth round of questions. So we start strategically. We look at it as a platform and is the growth sustainable and is it a market leadership or does it help the market leadership positions that we have in the current portfolio. And we answer all of those first. So would we be willing to do it? Sure. But it would have to be so compelling that we were convinced that it was the right thing to do for the long-term growth of the company. And frankly, we don't even think about size when we look at deals."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then for Chris, just in terms of the gross margin guidance that you provided, mix favorable by 20 to 40 basis points. I would have thought that would have been maybe a little bit better just with Lutonix coming in this year and also strong growth acro",80,"And then for Chris, just in terms of the gross margin guidance that you provided, mix favorable by 20 to 40 basis points. I would have thought that would have been maybe a little bit better just with Lutonix coming in this year and also strong growth across the BioSurgery business, which I thought was a little bit higher as well. Can you maybe just speak to us what are the, I guess, puts and takes from a mix perspective?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think there are other areas that are going to be -- continue to be important contributors but are not -- are lower margin. And I think we're working on improving the margins from the Rochester portfolio. That's going to take some time. We're not th",147,"Yes. I think there are other areas that are going to be -- continue to be important contributors but are not -- are lower margin. And I think we're working on improving the margins from the Rochester portfolio. That's going to take some time. We're not there yet. That's still another year to 2 out. Those products are growing nicely. And so that's actually something that's hurting us in this intervening period. And again, hopefully, as we get out 12 or 24 months from now, that will be a contributor. But I think 20 to 40 is a very nice number. And if that -- as we constructed the portfolio, we think it's something that's sustainable. We actually feel pretty good about that. Certainly, we'd like to see the number higher. But as we look at 2015 and the puts and takes, that's how we see it."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just to go back to Lutonix, that number that you quoted or the contribution, was there any stacking or are you on a consignment basis?",26,"And just to go back to Lutonix, that number that you quoted or the contribution, was there any stacking or are you on a consignment basis?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","We're -- I mean, there are certainly some initial stocking orders. We've also, though, seen very significant levels of reorder as well, which we're tracking closely. So it's impossible to say perfectly. But there's a healthy portion of customers that have",83,"We're -- I mean, there are certainly some initial stocking orders. We've also, though, seen very significant levels of reorder as well, which we're tracking closely. So it's impossible to say perfectly. But there's a healthy portion of customers that have reordered more than once already. And that's why -- listen, it's going to take a little bit of time for this to settle out. But to John's point, we feel great about the launch and certainly great about the initial demand."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of David Roman, Goldman Sachs.",11,"Next, we'll go to the line of David Roman, Goldman Sachs."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just start with the emerging markets, which clearly has been a very successful relatively fast return for you guys. Could you maybe just talk through kind of where you are in the -- just in the evolution of that strategy and ultimately where y",60,"I wanted to just start with the emerging markets, which clearly has been a very successful relatively fast return for you guys. Could you maybe just talk through kind of where you are in the -- just in the evolution of that strategy and ultimately where you can foresee that business going in terms of mix in the overall company?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. David, the -- as Tim said earlier, we are -- we've invested ahead of the growth potential within those markets. We're delighted with how well we've done in China since we embarked down this journey. We think we have an awful lot of runway yet ahead",178,"Sure. David, the -- as Tim said earlier, we are -- we've invested ahead of the growth potential within those markets. We're delighted with how well we've done in China since we embarked down this journey. We think we have an awful lot of runway yet ahead of us in China in many different product lines, especially new products that we have not yet launched in that specific geography. Emerging markets in -- within Europe, we're delighted with our uptick there across both Europe and Russia. And I'd say that we are anticipating the investments that we've made in Latin America yet to generate the results that we're expecting. So I think that '15 and '16 will be a particularly important year for us in the Latin American marketplace. We like the traction that we're getting around the world in the other markets that we've invested in. And I think that you'll continue to see this be a significant contributor to Bard's growth in the years to come. We don't have an upward limit in terms of this."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's helpful. And then in one of the prior questions, you alluded to Lutonix having the potential to give you a better foothold with the interventional cardiologists and potentially the vascular surgeon. To what extent over time can that become a",71,"Okay, that's helpful. And then in one of the prior questions, you alluded to Lutonix having the potential to give you a better foothold with the interventional cardiologists and potentially the vascular surgeon. To what extent over time can that become a potential leverage point? And do you have sufficient products in your bag really to use that call point potentially more efficiently? And how much of a focus is that?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","It's certainly an opportunity for us to use that call point more efficiency -- efficiently, I think, especially as we become a bigger part of those operating suites with DCB and the other products that can be utilized within this suite. I'd say that if yo",154,"It's certainly an opportunity for us to use that call point more efficiency -- efficiently, I think, especially as we become a bigger part of those operating suites with DCB and the other products that can be utilized within this suite. I'd say that if you look at it long term, though, that's only one aspect of our DCB strategy. You see the other indications that John talked about. I mean, it gives us a runway of new platforms for the next 5 years or so that we think will be very significant, and we'll have an opportunity to build large markets over the years. Below the knee is an obvious example as are the other indications that John talked about. So I'd say this is as much about being a larger part of the operating suites as well as being able to take this significant technology and move it to other indications."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to the line of David Turkaly, JMP Securities.",11,"Next, we'll go to the line of David Turkaly, JMP Securities."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Tim, just quickly, just a follow-up, I guess, maybe to wrap up this M&A lines. Your competitor mentioned that they thought the market was getting a little more competitive or it's harder to find things. Would you agree with that? Are you finding -- are yo",61,"Tim, just quickly, just a follow-up, I guess, maybe to wrap up this M&A lines. Your competitor mentioned that they thought the market was getting a little more competitive or it's harder to find things. Would you agree with that? Are you finding -- are you being presented with still interesting technologies? Or is the overall M&A environment more competitive today?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We're finding things. In fact, I just recently internally looked at a kind of scattergram of technologies and companies we've looked at. And it's as full as I've ever seen. So we're pleased with that. I think you worry a little bit down the road abou",150,"Yes. We're finding things. In fact, I just recently internally looked at a kind of scattergram of technologies and companies we've looked at. And it's as full as I've ever seen. So we're pleased with that. I think you worry a little bit down the road about the way venture capital money has shifted over the last several years within the sector. We haven't bumped into any troughs in the market flow because of that yet, but who knows down the road whether that happens. So -- and the other part of that is we're more actively -- as these emerging markets and other geographies grow, our expectation is there may be more opportunities in those sectors to look there. So we put more resource into that as well. So now we weren't pleased with our execution in 2014, but it wasn't because of a slowdown in the deal flow."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And would you say that it also was not because of evaluations or your evaluation sensitivity?",16,"And would you say that it also was not because of evaluations or your evaluation sensitivity?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think so. I mean, there are some things that, frankly, like anything else in life, when you go to buy something, it's a negotiation. You can look at somebody and say, ""You're crazy, we're not paying that"". And that happens but that's not new. That",101,"I don't think so. I mean, there are some things that, frankly, like anything else in life, when you go to buy something, it's a negotiation. You can look at somebody and say, ""You're crazy, we're not paying that"". And that happens but that's not new. That happened 5 years ago and 3 years ago, and that's the way life is, right? So I don't think we -- we certainly haven't changed our evaluation profile that we look at nor we do see any reason to do that. So that doesn't concern me at all relative to deal flow either."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to Matthew Taylor, Barclays.",7,"Next, we'll go to Matthew Taylor, Barclays."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to ask one about, I guess, your philosophy behind the Gore guidance because if we take your top line guidance, you're obviously forecasting some kind of decline. Is that just general uncertainty? Or is there something that you're expecting t",48,"I just wanted to ask one about, I guess, your philosophy behind the Gore guidance because if we take your top line guidance, you're obviously forecasting some kind of decline. Is that just general uncertainty? Or is there something that you're expecting that will cause it to decline?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","No, I think, Matt, it's just trying to be prudent about the range of scenarios that could happen. Again, we don't think there's a level of upside that again, that moves the guidance, which is why it's still at 5% rounded on the high end. It certainly coul",193,"No, I think, Matt, it's just trying to be prudent about the range of scenarios that could happen. Again, we don't think there's a level of upside that again, that moves the guidance, which is why it's still at 5% rounded on the high end. It certainly could continue at the current level, or as we've always said, it could decline. It's absolutely out of our control. And as we have said and we'll repeat again now, we don't have any information that leads us to believe that it will decline. But we wait, and on a quarterly basis, understand what sales were and what the royalties were. So we're trying to be prudent and make commitments to you guys that we can deliver on within a range of scenarios. And certainly, as we think about potential upside, we're giving you bottom line commitments that we're committed to delivering. We'd certainly like the ability to reinvest any upside back into the business while still delivering bottom line commitments. So we're trying to take in what we think are the likely scenarios and then make commitments that we're going to hit within those scenarios."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And this is a kind of a probability weighted forecast for you in terms of what could happen?",18,"And this is a kind of a probability weighted forecast for you in terms of what could happen?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, that's a good way to think about it.",9,"Yes, that's a good way to think about it."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Operator, we are well past an hour now. We're going to take 3 more, and we apologize to the rest of the people in queue. But obviously, you can call us and we can catch up after. But we'll take 3 more here on the call, operator.",47,"Operator, we are well past an hour now. We're going to take 3 more, and we apologize to the rest of the people in queue. But obviously, you can call us and we can catch up after. But we'll take 3 more here on the call, operator."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Joanne Wuensch, BMO Capital.",4,"Joanne Wuensch, BMO Capital."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I think a lot of us are focused on what are you going to buy next. But can we shift the topic a little bit to what you might divest next? How do you...",34,"I think a lot of us are focused on what are you going to buy next. But can we shift the topic a little bit to what you might divest next? How do you..."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So yes, let me deal with that. So it's always easier to divest a business than it is to divest product lines. With 14,000 plus SKUs at any point in time, we've got a number -- a large number of SKUs that are actually declining that, frankly, if we h",150,"Sure. So yes, let me deal with that. So it's always easier to divest a business than it is to divest product lines. With 14,000 plus SKUs at any point in time, we've got a number -- a large number of SKUs that are actually declining that, frankly, if we had our druthers we'd get rid of, sell, whatever. They are needed in the marketplace by patients and clinicians, which is why we continue to manufacture those and provide those. But they're also a time distraction to do that kind of thing. So we'd rather have our management's efforts and workforce focus on growth as opposed to divesting singular product lines. And there's really not a business as such that we have in total outside of what we did with electric physiology that would be nicely packaged for a divestiture. So no current plans at the moment for anything there."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","That's helpful. And then the other thing which I've always liked about your catheter business is that it sort of becomes the precursor of volume trends. And yet you're not really saying that you're seeing the pickup in volumes. Do you have an idea why you",61,"That's helpful. And then the other thing which I've always liked about your catheter business is that it sort of becomes the precursor of volume trends. And yet you're not really saying that you're seeing the pickup in volumes. Do you have an idea why you're not experiencing it while others are sort of starting to talk about it already?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, when you look at the catheter business, I think it's an interesting aspect of it. One is that hospitals have tried to reduce catheterization because of their need to reduce urinary tract infections or hospital-acquired infections. That's one aspect",96,"Well, when you look at the catheter business, I think it's an interesting aspect of it. One is that hospitals have tried to reduce catheterization because of their need to reduce urinary tract infections or hospital-acquired infections. That's one aspect of it. The other aspect is oftentimes on outpatient surgery, a patient will not be catheterized also. So you'll see the trend being very, very close on inpatient surgeries, but it won't capture demand from outpatient surgeries. I think that's -- there's a couple of the aspects of Foley catheterization that are nuanced in this case."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","I appreciate that clarification. But do you have an idea why you're not starting to see that kind of pickup that others are talking about?",25,"I appreciate that clarification. But do you have an idea why you're not starting to see that kind of pickup that others are talking about?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","I don't think we're seeing an inpatient surgery. We don't see inpatient surgeries increasing.",15,"I don't think we're seeing an inpatient surgery. We don't see inpatient surgeries increasing."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","Next, we'll go to Richard Newitter, Leerink.",7,"Next, we'll go to Richard Newitter, Leerink."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Ravi Misra in for Rich Newitter. I have 2 on Lutonix. One, maybe regarding the other indications that you're exploring. I was wondering if you were willing to put any aspirational timelines on some of those approvals? And then two, I think last fa",72,"This is Ravi Misra in for Rich Newitter. I have 2 on Lutonix. One, maybe regarding the other indications that you're exploring. I was wondering if you were willing to put any aspirational timelines on some of those approvals? And then two, I think last fall, we were discussing on these calls the publication that you guys were searching to put the Lutonix data in. An update on that would be appreciated."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So let me just jump on the approvals side. We've talked about starting the AV access study. So enrollment that's going to be -- if we started mid this year, which is the plan. We expect that to enroll relatively quickly. But with the timing of that,",264,"Sure. So let me just jump on the approvals side. We've talked about starting the AV access study. So enrollment that's going to be -- if we started mid this year, which is the plan. We expect that to enroll relatively quickly. But with the timing of that, that's probably sort of 2018 time frame for AV. Now below the knee, enrollment has been a little slower. We had hoped for a sort of 2017 approval. We think that's still possible probably later in the year, just based on the way that enrollment is going right now. And the in-stent restenosis indication, there's another one that we -- I want to hold back a little bit on that. We'd talked a little bit about a 2017 -- late 2017 kind of time frame in the past. But we're trying to see where we can get information and more data that could give us other opportunities. So I don't want to commit to anything at this point. But certainly, there aways out for U.S. indications. Now as far as the publication goes, I can tell you, no one is more frustrated at the timing than I am. But this is clearly something that's not within our control. As we understand it, the author's investigators have the manuscript under review with the journal. It's not within our control as much as I'd like it to be. And we continue to believe that it's important to get it published. So as soon as we know something and we have an opportunity to let you know, we will."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Operator","The last question will come from Mike Matson, Needham & Company.",11,"The last question will come from Mike Matson, Needham & Company."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just wondering, with the Lutonix product, obviously, you had good sales. But is reimbursement an issue at all? And with regard to the add-on payment, I mean, I think that's for inpatient. So how many of these are being done inpatient versus outpatient? Is",65,"Just wondering, with the Lutonix product, obviously, you had good sales. But is reimbursement an issue at all? And with regard to the add-on payment, I mean, I think that's for inpatient. So how many of these are being done inpatient versus outpatient? Is there any potential to get some type of pass-through or something for the outpatient setting that would increase reimbursement as well?"
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","So let me just jump in on reimbursement. First off, I think we're trying to track inpatient versus outpatient use. We don't have great visibility to that, frankly. But we believe that this is primarily outpatient use, which is typical for SFA popliteal ki",286,"So let me just jump in on reimbursement. First off, I think we're trying to track inpatient versus outpatient use. We don't have great visibility to that, frankly. But we believe that this is primarily outpatient use, which is typical for SFA popliteal kind of procedures. So we think that's probably sort of in the 60% range or so. On reimbursement, we think it is an issue. There are certainly certain value-conscious buyers that would be holding off until they hear more about reimbursement. Obviously, we're getting pickup in spite of that at this stage. But there are, as John mentioned earlier, 2 paths for reimbursement. There's the outpatient reimbursement piece, which CMS, there's really no official time line. They can work within whatever they want. We think an April time frame is reasonable. Again, CMS is not obligated to work within that time frame. But typically, sort of a couple of cycles of review is common. And we're in that time period from when we submitted our documentation to CMS last fall. Now as far as the inpatient piece goes, I just saw today, actually, on the CMS website the agenda for a meeting next week, a town hall meeting where drug-coated balloons will be reviewed. And I think that's the last step, is my understanding, at least, the last public step in the review process for the inpatient piece. But remember, inpatient only receives the approval or changes one time a year, which is typically the October time frame. So John alluded to a Q4 inpatient time period, which is what we think would be sort of the reasonable customary time frame. But again, CMS is not obligated to work within any of that."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then just in your surgical business, can give us an update on the natural tissue products? It seems like the market sort of had moved away from those and I guess where your antibiotic coated product would fit in.",40,"And then just in your surgical business, can give us an update on the natural tissue products? It seems like the market sort of had moved away from those and I guess where your antibiotic coated product would fit in."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think that entire market is under some significant pressure, I mean, primarily based around price. The ASPs of some of those grafts are very, very substantial. And I think that hospitals and clinicians are being very prudent about the use of natur",127,"Sure. I think that entire market is under some significant pressure, I mean, primarily based around price. The ASPs of some of those grafts are very, very substantial. And I think that hospitals and clinicians are being very prudent about the use of natural tissue products and really trying to focus those only when they're absolutely necessary. The product that we recently launched, Xen AB, is the first of its kind. It's the first product or graft that is antibiotic coated. We think that has significant opportunity to be utilized in those indications where patients may be compromised. We -- the excitement in the marketplace is substantial. Our launch was significant. And we're delighted as well as where we are in that initial launch in late December."
254131,281166647,752084,"CR Bard Inc., Q4 2014 Earnings Call, Jan 29, 2015",2015-01-29,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. Moderator, thank you very much for all of your assistance. Let me also thank everybody for joining us today. And I'd like to also take this opportunity to thank Bard employees around the world for a very solid year of execution. Looking forward to a",70,"Okay. Moderator, thank you very much for all of your assistance. Let me also thank everybody for joining us today. And I'd like to also take this opportunity to thank Bard employees around the world for a very solid year of execution. Looking forward to an even better one this year. And I also thank them for their dedication and commitment. And we'll talk to you after the first quarter."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard Inc. First Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand re",265,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard Inc. First Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations. 
Today Bard's management will discuss some forward-looking statements the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings release on the company's website at www.crbard.com. All information that is not historical is given only as of April 23, 2015, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much. I'd like to welcome everybody to Bard's first quarter 2015 earnings call and thank all of you for taking the time to join us today. We do expect the presentation portion of the call to last about 25 minutes. I am going to try to keep",614,"Thank you very much. I'd like to welcome everybody to Bard's first quarter 2015 earnings call and thank all of you for taking the time to join us today. We do expect the presentation portion of the call to last about 25 minutes. I am going to try to keep the total call to about 1 hour or less. 
The discussion today will go as follows. I'll begin with an overview of the results for the first quarter. John Weiland, were President and COO will review first quarter product line revenue. John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update in our productive development pipeline, after which Christopher Holland, our Senior VP and CFO, will cover the first quarter income statement and balance sheet as well as our expectations for Q2. And finally, we'll close with Q&A. 
First quarter 2015 net sales totaled $819.7 million. That's up 3% over Q1 last year on an as-reported basis and up 5% on a constant currency basis. The currency impact for the quarter versus last year was unfavorable by about 260 basis points. The quarterly royalty payment from Gore was $38.4 million, which represented slower growth than our product portfolio. So our organic revenue growth this quarter was about 5.3%, which was better than our guidance. 
Net income for the first quarter was $139.8 million. The diluted earnings per share were $1.82, that's down 6% and 2%, respectively, excluding certain items that affected the comparability of results between periods, which Chris will cover later. The first quarter 2015 net income was $142.4 million, up 6%. And diluted adjusted earnings per share, which excludes amortization, were $2.10, that's up 10%. This was also above our expectations despite the additional headwind from currency and represents a good start to what's an important year of execution for us. 
Looking at revenue growth geographically compared to the first quarter of last year. Q1 net sales in the U.S. grew 4% compared to a year ago. On a constant currency basis, in Europe, we were up 1%. Japan was up 5%. And our other international businesses were up 18%. 
We saw strong sales growth across all of our emerging market geographies in the first quarter as our investments over the last couple of years have strengthened our position in these faster growing markets. As a percentage of total sales in the first quarter, emerging markets represented between 8% and 9% of sales compared to just 7% a year ago. And while it's still small percentage of the portfolio in some of our major product lines, the actual dollar growth we saw in emerging markets exceeded the dollar growth of the same products in the U.S. this quarter. As you know, emerging markets is just one of the opportunities we've highlighted as a key long-term revenue growth driver for us. In fact, you'll hear as John takes you through the sales results, that each of the growth drivers we've highlighted as part of our strategic investment plan performed well this quarter. 
We remain focused on the execution of that plan and providing the expected returns on those investments in 2015 and beyond. Chris will provide the detail update to our guidance a bit later in the call, but I am pleased to tell you that our strong start to the year and our confidence in our ability to execute on the things we can control, we believe we can manage the challenging foreign exchange environment so far and maintain our original financial guidance for 2015. So with that, summary, let me now turn you over to John Weiland for a review of our product line revenue."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $23",855,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $231.9 million, up 6% over last year on a reported basis and up 10% on a constant currency basis. U.S. Vascular sales were up 8% in Q1 and international sales were up 11%. 
Sales in our Surgical Graft category were down 4% this quarter, within the range of recent experience. Our Endovascular business was up 10% in the first quarter and it was up 12%, excluding the Gore royalty. 
Our biopsy products had a strong quarter, up 9%, driven by good growth internationally, especially in emerging markets. 
Our peripheral PTA line increased 32% in the first quarter, with sales of our Lutonix DCB exceeding our expectations. We saw a good acceleration in the daily usage of the device after some large initial stocking orders in the fourth quarter. 
In Q1, we worked with Boston Scientific to train their reps in our product and in Q2, received our first order from them. As you probably saw, hospital outpatient procedures are now eligible for reimbursement through CMS as of the beginning of the second quarter, an important milestone for the category. 
Our vena cava filter line grew 6% in Q1. Our Stent business declined 3% in Q1 compared to the prior year and we continue to expect significant price pressure in this category. 
Now let's move to Urology. Total net sales were $205.6 million, up 2% versus the first quarter of last year on a reported basis and up 5% on a constant currency basis. The United States business was up 4% and internationally, we grew 6%. We saw double-digit growth in our Targeted Temperature Management products again this quarter. And we remain encouraged by the long-term opportunity here. Our basic drainage business was up 4% in Q1 and up 2% in the United States. Within that category, our I.C. Foley business was up 1% globally and down 2% in the United States. 
Our continence business was up 7% in Q1, driven by double-digit growth in our Dignicare [ph] and male-external catheter sales. 
Our women's health product lines continue to decline but now make up less than 20% of continence category and less than 1/2 of a percent of Bard's total sales. 
Sales in Urological Specialties were down 1% in the first quarter, with our brachytherapy down 4%. And finally, standalone sales of our StatLock catheter stabilization line increased 5% in Q1. 
Next is Oncology. Total net sales in this category were $224.6 million, an increase of 3% over Q1 last year on a reported basis, and up 5% on a constant currency basis. Geographically, net sales in the United States were up 1% and international sales were up 15%. 
Our port business was down 3% over Q1 of last year. We forecast that significant United States pricing pressure here related to GPO contracts signed in 2014, which drove the decline, as units were essentially flat with prior year. 
Our PICC revenues were up 9% globally with good growth in the United States and even better growth internationally. And the closeout of the category, our vascular access ultrasound product line grew 12% this quarter and our dialysis catheter product line was up 8%. 
So then let's finish with Surgical Specialties. Total net sales in this category were $135.9 million, up 1% on a reported basis, and up 3% on a constant currency basis. U.S. sales were up 5% and international sales were down 4% in the quarter. Most of that international decline was driven by our performance irrigation business, which was down 34% globally due to the discontinuation of certain products in this category, which now represents less than 1% of total Bard's sales. 
Our soft tissue business -- soft tissue repair business grew 5% this quarter. Within soft tissue, our synthetic business grew 8% in Q1. In biologics, we were very pleased with the first full quarter of sales from our XenMatrix AB product, which is a graft with an antibiotic coating. Thanks to the contribution from this new first-of-its-kind device, our total biologic category was flat in Q1, reversing a trend of double-digit declines. 
We have the broadest portfolio in hernia repair across all types of products, from a wide range of synthetics to natural tissue and now antibiotic coated natural tissue. We are working with physicians to identify the right product for the right patient and provide a wide range of options for them. 
Our hernia fixation line declined 9% this quarter -- 7% this quarter, within the range of recent experience. As you'll hear from John DeFord, we have some new products in our pipeline that we believe will help us get back to growth in this category. 
We are well past the anniversaries of our acquisitions of BioSurgery and that business grew double digits again this quarter. We remain bullish on the long-term opportunity here. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We started off 2015 with several product launches. And as you'll hear in my update, our pipeline and plans show a very active 2015 and beyond. I'll start with drug-coated balloons, where we're making good prog",1133,"Thanks, John, and good afternoon, everyone. We started off 2015 with several product launches. And as you'll hear in my update, our pipeline and plans show a very active 2015 and beyond. 
I'll start with drug-coated balloons, where we're making good progress on additional sizes and indications worldwide. We filed the PMA supplement for additional balloon sizes for use in the SFA and popliteal and anticipate launch in the back half of this year. 
In our clinical activities, we completed initial follow-up in our Levant 2 Japan study. We're in the data analysis phase and we expect to submit in the back half of the year for approval. Enrollment continues in our Below the Knee and in-stent restenosis IDE studies. And we recently submitted the IDE for our AV access study with enrollment anticipated to start in Q3. We're also working toward the start of our Levant China study and expect to begin enrollment in the back half of the year. The Levant 2 study design was described in detail in a recent publication authored by Dr. Michael and several investigators in the American Heart Journal. We also expect 24 months Levant 2 results to be presented at SBS in June. 
Also in Vascular, the LifeStream balloon expandable covered stent clinical study is recruiting quickly and we anticipate completing enrollment later this year. This IDE evaluates the technology for the treatment of iliac artery disease. 
In other stent graft news, our next-generation device for use in AV access is nearing completion and development and we anticipate launching in Europe in Q4. This product will require a clinical study for U.S. approval and we anticipate filing the IDE and initiating a study in the first half of 2016. 
We have a new venous stent project that is on a similar development pathway with launch anticipated in Europe in Q4 and an IDE study expected to begin around the end of the year. 
Next, moving to Urology. We've launched our new Skyline Sub 2 [ph]  French stone basket family and are working to expand the platform with 2.4 and 3 French versions expected later this year. 
Also in Endourology, we anticipate launching our new access sheath system in the back half of the year. We believe these new products provide the urologist with needed improvements to some of the tools they are currently using in this important interventional space. 
In home care, we are nearing the launch of a new intermittent self-catheterization product, the Magic 3 Touchless, slated for release in Q3. Magic 3 Touchless combines the comfort and insertion benefits of the Magic 3 platform, combined with our touchless closed system designed to reduce the risk of contamination and infection due to catheter insertion. We've got a couple of other products in our intermittent catheter family that are slated to launch later this year. But I'd hold back the details until we get closer to product release. 
Moving to Oncology. We recently received U.S. regulatory clearance for our free hand stereotactic system for Vascular Access, named Pinpoint GT. The Pinpoint GT technology would be offered on the new Site-Rite 8 ultrasound system, slated for launch later this year. We believe that the combination of the Site-Rite ultrasound, Pinpoint GT guidance and 3CG Diamond catheter tip confirmation in an integrated system will provide a complete clinical solution for vascular catheter placement. 
In PICC, we are on track for our Q3 regulatory submission for our new thromboresistant coating. Upon regulatory clearance, we plan to launch a broad line of catheters marketed under the Covert [ph] PICC trade name. We expect to follow the Covert PICC with a combined antimicrobial and thromboresistant coating, planned for launch in the back half of 2016. 
In midlines, we launched the 22 Gates PowerGlide catheter in Q1, completing our sizes in the PowerGlide product family. We're also making good progress on our next generation of midline catheters and anticipate our U.S. regulatory submission in Q4 with the first half 2016 launch. 
For the acute hemodialysis patient, we're expanding upon our market-leading Trialysis catheter family with the anticipated regulatory clearance on launch later this quarter of our new Trialysis slim. Trialysis slim incorporates superior flexibility, increased resistance and flow rates in excess of 400 milliliters per minute in a small 12-French triple lumen catheter configuration. 
I'll close my portion of the discussion today with surgery. On our last call, we told you about our launch of the first antibiotic coated biologic XenMatrix AB. As John Weiland told you, the product is receiving excellent early feedback. And we are working hard to expand the size matrix available, with additional launches expected over the course of the next several quarters. 
We're also making good progress toward the launch of a new product family that incorporates our proven separate barrier technology with our bioresorbable mesh family to create the Phasix ST. Phasix ST is designed for intra-abdominal placement and is on track to launch in Q3. This new offering supplements XenMatrix AB, XenMatrix and Phasix to allow us to offer proprietary and differentiated products designed to address the entire spectrum of complex abdominal wall repairs. 
Moving onto our BioSurgery product family. In early Q3 of 2014, we filed our PMA supplement for our Progel sealant, seeking expanded use in video-assisted and robot-assisted thoracic surgery. We received approval from FDA earlier this quarter. And I'm pleased to announce the launch is underway ahead of schedule. 
Also in January of this year, we completed follow-up in our Tridyne vascular sealant pivotal IDE study. Analysis is complete and the team is working toward PMA submission this quarter. Following this time line, we anticipate approval and launch in mid-2016. 
And finally, in mesh fixation, we're gearing up for the launch in the next couple of weeks of our first spring-loaded resolvable tack device named OPTIFIX. OPTIFIX has been designed to employ stored energy for ease and efficiency of tact delivery while reducing tissue trauma that's been associated with some competitive devices. 
In past calls, I've told you that we have another fixation platform under development, but we've not disclose the details. Now the time is right and I'm pleased to announce that we anticipate launching our new permanent fixation device named Capture later this quarter. Capture is the result of several years of analysis of the permanent fixation market and was designed to reduce the risk of tissue injury due to exposed and concern over adhesions and reliability, while providing the functional requirements of a permanent including the ability to penetrate hard tissues such as ligament. With these 2 fixation launches, we're excited to move back to playing offense in this highly competitive space. 
Thanks for your attention today. We look forward to updating you on our progress throughout the year. Now I'll hand our discussion over to Chris."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods credit and acquisition-related items of $9.2 million pretax, a $3.9 million pretax charge for restructuring and productivity initiatives a",648,"Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods credit and acquisition-related items of $9.2 million pretax, a $3.9 million pretax charge for restructuring and productivity initiatives and we recorded expense of $10.3 million, primarily related to the judge's order in the women's health litigation that we work up 500 cases simultaneously. The P&L impact of these items is detailed in the notes to the financial statements and in the reconciliation accompanying our Q1 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $508.5 million or 62% of sales for Q1. On an adjusted basis, GP was $498.6 million or 60.8% of sales, down 60 basis points from the prior year quarter, consistent with our guidance. FX costs us 30 basis points in GP this quarter and the new amortization from the Q4 2014 Lutonix approval was 40 basis points in Q1. 
Price pressure drove 130 basis points on the revenue line in Q1 and about 50 basis points of headwind on GP, consistent with our expectations. Our cost improvements drove about 40 basis points of benefit to GPs this quarter and mix was favorable by about 20 basis points. 
As we look to Q2, we expect gross margin to be similar to the Q2 2014 level, despite FX pressure and the incremental amortization. 
SG&A expenses were $235.7 million for the quarter or 28.8% of sales. On an adjusted basis, SG&A as a percent of sales was 28.7%, a decrease of 90 basis points. We are on track with our annual guidance of delivering improved P&L leverage for the full year. 
R&D expenditures totaled $60.6 million for the first quarter or 7.4% of sales on both the reported and adjusted basis, consistent with our guidance. Interest expense was $11.3 million for the first quarter. 
Other income and expense was $16.3 million of expense for the first quarter as reported and $1.6 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.3% on a reported basis and 24.9% on an adjusted basis, the same level as a year ago. And again, our full year guidance assumes the renewal of the R&D tax credit but that will not be included in the reported numbers until it is renewed. 
Diluted shares for the period were 75.8 million and we purchased 1.2 million shares during the first quarter. The net result is adjusted EPS of $2.10, which exceeded our expectations for the quarter. 
The balance sheet as of March 31 reflects cash, restricted cash and short-term investments of approximately $1.03 billion versus $1.01 billion at December 31. For the quarter, accounts receivable days were up 0.7 days and inventory days were up 0.3 days. Capital expenditures totaled $29 million for the quarter. 
On the liability side, total debt was $1.6 billion as of March 31 compared to $1.5 billion at the end of December. Debt-to-total cap at the end of the first quarter was about 48% and total shareholder investment was $1.7 billion at March 31. 
In looking at Q2, we're expecting constant currency sales growth between 4.5% and 5.5% and we expect organic growth to be within the same range. We are now expecting currency headwinds based on exchange rates at the current levels to reduce reported sales by about 4% for Q2 and the full year, up from about 3% in original -- in our original guidance in January. 
From an adjusted EPS standpoint, excluding items affecting comparability and the amortization of intangibles, we see the second quarter in the $2.15 to $2.19 range. 
Despite the challenging and volatile FX environment, based on exchange rates at the current levels, we expect to deliver adjusted EPS between $8.95 and $9.05 for the full year of the 2015. 
And with that, I'll hand the call back to Tim."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session. To accommodate the number of investors on the call, I would ask that you limit yourself to one question only.",44,"That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session. To accommodate the number of investors on the call, I would ask that you limit yourself to one question only."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] Our first question comes from Larry Keusch with Raymond James.",12,"[Operator Instructions] Our first question comes from Larry Keusch with Raymond James."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess for Tim and perhaps Chris. One of the consistent investor concerns is the ability to fill the gap when the Gore royalty cease really in 2020. So I was hoping that you guys might help us think a little bit about how you are thinking about that scen",67,"I guess for Tim and perhaps Chris. One of the consistent investor concerns is the ability to fill the gap when the Gore royalty cease really in 2020. So I was hoping that you guys might help us think a little bit about how you are thinking about that scenario and what options are available as you sit here today, thinking about how to fill the gap."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I appreciate your long-term perspective. That is clearly something that we are well aware of. We've known about it for quite a while now. We have fully, in fact frequently, discussed with the board and really putting it together to invest back in th",168,"Sure. I appreciate your long-term perspective. That is clearly something that we are well aware of. We've known about it for quite a while now. We have fully, in fact frequently, discussed with the board and really putting it together to invest back in the company to achieve growth at above market level. As that continues to manifest, if you will, and exponentially, the company gets larger becomes less of an issue that we have to deal with and frankly, doesn't really become a deal for us until the almost the end of I think the last quarter of 2019. So we got plenty of time to deal with it. We've got clear sight of what that is. But as the company gets larger, the issue becomes smaller. Investments are doing very well the ones that we put in place a couple of years ago, that's not -- that plan doesn't stop. It kind of continues and we would expect to continue to grow beyond that. Chris [indiscernible]"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I'd add and I think we talked to investors about this is in addition to the entire objective here of being to grow the company in a way that that portion of the income statement becomes smaller and smaller, which I think this quarter",145,"The only other thing I'd add and I think we talked to investors about this is in addition to the entire objective here of being to grow the company in a way that that portion of the income statement becomes smaller and smaller, which I think this quarter again this shows we're having good success in doing, we certainly overtime will have balance sheet flexibility as well as one other arrow in the quiver to deal with the final ending of the royalty. But as Tim said, that runs through August of 2019. And through a combination of growing the business, utilizing the balance sheet, certainly, we expect to continue to be adding through inorganic means over time as well. We think it's a problem if you want to call it a problem. That will be certainly manageable by the time we approach 2019."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Mike Weinstein with JPMorgan.",9,"Our next question is from Mike Weinstein with JPMorgan."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","The commentary upfront on Lutonix, obviously, it's tough to try and read market trends with the stock that goes competitor coming in. But it looked like the first quarter out-of-the-box, which is your fourth quarter, you had this really strong quarter. An",86,"The commentary upfront on Lutonix, obviously, it's tough to try and read market trends with the stock that goes competitor coming in. But it looked like the first quarter out-of-the-box, which is your fourth quarter, you had this really strong quarter. And then sequentially, it steps down a little bit because of the entrance of the competitor maybe less stocking. Can you say A is that generally an accurate depiction? And B, could you give us a bit of picture of what's happening underneath all that?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I'll take top line shot and then I'll give it to John. I think the -- what's important for us anyway internally within the management group is that the first quarter, we exceeded what our expectations were for the revenue of the products. So we're al",78,"Yes. I'll take top line shot and then I'll give it to John. I think the -- what's important for us anyway internally within the management group is that the first quarter, we exceeded what our expectations were for the revenue of the products. So we're all about a long ramp here in growing this market. And clearly, from what we have budgeted, we [indiscernible] for Q1 fourth quarter So I'll let John give you some more color."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that was the most important fact [indiscernible] quite frankly Secondly, I'd add to that is that we see our momentum building, not winning. And in addition, we completed our training of Boston Scientific in Q1 They'll come on board in Q second [ph",67,"I think that was the most important fact [indiscernible] quite frankly Secondly, I'd add to that is that we see our momentum building, not winning. And in addition, we completed our training of Boston Scientific in Q1 They'll come on board in Q second [ph] in certain areas. And quite frankly, as Tim said, we exceeded our expectations and we really like where we are right now."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just from an accounting standpoint perspective you guys get any stocking benefit from supplying Boston Scientific product in the second quarter?",21,"Just from an accounting standpoint perspective you guys get any stocking benefit from supplying Boston Scientific product in the second quarter?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that will be probably larger than typical order in the first quarter as they get the product broadly into the hands of their reps in -- our second quarter. And then again, we'll have to see over time how that plays out in Q3 and Q4 of this calenda",80,"I think that will be probably larger than typical order in the first quarter as they get the product broadly into the hands of their reps in -- our second quarter. And then again, we'll have to see over time how that plays out in Q3 and Q4 of this calendar year. But again, it's not overly material as we look at the total sales of Lutonix overall for the company. But it will be a slightly higher order out-of-the-box."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. Last question but can you just talk about the performance neurology business? That was probably the one business that was most notable ahead of our expectation. Can you just talk about relative to your own internal model and what was better than exp",44,"Okay. Last question but can you just talk about the performance neurology business? That was probably the one business that was most notable ahead of our expectation. Can you just talk about relative to your own internal model and what was better than expected?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think it's interesting. We talked for a while now that unfortunately, that business growth rate has been masked by some declining categories. Declining categories are starting to get relatively immaterial and it's allowing some of the good things g",179,"Yes. I think it's interesting. We talked for a while now that unfortunately, that business growth rate has been masked by some declining categories. Declining categories are starting to get relatively immaterial and it's allowing some of the good things going on there to really shine through. And it was really, I think, the Rochester business has done very well. We saw really good growth globally in Q1 there. The Targeted Temperature Management had a really strong quarter, again, globally. And we're trying to bring value to customers in the basic drainage in a market that from unit standpoint is pretty flat. But by really bringing trays that allow them to provide efficiency and effectiveness in terms of deploying that product around the hospital and getting the nurses to be able to insert it in a consistent way, we're seeing good growth. And so I think you're seeing the impact the short-step product in Q1 helping to contribute to that. So you put those things together and it lines up for a pretty nice quarter out of the gate."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Brooks West with Piper Jaffray.",10,"Our next question is from Brooks West with Piper Jaffray."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","On Lutonix again, guys, understanding the unwillingness to give us a specific number, can you speak to the market? There's been some speculation on The Street that maybe your initial thoughts on $100 million market should be expanded. Can you give us some",67,"On Lutonix again, guys, understanding the unwillingness to give us a specific number, can you speak to the market? There's been some speculation on The Street that maybe your initial thoughts on $100 million market should be expanded. Can you give us some commentary there? And then second is can you give us some of the dynamics between the U.S. and international markets on the Lutonix device?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take the first one. We are essentially almost 2 quarters -- a little over 1.5 quarters out-of-the-box in the U.S. new market. We referenced the stocking order in the fourth quarter. So that's difficult to -- I wouldn't change what we thought th",145,"Sure. I'll take the first one. We are essentially almost 2 quarters -- a little over 1.5 quarters out-of-the-box in the U.S. new market. We referenced the stocking order in the fourth quarter. So that's difficult to -- I wouldn't change what we thought the size of the market was based on what we're seeing so far. I will tell you this, we let -- we track the order rates. We like the way that's going. We like the anecdotal feedback that we're getting.  Both John and I have been out in the field recently ourselves. And we continue to feel very optimistic about the anecdotal feedback from the customer base. So too early to change any macro market size based on a couple of quarters. But we're very pleased with the progress so far and what we're hearing about the product and the technology."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'd say on the difference in dynamics between United States and international, really, international was really Europe to speak of, although we have some approvals that are coming through and we'll launch those products as the approval start is that w",151,"And I'd say on the difference in dynamics between United States and international, really, international was really Europe to speak of, although we have some approvals that are coming through and we'll launch those products as the approval start is that we continue to take share internationally, specifically in Europe. We like the momentum we have there. The United States speaks for itself. I think the market, as mentioned, we continue to focus on that [indiscernible] million in the first full year United States. And I'd say that what we're concentrating on is the rollout of the different indications as we finished the clinical trials with different indications in the United States. And then, geographically, as we finish the clinical trials and/or approvals in the major marketplaces, becomes a pretty powerful operation having both of those positive items as momentum builders as you go through the next number of years."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Bob Hopkins from Bank of America.",12,"We now have a question from Bob Hopkins from Bank of America."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple of really quick ones. First on Lutonix. Last quarter, you kind of suggested how much Lutonix contributed to the growth rate of the company. So we can understand what kind of the organic growth rate was of the base business. I was wondering if you",54,"A couple of really quick ones. First on Lutonix. Last quarter, you kind of suggested how much Lutonix contributed to the growth rate of the company. So we can understand what kind of the organic growth rate was of the base business. I was wondering if you're willing to comment on that this quarter?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Bob. It was just a little less than 2 points of the growth in Q1.",16,"Yes, Bob. It was just a little less than 2 points of the growth in Q1."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then just real quickly. I know it's early, but either for Tim or for John on how you're competing in the marketplace with Medtronic. It's really early. But are you guys confident that at a minimum, this can be 50-50 share? And then, lastly I wan",85,"Okay. And then just real quickly. I know it's early, but either for Tim or for John on how you're competing in the marketplace with Medtronic. It's really early. But are you guys confident that at a minimum, this can be 50-50 share? And then, lastly I want to see Tim can just comment on the kind of environment we're in right now from an M&A perspective and what you're seeing out there. Is the pipeline full? I just wanted to get an update there."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We actually don't internally predict market share goals or objectives. We just try to get a little bit more of it everyday. So we are pleased with the positioning of the product. We think as more of the real world data comes into play versus the cli",191,"Sure. We actually don't internally predict market share goals or objectives. We just try to get a little bit more of it everyday. So we are pleased with the positioning of the product. We think as more of the real world data comes into play versus the clinical trial, data was used for the that becomes increasingly meaningful for us and certainly, is perceived that way in the market, I can tell you firsthand from that. So we're pleased with where we are in technology that we think we thought it was going to be. As it relates to the M&A environment, we are still extremely active. And we are not pleased with the execution last year in terms of getting things done. It wasn't for lack of effort or emphasis. It's just kind of the way deal flow happens. There's a lot of things going on right now. And I wouldn't be surprised if you start hearing more from us soon about those kinds of things. But again, you got to have 2 sides to agree. And we're very active right now. So we'll let you know as things occur."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Turkaly with JMP Securities.",10,"Our next question is from David Turkaly with JMP Securities."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just quickly, what kind of diligence, if any, did Boston Scientific do on Lutonix? And I guess you could comment on sort of number of reps you guys will have combined with compared to Medtronic.",35,"Just quickly, what kind of diligence, if any, did Boston Scientific do on Lutonix? And I guess you could comment on sort of number of reps you guys will have combined with compared to Medtronic."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","We have to make sure that you knew how to spell it.  So we made sure [indiscernible]. Beyond that, I think with the publication of the data, the fact it was available in the market outside the United States. I think they certainly thought they had enough",56,"We have to make sure that you knew how to spell it.  So we made sure [indiscernible]. Beyond that, I think with the publication of the data, the fact it was available in the market outside the United States. I think they certainly thought they had enough diligence to make whatever decision they want to make."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think when you look at the combined commercial presence between ourselves and the sort of the proportion of Boston's reps time that you could expect would be spent detailing Lutonix, we are on  a pretty even playing field with the new Medtronic Covidien",60,"I think when you look at the combined commercial presence between ourselves and the sort of the proportion of Boston's reps time that you could expect would be spent detailing Lutonix, we are on  a pretty even playing field with the new Medtronic Covidien commercial footprint. So from that standpoint, I think we feel like we're in good shape."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Then we'll go next to Kristen Stewart with Deutsche Bank.",11,"Then we'll go next to Kristen Stewart with Deutsche Bank."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess I was wondering if you can just comment more broadly on like the Vascular landscape? I guess more Endovascular just with Cornel pending acquisition of and what that may mean just for your business. I know there's been a lot of pressure from stents",69,"I guess I was wondering if you can just comment more broadly on like the Vascular landscape? I guess more Endovascular just with Cornel pending acquisition of and what that may mean just for your business. I know there's been a lot of pressure from stents. Just kind of perspectives or any concerns that you may have as they try to I guess to some degree some end markets."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, I can only -- I can't speak for them. Obviously, you can [indiscernible] them what perspectives were. I can tell you that from our experience, in my own personal experience, in fact, a very interesting report that was just issued by one of the",183,"Sure. Well, I can only -- I can't speak for them. Obviously, you can [indiscernible] them what perspectives were. I can tell you that from our experience, in my own personal experience, in fact, a very interesting report that was just issued by one of the major consulting companies about an analysis done on product leadership versus breadth of line and which kind of wins out of the end of the daily. We had nothing to do with that analysis. But it does point out the fact, which is what we concur with, market leadership and technology leadership as opposed to line is where we would rather be. Let's put it that way. And I think that clearly, you don't get many companies larger than J&J. And they decided, for whatever their reasons were, to sell that that business. We like product leadership. We like -- even in this environment, we think having the best products that clinicians prefer for their patience is important. And beyond that, you have to probably [indiscernible] about their decisions and what they expected to do with that."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","You don't expect any additional pressure with this from a pricing standpoint?",13,"You don't expect any additional pressure with this from a pricing standpoint?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No, no.",2,"No, no."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess it's to be seen. Okay. And then maybe Chris, could you comment on just given the change in FX rate movement, what, if any, FX from an EPS perspective you are absorbing since you did maintain your EPS guidance?",42,"I guess it's to be seen. Okay. And then maybe Chris, could you comment on just given the change in FX rate movement, what, if any, FX from an EPS perspective you are absorbing since you did maintain your EPS guidance?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","It's relatively -- we talked about $0.25 for the full year. It's slightly higher than that, Kristen. There's a number of moving parts, as you can imagine. And certainly, their currency is weakened where we've got large expense basis as well. So it's just",112,"It's relatively -- we talked about $0.25 for the full year. It's slightly higher than that, Kristen. There's a number of moving parts, as you can imagine. And certainly, their currency is weakened where we've got large expense basis as well. So it's just slightly higher than the $25 million I think -- excuse me, $0.25 for the full year. And I think a range around where our currencies are today, I think we can manage through. If there's another material step down, we'll obviously have to reassess that. But clearly, the business and the operations are performing in a way that it's allowed us to absorb that slight incremental increase."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","The number was down pretty significantly this quarter. Can you just maybe remind us what is in there and why?",20,"The number was down pretty significantly this quarter. Can you just maybe remind us what is in there and why?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And that's why when we acquired Rochester, there were some distributor products in Europe that came with the acquisition that we essentially discontinued really April 1 of last year. So there's about $1 million in sales in last year's Q1 and ot",60,"Yes, sure. And that's why when we acquired Rochester, there were some distributor products in Europe that came with the acquisition that we essentially discontinued really April 1 of last year. So there's about $1 million in sales in last year's Q1 and other that we discontinued. So that's driving the large -- most of the decline there and other."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Dave Lewis with Morgan Stanley.",10,"Our next question is from Dave Lewis with Morgan Stanley."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just thinking about vascular guidance for the year, but you've given that Lutonix was roughly within a number -- within $1 million. The non-Lutonix business obviously did dramatically better I think with your vascular guidance for the Year. If Luto",100,"Chris, just thinking about vascular guidance for the year, but you've given that Lutonix was roughly within a number -- within $1 million. The non-Lutonix business obviously did dramatically better I think with your vascular guidance for the Year. If Lutonix builds momentum per some of the comments on the call, it just appears that Vascular guidance is either conservative or you're certainly going to be at the upper end of the range. Just wondering if you could talk about your nonvascular performance of Lutonix builds and what that means for Vascular guidance? And then I have a quick follow-up."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we'll take it a quarter at a time, David. Certainly, from that respect, we're off to a good start. We've got again good ambitions for the rest of the year in Vascular. We saw good performance in some of the other categories frankly better than wha",116,"I think we'll take it a quarter at a time, David. Certainly, from that respect, we're off to a good start. We've got again good ambitions for the rest of the year in Vascular. We saw good performance in some of the other categories frankly better than what we had expected in Q1, including in the filter segment as well. So we'll take it as we come. And we get through Q2. And we will certainly reassess we think the full year looks. But everybody in each of the businesses certainly is doing everything they can to get to the top end of their range for the year. But it's a good start for us."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And also I'll just add biopsy had a pretty strong Q1. And a lot of that outside of the US. So that's a focus product area for us the emerging product there.",33,"And also I'll just add biopsy had a pretty strong Q1. And a lot of that outside of the US. So that's a focus product area for us the emerging product there."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 quick follow-ups. #1, there were some commentary on the PICC business and GP position. There's been a lot of jockeying in the PICC market this last couple of years with some of your smaller competitors. I'm just sort of curious why now, why this ye",93,"Just 2 quick follow-ups. #1, there were some commentary on the PICC business and GP position. There's been a lot of jockeying in the PICC market this last couple of years with some of your smaller competitors. I'm just sort of curious why now, why this year and not the prior 2 years that we saw more significant GPO pricing? And then another follow-up was just on the suit as it relates to Gore. Any updated timing on when the proceeds may flow or just the update on some from your perspective?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think you meant the port business because we had a very strong PICC business in PICC results in Q1. So we did see some pressure in the port business, primarily around new GPO agreements that we signed early in 2014 so that the business really the first",93,"I think you meant the port business because we had a very strong PICC business in PICC results in Q1. So we did see some pressure in the port business, primarily around new GPO agreements that we signed early in 2014 so that the business really the first quarter, they're kicking in as new agreement for it. So there are some price pressure because of the lower prices in those GPO agreements. If you look at our units, we set our units were just about flat. It's more pricing than anything else there."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we're signaling on that Dave, on January call, we called specifically out port pricing pressure as our long-term contracts. We obviously thought strategically it made sense for us to sign them. And we'll obviously lap that pricing pressure over time.",93,"And we're signaling on that Dave, on January call, we called specifically out port pricing pressure as our long-term contracts. We obviously thought strategically it made sense for us to sign them. And we'll obviously lap that pricing pressure over time. On  we would expect as we sit here today to receive the funds at some point during Q2. All signs lead to that with interest, it's just under $209 million. And they have our bank account information and we're awaiting the receipt. But I would expect to be during in Q2."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Matthew Taylor with Barclays.",9,"Our next question comes from Matthew Taylor with Barclays."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually calling in for Matt. the first question, I guess, in the U.S., we've been hearing about a lot of improvement in terms of volume and utilization. Not a lot but incremental improvement. I guess  are you seeing that trend as well? And can yo",55,"This is actually calling in for Matt. the first question, I guess, in the U.S., we've been hearing about a lot of improvement in terms of volume and utilization. Not a lot but incremental improvement. I guess  are you seeing that trend as well? And can you talk about maybe from European perspective as well?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No. In fact, I think that while we've seen certain glimmers of improvement and primarily we saw a little glimmer in March improvement in terms of volumes, that is probably offset by January and February's volume, where there wasn't a substantial improveme",138,"No. In fact, I think that while we've seen certain glimmers of improvement and primarily we saw a little glimmer in March improvement in terms of volumes, that is probably offset by January and February's volume, where there wasn't a substantial improvement in hospitals in the United States. So if you aggregate all, I'd say, we're optimistic. But we have not seen anything extremely tangible. And I think I've evidenced that by the way we look at our basic business in drainage, quite frankly. In terms of Europe, there was a number of reimbursement issues that are going on in Europe. France is foremost in those. We didn't have great Q1 in our European business as you probably saw. But we are optimistic that those volumes will come back as we go through the course of the year."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then I guess quick second question regarding the emerging markets business. Can you just talk about some of the key geographies that are driving the growth as well as maybe the sustainability of that growth?",36,"And then I guess quick second question regarding the emerging markets business. Can you just talk about some of the key geographies that are driving the growth as well as maybe the sustainability of that growth?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. They're all mentioned previously. So there's -- the ones in Asia and then the  ones in Latin America and then Eastern Europe and the Middle East. And they're all doing very well right now.",35,"Yes. They're all mentioned previously. So there's -- the ones in Asia and then the  ones in Latin America and then Eastern Europe and the Middle East. And they're all doing very well right now."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Or next question comes from Richard Ritter with Partners.",9,"Or next question comes from Richard Ritter with Partners."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Robbie in for Richard Newitter. I have a couple of big picture questions. So starting with a lot of people talking about what assets you are going to buy. I'm curious just to get your thoughts on some of the businesses that you said that are now s",68,"This is Robbie in for Richard Newitter. I have a couple of big picture questions. So starting with a lot of people talking about what assets you are going to buy. I'm curious just to get your thoughts on some of the businesses that you said that are now sort of less than 1% of sales, perhaps P/I and women's health.  What's the strategic outlook for those segments?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me back up and give you a broad answer. So when you look at the portfolio of 14,000 SKUs, this is a new, this has been 23 years. It's been like this since I've been here. You have 25% or so of the SKUs that are actually declining over time. So t",164,"Well, let me back up and give you a broad answer. So when you look at the portfolio of 14,000 SKUs, this is a new, this has been 23 years. It's been like this since I've been here. You have 25% or so of the SKUs that are actually declining over time. So the balancing of the portfolio and where we make the investments and where we look for acquisition, where we expands sales force, et cetera, et cetera. You're constantly going after the higher growth areas. Probably very similar to the way you manage your own investment portfolios. So we don't get too hang up on movement of one or another. I will tell you this. Relative to divestiture decisions, it's a lot easier to get rid of the business than it is the product line. And we'd rather have -- having done both, we much rather have our management teams focused on increased revenue growth opportunity than creating or proving product lines."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add is obviously you'd expect and we do run an economic analysis to determine whether or not the value of some of those declining product lines are worth more to us if we resource them appropriately from a cash flow standpoint as op",85,"And the only thing I'd add is obviously you'd expect and we do run an economic analysis to determine whether or not the value of some of those declining product lines are worth more to us if we resource them appropriately from a cash flow standpoint as opposed to what you might see if anything gets to a sale of product line. So certainly, the things we are keeping rest assured we think that's the right decision even if they are in declining mode."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe 1 question on hernia. A lot of -- looks like the OPTIFIX and the Capture products coming out soon. I'd like to hear maybe your general view on how minimally invasive surgery and in terms of robotics can affect the long-term view or the long-term",61,"And maybe 1 question on hernia. A lot of -- looks like the OPTIFIX and the Capture products coming out soon. I'd like to hear maybe your general view on how minimally invasive surgery and in terms of robotics can affect the long-term view or the long-term outlook of that business, especially if there's more conversion from open to MIS procedures?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take the bigger picture. Relative -- we're very pleased by the way with the positioning of the entire hernia portfolio. We've got great breadth of line. We got strength in one area. We were kind of weakest in my view was the fixation area. John",187,"Sure. I'll take the bigger picture. Relative -- we're very pleased by the way with the positioning of the entire hernia portfolio. We've got great breadth of line. We got strength in one area. We were kind of weakest in my view was the fixation area. John DeFord talked about a couple of projects that we had alluded to previously but feel pretty good about them now. So we've got a great, probably if you were to go by category, maybe our single strongest portfolio right now across various vertical groups within that broader category. As it relates to robotics thing, our view is we provide the products, the implants, et cetera, that would be used with the robotic mix. So I don't see it dramatically impacting the business. In fact, several of our products to the extent that there are people, I think there's more talk than action right now relative to that. But I -- we know that a couple of our products have become the product of choice to be used in some of those procedures. With that, I'll let John DeFord put some..."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. just to weight in. Maybe you're alluding to in robotic surgeries fixation devices aren't typically needed because they can suit you with robotic device. And so again, I think we see that we are well-positioned. We don't see that happening overnight.",160,"Sure. just to weight in. Maybe you're alluding to in robotic surgeries fixation devices aren't typically needed because they can suit you with robotic device. And so again, I think we see that we are well-positioned. We don't see that happening overnight. And certainly, robotic surgery is pretty limited right now. There are some benefits, of course. You can close the abdominal wound before some of the fixation is required. You can do a few other things. But it's pretty limited in the procedures that you can use robotics in today. So we think we've got a good mix. As Tim and John had said earlier, we think we've got from a mesh or implant perspective, a great mix of products that work well with the robotic surgery as well as with laparoscopic and open. And we also think our fixation products are going to be useful in a number of different repairs that aren't necessarily meaningful to robotics today."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] Our next question will come from Dave Roman with Goldman Sachs.",13,"[Operator Instructions] Our next question will come from Dave Roman with Goldman Sachs."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just start with a follow-up on your M&A commentary, Tim. There's a tremendous amount of deal euphoria in health care as obviously, everyone has observed. But can you maybe just talk to us about how you're thinking about cash EPS accretion vers",89,"I wanted to just start with a follow-up on your M&A commentary, Tim. There's a tremendous amount of deal euphoria in health care as obviously, everyone has observed. But can you maybe just talk to us about how you're thinking about cash EPS accretion versus ROIC? I understand the benefit of a press release that goes out with a 15% accretion number in it. But also, obviously, you're stuck with the asset over time. So how you do think about really finding value given the M&A environment now?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","That's an interesting question. I think you go and this is a new thing. I mean, those kinds of properties and models, if you will, call it accretion versus revenue growth, if you just wanted to just book on the 2. I've always been there. We had our eyes w",181,"That's an interesting question. I think you go and this is a new thing. I mean, those kinds of properties and models, if you will, call it accretion versus revenue growth, if you just wanted to just book on the 2. I've always been there. We had our eyes wide open to those, especially when you get into larger deals. Some of that actually go find that synergy and execute against that that, that's always tend to be a little more difficult than people think. And while you're doing that, those are the same management groups that you're expecting to go the other business -- really the decision for management group is it where you want your people and your management teams spending the time. So we have lots -- what's occurred in the marketplace, we watch how investors have reacted to those deals. It's kind of interesting and we clearly have targets. We put them into different categories. But we security are more of the revenue growth mindset at the moment versus the accretive and slower revenue growth mode."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the other thing I would add, David, ROIC is very important to us. When we're evaluating opportunities, we're trying to be good stewards of shareholders capital. And we think the notion of near-term accretion for a transaction that frankly is not a goo",118,"And the other thing I would add, David, ROIC is very important to us. When we're evaluating opportunities, we're trying to be good stewards of shareholders capital. And we think the notion of near-term accretion for a transaction that frankly is not a good return for shareholders, we -- we're going to be very careful as how we deploy the capital. We're going to do it in a way that's not going to be driven by near-term accretion. It's got to make sense strategically from a return standpoint. And if it's accretive, that's obviously terrific as well. But if all of those factors are certainly important to us and we're not going to wait short-term accretion over ROI."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then, maybe just a follow-up on the business and perhaps sort of along the same lines. Emerging Markets obviously remains quite strong for you. But as a percentage of sales, it's relatively small compared to the peer group. It seems like going to take",122,"And then, maybe just a follow-up on the business and perhaps sort of along the same lines. Emerging Markets obviously remains quite strong for you. But as a percentage of sales, it's relatively small compared to the peer group. It seems like going to take a while to see that number move in sort of a step function type of way. And I guess we've seen some others in go into emerging markets and pay you decent premiums or assets there. I mean, is there a strategy -- is there a vehicle organically to accelerate the emerging market adoption where that can get to midteens, call it, percentage of sales number? Or is that something that have to come through external investments?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that the game plan that we put in place, which was investing heavily and building our teams of people around the world and then arming them with the products that come through our R&D pipeline and do that via great training of physicians is the ri",95,"I think that the game plan that we put in place, which was investing heavily and building our teams of people around the world and then arming them with the products that come through our R&D pipeline and do that via great training of physicians is the right long-term strategy for us. We've made the investments. We've seen the growth in all those segments. We like the game plan. And I think it's one step at a time for us. But we believe that's how you build meaningful business long-term that has great staying power."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think going back to ROI. I think if you look at some of those larger transactions in emerging markets. I'd question what the returns are going to be on those. Again, coming back to the right balance between risk and growth, to John's point, we think",106,"And I think going back to ROI. I think if you look at some of those larger transactions in emerging markets. I'd question what the returns are going to be on those. Again, coming back to the right balance between risk and growth, to John's point, we think we got the right strategy. We are looking for targets that make it through our filters. And we spend a lot of time looking. And again, our bar is reasonable but relatively high. And we clearly have done target that we think makes sense for us. In the meantime, we're doing a terrific job growing the business organically."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Josh Jennings with Cowan and company.",11,"Our next question is from Josh Jennings with Cowan and company."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just one for you. I was hoping you could help us think about long-term operating margin expansion opportunities and getting back to that levels that you had performed prior to 2013. Looks like you're doing a great job navigating those rolling FX th",70,"Chris, just one for you. I was hoping you could help us think about long-term operating margin expansion opportunities and getting back to that levels that you had performed prior to 2013. Looks like you're doing a great job navigating those rolling FX this year and seeing some operating margin expansion to get the midpoint of EPS range. But how should we think about operating margins in the out years?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think this year is going to be a nice down payment. I think Josh on returning to those levels. Certainly, as we talk about some of the portfolio moves we made in 2013 were dilutive in terms of exiting the EP business and adding Rochester in particular.",190,"I think this year is going to be a nice down payment. I think Josh on returning to those levels. Certainly, as we talk about some of the portfolio moves we made in 2013 were dilutive in terms of exiting the EP business and adding Rochester in particular. Those were the right moves for the company, no question. And we're really pleased with the portfolio. Having said that, it did set us back a bit. '15 will be a nice down payment. Every year, our commitment is to drive operating leverage and operating improvement. That's what the management team is tasked and committed to do. And I won't give you a point in time we will get back to that level. But I think we are well on our way you can get everything we've done in constructing the portfolio in terms of adding higher margin products. To John's point, we got infrastructures built in the emerging markets that are going to be leverage a blow for the number of years to come. We feel good about the ability for us to continue to move the entire year after year."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just one follow-up for John DeFord and maybe Tim can pitch in. On just the Vascular business now, being the leader in the stent as well as drug-coated balloons, is there anything else in the portfolio that you need to fill your bag with and maybe spec",67,"And just one follow-up for John DeFord and maybe Tim can pitch in. On just the Vascular business now, being the leader in the stent as well as drug-coated balloons, is there anything else in the portfolio that you need to fill your bag with and maybe specific commentary on your outlook for the combo of atherectomy and drug-coated balloons and to have an atherectomy technology?"
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We constantly look at what we think are the right combinations of products within all of our spaces, Vascular certainly. We've always had a close eye on atherectomy  in particular. We're always a little nervous about the reimbursement in that space.",107,"Sure. We constantly look at what we think are the right combinations of products within all of our spaces, Vascular certainly. We've always had a close eye on atherectomy  in particular. We're always a little nervous about the reimbursement in that space. That said, it seems to continue to hold much to my surprise. But it's something that we'll be continuing to capitalize eye on. We think the potential combination with DCB could be interesting. We are already seeing and running some studies around using our technology with stents, using our technology in other product cases. And so we're continuing to keep that as something to evaluate."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I would just add, I think a lot of the opportunity we have, we already own. So the ability to get further indications for Below the Knee, we think that's really interesting being able to go through smaller vessels with DCB. The whole AV access area we",90,"And I would just add, I think a lot of the opportunity we have, we already own. So the ability to get further indications for Below the Knee, we think that's really interesting being able to go through smaller vessels with DCB. The whole AV access area we think is a huge opportunity. Relative to stent grafts, drug-coated technology and combination of those. So we think there's a lot of runway left both in our internal revenue and in expanding the markets, just with the platforms that we have today."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we just mentioned today a couple of new product that we expect to be launching in Europe by the end of the year, entering the venous market with Venus stent technology and also, our AV access and next-generation stent graft kind of products. So we thi",58,"And we just mentioned today a couple of new product that we expect to be launching in Europe by the end of the year, entering the venous market with Venus stent technology and also, our AV access and next-generation stent graft kind of products. So we think those organic ways to continue to expand the pipeline as well."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And that does conclude our Q&A session. I'd like to turn the call back over to management for closing or additional comments.",23,"And that does conclude our Q&A session. I'd like to turn the call back over to management for closing or additional comments."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Thanks, everybody for staying with us. Sorry, we went a little bit over the hour. I'd like to take this opportunity and thank Bard employees around the world. We have a very strong start for the year and look forward to updating you on our prog",55,"Thank you. Thanks, everybody for staying with us. Sorry, we went a little bit over the hour. I'd like to take this opportunity and thank Bard employees around the world. We have a very strong start for the year and look forward to updating you on our progress at the end of the next quarter."
254131,290174664,793575,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Okay thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect.",28,"Okay thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand r",268,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations. 
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors each in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings release on the company's website at www.crbard.com. All information that is not historical is given only as of April 23, 2015, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much. I'd like to welcome everybody to Bard's first quarter 2015 earnings call and thank all of you for taking the time to join us today. We'd expect the presentation portion of the call to last about 25 minutes. And we're going to try to k",613,"Thank you very much. I'd like to welcome everybody to Bard's first quarter 2015 earnings call and thank all of you for taking the time to join us today. We'd expect the presentation portion of the call to last about 25 minutes. And we're going to try to keep the total call to about 1 hour or less. 
The discussion today will go as follows. I'll begin with an overview of the results for the first quarter. John Weiland, our President and COO will review first quarter product line revenue. John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our productive development pipeline, after which, Chris Holland, our Senior VP and CFO, will cover the first quarter income statement and balance sheet as well as our expectations for Q2. And finally, we'll close with Q&A. 
First quarter 2015 net sales totaled $819.7 million. That's up 3% over Q1 last year on an as-reported basis and up 5% on a constant currency basis. The currency impact for the quarter versus last year was unfavorable by about 260 basis points. The quarterly royalty payment from Gore was $38.4 million, which represented slower growth than our product portfolio. So our organic revenue growth this quarter was about 5.3%, which was better than our guidance. 
Net income for the first quarter was $139.8 million, and diluted earnings per share were $1.82. That's down 6% and 2%, respectively, excluding certain items that affected the comparability of results between periods, which Chris will cover later. The first quarter 2015 net income was $142.4 million, up 6%. And diluted adjusted earnings per share, which exclude amortization, were $2.10. That's up 10%. This was also above our expectations despite the additional headwind from currency and represents a good start to what's an important year of execution for us. 
Looking at revenue growth geographically compared to the first quarter of last year. Q1 net sales in the U.S. grew 4% compared to a year ago. On a constant currency basis, in Europe, we were up 1%. Japan was up 5%. And our other international businesses were up 18%. 
We saw strong sales growth across all of our emerging market geographies in the first quarter as our investments over the last couple of years have strengthened our position in these faster growing markets. As a percentage of total sales in the first quarter, emerging markets represented between 8% and 9% of sales compared to just 7% a year ago. And while it's still a small percentage of portfolio, in some of our major product lines, the actual dollar growth we saw in emerging markets exceeded the dollar growth of the same products in the U.S. this quarter. 
As you know, emerging markets is just one of the opportunities we've highlighted as a key long-term revenue growth driver for us. In fact, you'll hear, as John Weiland takes you through the sales results, that each of the growth drivers we highlighted as part of our strategic investment plan performed well this quarter. 
We remain focused on the execution of that plan and providing the expected returns on those investments in 2015 and beyond. Chris will provide the detailed update to our guidance a bit later in the call, but I'm pleased to tell you that our strong start to the year and our confidence in our ability to execute on the things we can control, we believe we can manage the challenging foreign exchange environment so far and maintain our original financial guidance for 2015. 
So with that summary, let me now turn you over to John Weiland for a review of our product line revenue."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $23",858,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $231.9 million, up 6% over last year on a reported basis and up 10% on a constant currency basis. U.S. Vascular sales were up 8% in Q1 and international sales were up 11%. 
Sales in our Surgical Graft category were down 4% this quarter within the range of recent experience. Our Endovascular business was up 10% in the first quarter, and it was up 12%, excluding the Gore royalty. 
Our biopsy products had a strong quarter, up 9%, and driven by good growth internationally, especially in emerging markets. 
Our peripheral PTA line increased 32% in the first quarter, with sales of our Lutonix DCB exceeding our expectations. We saw a good acceleration in the daily usage of the device after some large initial stocking orders in the fourth quarter. 
In Q1, we worked with Boston Scientific to train their reps on the product and, in Q2, received our first order from them. As you probably saw, hospital outpatient procedures are now eligible for reimbursement through CMS as of the beginning of the second quarter, an important milestone for the category. 
Our vena cava filter line grew 6% in Q1. Our Stent business declined 3% in Q1 compared to the prior year, and we continue to expect significant price pressure in this category. 
Now let's move to Urology. Total net sales were $205.6 million, up 2% versus the first quarter of last year on a reported basis and up 5% on a constant currency basis. The United States business was up 4%, and internationally, we grew 6%. We saw double-digit growth in our Targeted Temperature Management products again this quarter. And we remain encouraged by the long-term opportunity here. Our basic drainage business was up 4% in Q1 and up 2% in the United States. Within that category, our I.C. Foley business was up 1% globally and down 2% in the United States. 
Our continence business was up 7% in Q1, driven by double-digit growth in our DIGNICARE and male-external catheter sales. 
Our women's health product lines continue to decline but now make up less than 20% of the continence category and less than 1/2 of a percent of Bard's total sales. 
Sales in Urological Specialties were down 1% in the first quarter, with our brachytherapy down 4%. And finally, standalone sales of our StatLock catheter stabilization line increased 5% in Q1. 
Next is Oncology. Total net sales in this category were $224.6 million, an increase of 3% over Q1 last year on a reported basis and up 5% on a constant currency basis. Geographically, net sales in the United States were up 1%, and international sales were up 15%. 
Our port business was down 3% over Q1 of last year. We forecast that significant United States pricing pressure here related to GPO contracts signed in 2014, which drove the decline as units were essentially flat with prior year. 
Our PICC revenues were up 9% globally with good growth in the United States and even better growth internationally. And to close out the category, our vascular access ultrasound product line grew 12% this quarter, and our dialysis catheter product line was up 8%. 
So then let's finish with Surgical Specialties. Total net sales in this category were $135.9 million, up 1% on a reported basis, and up 3% on a constant currency basis. U.S. sales were up 5%, and international sales were down 4% in the quarter. Most of that international decline was driven by our performance irrigation business, which was down 34% globally due to the discontinuation of certain products in this category, which now represents less than 1% of total Bard sales. 
Our soft tissue business -- soft tissue repair business grew 5% this quarter. Within soft tissue, our synthetic hernia business grew 8% in Q1. 
In biologics, we were very pleased with the first full quarter of sales from our XenMatrix AB product, which is a porcine graft with an antibiotic coating. Thanks to the contribution from this new first-of-its-kind device, our total biologic category was flat in Q1, reversing a trend of double-digit declines. 
We have the broadest portfolio in hernia repair across all types of products, from a wide range of synthetics to natural tissue and now antibiotic coated natural tissue. We are working with physicians to identify the right product for the right patient and provide a wide range of options for them. 
Our hernia fixation line declined 9% this quarter -- 7% this quarter, within the range of recent experience. As you'll hear from John DeFord, we have some new products in our pipeline that we believe will help us get back to growth in this category. 
We are well past the anniversaries of our acquisitions of BioSurgery, and that business grew double digits again this quarter. We remain bullish on the long-term opportunity here. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We started off 2015 with several product launches. And as you'll hear in my update, our pipeline and plans show a very active 2015 and beyond. I'll start with drug-coated balloons, where we're making good prog",1131,"Thanks, John, and good afternoon, everyone. We started off 2015 with several product launches. And as you'll hear in my update, our pipeline and plans show a very active 2015 and beyond. 
I'll start with drug-coated balloons, where we're making good progress on additional sizes and indications worldwide. We filed the PMA supplement for additional balloon sizes for use in the SFA and popliteal and anticipate launch in the back half of this year. 
In our clinical activities, we've completed initial follow-up in our Levant 2 Japan study. We're in the data analysis phase, and we expect to submit in the back half of the year for approval. Enrollment continues in our Below the Knee and in-stent restenosis IDE studies. And we recently submitted the IDE for our AV access study with enrollment anticipated to start in Q3. We're also working toward the start of our Levant China study and expect to begin enrollment in the back half of the year. 
The Levant 2 study design was described in detail in a recent publication authored by Dr. Michael Jaff and several investigators in the American Heart Journal. We also expect the 24-months Levant 2 results to be presented at SVS [ph] in June. 
Also in Vascular, the LifeStream Balloon Expandable Covered Stent clinical study is recruiting quickly, and we anticipate completing enrollment later this year. This IDE evaluates the technology for the treatment of iliac artery disease. 
In other stent graft news, our next-generation device for use in AV access is nearing completion and development, and we anticipate launching in Europe in Q4. This product will require a clinical study for U.S. approval, and we anticipate filing the IDE and initiating a study in the first half of 2016. 
We have a new venous stent project that's on a similar development pathway with launch anticipated in Europe in Q4 and an IDE study expected to begin around the end of the year. 
Next, moving to Urology. We've launched our new skyline sub 2 French stone basket family and are working to expand the platform with 2.4 and 3 French versions expected later this year. 
Also in endourology, we anticipate launching our new access sheath system in the back half of the year. We believe these new products provide the urologist with needed improvements to some of the tools they're currently using in this important interventional space. 
In home care, we're nearing the launch of a new intermittent self-catheterization product, the Magic 3 Touchless, slated for release in Q3. Magic 3 Touchless combines the comfort and insertion benefits of the Magic 3 platform, combined with our touchless closed system designed to reduce the risk of contamination and infection due to catheter insertion. We've got a couple of other products in our intermittent catheter family that are slated to launch later this year. But I'll hold back the details until we get closer to product release. 
Moving to Oncology. We recently received U.S. regulatory clearance for our freehand stereotactic system for Vascular Access, named Pinpoint GT. The Pinpoint GT technology will be offered on the new Site-Rite 8 ultrasound system slated for launch later in the year. We believe the combination of Site-Rite ultrasound, Pinpoint GT yield guidance and 3CG Diamond catheter tip confirmation in an integrated system will provide a complete clinical solution for vascular catheter placement. 
In PICC, we're on track for a Q3 regulatory submission for our new thromboresistant coating. Upon regulatory clearance, we plan to launch a broad line of catheters marketed under the COVERT PICC trade name. We expect to follow the COVERT PICC with a combined antimicrobial and thromboresistant coating planned for launch in the back half of 2016. 
In midlines, we launched the 22-gauge PowerGlide catheter in Q1, completing our sizes in the PowerGlide product family. We're also making good progress on our next generation of midline catheters and anticipate our U.S. regulatory submission in Q4 with a first half 2016 launch. 
For the acute hemodialysis patient, we're expanding upon our market-leading Trialysis catheter family with the anticipated regulatory clearance and launch later this quarter of our new Trialysis slim. Trialysis slim incorporates superior flexibility, kink resistance and flow rates in excess of 400 milliliters per minute in a small 12-French triple lumen catheter configuration. 
I'll close my portion of the discussion today with surgery. On our last call, we told you about our launch of the first antibiotic coated biologic mesh, XenMatrix AB. As John Weiland told you, the product is receiving excellent early feedback, and we're working hard to expand the size matrix available, with additional launches expected over the course of the next several quarters. 
We're also making good progress toward the launch of a new product family that incorporates our proven Sepra barrier technology with our Phasix bioresorbable mesh family to create the Phasix ST. Phasix ST is designed for intra-abdominal placement and is on track to launch in Q3. This new offering supplements XenMatrix AB, XenMatrix and Phasix to allow us to offer proprietary and differentiated products designed to address the entire spectrum of complex abdominal wall repairs. 
Moving onto our BioSurgery product family. In early Q3 of 2014, we filed our PMA supplement for our Progel sealant, seeking expanded use in video-assisted and robot-assisted thoracic surgery. We received approval from FDA earlier this quarter, and I'm pleased to announce the launch is underway ahead of schedule. 
Also in January of this year, we completed follow-up in our Tridyne vascular sealant pivotal IDE study. Analysis is complete and the team is working toward PMA submission this quarter. Following this time line, we anticipate approval and launch in mid-2016. 
And finally, in mesh fixation, we're gearing up for the launch in the next couple of weeks of our first spring-loaded resorbable tack device named OPTIFIX. OPTIFIX has been designed to employ stored energy for ease and efficiency of tack delivery while reducing tissue trauma that's been associated with some competitive devices. 
In past calls, I've told you that we have another fixation platform under development, but we've not disclosed the details. Now the time is right and I'm pleased to announce that we anticipate launching our new permanent fixation device named Capsure later this quarter. Capsure is the result of several years of analysis of the permanent fixation market and was designed to reduce the risk of tissue injury due to exposed sharps and concern over adhesions and reliability, while providing the functional requirements of a permanent tack, including the ability to penetrate hard tissues such as Cooper's ligament. With these 2 fixation launches, we're excited to move back to playing offense in this highly competitive space. 
Thanks for your attention today. We look forward to updating you on our progress throughout the year. Now I'll hand our discussion over to Chris."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We got a credit and acquisition-related items of $9.2 million pretax, a $3.9 million pretax charge for restructuring and productivity ini",650,"Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We got a credit and acquisition-related items of $9.2 million pretax, a $3.9 million pretax charge for restructuring and productivity initiatives, and we recorded expense of $10.3 million, primarily related to the judge's order in the women's health litigation that we work up 500 cases simultaneously. The P&L impact of these items is detailed in the notes to the financial statements and in the reconciliation accompanying our Q1 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $508.5 million or 62% of sales for Q1. On an adjusted basis, GP was $498.6 million or 60.8% of sales, down 60 basis points from the prior year quarter, consistent with our guidance. FX costs us 30 basis points in GP this quarter and the new amortization from the Q4 2014 Lutonix approval was 40 basis points in Q1. 
Price pressure drove 130 basis points on the revenue line in Q1 and about 50 basis points of headwind on GPs, consistent with our expectations. Our cost improvements drove about 40 basis points of benefit to GPs this quarter, and mix was favorable by about 20 basis points. 
As we look to Q2, we expect gross margin to be similar to the Q2 2014 level, despite FX pressure and the incremental amortization. 
SG&A expenses were $235.7 million for the quarter or 28.8% of sales. On an adjusted basis, SG&A as a percent of sales was 28.7%, a decrease of 90 basis points. We are on track with our annual guidance of delivering improved P&L leverage for the full year. 
R&D expenditures totaled $60.6 million for the first quarter or 7.4% of sales on both a reported and adjusted basis, consistent with our guidance. Interest expense was $11.3 million for the first quarter. 
Other income and expense was $16.3 million of expense for the first quarter as reported and $1.6 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.3% on a reported basis and 24.9% on an adjusted basis, the same level as a year ago. And again, our full year guidance assumes the renewal of the R&D tax credit, but that will not be included in the reported numbers until it is renewed. 
Diluted shares for the period were 75.8 million, and we purchased 1.2 million shares during the first quarter. The net result is adjusted EPS of $2.10, which exceeded our expectations for the quarter. 
The balance sheet as of March 31 reflects cash, restricted cash and short-term investments of approximately $1.03 billion versus $1.01 billion at December 31. For the quarter, accounts receivable days were up 0.7 days, and inventory days were up 0.3 days. Capital expenditures totaled $29 million for the quarter. 
On the liability side, total debt was $1.6 billion as of March 31 compared to $1.5 billion at the end of December. Debt-to-total cap at the end of the first quarter was about 48%, and total shareholder investment was $1.7 billion at March 31. 
In looking at Q2, we're expecting constant currency sales growth between 4.5% and 5.5% and would expect organic growth to be within the same range. We are now expecting currency headwinds based on exchange rates at their current levels to reduce reported sales by about 4% for Q2 and the full year, up from about 3% in original -- in our original guidance in January. 
From an adjusted EPS standpoint, excluding items affecting comparability and the amortization of intangibles, we see the second quarter in the $2.15 to $2.19 range. 
Despite the challenging and volatile FX environment, based on exchange rates at their current levels, we expect to deliver adjusted EPS between $8.95 and $9.05 for the full year of 2015. 
And with that, I'll hand the call back to Tim."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session. To accommodate the number of investors on the call, I would ask that you limit yourself to one question only.",44,"That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session. To accommodate the number of investors on the call, I would ask that you limit yourself to one question only."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] Our first question comes from Larry Keusch with Raymond James.",12,"[Operator Instructions] Our first question comes from Larry Keusch with Raymond James."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess for Tim and perhaps Chris, one of the consistent investor concerns is the ability to fill the gap when the Gore royalties cease really in 2020. So I was hoping that you guys might help us think a little bit about how you are thinking about that sc",67,"I guess for Tim and perhaps Chris, one of the consistent investor concerns is the ability to fill the gap when the Gore royalties cease really in 2020. So I was hoping that you guys might help us think a little bit about how you are thinking about that scenario and what options are available as you sit here today thinking about how to fill the gap."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I appreciate your long-term perspective. That is clearly something that we're well aware of. We've known about it for quite a while now. We have fully, in fact, frequently discussed with the board. And clearly have put a plan together to invest back",171,"Sure. I appreciate your long-term perspective. That is clearly something that we're well aware of. We've known about it for quite a while now. We have fully, in fact, frequently discussed with the board. And clearly have put a plan together to invest back in the company to achieve growth at above market level. As that continues to manifest, if you will, and exponentially the company gets larger, becomes less of an issue that we have to deal with and, frankly, doesn't really become a deal -- an issue for us until almost the end of, I think, the last quarter of 2019. So we got plenty of time to deal with it. We've got clear sight of what that is. But as the company gets larger, the issue becomes smaller. Investments are doing very well. The ones that we put in place a couple of years ago, that's not -- that plan doesn't stop. It kind of continues, and we would expect to continue to grow beyond that. Chris [indiscernible]"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think, Larry, the only other thing I'd add and I think we've talked to investors about, this is in addition to the entire objective here of being able to grow the company in a way that, that portion of the income statement becomes smaller and smaller, w",150,"I think, Larry, the only other thing I'd add and I think we've talked to investors about, this is in addition to the entire objective here of being able to grow the company in a way that, that portion of the income statement becomes smaller and smaller, which I think where this quarter again shows we're having good success in doing, we certainly, over time, will have balance sheet flexibility as well as one other arrow in the quiver to deal with the final ending of the royalty. But as Tim says, that runs through August of 2019. And through a combination of growing the business, utilizing the balance sheet, certainly, we expect to continue to be adding through inorganic means over time as well. We think it's a problem -- if you want to call it a problem, that will be certainly manageable by the time we approach 2019."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And to our next question is from Mike Weinstein with JPMorgan.",11,"And to our next question is from Mike Weinstein with JPMorgan."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I'm going to apologize upfront because we have a couple of calls going on at the same time, so I may have missed some of this. But just the commentary upfront on Lutonix, obviously, it's tough to try and read market trends with the stock and that goes on",122,"I'm going to apologize upfront because we have a couple of calls going on at the same time, so I may have missed some of this. But just the commentary upfront on Lutonix, obviously, it's tough to try and read market trends with the stock and that goes on and now a competitor coming in. But it looked like the first quarter out-of-the-box, which is your fourth quarter, you have this really strong quarter. And then, sequentially, it steps down a little bit because of the entrance of the competitor and maybe less stocking. Can you just say, a, is that generally an accurate depiction? And b, can you give us more of a picture of what's happening underneath all that?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I'll take a top line shot, and then I'll give it to John. I think the -- what's important to us anyway internally within the management group is that the first quarter, we exceeded what our expectations were for the revenue for the products. So we're",85,"Yes. I'll take a top line shot, and then I'll give it to John. I think the -- what's important to us anyway internally within the management group is that the first quarter, we exceeded what our expectations were for the revenue for the products. So we're all about a long ramp here in growing this market. And clearly, from what we have budgeted, is we have figured that for Q1, fourth quarter aside. So I'm going to let John give you some more color."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that was the most important fact, quite frankly, Mike. Secondly, I'd add to that is that we see our momentum building, not waning. And in addition, we completed our training of Boston Scientific in Q1. They'll come on board in Q second in certain",66,"I think that was the most important fact, quite frankly, Mike. Secondly, I'd add to that is that we see our momentum building, not waning. And in addition, we completed our training of Boston Scientific in Q1. They'll come on board in Q second in certain areas. And quite frankly, as Tim said, we exceeded our expectations and we really like where we are right now."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just from an accounting standpoint, Chris, will you guys get any stocking benefit from supplying Boston Scientific reps with product in the second quarter?",24,"Just from an accounting standpoint, Chris, will you guys get any stocking benefit from supplying Boston Scientific reps with product in the second quarter?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think there'll be a probably a larger than typical order in the first quarter as they get the product broadly into the hands of their reps in Q -- our second quarter. And then again, we'll have to see over time how that plays out in Q3 and Q4 of this ca",84,"I think there'll be a probably a larger than typical order in the first quarter as they get the product broadly into the hands of their reps in Q -- our second quarter. And then again, we'll have to see over time how that plays out in Q3 and Q4 of this calendar year. But again, it's not overly material as we look at the total sales of Lutonix and overall for the company. But it will be a slightly higher order out-of-the-box."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then last question and let somebody just jump in here. But could you just talk about the performance of the Urology business? That was probably the one business that was probably the most notable ahead of our expectations. Can you just talk abou",57,"Okay. And then last question and let somebody just jump in here. But could you just talk about the performance of the Urology business? That was probably the one business that was probably the most notable ahead of our expectations. Can you just talk about relative to your own internal model and what was better than expected?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think it's interesting. And we've talked for a while now that, unfortunately, that business's growth rate has been masked by some declining categories. Those declining categories are starting to get relatively immaterial, and it's allowing some of",182,"Yes. I think it's interesting. And we've talked for a while now that, unfortunately, that business's growth rate has been masked by some declining categories. Those declining categories are starting to get relatively immaterial, and it's allowing some of the good things going on there to really shine through. And it was really, I think, the Rochester business has done very well. We saw really good growth globally in Q1 there. The Targeted Temperature Management had a really strong quarter, again, globally. And we're trying to bring value to customers in the basic drainage in a market that from a unit standpoint is pretty flat. But by really bringing trays that allow them to provide efficiency and effectiveness in terms of deploying that product around the hospital and getting nurses to be able to insert it in a consistent way, we're seeing good growth. And so I think you're seeing the impact of the SURESTEP product in Q1 helping to contribute to that. So you put those things together, and it lines up for a pretty nice quarter out of the gate."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Brooks West with Piper Jaffray.",10,"Our next question is from Brooks West with Piper Jaffray."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","On Lutonix again, guys, understanding the unwillingness to give us a specific number, can you speak to the market? There's been some speculation on The Street that your -- maybe your initial thoughts on $100 million market should be expanded. Can you give",69,"On Lutonix again, guys, understanding the unwillingness to give us a specific number, can you speak to the market? There's been some speculation on The Street that your -- maybe your initial thoughts on $100 million market should be expanded. Can you give us some commentary there? And then second is can you give us some of the dynamics between the U.S. and international markets on the Lutonix device?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","So I'll take the first one. We're essentially almost 2 quarters -- a little over 1.5 quarters out-of-the-box in the U.S. in a new market. We referenced the stocking order in the fourth quarter. So it's difficult to -- I wouldn't change what we thought the",145,"So I'll take the first one. We're essentially almost 2 quarters -- a little over 1.5 quarters out-of-the-box in the U.S. in a new market. We referenced the stocking order in the fourth quarter. So it's difficult to -- I wouldn't change what we thought the size of the market was based on what we're seeing so far. I will tell you this, we like -- we track reorder rates. We like the way that's going. We like the anecdotal feedback that we're getting.  Both John and I have been out in the field recently ourselves. And continue to feel very optimistic about the anecdotal feedback from the customer base. So too early to change any macro market size based on a couple of quarters. But we're very pleased with the progress so far and what we're hearing about the product and the technology."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'd say on the difference in dynamics between the United States and international, really, international now was only really Europe to speak of, although we have some approvals that are coming through, and we'll launch those products as the approval s",159,"And I'd say on the difference in dynamics between the United States and international, really, international now was only really Europe to speak of, although we have some approvals that are coming through, and we'll launch those products as the approval start, is that we continue to take share internationally, specifically in Europe. We like the momentum we have there. The United States speaks for itself. I think the market, as Tim mentioned, we continue to focus on that say $100 million in the first full year in the United States. And I'd say that what we're concentrating on is the rollout of the different indications as we finish the clinical trials with the different indications in the United States. And then, geographically, as we finish the clinical trials and/or approvals in the major marketplaces, becomes a pretty powerful operation having both of those positive items as momentum builders as you go through the next number of years."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Bob Hopkins with Bank of America.",12,"We now have a question from Bob Hopkins with Bank of America."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple of really quick ones. First on Lutonix. Last quarter, you kind of suggested how much Lutonix contributed to the growth rate of the company so we could understand what the kind of organic growth rate was of the base business. And I was wondering i",59,"A couple of really quick ones. First on Lutonix. Last quarter, you kind of suggested how much Lutonix contributed to the growth rate of the company so we could understand what the kind of organic growth rate was of the base business. And I was wondering if you'd be willing to kind of comment on that here this quarter?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Bob. It was just a little less than 2 points of the growth in Q1.",16,"Yes, Bob. It was just a little less than 2 points of the growth in Q1."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then just real quickly. And I know it's early, but either for Tim or for John, your thoughts on how you're competing in the marketplace with Medtronic. It's really early, but are you guys confident that at a minimum, this can be 50-50 share? And",89,"Okay. And then just real quickly. And I know it's early, but either for Tim or for John, your thoughts on how you're competing in the marketplace with Medtronic. It's really early, but are you guys confident that at a minimum, this can be 50-50 share? And then, lastly, I want to see if Tim would just comment on the kind of environment we're in right now from an M&A perspective and what you're seeing out there. Is the pipeline full? I just wanted to get an update there."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We don't -- we actually don't even internally predict market share goals or objectives. We just try to get a little bit more everyday. So we're pleased with the positioning of the product. We think as more the real world data comes into play versus",190,"Sure. We don't -- we actually don't even internally predict market share goals or objectives. We just try to get a little bit more everyday. So we're pleased with the positioning of the product. We think as more the real world data comes into play versus the clinical trial, data that was used for the approvals, that becomes increasingly meaningful for us. And certainly, it's perceived that way in the market, I can tell you firsthand from that. So we're pleased with where we are, and technology is everything we thought it was going to be. As it relates to the M&A environment, we're still extremely active. And we're not pleased with the execution last year in terms of getting things done. It wasn't for lack of effort or emphasis. It's just kind of the way deal flow happens. There's a lot of things going on right now. And I wouldn't be surprised if you start hearing more from us soon about those kind of things. But again, you got to have 2 sides to agree. And we're very active right now. So we'll let you know as things occur."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Turkaly with JMP Securities.",10,"Our next question is from David Turkaly with JMP Securities."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just quickly, what kind of diligence, if any, did Boston Sci do on Lutonix? And I guess if you could just comment on how sort of the number of reps you guys will have combined will compare to Medtronic.",39,"Just quickly, what kind of diligence, if any, did Boston Sci do on Lutonix? And I guess if you could just comment on how sort of the number of reps you guys will have combined will compare to Medtronic."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","We had to make sure they knew how to spell it.  So we made sure we trained on that. Beyond that, I think with the publication of the data, the fact that it was available in the market outside the United States, I think they certainly thought they had enou",59,"We had to make sure they knew how to spell it.  So we made sure we trained on that. Beyond that, I think with the publication of the data, the fact that it was available in the market outside the United States, I think they certainly thought they had enough diligence to make whatever decisions they ended up making."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, Dave, when you look at the combined commercial presence between ourselves and the sort of the proportion of Boston's reps time that you could expect would be spent detailing Lutonix, we're on a pretty even playing field with the new Medtroni",60,"Yes, I think, Dave, when you look at the combined commercial presence between ourselves and the sort of the proportion of Boston's reps time that you could expect would be spent detailing Lutonix, we're on a pretty even playing field with the new Medtronic Covidien commercial footprint. So from that standpoint, I think we feel like we're in good shape."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Then we'll go next to Kristen Stewart with Deutsche Bank.",11,"Then we'll go next to Kristen Stewart with Deutsche Bank."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess, Tim, I was wondering if you can just comment more broadly just on like the Vascular landscape, I guess more endovascular just with Cardinal's pending acquisition of Cordis and what that may mean just for your business. I know there's been a lot o",76,"I guess, Tim, I was wondering if you can just comment more broadly just on like the Vascular landscape, I guess more endovascular just with Cardinal's pending acquisition of Cordis and what that may mean just for your business. I know there's been a lot of pressure from the stents. Just kind of perspectives on or any concerns that you may have as they try to, I guess, genericize [ph] to some degree some end markets."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, I can only -- I don't -- I can't speak for them. Obviously, you're going to have to ask them what their perspectives were. I can tell you that from our own experience, in my own personal experience, in fact, there's a very interesting report t",195,"Sure. Well, I can only -- I don't -- I can't speak for them. Obviously, you're going to have to ask them what their perspectives were. I can tell you that from our own experience, in my own personal experience, in fact, there's a very interesting report that was just issued by one of the major consulting companies about an analysis done on product leadership versus breadth of line and which kind of wins out at the end of the day. We had nothing to do with that analysis. But it does point out the fact, which is one we concur with, market leadership and technology leadership as opposed to breadth of line is where we would rather be. Let's put it that way. And I think that clearly, you don't get many companies larger than J&J. And they decided, for whatever their reasons were, to sell that business. We like product leadership. We like -- even in this environment, we think having the best products that clinicians prefer for their patients is important. And beyond that, you have to probably ask them about their decisions there and what they expect to do with that."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","You don't expect any additional pressure thus from a pricing standpoint?",12,"You don't expect any additional pressure thus from a pricing standpoint?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Don't know.",3,"Don't know."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess it's to be seen. Okay. And then maybe Chris, could you comment on just given the change in FX rate movements, what, if any, FX from an EPS perspective you are absorbing since you did maintain your EPS guidance?",42,"I guess it's to be seen. Okay. And then maybe Chris, could you comment on just given the change in FX rate movements, what, if any, FX from an EPS perspective you are absorbing since you did maintain your EPS guidance?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","It's relatively -- we talked about $0.25 for the full year. It's slightly higher than that, Kristen. There's a number of moving parts, as you can imagine. And certainly, there are currencies that have weakened where we've got large expense basis as well.",113,"It's relatively -- we talked about $0.25 for the full year. It's slightly higher than that, Kristen. There's a number of moving parts, as you can imagine. And certainly, there are currencies that have weakened where we've got large expense basis as well. So it's probably just slightly higher than the $25 million I think -- excuse me, $0.25 for the full year. And I think a range around where currencies are today, I think we can manage through. If there's another material step-down, we'll obviously have to reassess that. But clearly, the business and the operations are performing in a way that it's allowed us to absorb that slight incremental increase."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Last kind of random one, other was down pretty significantly this quarter. Can you just maybe remind us what's in there and why?",23,"Last kind of random one, other was down pretty significantly this quarter. Can you just maybe remind us what's in there and why?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And actually that was when we acquired Rochester, there were some distributor products in Europe that came with the acquisition that we essentially discontinued really April 1 of last year. So there's about $101 million of sales in last year's",61,"Yes, sure. And actually that was when we acquired Rochester, there were some distributor products in Europe that came with the acquisition that we essentially discontinued really April 1 of last year. So there's about $101 million of sales in last year's Q1 in other that we discontinued. So that's driving the large -- most of the decline there in other."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Lewis with Morgan Stanley.",10,"Our next question is from David Lewis with Morgan Stanley."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just thinking about vascular, I know you did update guidance for the year, but given that Lutonix was roughly in line with the number -- within $1 million, the non-Lutonix business, obviously, did dramatically better. And I think about your Vascula",108,"Chris, just thinking about vascular, I know you did update guidance for the year, but given that Lutonix was roughly in line with the number -- within $1 million, the non-Lutonix business, obviously, did dramatically better. And I think about your Vascular guidance for the year. If Lutonix builds momentum, per some of the comments on the call, it just appears that the Vascular guidance is either conservative or you're certainly going to be at the upper end of the range. So just wondering if you could talk about your non-Vascular performance if Lutonix builds or what that means for Vascular guidance? Then I had a quick follow-up."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think we'll take it a quarter at a time, David. Certainly, from that respect, we're off to a very good start. We've got again good ambitions for the rest of the year in Vascular. We saw good performance in some of the other categories frankly bette",117,"Yes, I think we'll take it a quarter at a time, David. Certainly, from that respect, we're off to a very good start. We've got again good ambitions for the rest of the year in Vascular. We saw good performance in some of the other categories frankly better than we had expected in Q1, including in the filter segment as well. So we'll take it as we come. And we get through Q2. And we will certainly reassess how we think the full year looks. But everybody in each of the businesses certainly is doing everything they can to get to the top end of the range for the year. But it's a good start for us."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'll also just add biopsy had a pretty strong Q1. And a lot of that is outside of the US. So that's a focus product area for us in emerging market [indiscernible].",34,"And I'll also just add biopsy had a pretty strong Q1. And a lot of that is outside of the US. So that's a focus product area for us in emerging market [indiscernible]."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 quick follow-ups. Number one, there was some commentary on the PICC business and GPO positioning. There's been a lot of jockeying in the PICC market these last couple of years with some of your smaller competitors. I'm just sort of curious why now,",95,"Just 2 quick follow-ups. Number one, there was some commentary on the PICC business and GPO positioning. There's been a lot of jockeying in the PICC market these last couple of years with some of your smaller competitors. I'm just sort of curious why now, why this year and not the prior 2 years that we saw more significant GPO pricing? And the other follow-up was just on the willfulness suit as it relates to Gore. Any updated timing on when the proceeds may flow or just the updated legal timing from your perspective?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think you meant the port business because we had a very strong PICC business and PICC results in Q1. So we did see some pressure in the port business, primarily around new GPO agreements that we signed early in 2014 so that the this is the really the fi",98,"I think you meant the port business because we had a very strong PICC business and PICC results in Q1. So we did see some pressure in the port business, primarily around new GPO agreements that we signed early in 2014 so that the this is the really the first quarter they're kicking in as a new agreement for us. So there is some price pressure because of the lower prices in those GPO agreements. If you looked at our units, we said that our units were just about flat. But it's more pricing than anything else there."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we had actually signaled that, David, on the January call, we called specifically out port pricing pressure. Those are long-term contracts. We obviously thought strategically it made sense for us to sign them. And we'll obviously lap that pricing pres",97,"And we had actually signaled that, David, on the January call, we called specifically out port pricing pressure. Those are long-term contracts. We obviously thought strategically it made sense for us to sign them. And we'll obviously lap that pricing pressure over time. On willfulness we would expect as we sit here today to receive the funds at some point during Q2. All signs lead to that with interest, it's just under $209 million. And they have our bank account information, and we're anxiously waiting the receipt. But I would expect it would be during in Q2."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Matthew Taylor with Barclays.",9,"Our next question comes from Matthew Taylor with Barclays."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Zhang Weiye in for Matt. The first question, I guess, in the U.S., we've been hearing about a lot of improvement in terms of volume and utilization, not a lot but incremental improvement. I guess  are you seeing that trend as well? And ca",57,"This is actually Zhang Weiye in for Matt. The first question, I guess, in the U.S., we've been hearing about a lot of improvement in terms of volume and utilization, not a lot but incremental improvement. I guess  are you seeing that trend as well? And can you talk about maybe from a European perspective as well?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No. In fact, I think that while we've seen certain glimmers of improvement and primarily saw a little glimmer in March's improvement in terms of volumes, that was probably offset by January and February's volumes, where there wasn't a substantial improvem",138,"No. In fact, I think that while we've seen certain glimmers of improvement and primarily saw a little glimmer in March's improvement in terms of volumes, that was probably offset by January and February's volumes, where there wasn't a substantial improvement in hospitals in the United States. So if you aggregate it all, I'd say, we're optimistic. But we have not seen anything extremely tangible. And I think I've evidenced that by the way we look at our basic business in drainage, quite frankly. In terms of Europe, there was a number of reimbursement issues that are going on in Europe. France is foremost in those. We didn't have a great Q1 in our European business as you probably saw. But we're optimistic that those volumes will come back as we go through the course of the year."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, great. And I guess a quick second question regarding the emerging markets business. Can you just talk about some of the key geographies that are driving the growth as well as maybe the sustainability of that growth?",38,"Okay, great. And I guess a quick second question regarding the emerging markets business. Can you just talk about some of the key geographies that are driving the growth as well as maybe the sustainability of that growth?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. They're all the ones we mentioned previously. So there's -- the ones in Asia and then the ones in Latin America and then Eastern Europe and the Middle East. And they're all doing very well right now.",38,"Yes. They're all the ones we mentioned previously. So there's -- the ones in Asia and then the ones in Latin America and then Eastern Europe and the Middle East. And they're all doing very well right now."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Or next question comes from Richard Newitter with Leerink Partners.",10,"Or next question comes from Richard Newitter with Leerink Partners."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Ravi in for Rich Newitter. I have a couple of maybe big picture questions. First start with a lot of people talking about what assets you are going to buy. I'm curious just to get your thoughts on some of the businesses that you said that are now",69,"This is Ravi in for Rich Newitter. I have a couple of maybe big picture questions. First start with a lot of people talking about what assets you are going to buy. I'm curious just to get your thoughts on some of the businesses that you said that are now sort of less than 1% of sales, perhaps PI and women's health.  What's the strategic outlook for those segments?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me back up and give you a broader answer. So when you look at the portfolio of 14,000 SKUs, this isn't new. This has been -- I've been here 23 years. It's been like this since I've been here. You have 25% or so of the SKUs that are actually decl",168,"Well, let me back up and give you a broader answer. So when you look at the portfolio of 14,000 SKUs, this isn't new. This has been -- I've been here 23 years. It's been like this since I've been here. You have 25% or so of the SKUs that are actually declining over time. So the balancing of the portfolio and where we make the investments and where we look for acquisitions, where we expand sales forces, et cetera, et cetera, you're constantly going after the higher growth areas. Probably very similar to the way you manage your own investment portfolios. So we don't get too hung up on movement of one or another, I will tell you this, relative to divestiture decisions. It's a lot easier to get rid of a business than it is a product line. And we'd rather have -- having done both, we'd much rather have our management teams focused on increased revenue growth opportunities than creating or pruning off product lines."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, and the only thing I'd add, Ravi, is obviously you'd expect and we do run an economic analysis to determine whether or not the value of some of those declining product lines are worth more to us if we resource them appropriately from a cash flow stan",87,"Yes, and the only thing I'd add, Ravi, is obviously you'd expect and we do run an economic analysis to determine whether or not the value of some of those declining product lines are worth more to us if we resource them appropriately from a cash flow standpoint as opposed to what you might if anything get to a sale of a product line. So certainly, the things we are keeping, rest assured we think that's the right decision even if they are in a declining mode."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe 1 question on hernia. A lot of -- looks like the OPTIFIX and the Capsure product is coming out soon. I'd like to hear maybe your general view on how minimally invasive surgery and potentially in robotics can affect the long-term view or the long",61,"And maybe 1 question on hernia. A lot of -- looks like the OPTIFIX and the Capsure product is coming out soon. I'd like to hear maybe your general view on how minimally invasive surgery and potentially in robotics can affect the long-term view or the long-term outlook of that business, especially if there's more conversion from open to MIS procedures?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take the bigger picture. Relative -- we're very pleased by the way with the positioning of the entire hernia portfolio. We've got great breadth of line. We've got strength now. The one area we were kind of weakest in my view was the fixation ar",190,"Sure. I'll take the bigger picture. Relative -- we're very pleased by the way with the positioning of the entire hernia portfolio. We've got great breadth of line. We've got strength now. The one area we were kind of weakest in my view was the fixation area. John DeFord talked about a couple of projects that we had alluded to previously but feel pretty good about them now. So we've got a great, probably if you were to go by category, maybe our single strongest portfolio right now across the various vertical groups within that broader category. As it relates to the robotics thing, our view is we provide the products, the implants, et cetera that would be used with the robotic thing. So I don't see it dramatically impacting the business. In fact, several of our products, to the extent that there are people, I think there's more talk than action right now relative to that. But I -- we know that a couple of our products have become the product of choice to be used in some of those procedures. With that, I'll let John DeFord put some..."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think just to weigh it in, I think maybe you were alluding to in robotic surgeries fixation devices aren't typically needed because they can suit you with a robotic device. And so again, I think we see that we're well-positioned. We don't see that",166,"Sure. I think just to weigh it in, I think maybe you were alluding to in robotic surgeries fixation devices aren't typically needed because they can suit you with a robotic device. And so again, I think we see that we're well-positioned. We don't see that happening overnight. And certainly, robotic surgery is pretty limited right now. There are some benefits, of course. You can close the abdominal wound before some of the fixation is required. You can do a few other things. But it's pretty limited in the procedures that you can use robotics in today. So we think we've got a good mix. As Tim and John had said earlier, we think we've got from a mesh or implant perspective, a great mix of products that work well with the robotic surgery as well as with laparoscopic and open. And we also think our fixation products are going to be useful in a number of different repairs that aren't necessarily amenable to robotics today."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] Our next question will come from Dave Roman with Goldman Sachs.",13,"[Operator Instructions] Our next question will come from Dave Roman with Goldman Sachs."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted just to start with a follow-up on your M&A commentary, Tim. There's a tremendous amount of deal euphoria in health care as, obviously, everyone has observed. But can you maybe just talk to us about how you think about cash EPS accretion versus RO",91,"I wanted just to start with a follow-up on your M&A commentary, Tim. There's a tremendous amount of deal euphoria in health care as, obviously, everyone has observed. But can you maybe just talk to us about how you think about cash EPS accretion versus ROIC? I mean, I understand the benefit of a press release that goes out with a 15% accretion number in it. But also, obviously, you're stuck with the asset over time. So how do you think about really finding value given the M&A environment now?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I know. It's an interesting question. So I think you'd go -- and this isn't a new thing. I mean those kinds of properties and models, if you will, call it accretion versus revenue growth, if want to just bookend the two, have always been there. We've",189,"Yes, I know. It's an interesting question. So I think you'd go -- and this isn't a new thing. I mean those kinds of properties and models, if you will, call it accretion versus revenue growth, if want to just bookend the two, have always been there. We've had our eyes wide open to those, especially when you get into larger deals. Someone's actually got to go find that synergy and execute against that. And that's -- always tends to be a little bit more difficult than people think. And while you're doing that, those are the same management groups that you're expecting to go grow the other part of the business that you had. So really the decision for a management group is where you want your people and your management teams spending their time. So we have watched what's occurred in the marketplace, we've watched how investors have reacted to those deals. It's kind of interesting, and we clearly have targets. We put them into different categories, but with clearly more of the revenue growth mindset at the moment versus the accretive and slower revenue growth mode."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add, David, is ROI is very important to us. So when we're evaluating opportunities, we're trying to be good stewards of shareholders capital. And we think the notion of near-term accretion for a transaction that frankly is not a goo",124,"And the only thing I'd add, David, is ROI is very important to us. So when we're evaluating opportunities, we're trying to be good stewards of shareholders capital. And we think the notion of near-term accretion for a transaction that frankly is not a good return for shareholders, we think -- we're going to be very careful as to how we deploy capital. And we're going to do it in a way that's not going to only be driven by near-term accretion. It's got to make sense strategically from a returns standpoint. And if it's accretive, that's obviously terrific as well. But it's -- all of those factors are certainly important to us and we're not going to weight short-term accretion over ROI."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's helpful context. And then, maybe just a follow-up on the business and perhaps sort of along the same lines. Emerging markets obviously remains quite strong for you. But still as a percentage of sales, it's relatively small compared to the pee",133,"Okay, that's helpful context. And then, maybe just a follow-up on the business and perhaps sort of along the same lines. Emerging markets obviously remains quite strong for you. But still as a percentage of sales, it's relatively small compared to the peer group. And it just seems like it's going to take a while to see that number move in sort of a step function type of way. And I guess we've seen some others in med tech go into emerging markets and pay big -- decent premiums for assets there. I mean, is there a strategy -- is there a vehicle organically to accelerate the emerging markets adoption where that can get to midteens, call it, percentage of sales number? Or is that something that have to come through external investment?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that the game plan that we put in place, which was investing heavily and building our teams of people around the world and then arming them with the products that come through our R&D pipeline and do that via great training of physicians is the ri",96,"I think that the game plan that we put in place, which was investing heavily and building our teams of people around the world and then arming them with the products that come through our R&D pipeline and do that via great training of physicians is the right long-term strategy for us. We made the investments. We're seeing the growth in all those segments. We like the game plan. And I think it's one step at a time for us. But we believe that's how you build a meaningful business long-term that has great staying power."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think coming back to ROI. I think if you look at some of those larger transactions in emerging markets. I'd question what the returns are going to be on those. And again, coming back to the right balance between risk and growth, to John's point, we",109,"And I think coming back to ROI. I think if you look at some of those larger transactions in emerging markets. I'd question what the returns are going to be on those. And again, coming back to the right balance between risk and growth, to John's point, we think we've got the right strategy. We certainly are looking for targets that make it through our filters. And we spend a lot of time looking. And again, our bar is reasonable but relatively high. And we clearly have knocked down targets that we think makes sense for us. In the meantime, we're doing a terrific job growing the business organically."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Josh Jennings with Cowen and Company.",11,"Our next question is from Josh Jennings with Cowen and Company."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just one for you. I was hoping you could help us think about longer-term operating margin expansion opportunities and getting back to that -- the levels that you had prior to -- performed that  prior to 2013. Looks like you're doing a great job nav",79,"Chris, just one for you. I was hoping you could help us think about longer-term operating margin expansion opportunities and getting back to that -- the levels that you had prior to -- performed that  prior to 2013. Looks like you're doing a great job navigating those rolling the FX this year and seeing some operating margin expansion to get to the midpoint of the EPS range. But how should we think about operating margins in the out years?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think this year is going to be a nice down payment, I think, Josh on returning to those levels. Certainly, as we talked about some of the portfolio moves we made in 2013 were dilutive in terms of exiting the EP business and adding Rochester in particula",183,"I think this year is going to be a nice down payment, I think, Josh on returning to those levels. Certainly, as we talked about some of the portfolio moves we made in 2013 were dilutive in terms of exiting the EP business and adding Rochester in particular. Those were the right moves for the company, no question. And we're really pleased with the portfolio. Having said that, it did set us back a bit. '15 will be a nice down payment. Every year, our commitment is to drive operating leverage and operating improvement. That's what the management team is tasked and committed to do. And I won't give you a point in time when we'll get back to that level. But I think we're well on our way. And everything we've done in constructing the portfolio in terms of adding higher margin products. To John's point, we've got infrastructures built in emerging markets that are going to be leveragable for a number of years to come. We feel good about the ability for us to continue to move higher year after year."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just one follow-up for John DeFord and maybe Tim can pitch in. On just the Vascular business now, being the leader in the stents as well as drug-coated balloons, is there anything else in the portfolio that you need to fill your bag with and maybe spe",71,"And just one follow-up for John DeFord and maybe Tim can pitch in. On just the Vascular business now, being the leader in the stents as well as drug-coated balloons, is there anything else in the portfolio that you need to fill your bag with and maybe specific commentary on your outlook for the combo of atherectomy and drug-coated balloons and the need for Bard to have an atherectomy technology?"
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We constantly look at what we think are the right combinations of products within all of our spaces, Vascular certainly. We've always had a close eye on atherectomy in particular. We're always a little nervous about the reimbursement in that space.",109,"Sure. We constantly look at what we think are the right combinations of products within all of our spaces, Vascular certainly. We've always had a close eye on atherectomy in particular. We're always a little nervous about the reimbursement in that space. That said, it seems to continue to hold much to my surprise. But it's something that we'll be continuing to keep a close eye on. We think the potential combination with DCB could be interesting. We're already seeing and running some studies around using our technology with stents, using our technology in other kind of cases. And so we'll continue to keep that as something to evaluate."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I would just add, I think a lot of the opportunity we have, we already own. So the ability to get further indications for Below the Knee, we think that's really interesting, being able to go after smaller vessels with DCBs. The whole AV access area we",93,"And I would just add, I think a lot of the opportunity we have, we already own. So the ability to get further indications for Below the Knee, we think that's really interesting, being able to go after smaller vessels with DCBs. The whole AV access area we think is a huge opportunity both relative to stent grafts and the drug-coated technology and/or combinations of those. So we think there's a lot of runway left both in our internal revenue and in expanding the markets, just with the platforms that we have today."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we just mentioned today a couple new products that we expect to be launching in Europe by the end of the year, entering the venous market with the venous stent technology and also, our AV access and next-generation stent graft kind of products. So we",59,"And we just mentioned today a couple new products that we expect to be launching in Europe by the end of the year, entering the venous market with the venous stent technology and also, our AV access and next-generation stent graft kind of products. So we think those are organic ways to continue to expand the pipeline as well."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And this does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments.",24,"And this does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Thanks, everybody for staying with us. Sorry, went over a little bit over the hour. I'd like to take this opportunity to thank Bard employees around the world for a very strong start to the year and look forward to updating you on our progress",54,"Thank you. Thanks, everybody for staying with us. Sorry, went over a little bit over the hour. I'd like to take this opportunity to thank Bard employees around the world for a very strong start to the year and look forward to updating you on our progress at the end of the next quarter."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks.",1,"Thanks."
254131,290174664,793855,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Okay, thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect.",28,"Okay, thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand r",268,"Ladies and gentlemen, thank you for standing by. Welcome to the C.R. Bard, Inc. First Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations. 
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information and the information under the caption Risk Factors each in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings release on the company's website at www.crbard.com. All information that is not historical is given only as of April 23, 2015, and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead, sir."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much. I'd like to welcome everybody to Bard's first quarter 2015 earnings call and thank all of you for taking the time to join us today. We'd expect the presentation portion of the call to last about 25 minutes. And we're going to try to k",613,"Thank you very much. I'd like to welcome everybody to Bard's first quarter 2015 earnings call and thank all of you for taking the time to join us today. We'd expect the presentation portion of the call to last about 25 minutes. And we're going to try to keep the total call to about 1 hour or less. 
The discussion today will go as follows. I'll begin with an overview of the results for the first quarter. John Weiland, our President and COO will review first quarter product line revenue. John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our productive development pipeline, after which, Chris Holland, our Senior VP and CFO, will cover the first quarter income statement and balance sheet as well as our expectations for Q2. And finally, we'll close with Q&A. 
First quarter 2015 net sales totaled $819.7 million. That's up 3% over Q1 last year on an as-reported basis and up 5% on a constant currency basis. The currency impact for the quarter versus last year was unfavorable by about 260 basis points. The quarterly royalty payment from Gore was $38.4 million, which represented slower growth than our product portfolio. So our organic revenue growth this quarter was about 5.3%, which was better than our guidance. 
Net income for the first quarter was $139.8 million, and diluted earnings per share were $1.82. That's down 6% and 2%, respectively, excluding certain items that affected the comparability of results between periods, which Chris will cover later. The first quarter 2015 net income was $142.4 million, up 6%. And diluted adjusted earnings per share, which exclude amortization, were $2.10. That's up 10%. This was also above our expectations despite the additional headwind from currency and represents a good start to what's an important year of execution for us. 
Looking at revenue growth geographically compared to the first quarter of last year. Q1 net sales in the U.S. grew 4% compared to a year ago. On a constant currency basis, in Europe, we were up 1%. Japan was up 5%. And our other international businesses were up 18%. 
We saw strong sales growth across all of our emerging market geographies in the first quarter as our investments over the last couple of years have strengthened our position in these faster growing markets. As a percentage of total sales in the first quarter, emerging markets represented between 8% and 9% of sales compared to just 7% a year ago. And while it's still a small percentage of portfolio, in some of our major product lines, the actual dollar growth we saw in emerging markets exceeded the dollar growth of the same products in the U.S. this quarter. 
As you know, emerging markets is just one of the opportunities we've highlighted as a key long-term revenue growth driver for us. In fact, you'll hear, as John Weiland takes you through the sales results, that each of the growth drivers we highlighted as part of our strategic investment plan performed well this quarter. 
We remain focused on the execution of that plan and providing the expected returns on those investments in 2015 and beyond. Chris will provide the detailed update to our guidance a bit later in the call, but I'm pleased to tell you that our strong start to the year and our confidence in our ability to execute on the things we can control, we believe we can manage the challenging foreign exchange environment so far and maintain our original financial guidance for 2015. 
So with that summary, let me now turn you over to John Weiland for a review of our product line revenue."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. So let's begin with Vascular. Total net sales were $23",858,"Good afternoon, everyone. Before I start, let me point out that I'll be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted. 
So let's begin with Vascular. Total net sales were $231.9 million, up 6% over last year on a reported basis and up 10% on a constant currency basis. U.S. Vascular sales were up 8% in Q1 and international sales were up 11%. 
Sales in our Surgical Graft category were down 4% this quarter within the range of recent experience. Our Endovascular business was up 10% in the first quarter, and it was up 12%, excluding the Gore royalty. 
Our biopsy products had a strong quarter, up 9%, and driven by good growth internationally, especially in emerging markets. 
Our peripheral PTA line increased 32% in the first quarter, with sales of our Lutonix DCB exceeding our expectations. We saw a good acceleration in the daily usage of the device after some large initial stocking orders in the fourth quarter. 
In Q1, we worked with Boston Scientific to train their reps on the product and, in Q2, received our first order from them. As you probably saw, hospital outpatient procedures are now eligible for reimbursement through CMS as of the beginning of the second quarter, an important milestone for the category. 
Our vena cava filter line grew 6% in Q1. Our Stent business declined 3% in Q1 compared to the prior year, and we continue to expect significant price pressure in this category. 
Now let's move to Urology. Total net sales were $205.6 million, up 2% versus the first quarter of last year on a reported basis and up 5% on a constant currency basis. The United States business was up 4%, and internationally, we grew 6%. We saw double-digit growth in our Targeted Temperature Management products again this quarter. And we remain encouraged by the long-term opportunity here. Our basic drainage business was up 4% in Q1 and up 2% in the United States. Within that category, our I.C. Foley business was up 1% globally and down 2% in the United States. 
Our continence business was up 7% in Q1, driven by double-digit growth in our DIGNICARE and male-external catheter sales. 
Our women's health product lines continue to decline but now make up less than 20% of the continence category and less than 1/2 of a percent of Bard's total sales. 
Sales in Urological Specialties were down 1% in the first quarter, with our brachytherapy down 4%. And finally, standalone sales of our StatLock catheter stabilization line increased 5% in Q1. 
Next is Oncology. Total net sales in this category were $224.6 million, an increase of 3% over Q1 last year on a reported basis and up 5% on a constant currency basis. Geographically, net sales in the United States were up 1%, and international sales were up 15%. 
Our port business was down 3% over Q1 of last year. We forecast that significant United States pricing pressure here related to GPO contracts signed in 2014, which drove the decline as units were essentially flat with prior year. 
Our PICC revenues were up 9% globally with good growth in the United States and even better growth internationally. And to close out the category, our vascular access ultrasound product line grew 12% this quarter, and our dialysis catheter product line was up 8%. 
So then let's finish with Surgical Specialties. Total net sales in this category were $135.9 million, up 1% on a reported basis, and up 3% on a constant currency basis. U.S. sales were up 5%, and international sales were down 4% in the quarter. Most of that international decline was driven by our performance irrigation business, which was down 34% globally due to the discontinuation of certain products in this category, which now represents less than 1% of total Bard sales. 
Our soft tissue business -- soft tissue repair business grew 5% this quarter. Within soft tissue, our synthetic hernia business grew 8% in Q1. 
In biologics, we were very pleased with the first full quarter of sales from our XenMatrix AB product, which is a porcine graft with an antibiotic coating. Thanks to the contribution from this new first-of-its-kind device, our total biologic category was flat in Q1, reversing a trend of double-digit declines. 
We have the broadest portfolio in hernia repair across all types of products, from a wide range of synthetics to natural tissue and now antibiotic coated natural tissue. We are working with physicians to identify the right product for the right patient and provide a wide range of options for them. 
Our hernia fixation line declined 9% this quarter -- 7% this quarter, within the range of recent experience. As you'll hear from John DeFord, we have some new products in our pipeline that we believe will help us get back to growth in this category. 
We are well past the anniversaries of our acquisitions of BioSurgery, and that business grew double digits again this quarter. We remain bullish on the long-term opportunity here. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. We started off 2015 with several product launches. And as you'll hear in my update, our pipeline and plans show a very active 2015 and beyond. I'll start with drug-coated balloons, where we're making good prog",1130,"Thanks, John, and good afternoon, everyone. We started off 2015 with several product launches. And as you'll hear in my update, our pipeline and plans show a very active 2015 and beyond. 
I'll start with drug-coated balloons, where we're making good progress on additional sizes and indications worldwide. We filed the PMA supplement for additional balloon sizes for use in the SFA and popliteal and anticipate launch in the back half of this year. 
In our clinical activities, we've completed initial follow-up in our Levant 2 Japan study. We're in the data analysis phase, and we expect to submit in the back half of the year for approval. Enrollment continues in our Below the Knee and in-stent restenosis IDE studies. And we recently submitted the IDE for our AV access study with enrollment anticipated to start in Q3. We're also working toward the start of our Levant China study and expect to begin enrollment in the back half of the year. 
The Levant 2 study design was described in detail in a recent publication authored by Dr. Michael Jaff and several investigators in the American Heart Journal. We also expect the 24-months Levant 2 results to be presented at SVS in June. 
Also in Vascular, the LifeStream Balloon Expandable Covered Stent clinical study is recruiting quickly, and we anticipate completing enrollment later this year. This IDE evaluates the technology for the treatment of iliac artery disease. 
In other stent graft news, our next-generation device for use in AV access is nearing completion and development, and we anticipate launching in Europe in Q4. This product will require a clinical study for U.S. approval, and we anticipate filing the IDE and initiating a study in the first half of 2016. 
We have a new venous stent project that's on a similar development pathway with launch anticipated in Europe in Q4 and an IDE study expected to begin around the end of the year. 
Next, moving to Urology. We've launched our new skyline sub 2 French stone basket family and are working to expand the platform with 2.4 and 3 French versions expected later this year. 
Also in endourology, we anticipate launching our new access sheath system in the back half of the year. We believe these new products provide the urologist with needed improvements to some of the tools they're currently using in this important interventional space. 
In home care, we're nearing the launch of a new intermittent self-catheterization product, the Magic 3 Touchless, slated for release in Q3. Magic 3 Touchless combines the comfort and insertion benefits of the Magic 3 platform, combined with our touchless closed system designed to reduce the risk of contamination and infection due to catheter insertion. We've got a couple of other products in our intermittent catheter family that are slated to launch later this year. But I'll hold back the details until we get closer to product release. 
Moving to Oncology. We recently received U.S. regulatory clearance for our freehand stereotactic system for Vascular Access, named Pinpoint GT. The Pinpoint GT technology will be offered on the new Site-Rite 8 ultrasound system slated for launch later in the year. We believe the combination of Site-Rite ultrasound, Pinpoint GT Needle Guidance and 3CG Diamond catheter tip confirmation in an integrated system will provide a complete clinical solution for vascular catheter placement. 
In PICC, we're on track for a Q3 regulatory submission for our new thromboresistant coating. Upon regulatory clearance, we plan to launch a broad line of catheters marketed under the COVERT PICC trade name. We expect to follow the COVERT PICC with a combined antimicrobial and thromboresistant coating planned for launch in the back half of 2016. 
In midlines, we launched the 22-gauge PowerGlide catheter in Q1, completing our sizes in the PowerGlide product family. We're also making good progress on our next generation of midline catheters and anticipate our U.S. regulatory submission in Q4 with a first half 2016 launch. 
For the acute hemodialysis patient, we're expanding upon our market-leading Trialysis catheter family with the anticipated regulatory clearance and launch later this quarter of our new Trialysis slim. Trialysis slim incorporates superior flexibility, kink resistance and flow rates in excess of 400 milliliters per minute in a small 12-French triple lumen catheter configuration. 
I'll close my portion of the discussion today with surgery. On our last call, we told you about our launch of the first antibiotic coated biologic mesh, XenMatrix AB. As John Weiland told you, the product is receiving excellent early feedback, and we're working hard to expand the size matrix available, with additional launches expected over the course of the next several quarters. 
We're also making good progress toward the launch of a new product family that incorporates our proven Sepra barrier technology with our Phasix bioresorbable mesh family to create the Phasix ST. Phasix ST is designed for intra-abdominal placement and is on track to launch in Q3. This new offering supplements XenMatrix AB, XenMatrix and Phasix to allow us to offer proprietary and differentiated products designed to address the entire spectrum of complex abdominal wall repairs. 
Moving onto our BioSurgery product family. In early Q3 of 2014, we filed our PMA supplement for our Progel sealant, seeking expanded use in video-assisted and robot-assisted thoracic surgery. We received approval from FDA earlier this quarter, and I'm pleased to announce the launch is underway ahead of schedule. 
Also in January of this year, we completed follow-up in our Tridyne vascular sealant pivotal IDE study. Analysis is complete and the team is working toward PMA submission this quarter. Following this time line, we anticipate approval and launch in mid-2016. 
And finally, in mesh fixation, we're gearing up for the launch in the next couple of weeks of our first spring-loaded resorbable tack device named OPTIFIX. OPTIFIX has been designed to employ stored energy for ease and efficiency of tack delivery while reducing tissue trauma that's been associated with some competitive devices. 
In past calls, I've told you that we have another fixation platform under development, but we've not disclosed the details. Now the time is right and I'm pleased to announce that we anticipate launching our new permanent fixation device named Capsure later this quarter. Capsure is the result of several years of analysis of the permanent fixation market and was designed to reduce the risk of tissue injury due to exposed sharps and concern over adhesions and reliability, while providing the functional requirements of a permanent tack, including the ability to penetrate hard tissues such as Cooper's ligament. With these 2 fixation launches, we're excited to move back to playing offense in this highly competitive space. 
Thanks for your attention today. We look forward to updating you on our progress throughout the year. Now I'll hand our discussion over to Chris."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We got a credit and acquisition-related items of $9.2 million pretax, a $3.9 million pretax charge for restructuring and productivity ini",650,"Thank you, John. Let me start by covering certain items that affect the comparability of our results between periods. We got a credit and acquisition-related items of $9.2 million pretax, a $3.9 million pretax charge for restructuring and productivity initiatives, and we recorded expense of $10.3 million, primarily related to the judge's order in the women's health litigation that we work up 500 cases simultaneously. The P&L impact of these items is detailed in the notes to the financial statements and in the reconciliation accompanying our Q1 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $508.5 million or 62% of sales for Q1. On an adjusted basis, GP was $498.6 million or 60.8% of sales, down 60 basis points from the prior year quarter, consistent with our guidance. FX costs us 30 basis points in GP this quarter and the new amortization from the Q4 2014 Lutonix approval was 40 basis points in Q1. 
Price pressure drove 130 basis points on the revenue line in Q1 and about 50 basis points of headwind on GPs, consistent with our expectations. Our cost improvements drove about 40 basis points of benefit to GPs this quarter, and mix was favorable by about 20 basis points. 
As we look to Q2, we expect gross margin to be similar to the Q2 2014 level, despite FX pressure and the incremental amortization. 
SG&A expenses were $235.7 million for the quarter or 28.8% of sales. On an adjusted basis, SG&A as a percent of sales was 28.7%, a decrease of 90 basis points. We are on track with our annual guidance of delivering improved P&L leverage for the full year. 
R&D expenditures totaled $60.6 million for the first quarter or 7.4% of sales on both a reported and adjusted basis, consistent with our guidance. Interest expense was $11.3 million for the first quarter. 
Other income and expense was $16.3 million of expense for the first quarter as reported and $1.6 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.3% on a reported basis and 24.9% on an adjusted basis, the same level as a year ago. And again, our full year guidance assumes the renewal of the R&D tax credit, but that will not be included in the reported numbers until it is renewed. 
Diluted shares for the period were 75.8 million, and we purchased 1.2 million shares during the first quarter. The net result is adjusted EPS of $2.10, which exceeded our expectations for the quarter. 
The balance sheet as of March 31 reflects cash, restricted cash and short-term investments of approximately $1.03 billion versus $1.01 billion at December 31. For the quarter, accounts receivable days were up 0.7 days, and inventory days were up 0.3 days. Capital expenditures totaled $29 million for the quarter. 
On the liability side, total debt was $1.6 billion as of March 31 compared to $1.5 billion at the end of December. Debt-to-total cap at the end of the first quarter was about 48%, and total shareholder investment was $1.7 billion at March 31. 
In looking at Q2, we're expecting constant currency sales growth between 4.5% and 5.5% and would expect organic growth to be within the same range. We are now expecting currency headwinds based on exchange rates at their current levels to reduce reported sales by about 4% for Q2 and the full year, up from about 3% in original -- in our original guidance in January. 
From an adjusted EPS standpoint, excluding items affecting comparability and the amortization of intangibles, we see the second quarter in the $2.15 to $2.19 range. 
Despite the challenging and volatile FX environment, based on exchange rates at their current levels, we expect to deliver adjusted EPS between $8.95 and $9.05 for the full year of 2015. 
And with that, I'll hand the call back to Tim."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session. To accommodate the number of investors on the call, I would ask that you limit yourself to one question only.",44,"That does conclude the formal part of the presentation. Let me now turn the call back to the moderator to facilitate the Q&A session. To accommodate the number of investors on the call, I would ask that you limit yourself to one question only."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] Our first question comes from Larry Keusch with Raymond James.",12,"[Operator Instructions] Our first question comes from Larry Keusch with Raymond James."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess for Tim and perhaps Chris, one of the consistent investor concerns is the ability to fill the gap when the Gore royalties cease really in 2020. So I was hoping that you guys might help us think a little bit about how you are thinking about that sc",67,"I guess for Tim and perhaps Chris, one of the consistent investor concerns is the ability to fill the gap when the Gore royalties cease really in 2020. So I was hoping that you guys might help us think a little bit about how you are thinking about that scenario and what options are available as you sit here today thinking about how to fill the gap."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I appreciate your long-term perspective. That is clearly something that we're well aware of. We've known about it for quite a while now. We have fully, in fact, frequently discussed with the board. And clearly have put a plan together to invest back",177,"Sure. I appreciate your long-term perspective. That is clearly something that we're well aware of. We've known about it for quite a while now. We have fully, in fact, frequently discussed with the board. And clearly have put a plan together to invest back in the company to achieve growth at above market level. As that continues to manifest, if you will, and exponentially the company gets larger, becomes less of an issue that we have to deal with and, frankly, doesn't really become a deal -- an issue for us until almost the end of, I think, the last quarter of 2019. So we got plenty of time to deal with it. We've got clear sight of what that is. But as the company gets larger, the issue becomes smaller. Investments are doing very well. The ones that we put in place a couple of years ago, that's not -- that plan doesn't stop. It kind of continues, and we would expect to continue to grow beyond that. Chris, I don't know if you want to..."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think, Larry, the only other thing I'd add and I think we've talked to investors about, this is in addition to the entire objective here of being able to grow the company in a way that, that portion of the income statement becomes smaller and smaller, w",150,"I think, Larry, the only other thing I'd add and I think we've talked to investors about, this is in addition to the entire objective here of being able to grow the company in a way that, that portion of the income statement becomes smaller and smaller, which I think where this quarter again shows we're having good success in doing, we certainly, over time, will have balance sheet flexibility as well as one other arrow in the quiver to deal with the final ending of the royalty. But as Tim says, that runs through August of 2019. And through a combination of growing the business, utilizing the balance sheet, certainly, we expect to continue to be adding through inorganic means over time as well. We think it's a problem -- if you want to call it a problem, that will be certainly manageable by the time we approach 2019."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And to our next question is from Mike Weinstein with JPMorgan.",11,"And to our next question is from Mike Weinstein with JPMorgan."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I'm going to apologize upfront because we have a couple of calls going on at the same time, so I may have missed some of this. But just the commentary upfront on Lutonix, obviously, it's tough to try and read market trends with the stocking that goes on a",121,"I'm going to apologize upfront because we have a couple of calls going on at the same time, so I may have missed some of this. But just the commentary upfront on Lutonix, obviously, it's tough to try and read market trends with the stocking that goes on and now a competitor coming in. But it looked like the first quarter out-of-the-box, which is your fourth quarter, you have this really strong quarter. And then, sequentially, it steps down a little bit because of the entrance of the competitor and maybe less stocking. Can you just say, a, is that generally an accurate depiction? And b, can you give us more of a picture of what's happening underneath all that?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I'll take a top line shot, and then I'll give it to John. I think the -- what's important to us anyway internally within the management group is that the first quarter, we exceeded what our expectations were for the revenue for the products. So we're",85,"Yes. I'll take a top line shot, and then I'll give it to John. I think the -- what's important to us anyway internally within the management group is that the first quarter, we exceeded what our expectations were for the revenue for the products. So we're all about a long ramp here in growing this market. And clearly, from what we have budgeted, is we have figured that for Q1, fourth quarter aside. So I'm going to let John give you some more color."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that was the most important fact, quite frankly, Mike. Secondly, I'd add to that is that we see our momentum building, not waning. And in addition, we completed our training of Boston Scientific in Q1. They'll come on board in Q second in certain",66,"I think that was the most important fact, quite frankly, Mike. Secondly, I'd add to that is that we see our momentum building, not waning. And in addition, we completed our training of Boston Scientific in Q1. They'll come on board in Q second in certain areas. And quite frankly, as Tim said, we exceeded our expectations and we really like where we are right now."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just from an accounting standpoint, Chris, will you guys get any stocking benefit from supplying Boston Scientific reps with product in the second quarter?",24,"Just from an accounting standpoint, Chris, will you guys get any stocking benefit from supplying Boston Scientific reps with product in the second quarter?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think there'll be a probably a larger than typical order in the first quarter as they get the product broadly into the hands of their reps in Q -- our second quarter. And then again, we'll have to see over time how that plays out in Q3 and Q4 of this ca",84,"I think there'll be a probably a larger than typical order in the first quarter as they get the product broadly into the hands of their reps in Q -- our second quarter. And then again, we'll have to see over time how that plays out in Q3 and Q4 of this calendar year. But again, it's not overly material as we look at the total sales of Lutonix and overall for the company. But it will be a slightly higher order out-of-the-box."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then last question and let somebody just jump in here. But could you just talk about the performance of the Urology business? That was probably the one business that was probably the most notable ahead of our expectations. Can you just talk abou",57,"Okay. And then last question and let somebody just jump in here. But could you just talk about the performance of the Urology business? That was probably the one business that was probably the most notable ahead of our expectations. Can you just talk about relative to your own internal model and what was better than expected?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think it's interesting. And we've talked for a while now that, unfortunately, that business's growth rate has been masked by some declining categories. Those declining categories are starting to get relatively immaterial, and it's allowing some of",182,"Yes. I think it's interesting. And we've talked for a while now that, unfortunately, that business's growth rate has been masked by some declining categories. Those declining categories are starting to get relatively immaterial, and it's allowing some of the good things going on there to really shine through. And it was really, I think, the Rochester business has done very well. We saw really good growth globally in Q1 there. The Targeted Temperature Management had a really strong quarter, again, globally. And we're trying to bring value to customers in the basic drainage in a market that from a unit standpoint is pretty flat. But by really bringing trays that allow them to provide efficiency and effectiveness in terms of deploying that product around the hospital and getting nurses to be able to insert it in a consistent way, we're seeing good growth. And so I think you're seeing the impact of the SURESTEP product in Q1 helping to contribute to that. So you put those things together, and it lines up for a pretty nice quarter out of the gate."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Brooks West with Piper Jaffray.",10,"Our next question is from Brooks West with Piper Jaffray."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","On Lutonix again, guys, understanding the unwillingness to give us a specific number, can you speak to the market? There's been some speculation on The Street that your -- maybe your initial thoughts on $100 million market should be expanded. Can you give",69,"On Lutonix again, guys, understanding the unwillingness to give us a specific number, can you speak to the market? There's been some speculation on The Street that your -- maybe your initial thoughts on $100 million market should be expanded. Can you give us some commentary there? And then second is can you give us some of the dynamics between the U.S. and international markets on the Lutonix device?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","So I'll take the first one. We're essentially almost 2 quarters -- a little over 1.5 quarters out-of-the-box in the U.S. in a new market. We referenced the stocking order in the fourth quarter. So it's difficult to -- I wouldn't change what we thought the",145,"So I'll take the first one. We're essentially almost 2 quarters -- a little over 1.5 quarters out-of-the-box in the U.S. in a new market. We referenced the stocking order in the fourth quarter. So it's difficult to -- I wouldn't change what we thought the size of the market was based on what we're seeing so far. I will tell you this, we like -- we track reorder rates. We like the way that's going. We like the anecdotal feedback that we're getting.  Both John and I have been out in the field recently ourselves. And continue to feel very optimistic about the anecdotal feedback from the customer base. So too early to change any macro market size based on a couple of quarters. But we're very pleased with the progress so far and what we're hearing about the product and the technology."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'd say on the difference in dynamics between the United States and international, really, international now is only really Europe to speak of, although we have some approvals that are coming through, and we'll launch those products as the approval st",159,"And I'd say on the difference in dynamics between the United States and international, really, international now is only really Europe to speak of, although we have some approvals that are coming through, and we'll launch those products as the approval start, is that we continue to take share internationally, specifically in Europe. We like the momentum we have there. The United States speaks for itself. I think the market, as Tim mentioned, we continue to focus on that say, $100 million in the first full year in the United States. And I'd say that what we're concentrating on is the rollout of the different indications as we finish the clinical trials with the different indications in the United States. And then, geographically, as we finish the clinical trials and/or approvals in the major marketplaces, becomes a pretty powerful operation having both of those positive items as momentum builders as you go through the next number of years."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","We now have a question from Bob Hopkins with Bank of America.",12,"We now have a question from Bob Hopkins with Bank of America."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple of really quick ones. First on Lutonix. Last quarter, you kind of suggested how much Lutonix contributed to the growth rate of the company so we could understand what the kind of organic growth rate was of the base business. And I was wondering i",59,"A couple of really quick ones. First on Lutonix. Last quarter, you kind of suggested how much Lutonix contributed to the growth rate of the company so we could understand what the kind of organic growth rate was of the base business. And I was wondering if you'd be willing to kind of comment on that here this quarter?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Bob. It was just a little less than 2 points of the growth in Q1.",16,"Yes, Bob. It was just a little less than 2 points of the growth in Q1."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then just real quickly. And I know it's early, but either for Tim or for John, your thoughts on how you're competing in the marketplace with Medtronic. It's really early, but are you guys confident that at a minimum, this can be 50-50 share? And",89,"Okay. And then just real quickly. And I know it's early, but either for Tim or for John, your thoughts on how you're competing in the marketplace with Medtronic. It's really early, but are you guys confident that at a minimum, this can be 50-50 share? And then, lastly, I wanted to see if Tim would just comment on the kind of environment we're in right now from an M&A perspective and what you're seeing out there. Is the pipeline full? I just wanted to get an update there."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We don't -- we actually don't even internally predict market share goals or objectives. We just try to get a little bit more everyday. So we're pleased with the positioning of the product. We think as more the real world data comes into play versus",190,"Sure. We don't -- we actually don't even internally predict market share goals or objectives. We just try to get a little bit more everyday. So we're pleased with the positioning of the product. We think as more the real world data comes into play versus the clinical trial, data that was used for the approvals, that becomes increasingly meaningful for us. And certainly, it's perceived that way in the market, I can tell you firsthand from that. So we're pleased with where we are, and technology is everything we thought it was going to be. As it relates to the M&A environment, we're still extremely active. And we're not pleased with the execution last year in terms of getting things done. It wasn't for lack of effort or emphasis. It's just kind of the way deal flow happens. There's a lot of things going on right now. And I wouldn't be surprised if you start hearing more from us soon about those kind of things. But again, you got to have 2 sides to agree. And we're very active right now. So we'll let you know as things occur."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Turkaly with JMP Securities.",10,"Our next question is from David Turkaly with JMP Securities."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just quickly, what kind of diligence, if any, did Boston Sci do on Lutonix? And I guess if you could just comment on how sort of the number of reps you guys will have combined will compare to Medtronic.",39,"Just quickly, what kind of diligence, if any, did Boston Sci do on Lutonix? And I guess if you could just comment on how sort of the number of reps you guys will have combined will compare to Medtronic."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","We had to make sure they knew how to spell it.  So we made sure we trained on that. Beyond that, I think with the publication of the data, the fact that it was available in the market outside the United States, I think they certainly thought they had enou",59,"We had to make sure they knew how to spell it.  So we made sure we trained on that. Beyond that, I think with the publication of the data, the fact that it was available in the market outside the United States, I think they certainly thought they had enough diligence to make whatever decisions they ended up making."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, Dave, when you look at the combined commercial presence between ourselves and the sort of the proportion of Boston's reps time that you could expect would be spent detailing Lutonix, we're on a pretty even playing field with the new Medtroni",60,"Yes, I think, Dave, when you look at the combined commercial presence between ourselves and the sort of the proportion of Boston's reps time that you could expect would be spent detailing Lutonix, we're on a pretty even playing field with the new Medtronic Covidien commercial footprint. So from that standpoint, I think we feel like we're in good shape."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Then we'll go next to Kristen Stewart with Deutsche Bank.",11,"Then we'll go next to Kristen Stewart with Deutsche Bank."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess, Tim, I was wondering if you can just comment more broadly just on like the Vascular landscape, I guess more endovascular just with Cardinal's pending acquisition of Cordis and what that may mean just for your business. I know there's been a lot o",76,"I guess, Tim, I was wondering if you can just comment more broadly just on like the Vascular landscape, I guess more endovascular just with Cardinal's pending acquisition of Cordis and what that may mean just for your business. I know there's been a lot of pressure from the stents. Just kind of perspectives on or any concerns that you may have as they try to, I guess, genericize [ph] to some degree some end markets."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, I can only -- I don't -- I can't speak for them. Obviously, you're going to have to ask them what their perspectives were. I can tell you that from our own experience, in my own personal experience, in fact, there's a very interesting report t",195,"Sure. Well, I can only -- I don't -- I can't speak for them. Obviously, you're going to have to ask them what their perspectives were. I can tell you that from our own experience, in my own personal experience, in fact, there's a very interesting report that was just issued by one of the major consulting companies about an analysis done on product leadership versus breadth of line and which kind of wins out at the end of the day. We had nothing to do with that analysis. But it does point out the fact, which is one we concur with, market leadership and technology leadership as opposed to breadth of line is where we would rather be. Let's put it that way. And I think that clearly, you don't get many companies larger than J&J. And they decided, for whatever their reasons were, to sell that business. We like product leadership. We like -- even in this environment, we think having the best products that clinicians prefer for their patients is important. And beyond that, you have to probably ask them about their decisions there and what they expect to do with that."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","You don't expect any additional pressure I guess from a pricing standpoint?",13,"You don't expect any additional pressure I guess from a pricing standpoint?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Don't know.",3,"Don't know."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I guess it's to be seen. Okay. And then maybe Chris, could you comment on just given the change in FX rate movements, what, if any, FX from an EPS perspective you are absorbing since you did maintain your EPS guidance?",42,"I guess it's to be seen. Okay. And then maybe Chris, could you comment on just given the change in FX rate movements, what, if any, FX from an EPS perspective you are absorbing since you did maintain your EPS guidance?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","It's relatively -- we talked about $0.25 for the full year. It's slightly higher than that, Kristen. There's a number of moving parts, as you can imagine. And certainly, there are currencies that have weakened where we've got large expense bases as well.",113,"It's relatively -- we talked about $0.25 for the full year. It's slightly higher than that, Kristen. There's a number of moving parts, as you can imagine. And certainly, there are currencies that have weakened where we've got large expense bases as well. So it's probably just slightly higher than the $25 million I think -- excuse me, $0.25 for the full year. And I think a range around where currencies are today, I think we can manage through. If there's another material step-down, we'll obviously have to reassess that. But clearly, the business and the operations are performing in a way that it's allowed us to absorb that slight incremental increase."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Last kind of random one, other was down pretty significantly this quarter. Can you just maybe remind us what's in there and why?",23,"Last kind of random one, other was down pretty significantly this quarter. Can you just maybe remind us what's in there and why?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And actually that was when we acquired Rochester, there were some distributor products in Europe that came with the acquisition that we essentially discontinued really April 1 of last year. So there's about $101 million of sales in last year's",61,"Yes, sure. And actually that was when we acquired Rochester, there were some distributor products in Europe that came with the acquisition that we essentially discontinued really April 1 of last year. So there's about $101 million of sales in last year's Q1 in other that we discontinued. So that's driving the large -- most of the decline there in other."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from David Lewis with Morgan Stanley.",10,"Our next question is from David Lewis with Morgan Stanley."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just thinking about vascular, I know you did update guidance for the year, but given that Lutonix was roughly in line with the number -- within $1 million, the non-Lutonix business, obviously, did dramatically better. And I think about your Vascula",108,"Chris, just thinking about vascular, I know you did update guidance for the year, but given that Lutonix was roughly in line with the number -- within $1 million, the non-Lutonix business, obviously, did dramatically better. And I think about your Vascular guidance for the year. If Lutonix builds momentum, per some of the comments on the call, it just appears that the Vascular guidance is either conservative or you're certainly going to be at the upper end of the range. So just wondering if you could talk about your non-Vascular performance if Lutonix builds or what that means for Vascular guidance? Then I had a quick follow-up."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think we'll take it a quarter at a time, David. Certainly, from that respect, we're off to a very good start. We've got again good ambitions for the rest of the year in Vascular. We saw good performance in some of the other categories frankly bette",117,"Yes, I think we'll take it a quarter at a time, David. Certainly, from that respect, we're off to a very good start. We've got again good ambitions for the rest of the year in Vascular. We saw good performance in some of the other categories frankly better than we had expected in Q1, including in the filter segment as well. So we'll take it as we come. And we get through Q2. And we will certainly reassess how we think the full year looks. But everybody in each of the businesses certainly is doing everything they can to get to the top end of the range for the year. But it's a good start for us."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'll also just add biopsy had a pretty strong Q1. And a lot of that is outside of the US. So that's a focus product area for us in emerging market [indiscernible].",34,"And I'll also just add biopsy had a pretty strong Q1. And a lot of that is outside of the US. So that's a focus product area for us in emerging market [indiscernible]."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 quick follow-ups. Number one, there was some commentary on the PICC business and GPO positioning. There's been a lot of jockeying in the PICC market these last couple of years with some of your smaller competitors. I'm just sort of curious why now,",95,"Just 2 quick follow-ups. Number one, there was some commentary on the PICC business and GPO positioning. There's been a lot of jockeying in the PICC market these last couple of years with some of your smaller competitors. I'm just sort of curious why now, why this year and not the prior 2 years that we saw more significant GPO pricing? And the other follow-up was just on the willfulness suit as it relates to Gore. Any updated timing on when the proceeds may flow or just the updated legal timing from your perspective?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think you meant the port business because we had a very strong PICC business and PICC results in Q1. So we did see some pressure in the port business, primarily around new GPO agreements that we signed early in 2014 so that the this is the really the fi",98,"I think you meant the port business because we had a very strong PICC business and PICC results in Q1. So we did see some pressure in the port business, primarily around new GPO agreements that we signed early in 2014 so that the this is the really the first quarter they're kicking in as a new agreement for us. So there is some price pressure because of the lower prices in those GPO agreements. If you looked at our units, we said that our units were just about flat. But it's more pricing than anything else there."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we had actually signaled that, David, on the January call, we called specifically out port pricing pressure. Those are long-term contracts. We obviously thought strategically it made sense for us to sign them. And we'll obviously lap that pricing pres",97,"And we had actually signaled that, David, on the January call, we called specifically out port pricing pressure. Those are long-term contracts. We obviously thought strategically it made sense for us to sign them. And we'll obviously lap that pricing pressure over time. On willfulness we would expect as we sit here today to receive the funds at some point during Q2. All signs lead to that. With interest, it's just under $209 million. And they have our bank account information, and we're anxiously waiting the receipt. But I would expect it would be during in Q2."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question comes from Matthew Taylor with Barclays.",9,"Our next question comes from Matthew Taylor with Barclays."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is actually Zhang Weiye in for Matt. The first question, I guess, in the U.S., we've been hearing about a lot of improvement in terms of volume and utilization, not a lot but incremental improvement. I guess  are you seeing that trend as well? And ca",57,"This is actually Zhang Weiye in for Matt. The first question, I guess, in the U.S., we've been hearing about a lot of improvement in terms of volume and utilization, not a lot but incremental improvement. I guess  are you seeing that trend as well? And can you talk about maybe from a European perspective as well?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No. In fact, I think that while we've seen certain glimmers of improvement and primarily saw a little glimmer in March's improvement in terms of volumes, that was probably offset by January and February's volumes, where there wasn't a substantial improvem",138,"No. In fact, I think that while we've seen certain glimmers of improvement and primarily saw a little glimmer in March's improvement in terms of volumes, that was probably offset by January and February's volumes, where there wasn't a substantial improvement in hospitals in the United States. So if you aggregate it all, I'd say, we're optimistic. But we have not seen anything extremely tangible. And I think I've evidenced that by the way we look at our basic business in drainage, quite frankly. In terms of Europe, there was a number of reimbursement issues that are going on in Europe. France is foremost in those. We didn't have a great Q1 in our European business as you probably saw. But we're optimistic that those volumes will come back as we go through the course of the year."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, great. And I guess a quick second question regarding the emerging markets business. Can you just talk about some of the key geographies that are driving the growth as well as maybe the sustainability of that growth?",38,"Okay, great. And I guess a quick second question regarding the emerging markets business. Can you just talk about some of the key geographies that are driving the growth as well as maybe the sustainability of that growth?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. They're all the ones we mentioned previously. So there's -- the ones in Asia and then the ones in Latin America and then Eastern Europe and the Middle East. And they're all doing very well right now.",38,"Yes. They're all the ones we mentioned previously. So there's -- the ones in Asia and then the ones in Latin America and then Eastern Europe and the Middle East. And they're all doing very well right now."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Or next question comes from Richard Newitter with Leerink Partners.",10,"Or next question comes from Richard Newitter with Leerink Partners."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Ravi in for Rich Newitter. I have a couple of maybe big picture questions. First start with a lot of people talking about what assets you are going to buy. I'm curious just to get your thoughts on some of the businesses that you said that are now",69,"This is Ravi in for Rich Newitter. I have a couple of maybe big picture questions. First start with a lot of people talking about what assets you are going to buy. I'm curious just to get your thoughts on some of the businesses that you said that are now sort of less than 1% of sales, perhaps PI and women's health.  What's the strategic outlook for those segments?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me back up and give you a broader answer. So when you look at the portfolio of 14,000 SKUs, this isn't new. This has been -- I've been here 23 years. It's been like this since I've been here. You have 25% or so of the SKUs that are actually decl",168,"Well, let me back up and give you a broader answer. So when you look at the portfolio of 14,000 SKUs, this isn't new. This has been -- I've been here 23 years. It's been like this since I've been here. You have 25% or so of the SKUs that are actually declining over time. So the balancing of the portfolio and where we make the investments and where we look for acquisitions, where we expand sales forces, et cetera, et cetera, you're constantly going after the higher growth areas. Probably very similar to the way you manage your own investment portfolios. So we don't get too hung up on movement of one or another. I will tell you this, relative to divestiture decisions, it's a lot easier to get rid of a business than it is a product line. And we'd rather have -- having done both, we'd much rather have our management teams focused on increased revenue growth opportunities than preening or pruning off product lines."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, and the only thing I'd add, Ravi, is obviously you'd expect and we do run an economic analysis to determine whether or not the value of some of those declining product lines are worth more to us if we resource them appropriately from a cash flow stan",88,"Yes, and the only thing I'd add, Ravi, is obviously you'd expect and we do run an economic analysis to determine whether or not the value of some of those declining product lines are worth more to us if we resource them appropriately from a cash flow standpoint as opposed to what you might if even anything get through a sale of a product line. So certainly, the things we are keeping, rest assured we think that's the right decision even if they are in a declining mode."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And maybe 1 question on hernia. A lot of -- looks like the OPTIFIX and the Capsure product is coming out soon. I'd like to hear maybe your general view on how minimally invasive surgery and potentially in robotics can affect the long-term view or the long",61,"And maybe 1 question on hernia. A lot of -- looks like the OPTIFIX and the Capsure product is coming out soon. I'd like to hear maybe your general view on how minimally invasive surgery and potentially in robotics can affect the long-term view or the long-term outlook of that business, especially if there's more conversion from open to MIS procedures?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take the bigger picture. Relative -- we're very pleased by the way with the positioning of the entire hernia portfolio. We've got great breadth of line. We've got strength now. The one area we were kind of weakest in my view was the fixation ar",190,"Sure. I'll take the bigger picture. Relative -- we're very pleased by the way with the positioning of the entire hernia portfolio. We've got great breadth of line. We've got strength now. The one area we were kind of weakest in my view was the fixation area. John DeFord talked about a couple of projects that we had alluded to previously but feel pretty good about them now. So we've got a great, probably if you were to go by category, maybe our single strongest portfolio right now across the various vertical groups within that broader category. As it relates to the robotics thing, our view is we provide the products, the implants, et cetera that would be used with the robotic thing. So I don't see it dramatically impacting the business. In fact, several of our products, to the extent that there are people, I think there's more talk than action right now relative to that. But I -- we know that a couple of our products have become the product of choice to be used in some of those procedures. With that, I'll let John DeFord put some..."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think just to weigh it in, I think maybe you were alluding to in robotic surgeries, fixation devices aren't typically needed because they can suture with a robotic device. And so again, I think we see that we're well-positioned. We don't see that",165,"Sure. I think just to weigh it in, I think maybe you were alluding to in robotic surgeries, fixation devices aren't typically needed because they can suture with a robotic device. And so again, I think we see that we're well-positioned. We don't see that happening overnight. And certainly, robotic surgery is pretty limited right now. There are some benefits, of course. You can close the abdominal wound before some of the fixation is required. You can do a few other things. But it's pretty limited in the procedures that you can use robotics in today. So we think we've got a good mix. As Tim and John had said earlier, we think we've got from a mesh or implant perspective, a great mix of products that work well with the robotic surgery as well as with laparoscopic and open. And we also think our fixation products are going to be useful in a number of different repairs that aren't necessarily amenable to robotics today."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] Our next question will come from Dave Roman with Goldman Sachs.",13,"[Operator Instructions] Our next question will come from Dave Roman with Goldman Sachs."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted just to start with a follow-up on your M&A commentary, Tim. There's a tremendous amount of deal euphoria in health care as, obviously, everyone has observed. But can you maybe just talk to us about how you think about cash EPS accretion versus RO",91,"I wanted just to start with a follow-up on your M&A commentary, Tim. There's a tremendous amount of deal euphoria in health care as, obviously, everyone has observed. But can you maybe just talk to us about how you think about cash EPS accretion versus ROIC? I mean, I understand the benefit of a press release that goes out with a 15% accretion number in it. But also, obviously, you're stuck with the asset over time. So how do you think about really finding value given the M&A environment now?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I know. It's an interesting question. So I think you'd go -- and this isn't a new thing. I mean those kinds of properties and models, if you will, call it accretion versus revenue growth, if want to just bookend the two, have always been there. We've",191,"Yes, I know. It's an interesting question. So I think you'd go -- and this isn't a new thing. I mean those kinds of properties and models, if you will, call it accretion versus revenue growth, if want to just bookend the two, have always been there. We've had our eyes wide open to those, especially when you get into larger deals. Someone's actually got to go find that synergy and execute against that. And that's -- always tends to be a little bit more difficult than people think. And while you're doing that, those are the same management groups that you're expecting to go grow the other part of the business that you had. So really the decision for a management group is where do you want your people and your management teams spending their time. So we have watched what's occurred in the marketplace, we've watched how investors have reacted to those deals. It's kind of interesting, and we clearly have targets. We put them into different categories, but with clearly are more of the revenue growth mindset at the moment versus the accretive and slower revenue growth mode."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add, David, is ROI is very important to us. So when we're evaluating opportunities, we're trying to be good stewards of shareholders capital. And we think the notion of near-term accretion for a transaction that frankly is not a goo",124,"And the only thing I'd add, David, is ROI is very important to us. So when we're evaluating opportunities, we're trying to be good stewards of shareholders capital. And we think the notion of near-term accretion for a transaction that frankly is not a good return for shareholders, we think -- we're going to be very careful as to how we deploy capital. And we're going to do it in a way that's not going to only be driven by near-term accretion. It's got to make sense strategically from a returns standpoint. And if it's accretive, that's obviously terrific as well. But it's -- all of those factors are certainly important to us and we're not going to weight short-term accretion over ROI."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's helpful context. And then, maybe just a follow-up on the business and perhaps sort of along the same lines. Emerging markets obviously remains quite strong for you. But still as a percentage of sales, it's relatively small compared to the pee",133,"Okay, that's helpful context. And then, maybe just a follow-up on the business and perhaps sort of along the same lines. Emerging markets obviously remains quite strong for you. But still as a percentage of sales, it's relatively small compared to the peer group. And it just seems like it's going to take a while to see that number move in sort of a step function type of way. And I guess we've seen some others in med tech go into emerging markets and pay big -- decent premiums for assets there. I mean, is there a strategy -- is there a vehicle organically to accelerate the emerging markets adoption where that can get to midteens, call it, percentage of sales number? Or is that something that has to come through external investment?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think that the game plan that we put in place, which was investing heavily and building our teams of people around the world and then arming them with the products that come through our R&D pipeline and do that via great training of physicians is the ri",96,"I think that the game plan that we put in place, which was investing heavily and building our teams of people around the world and then arming them with the products that come through our R&D pipeline and do that via great training of physicians is the right long-term strategy for us. We made the investments. We're seeing the growth in all those segments. We like the game plan. And I think it's one step at a time for us. But we believe that's how you build a meaningful business long-term that has great staying power."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think coming back to ROI. I think if you look at some of those larger transactions in emerging markets. I'd question what the returns are going to be on those. And again, coming back to the right balance between risk and growth, to John's point, we",109,"And I think coming back to ROI. I think if you look at some of those larger transactions in emerging markets. I'd question what the returns are going to be on those. And again, coming back to the right balance between risk and growth, to John's point, we think we've got the right strategy. We certainly are looking for targets that make it through our filters. And we spend a lot of time looking. And again, our bar is reasonable but relatively high. And we clearly have not found targets that we think makes sense for us. In the meantime, we're doing a terrific job growing the business organically."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question is from Josh Jennings with Cowen and Company.",11,"Our next question is from Josh Jennings with Cowen and Company."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just one for you. I was hoping you could help us think about longer-term operating margin expansion opportunities and getting back to that -- the levels that you had -- Bard had performed at  prior to 2013. Looks like you're doing a great job navig",79,"Chris, just one for you. I was hoping you could help us think about longer-term operating margin expansion opportunities and getting back to that -- the levels that you had -- Bard had performed at  prior to 2013. Looks like you're doing a great job navigating those rolling the FX this year and seeing some operating margin expansion to get to the midpoint of the EPS range. But how should we think about operating margins in the out years?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think this year is going to be a nice down payment, I think, Josh on returning to those levels. Certainly, as we talked about some of the portfolio moves we made in 2013 were dilutive in terms of exiting the EP business and adding Rochester in particula",183,"I think this year is going to be a nice down payment, I think, Josh on returning to those levels. Certainly, as we talked about some of the portfolio moves we made in 2013 were dilutive in terms of exiting the EP business and adding Rochester in particular. Those were the right moves for the company, no question. And we're really pleased with the portfolio. Having said that, it did set us back a bit. '15 will be a nice down payment. Every year, our commitment is to drive operating leverage and operating improvement. That's what the management team is tasked and committed to do. And I won't give you a point in time when we'll get back to that level. But I think we're well on our way. And everything we've done in constructing the portfolio in terms of adding higher margin products. To John's point, we've got infrastructures built in emerging markets that are going to be leveragable for a number of years to come. We feel good about the ability for us to continue to move higher year after year."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And just one follow-up for John DeFord and maybe Tim can pitch in. On just the Vascular business now, being the leader in the stents as well as drug-coated balloons, is there anything else in the portfolio that you need to fill your bag with and maybe spe",71,"And just one follow-up for John DeFord and maybe Tim can pitch in. On just the Vascular business now, being the leader in the stents as well as drug-coated balloons, is there anything else in the portfolio that you need to fill your bag with and maybe specific commentary on your outlook for the combo of atherectomy and drug-coated balloons and the need for Bard to have an atherectomy technology?"
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. We constantly look at what we think are the right combinations of products within all of our spaces, Vascular certainly. We've always had a close eye on atherectomy in particular. We're always a little nervous about the reimbursement in that space.",109,"Sure. We constantly look at what we think are the right combinations of products within all of our spaces, Vascular certainly. We've always had a close eye on atherectomy in particular. We're always a little nervous about the reimbursement in that space. That said, it seems to continue to hold much to my surprise. But it's something that we'll be continuing to keep a close eye on. We think the potential combination with DCB could be interesting. We're already seeing and running some studies around using our technology with stents, using our technology in other kind of cases. And so we'll continue to keep that as something to evaluate."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And I would just add, I think a lot of the opportunity we have, we already own. So the ability to get further indications for Below the Knee, we think that's really interesting, being able to go after smaller vessels with DCBs. The whole AV access area we",93,"And I would just add, I think a lot of the opportunity we have, we already own. So the ability to get further indications for Below the Knee, we think that's really interesting, being able to go after smaller vessels with DCBs. The whole AV access area we think is a huge opportunity both relative to stent grafts and the drug-coated technology and/or combinations of those. So we think there's a lot of runway left both in our internal revenue and in expanding the markets, just with the platforms that we have today."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we just mentioned today a couple new products that we expect to be launching in Europe by the end of the year, entering the venous market with the venous stent technology and also, our AV access and next-generation stent graft kind of products. So we",59,"And we just mentioned today a couple new products that we expect to be launching in Europe by the end of the year, entering the venous market with the venous stent technology and also, our AV access and next-generation stent graft kind of products. So we think those are organic ways to continue to expand the pipeline as well."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And this does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments.",24,"And this does conclude our Q&A session. I'd like to turn the call back over to Bard's management for closing or additional comments."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. Thanks, everybody for staying with us. Sorry, went over a little bit over the hour. I'd like to take this opportunity to thank Bard employees around the world for a very strong start to the year and look forward to updating you on our progress",54,"Thank you. Thanks, everybody for staying with us. Sorry, went over a little bit over the hour. I'd like to take this opportunity to thank Bard employees around the world for a very strong start to the year and look forward to updating you on our progress at the end of the next quarter."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks.",1,"Thanks."
254131,290174664,793951,"CR Bard Inc., Q1 2015 Earnings Call, Apr 23, 2015",2015-04-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Okay, thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect.",28,"Okay, thank you. Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation and for using AT&T executive teleconference. You may now disconnect."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the C. R. Bard, Inc. Second Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand repl",275,"Ladies and gentlemen, thank you for standing by. Welcome to the C. R. Bard, Inc. Second Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations. 
Today, Bard's management team will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's March 31, 2015, Form 10-Q, and the information under the caption, Risk Factors, in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. 
During the call, references will be made to certain non-GAAP measures which, management believes, provide an additional meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 23, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted, all comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. I'd like to welcome all of you to Bard's Second Quarter 2015 Earnings Call, and thank all of you for taking the time to join us today. We would expect the presentation portion of the call to last about 25 minutes and the total call to last abou",631,"Thank you. I'd like to welcome all of you to Bard's Second Quarter 2015 Earnings Call, and thank all of you for taking the time to join us today. We would expect the presentation portion of the call to last about 25 minutes and the total call to last about an hour. The agenda today will go as follows: I'll begin with an overview of the results for the second quarter; John Weiland, our President and Chief Operating Officer, will review our second quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and Chief Financial Officer, will review the second quarter income statement, and the balance sheet, as well as our expectations for the third quarter and the remainder of the year. And then finally, we'll close with Q&A. 
Second quarter 2015 net sales totaled $859.8 million, that's up 4% over Q2 of last year and on an as-reported basis, and up 8% on a constant currency basis. Currency impact for the quarter was unfavorable by about 380 basis points. The royalty payment we received from Gore in the quarter was approximately $36.9 million, that's down 2% from a year ago. We believe the decline's due to the FX headwinds, but we don't receive that level of detail from them. Our organic revenue growth was approximately 8.2% this quarter, which exceeded our expectations, that does include a little more than 250 basis points of benefit from drug-coated balloon sales in the U.S. alone. 
Net loss for the second quarter of 2015 was $54.7 million and diluted loss per share was $0.74, which included the net charge for product liability. Excluding this and other items that affected the comparability of results between periods, which Chris will cover later, adjusted second quarter 2015 net income and diluted earnings per share were $154.3 million and $2.27, that's up 8% and 10%, respectively. These adjusted results exceeded the guidance we provided for the quarter and the first half of the year is coming little bit better than we projected. 
Looking at the revenue growth geographically compared to the second quarter of 2014. Net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%, Japan was up 2% and our other international businesses grew 20%. We continue to be very pleased with the acceleration we're seeing in emerging markets, which represented 10% of our total sales in the second quarter, with all of our major geographic categories contributing strong double-digit growth. We are seeing good returns from our increased investments over the last couple of years. 
As we told you, a key objective of our investment plan was to accelerate the growth rates of the company. In Q2, every business performed either at the top or above our stated guidance range for each category. And each of the major growth drivers that we've been highlighting, mainly, emerging markets, drug-coated balloons, BioSurgery, homecare and Targeted Temperature Management, all grew in the healthy double-digit for the quarter. We continue to believe that executing our investment plan will allow us to provide a sustainable, above market revenue growth rate for the overall portfolio in the mid- to high single digits for the track of returns for shareholders. 
On the business development front, in early July, we acquired Vascular Pathways and this technology to enhance our wider assisted Vascular Access devices for approximately $90 million, plus milestones. While the existing revenue's very small, we believe this strengthens our future pipeline and revenue opportunity long term in a very large and important market for us. 
With that, let me turn you over to John Weiland for a review of our product line growth revenue."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth dated comparison to prior year period on a constant currency basis, unless noted otherwise. So let's begin with Vascular. Total net sales were $248.",729,"Good afternoon, everyone. 
Before I start, let me point out that I will be giving all percentage growth dated comparison to prior year period on a constant currency basis, unless noted otherwise. 
So let's begin with Vascular. Total net sales were $248.6 million, up 7% over last year on an as-reported basis and 12% on a constant currency basis. Excluding the royalty payment that a transition agreement related to the divestiture of electrophysiology products, total Vascular sales were up 15% in Q2, with the United States business up 18% and international up 11%. Sales in our Surgical Graft target category were down 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 17% in the second quarter, excluding the Gore royalty. The key driver of this growth was strong Lutonix sales globally, which drove our peripheral PTA line to increase 45%. Our Stent business declined 3% in Q2, consistent with recent trends. Sales in our vena cava filter line were up 8% in Q2 and as disclosed previously, we recently had FDA inspections that resulted in a warning letter and we are working closely with the agency to resolve the issues identified. And to complete the Vascular category, our biopsy family of products grew 11% this quarter, driven by over 40% growth in emerging markets. Biopsy is one of our more global product lines in the portfolio, with approximately 60% of our sales coming from outside the United States. 
Let's go to Urology. Total net sales were $209.2 million, up 1% on an as-reported basis and up 4% on a constant currency basis compared to the second quarter of 2014. The United States business was up 4% while internationally, we grew 6%. Our basic drainage business was up 3%, both globally and in the United States, with our IC Foley business down 2% globally and 4% in the United States. Our Targeted Temperature Management products grew in the healthy double-digits again this quarter. Our continence business was up 4% in Q2 compared to a year ago. Sales in urological specialties were up 3% this quarter, including our therapy business, which grew at 1%. And finally, in this category, standalone sales of our StatLock catheter stabilization line increased 2% in the second quarter. 
So let's move on to Oncology. Total net sales in this category were $235.2 million, an increase of 5% on an as-reported basis and 8% on a constant currency basis over Q2 last year. Geographically, net sales in the United States were up 5% and international sales were up 17%. Our fourth business was up 1% versus Q2 of last year. Our PICC revenue was up 11% this quarter, with each of our major geographical regions performing well. As we've said before, we believe PICCs represent our largest single, outside of the United States revenue growth opportunity and we are focused on developing the international markets and advancing lives in the delivery of health care across the globe. Our Vascular Access Ultrasound product line grew 20% this quarter, with significant growth coming from both the United States and internationally. And to close out this category, our Dialysis Access product line was up 7% this quarter. 
Let's conclude with our Surgical Specialties business. Total net sales in this category were $143.8 million, up 3% as reported and up 6% on a constant currency basis. United States sales were up 6% and international sales were up 9% this quarter. We are pleased with the continued momentum from our BioSurgery business, which grew in the healthy double-digits, again, this quarter. Our soft tissue repair business grew 8% in the second quarter, which is the best result since the first quarter of 2011. Our synthetic hernia products grew 9% this quarter and our natural tissue products grew 8%, driven by our new XenMatrix, antibacterial NAB. And our hernia fixation business, which is included in the soft tissue repair subtotal, declined 5% this quarter. John DeFord will tell you about a couple of launches that we hope can change the trajectory here. 
Closing out the surgical category in Q2, our performance irrigation business was down 35%, similar to last quarter as we told you that we discontinued certain product lines in this category at the beginning of 2015. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for our pipeline update."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Q2 is a pretty busy quarter for our R&D teams and for the second time, I'll just hit some of the highlights today. I'll start with drug-coated balloons, where we're excited to report publication of the Levant",1039,"Thanks, John, and good afternoon, everyone. Q2 is a pretty busy quarter for our R&D teams and for the second time, I'll just hit some of the highlights today. 
I'll start with drug-coated balloons, where we're excited to report publication of the Levant 2 study and the New England Journal of Medicine in July. We also released a first look at the 24-month results from the Levant 2 study and data from our global registry at the society of Vascular surgery meeting in mid-June. While those are important events, we're continuing to push forward with additional configuration, sizes and indications worldwide. Our PMA supplement for 120 and 150-millimeter balloon links was recently approved in the rollout of these sizes is underway for use in the SFA and popliteal arteries. Enrollment continues in our IDE and in-stent restenosis studies and we received IDE approval and enrolled the first few patients in our AV Access drug-coated balloons study. We're also on track to start our Levant China clinical trial and enroll our first patient before the end of the year. 
Also in Vascular, the live stream balloon expandable covered stent IDE continues to enroll very rapidly and I'm pleased to announce that we've completed enrollment of the initial cohort required for analysis of our primary endpoint. We're continuing to enroll a larger cohort and anticipate completing recruitment by the end of the year. This clinical study's evaluating the technology for the treatment of iliac artery disease with a 9-month follow-up. 
In other Stent graft news, our next-generation device for using AV Access is in final internal testing and we anticipate launching in Europe in Q4. This product will require a clinical study for U.S. approval and we anticipate filing the IDE and initiating the study in the first half of 2016. Our Stent project is on a similar development pathway and we anticipate launching in Europe in Q4 and initiating an IDE study around the end of the year. 
Next, moving to Urology and homecare. We're anticipating the launch of a new intermittent self catheterization product, the Magic 3 touch list, later this quarter. Magic 3 touch list combines the comfort and insertion benefits of the Magic 3 platform with our touch list closed system to reduce the risk of contamination and infection due to catheter insertion in more challenging environments outside of the hospital. In June, we launched our new Hydro 2 intermittent catheter designed specifically for the female patient. Hydro cirrhosis 2 incorporates a new handle design to further ease insertion with the technology of our Magic 3 silicone catheter and very low friction coating. The new handle's also designed to simplify the interface of the catheter with the drainage bag for enhanced patient control. 
Closing this category, I'm happy to tell you about our new self lubricating catheterization product, the Magic 3 Go. This new family of catheters anticipated to begin rollout around the end of the year, incorporates our new and proprietary coating technology that provides a hydrophilic low friction insertion without the mess and inconvenience of a water sachet. This new coating provides a sterile and wetted catheter service straight from the package without excess moisture and is designed specifically to address the needs of users outside the acute setting that may have limited dexterity. 
Moving to Oncology. Earlier this month, we launched the new Site-Rite 8 ultrasound system with integrated 3CG Diamond in Europe. This Site-Rite 8 with pinpoint GT technology and 3CG Diamond is slated for U.S. launch in Q4. We believe the combination of ultrasound, needle guidance and catheter tip confirmation in an integrated system will provide a full-featured, user-friendly and intuitive solution for Vascular catheter placement. 
In PICCs, we submitted for U.S. regulatory clearance a new catheter line that's highly resistant to the chemicals used in chemotherapy, as well as cleaning and disinfecting agents. This new and proprietary material is designed for extended exposure to these various solutions while maintaining the catheter characteristics that have made our PICCs the market leader. We anticipate product launch in Q4. 
As Tim announced, we've recently closed the acquisition of Vascular Pathways and have begun selling the acu-cath product. We believe the combination of our PICCs, power glide, midline family and acu-cath will help us bring the best guide wire system peripheral devices to a broad spectrum of patients with Vascular Access needs. 
We're also working toward the launch in the first half of 2016 of a next generation of both the POWERGLIDE and acu-cath products. 
For the acute hemodialysis patient, we've recently launched our new Trialysis Slim catheter. Trialysis Slim incorporates superior visibility and kink resistance, which flow rates in excess of 400 milliliters per minute in a small 12 French triple [indiscernible] catheter configuration. 
I'll close my portion of the discussion today with surgery, and I'm pleased to present a series of launches ongoing or anticipated this quarter. First, in hernia repair, our new physics ST is expected to launch in just a couple of weeks. Physics ST incorporates our proven separate barrier technology with our bioresorbable physics mash to provide a fully resolvable hernia repair solution. This new offering supplements XenMatrix AB, XenMatrix and phasics and allows us to offer proprietary and differentiated products that address the spectrum of complex of domino wall repairs. 
Moving on to our BioSurgery product family. In Q2, we filed our PMA supplement, seeking approval for our new Vascular sealant and continue to anticipate approval in launch in mid-2016. 
And finally, in mesh fixation, we're in the early launch phase of our OPTIFIX spring-loaded resolvable tack device. OPTIFIX has been designed to employ stored energy for ease and efficiency of tack differently while reducing tissue trauma that's been associated with some other fixation devices. We're also in the early rollout of our new permanent fixation device named Capsure. Capsure's designed to reduce the risk of tissue injury due to exposed sharps seen on some other permanent fixation devices and incorporate to small cap on the tack to reduce the risk of adhesions, also seen with some other products. With these 2 fixation launches, we're excited to move back to playing offense in this highly competitive space. 
Thanks for your attention. Let me now hand it over to Chris."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's first start with the items that affect the comparability of our results between periods. First quarter, we received $210.5 million related to the ruling in the Gore litigation. In product liability matters, based on recent develop",952,"Thank you, John. Let's first start with the items that affect the comparability of our results between periods. 
First quarter, we received $210.5 million related to the ruling in the Gore litigation. In product liability matters, based on recent developments, including progress on several large settlements, in Q2, we recorded a net charge of $343.7 million, primarily related to pelvic health product litigation. We also had acquisition-related items of $4.5 million in the quarter and charges of $8.5 million related to restructuring and productivity initiatives. The P&L impact for these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q2 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $526.1 million or 61.2% of sales for Q2. On an adjusted basis, GP was 61.4% of sales, up 10 basis points from the prior year quarter, a little better than we expected. New amortization of intangibles relating to activity in the last 12 months cost us about 30 basis points year-over-year this quarter. Price was unfavorable at 120 basis points on the revenue line and 40 basis points in gross profit, consistent with expectations. And foreign exchange was about a 50 basis point headwind to gross margin in the quarter. Mix was favorable by 40 basis points and our cost improvements and the timing of manufacturing variances drove approximately 90 basis points of favorability in GP in Q2. 
As we've described in the past, manufacturing variances can be somewhat lumpy from quarter-to-quarter and in comparison to prior year, causing some ebbs and flows in GP. So in Q3, we expect the gross margin of about 61% even. Our cost savings and margin improvement programs are on track and we remain comfortable with our full year guidance of GPs of between 61.4% and 61.8%. 
SG&A expenses were $250 million for the quarter or 29.1% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29% even or 60 basis points lower than Q2 of 2014, consistent with our full year guidance. R&D expenditures totaled $64 million for the second quarter or 7.4% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.3%. Again, consistent with our full year guidance. I'll remind you that a couple of years ago, we significantly increased the level of R&D investment and we are now seeing leverage from that higher investment level as sales increase. We remain on offense from an investment standpoint and based on what we've seen in the results in the first half of the year, on sales and income, we intend to increase funding towards certain projects in both SG&A and R&D that we believe that drive long-term shareholder value. Interest expense was $11.2 million for the second quarter and other income and expense was $141.7 million of expense for the second quarter as reported or zero on an adjusted basis. 
The effective tax rate for the quarter was 24.9%, down 80 basis points from the prior year. We continue to expect the effective tax rate for the full year to improve between zero and 50 basis points when compared to the full year 2014. As a reminder, our full year EPS guidance continues to assume the renewal of the R&D tax credit in Q4. 
Diluted shares for the period were $75.5 million and we repurchased approximately 194,000 shares in the second quarter. The net result is adjusted EPS of $2.27, well above the range we provided for the quarter, driven primarily by the over achievement in sales. 
The balance sheet as of June 30 reflects cash, restricted cash and short-term investments of $1.1 billion compared to $1.03 billion at March 31. For the quarter, accounts receivables days were down 0.4 days and inventory days were up 0.6 days. Capital expenditures totaled $28.4 million in the quarter. 
On the liability side. Total debt was $1.4 billion as of June 30 compared to $1.6 billion at March 31. Debt-to-total capital at the end of the second quarter was about 46% and total shareholder investment was $1.7 billion as of June 30. 
Now moving to financial guidance. For Q3, we are expecting constant currency sales growth between 6% and 7% and organic sales growth between 6.5% and 7.5%. We expect the Gore royalty to decline compared to the prior year due to foreign exchange. With regard to the full year, we now expect constant currency sales growth to be between 5% and 6% and organic sales growth to be between 5.5% and 6.5%, which is a full 150 basis point improvement from our original guidance in January. And we now expect foreign exchange to reduce sales for both Q3 and the full year by about 350 basis points. From an EPS standpoint, excluding items affecting comparability, we expect the third quarter in the range of $2.21 to $2.25 per share, reflecting a somewhat lower gross margin and the higher R&D spend compared to Q2 in the prior year. For the full year, we're increasing our adjusted EPS guidance by $0.05 to a range of $9 to $9.10. This higher range reflects modest dilution from a recent acquisition and the increased investments we expect to make in SG&A and R&D during the second half of 2015. 
In summary, the first half of the year has gone quite well from both a sales and profitability perspective. As we now move to the second half, we remain focused on executing our investment plan and pursuing strategic opportunities, with the clear objective of driving attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn you back to Tim."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. Due to the number of investors on the call, I'd ask that you please limit yourself to one question and one f",47,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. Due to the number of investors on the call, I'd ask that you please limit yourself to one question and one follow-up."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Bob.",2,"Sure, Bob."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Given the outperformance in revenues, I wanted to focus my questions there. So I guess from a top-down perspective, as you look at the composition of the growth drivers, is there anything in this quarter that you think was maybe one time in nature? And al",74,"Given the outperformance in revenues, I wanted to focus my questions there. So I guess from a top-down perspective, as you look at the composition of the growth drivers, is there anything in this quarter that you think was maybe one time in nature? And also, Tim, for you. Do you think this was anything to do kind of a pickup in markets? Or is this really more Bard-specific innovation that's driving the growth?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. With respect to the first question, Bob, and I think we've tried to capture it in our guidance, organic revenue growth guidance for Q3. Of course, Q2 was the first quarter, in which Boston Scientific was distributing the Lutonix balloon as well",128,"Yes, sure. With respect to the first question, Bob, and I think we've tried to capture it in our guidance, organic revenue growth guidance for Q3. Of course, Q2 was the first quarter, in which Boston Scientific was distributing the Lutonix balloon as well. As we have talked about, we certainly expected some of those initial orders to be stocking orders. It's difficult to be at all precise in terms of what portion of it were but certainly, that probably would be the one item. And we had signaled that clearly coming in to the quarter that is relatively one time in nature. Obviously, will need a couple of quarters to cycle through that. Otherwise, I think everything else is really part of the core at this point."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, as it relates, Bob, to the underlying market. It still is hard to say exactly. I mean, things feel a little bit better. It's hard to hand your head on a lot of specifics. Clearly, we watch other competitors and companies in our space as close to it,",126,"Yes, as it relates, Bob, to the underlying market. It still is hard to say exactly. I mean, things feel a little bit better. It's hard to hand your head on a lot of specifics. Clearly, we watch other competitors and companies in our space as close to it, and ancillary space system and try to get a feel for their trends. I'd say, for the first half year, it's been somewhat positive, although we did see some mix when you look at some of the larger companies there. So it's hard to say. I would say, we're pleased with our emerging market growth and that's a lot of moving parts, but everything seems to be moving in the right direction and it works for us."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes. That was -- so my second question, as always, impressive, is that in addition to drug-coated balloons, it looks like the underlying core business also accelerated here. So as emerging markets kind of in that 20% threshold, like you've been seeing? Or",118,"Yes. That was -- so my second question, as always, impressive, is that in addition to drug-coated balloons, it looks like the underlying core business also accelerated here. So as emerging markets kind of in that 20% threshold, like you've been seeing? Or did that accelerate? And then maybe lastly, if you could just comment a little bit on hernia because you've got some product momentum going there, which I know is a very high margin business, if you can just talk about maybe a little more detail some of these launches that you recently had and have coming in your future? And just put those in perspective for us about how big an opportunity those might be?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the quarter could be some that we had really very consistent growth through all of the different businesses and geographies. I mean, it was hard to go through our entire portfolio and find the weakness this quarter. As it relates to emerging marke",84,"I think the quarter could be some that we had really very consistent growth through all of the different businesses and geographies. I mean, it was hard to go through our entire portfolio and find the weakness this quarter. As it relates to emerging markets and we actually, without giving out any numbers of what our actual growth was, we did see an uptick in growth. And it really was across the board in emerging markets. Again, the consistency theme that we started with."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And Bob, just jumping in on the pipeline and some of the launches. I think we have had pretty good stream here on some good launches around the company. Xen AB, for example, that John talked about, the product and the synthetics seems to be doing well. We",125,"And Bob, just jumping in on the pipeline and some of the launches. I think we have had pretty good stream here on some good launches around the company. Xen AB, for example, that John talked about, the product and the synthetics seems to be doing well. We've talked about ST as upcoming launch here in the next few weeks and then obviously, OPTIFIX and Capsure really too new to have changed the trajectory yet. But we think that all of those and you talked about hernia in particular, are, I think, a pretty reasonable bag that we've got right now of new technology, a lot of stuff for the rest to talk about and I think a lot of good products to help patients."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Larry Kuesch of Raymond James from Raymond James is next.",10,"Larry Kuesch of Raymond James from Raymond James is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","For Tim and Chris, I wanted to touch on the capital allocation. Obviously, Tim, you've stated in the past that you're a little disappointed with the cadence of M&A last year and kind of here we are, sitting in July with not much done yet. So I'm wondering",109,"For Tim and Chris, I wanted to touch on the capital allocation. Obviously, Tim, you've stated in the past that you're a little disappointed with the cadence of M&A last year and kind of here we are, sitting in July with not much done yet. So I'm wondering if you can talk a little bit about the environment and do you still you think you have some opportunities there? And then, obviously, not a whole lot of the stock repurchase during the quarter. So I'm just trying to understand, you guys have a lot of cash, a lot of cash flow generation, kind of what the plans there are?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll cover that broadly and if Chris wants to comment relative and specific to, I'll let him jump in. Our strategic use of cash has not changed. Strategic first but we continue to be extremely active in the business, the development front, there's a",97,"Sure. I'll cover that broadly and if Chris wants to comment relative and specific to, I'll let him jump in. Our strategic use of cash has not changed. Strategic first but we continue to be extremely active in the business, the development front, there's a bit opportunistic and timing to bring things along but we're as activist as we've been and hopefully, we'll be able to focus in more things on core but certainly, that's more timing-related than effort. We're focused, really. And the share buyback would be effective use of cash and [indiscernible] beyond that. [indiscernible]."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we'll continue to both. Obviously, we knew we'll be closing the acquisition in early July so obviously, we had a use of cash coming in to Q3. And as we move forward through Q3 and Q4, I would expect us to continue to be active on the repurchase",146,"And Larry, we'll continue to both. Obviously, we knew we'll be closing the acquisition in early July so obviously, we had a use of cash coming in to Q3. And as we move forward through Q3 and Q4, I would expect us to continue to be active on the repurchase side, always with a view to what the pipeline looks like. And as Tim said, and as you guys all well know, it's ebbs and flows and you can't exactly predict which ones you're going to get over the finish line despite the, I think, very high level of activity that we have. So the priorities are clear. We love to be closing more. We're certainly trying and absent that and in conjunction with that, we'll continue to return the cash to shareholders in a pretty consistent basis between buybacks and obviously, the slightly increased dividend."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Mike Weinstein with JPMorgan is next.",6,"Mike Weinstein with JPMorgan is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","So Tim, this is your best quarter since, I think, the fourth quarter of 2008. What do you think, besides Lutonix in the launch, which we're all aware of, what do you think kicked in this quarter on the base business? And it looks like you had some U.S. bu",105,"So Tim, this is your best quarter since, I think, the fourth quarter of 2008. What do you think, besides Lutonix in the launch, which we're all aware of, what do you think kicked in this quarter on the base business? And it looks like you had some U.S. businesses that did a lot better and they've been doing trend wise. But you also have surgery at a really big business outside the U.S. What -- so it's kind of all over the map. What was special this quarter that kicked in? And obviously, based on your guidance, you're assuming a high level of sustainability."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Really, there wasn't any magic formula. We've been making a number of different investments, as you know, for several years across the board across, both in SG&A and sales force expansion and R&D and a lot of those just happen to come together from a",97,"Yes. Really, there wasn't any magic formula. We've been making a number of different investments, as you know, for several years across the board across, both in SG&A and sales force expansion and R&D and a lot of those just happen to come together from an execution point of view in the quarter. As John said, it was very consistent across the board, both from a product and geographic standpoint. And I give a lot of credit to the management teams and the employees around the world for a very high level of execution in the quarter."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, so like, if I look at the different businesses, so surgery outside the U.S., as I mentioned, was up 9% this quarter versus down 4% last quarter. Part of that was because the product lines you discontinued in irrigation but like that high single-digi",72,"Okay, so like, if I look at the different businesses, so surgery outside the U.S., as I mentioned, was up 9% this quarter versus down 4% last quarter. Part of that was because the product lines you discontinued in irrigation but like that high single-digit performance in the surgery outside the U.S., that's sustainable. Obviously, the Oncology performance outside the U.S, which has been fantastic, in the mid-teens or better, that's sustainable?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I would disagree with your viewpoint on that, Mike.",9,"I would disagree with your viewpoint on that, Mike."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I mean, we thought for a while, getting productivities in the sales force is that we've expanded. We talked a lot about the pipeline of registrations in markets around the world. All of that's been happening. And you've got now larger, more productiv",75,"Yes, I mean, we thought for a while, getting productivities in the sales force is that we've expanded. We talked a lot about the pipeline of registrations in markets around the world. All of that's been happening. And you've got now larger, more productive salesforces with more products in their bag. And again, it's 2 plus years into the investment plan, I think you're seeing again, Mike, a lot of the results of those investments."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Dave Lewis with Morgan Stanley is next.",7,"Dave Lewis with Morgan Stanley is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 quick questions. Chris, just first for you on the reinvestment. Obviously, dramatic opportunity in the top line reinvesting some of that away. But given the prior investment in the last 18 months, can you give us a sense of where you see investment",91,"Just 2 quick questions. Chris, just first for you on the reinvestment. Obviously, dramatic opportunity in the top line reinvesting some of that away. But given the prior investment in the last 18 months, can you give us a sense of where you see investments in the second of the year are going well to where the prior investments were in the last 15 or 18 months? And what does this tell us about the ability to drive leverage as we look forward into '16? And I have a quick follow-up."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think, clearly, even with these investments, David, over the coming years, we certainly intend to believe we can continue to drive leverage. I think the balance we're trying to strike is the sustainability question, to take advantage of strength, t",223,"Yes. I think, clearly, even with these investments, David, over the coming years, we certainly intend to believe we can continue to drive leverage. I think the balance we're trying to strike is the sustainability question, to take advantage of strength, to make sure that we're doing everything we can with the pipeline and with the emerging geographies to continue to strengthen them over time. And again, I think this quarter, and how we've done in the first half, gives us some of that luxury. We're frankly looking at some additional opportunities in the emerging markets on the sales force side with a couple of product categories, including in China. We're ramping up some of the clinical trial work in a number of places and John DeFord mentioned the trial in China. And there are couple of other projects that, frankly, we're able to turn on as we move in to the back half of the year than we probably wouldn't have been able to, if we haven't performed quite as well as we have through the first half. So we're trying to strike a balance with delivering strong returns in the near term but also, continue and set the portfolio up to drive attractive organic growth rates for the long-term. And that's the challenge and that's how we're trying to manage it."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's fair enough. And then John, you spent a fair amount of time in the call talking about intermittent catheters and that doesn't happen that often. So I wonder if you can talk about how you're seeing your portfolio and you could exploit that opp",54,"Okay, that's fair enough. And then John, you spent a fair amount of time in the call talking about intermittent catheters and that doesn't happen that often. So I wonder if you can talk about how you're seeing your portfolio and you could exploit that opportunity in light of the coming up for cath?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, I think, again, just as Chris said and as Tim said, we've had a lot of focus on execution and getting products through our development pipeline. And so you see we're in the position to talk about some of these products that have been in the de",126,"Sure. Well, I think, again, just as Chris said and as Tim said, we've had a lot of focus on execution and getting products through our development pipeline. And so you see we're in the position to talk about some of these products that have been in the development pipeline and we're either launching or very near launch. So it is a pretty exciting time for us. I think, as far as the intellectual property goes, look, you were certainly aware of all of that. We already had internal developments of our own. We think they were in good shape and obviously, on a go-forward basis, we'll continue to look at ways that we can expand and develop products to meet the needs of our patients."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Kristen Stewart with Deutsche Bank is next.",7,"Kristen Stewart with Deutsche Bank is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to, I guess, suggest a couple of things. First, with respect for the willfulness. How should we think about the cash that you're going to be receiving? Should we think about it in the same context with respect to the lump sum that you receiv",100,"I just wanted to, I guess, suggest a couple of things. First, with respect for the willfulness. How should we think about the cash that you're going to be receiving? Should we think about it in the same context with respect to the lump sum that you received in terms of reinvestment, in the context of giving back half to shareholders and reinvesting the rest back into the business? Or should we just think about that in terms of going to offset maybe some of the increased product liability? Claims that you have, how should we think about that offsetting..."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the cash actually was received in Q2. So it will be reflected in the balance sheet for the quarter. It's about $150 million after tax. And I think we've been pretty consistent and it sort of goes into the caveat. Obviously, gives us some increased fl",129,"Yes, the cash actually was received in Q2. So it will be reflected in the balance sheet for the quarter. It's about $150 million after tax. And I think we've been pretty consistent and it sort of goes into the caveat. Obviously, gives us some increased flexibility. But it's not like we're going to do an incremental $75 million buyback on the back of the receipt of that cash. So we'll, as I said, continue to be active from a buyback standpoint. The money's already in the bank and again, as Tim said, we're also actively looking at opportunities on the business development side. And again, just a reminder, with respect to the product liability, those cash needs, yes, we'll be able to be service with our U.S. cash."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And you also have, like half of it, you have is offset by, you can claim again so I guess it's now Medtronic or your other partner, major manufacturer, right?",30,"And you also have, like half of it, you have is offset by, you can claim again so I guess it's now Medtronic or your other partner, major manufacturer, right?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. And as we've said, the Q will be out tomorrow and actually, obviously, there's been a lot of activity the quarter, vis--vis product liability and settle a lot of the disclosure for you. But about half the claims, as we've talked about, relate to Me",89,"Yes. And as we've said, the Q will be out tomorrow and actually, obviously, there's been a lot of activity the quarter, vis--vis product liability and settle a lot of the disclosure for you. But about half the claims, as we've talked about, relate to Medtronic and there's been good progress there as well with respect to a settlement. So I think a lot of, frankly, productive activity as it relates to the product liability exposure. And I think we feel good about where we are now exiting Q2."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then, just walking to the guidance. It looks like your -- just, can you help me understand to see underlying changes within the sales growth rate? It looks like Gore is expected to decline due to FX and then you have the base, organic sales growth cha",82,"And then, just walking to the guidance. It looks like your -- just, can you help me understand to see underlying changes within the sales growth rate? It looks like Gore is expected to decline due to FX and then you have the base, organic sales growth change, which is an improvement from January depending you're leaving full year EPS by just $0.05, just kind of the moving parts, maybe bridging EPS reflecting the change in Gore relative to acquisitions and investments?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And it's a little unusual because organic growth is higher than constant currency and so that's why we're calling it out. But so for Q3, organic of 6.5% to 7.5%, we're saying a negative 50 basis points related to decline in Gore so constant cur",223,"Yes, sure. And it's a little unusual because organic growth is higher than constant currency and so that's why we're calling it out. But so for Q3, organic of 6.5% to 7.5%, we're saying a negative 50 basis points related to decline in Gore so constant currency of 6% to 7% and FX impact of 3.5%. So again, a strong quarter. And again, the difference between Q3 and Q2 is Boston stocking orders in Q2. For the full year, the other impact, organic at 5.5% to 6.5%, there -- the loss you see in Q4, a decline in our sales to Boston Scientific related to the electrophysiology products. And that's actually material. So that's why we've got this difference in for the full year, from a constant currency basis, to the organic number. And again, currency impacting negatively by about 3.5%. So a nice, strong improvement in organic. From an earnings standpoint, we've talked about some dilution from the acquisition of $0.02 to $0.03, and you'll see some stepped up investment in R&D and SG&A relative to what we would've done frankly otherwise, given the strength in the top line. So I think that kind of organic growth commitment for the full year moving earnings higher but still being able to maintain a high level of investment, I think, strikes the right balance."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","David Roman with Goldman Sachs is next.",7,"David Roman with Goldman Sachs is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted just to start with the Surgical Specialties business, which, as a number of others have commented, had a very nice pick up here. And I think in your prepared remarks, John, you talked about the soft tissue repair franchisee, that's grown since 20",92,"I wanted just to start with the Surgical Specialties business, which, as a number of others have commented, had a very nice pick up here. And I think in your prepared remarks, John, you talked about the soft tissue repair franchisee, that's grown since 2011, can you maybe just elaborate on that in a little bit more detail? Are we seeing sort of a bottoming out of utilization in that category and some of the concerns that had driven those declines, both 2011 are behind us? Or is it more new product-related?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No, David. I'd say it's all new products related. We launched the year before last. We have had great momentum building that business.  They continue to have strong momentum with. The uptick of XenMatrix AB. Having an antibiotic in challenged cases in is",134,"No, David. I'd say it's all new products related. We launched the year before last. We have had great momentum building that business.  They continue to have strong momentum with. The uptick of XenMatrix AB. Having an antibiotic in challenged cases in is a big deal. And we saw outstanding uptake in Xen AB in its first full quarter out there and we don't have any reason to believe we're not going to continue to be very successful in converting biological accounts to Xen AB for those challenged cases. So the pipeline is what's driving it. We're delighted to say that with the 2 new fixation launches that we have over the next few quarters, we expect the momentum that we started, opened biologics, to continue and build on that with the fixation launches."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then maybe just a follow-up on the M&A topic. Tim, on the last call, I'd ask about kind of your view on looking at ROIC or cash growth versus just cash EPS accretion. I mean, over the past 90 days, you've seen obviously continued M&A activity ac",131,"Okay. And then maybe just a follow-up on the M&A topic. Tim, on the last call, I'd ask about kind of your view on looking at ROIC or cash growth versus just cash EPS accretion. I mean, over the past 90 days, you've seen obviously continued M&A activity across the landscape and; valuation continue to move high year but somewhat more mixed equity market reaction to deals they announce. Is there any sort of update on your thinking as you see the landscape unfold in front of you and the activity that's taken place over the last couple of months? And how you're sort of sizing up your parameters for thinking about M&A at this point? And how does the target environment maybe change as you put it into that context?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No, we haven't changed our filters at all relative to the way we look at things. And I think, if you were to go back and look at a lot of the growth or some of the growth from this quarter over the last several years, a lot of it are platforms that we've",130,"No, we haven't changed our filters at all relative to the way we look at things. And I think, if you were to go back and look at a lot of the growth or some of the growth from this quarter over the last several years, a lot of it are platforms that we've invested internally, like in the surgical area. You've got, big investment in that whole biosurgical area, both with acquisitions internally. And you're starting to see those pay off with increased revenue growth at a very nice margin. So that's kind of a discipline that we have and frankly, the external environment of diluting revenue growth for more accretion, we watch that. It hasn't changed our thinking at all in terms of how we look at acquisition."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And Richard Newitter with Leerink Partners is next.",8,"And Richard Newitter with Leerink Partners is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's Ravi here for Rich. Can you hear me?",10,"It's Ravi here for Rich. Can you hear me?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we can, Ravi.",4,"Yes, we can, Ravi."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple of questions, one on the acquisition and one, maybe a longer-term question on the Gore royalty. So I was hoping you could help me understand sort of the dilution around the Vascular Pathways. Is that going to be just a portion on your gross margi",137,"A couple of questions, one on the acquisition and one, maybe a longer-term question on the Gore royalty. So I was hoping you could help me understand sort of the dilution around the Vascular Pathways. Is that going to be just a portion on your gross margins? Or SG&A going forward? Or how should we think about that as we model going forward? And then with Gore, I think the royalty comes off in 2019. And just trying to figure out, at this point, since it's a while away, what are you thinking about in terms of how do you replace it? Is it mostly new indications really sort of organic, organic  growth, other segments of the business step up, inorganic acquisitions? Or how should we think about what's going to replace that in the long run?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","So first on the acquisition, Ravi, there's really no material sales at all in '15. We'll be looking to really relaunch it more broadly in '16. So I said it's $0.02 to $0.03 dilutive in '15, we're obviously covering that while still increasing our guidance",316,"So first on the acquisition, Ravi, there's really no material sales at all in '15. We'll be looking to really relaunch it more broadly in '16. So I said it's $0.02 to $0.03 dilutive in '15, we're obviously covering that while still increasing our guidance for the year. It will be relatively limited sales and breakeven on a cash EPS standpoint in '16 and then, it'll become accretive in '17 beyond. As John DeFord said, it's really interesting technology addition to the Vascular Access product portfolio for us and we think it will be an excellent long-term value creating investment for us. But again, I mean, I think it's too small at this stage for you to worry too much about and from a near term standpoint, we've covered the dilution. I think the Gore royalty in 2019, we've talked about for a number of quarters now, the objective of everything we're doing is frankly, by 2019, to make that royalty a smaller and smaller and less significant portion of the P&L. Obviously, this quarter helps in that regard. We're looking, internally and externally, to find things that will provide good organic growth and then good through so as we get to 2019, again, our portfolio's performing in a way that helps to overcome some of that. And I think we've been pretty frank about continuing that a lot of balance sheet flexibility to help mitigate that impact as you jump from '19 to '20 through utilizing the balance sheet through increased share repurchase activity. So we spent a lot of time planning and thinking about it and obviously, as we get to 2019, there'll be an opportunity for us to give you more visibility. But we're certainly thinking about it in a way that it's -- it will be manageable and we'll make sure we do everything we can to mitigate the impact for investors."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Dave Turkaly with JMP Securities is next.",7,"Dave Turkaly with JMP Securities is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is John on for Dave, can you hear me okay?",11,"This is John on for Dave, can you hear me okay?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, John.",2,"Sure, John."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","So first thing, just wanted to follow-up on the question Bob asked earlier on Lutonix. Granted it's a different ballgame now, with Boston on board and strong registry data out there, but given the stocking orders that have taken place, make it a little bi",79,"So first thing, just wanted to follow-up on the question Bob asked earlier on Lutonix. Granted it's a different ballgame now, with Boston on board and strong registry data out there, but given the stocking orders that have taken place, make it a little bit tricky to evaluate what's going on, I think it might be helpful to get a sense of any trends you're seeing in reorder rates. Any color you can give us there will be helpful."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I would say that consistent with last quarter, we're seeing uptick and uptake that has b-ball of our internal projections, which we're delighted with. This quarter's no different than last quarter. We like the moment that we're building ourselves. We have",170,"I would say that consistent with last quarter, we're seeing uptick and uptake that has b-ball of our internal projections, which we're delighted with. This quarter's no different than last quarter. We like the moment that we're building ourselves. We have great expectations where the momentum Boston will bring to it. In addition, one of the areas that I would not discount is the additional reimbursement that was given to Lutonix during the quarter. And I think a good way to look at that is that in essence, there's full reimbursement now for Lutonix in all of these cases. And the question would be, based on the efficacy that you'll see in all the data sets, registry datas, et cetera, why wouldn't you use Lutonix in a purple case? So I think that the momentum we're building at a field selling standpoint, the momentum that the full reimbursement will give us and the fact that our own internal results are being our expectations, we like where we are right now."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And then a couple of people have hit on it already, but I just wanted to dig a little bit more into the uses of cash. So if we look back historically, at the M&A, there was a period of pretty significant activity from sort of late 2011 to late 2013. A num",142,"And then a couple of people have hit on it already, but I just wanted to dig a little bit more into the uses of cash. So if we look back historically, at the M&A, there was a period of pretty significant activity from sort of late 2011 to late 2013. A number of acquisitions, divestiture of the EP business and then, it kind of dropped off and during that time, across life sciences, there was obviously a lot of activity. There's been an enormous amount in the first half of 2015. And it's great to see the Vascular Pathways deal. Is that a signal that you're refocusing on that in any way? Or is it just the targets have been harder to find, sellers' expectations have been too lofty, maybe if you can just comment on that, that will be helpful."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take a stab at the broader kind of environment comment. There's a lot of things that when looking at deals and including our high filters, there've been some assets that have trended over the last couple of years and frankly, we've taken a look",167,"Sure. I'll take a stab at the broader kind of environment comment. There's a lot of things that when looking at deals and including our high filters, there've been some assets that have trended over the last couple of years and frankly, we've taken a look at it and passed on, all those companies have gotten forward and played at those. They didn't meet our expectations on what our filters are, which are focused primarily on being a market leader #1 and #2, product leadership, the sustainability and the of the revenue growth profile projected on a sustainable basis. So it just takes time and we're turning over a lot of rocks. And all I can tell you is we haven't changed our strategy or mindset relative to doing those things. We look at those as adding platforms to do more investment with going forward as just buying revenue. So I wouldn't read anything into 1 deal changing our outlook, one way or the other, from quarter-to-quarter."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add to that is, if we look back at the transactions that we made the decision on, we wanted to complete, our success rate is very, very, very high and I'd use Lutonix as a good example today.",44,"And the only thing I'd add to that is, if we look back at the transactions that we made the decision on, we wanted to complete, our success rate is very, very, very high and I'd use Lutonix as a good example today."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] The next question is coming from the line of Matt Taylor with Barclays.",15,"[Operator Instructions] The next question is coming from the line of Matt Taylor with Barclays."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just drill down a little bit more on the emerging market growth and if you can provide some details but I was wondering if this quarter, there was more of a step up and sometimes, I don't like this analogy, but what inning of your investment a",62,"I wanted to just drill down a little bit more on the emerging market growth and if you can provide some details but I was wondering if this quarter, there was more of a step up and sometimes, I don't like this analogy, but what inning of your investment are you in there? And how long of a runway do you have?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, the best way I can describe that is, we think we're kind of in the second inning. And I'd say that for this reason. 35% of our worldwide sales force is in emerging markets. Yet, it represents only 10% of our revenue today. We made the investments an",92,"Well, the best way I can describe that is, we think we're kind of in the second inning. And I'd say that for this reason. 35% of our worldwide sales force is in emerging markets. Yet, it represents only 10% of our revenue today. We made the investments and we'll continue to make investments in those geographies but I would say, we're very early in the cycle. And that adds tremendously to the accretive nature of those investments that are already made as it relates to future revenues that come from them."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And one follow-up on Lutonix. I guess, just given the strength, are you willing to give any kind of update in terms of your thoughts on market size or market share or the, I guess, kind of future applications?",40,"And one follow-up on Lutonix. I guess, just given the strength, are you willing to give any kind of update in terms of your thoughts on market size or market share or the, I guess, kind of future applications?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I'll take that. We are #1 or #2.",9,"Yes. I'll take that. We are #1 or #2."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Market share hasn't come up for a while. We're pleased with the momentum and the build in the market. I think if you -- a lot of analysts have listened that they look at the size of the U.S. market being closer to the $140 to $160 million size on an annua",115,"Market share hasn't come up for a while. We're pleased with the momentum and the build in the market. I think if you -- a lot of analysts have listened that they look at the size of the U.S. market being closer to the $140 to $160 million size on an annualized basis, it's hard for us to project that but that's probably close to being right, I think. We initially thought it was going to be closer to $100 million. So all that indicative of a lot of excitement and uptake in the market for technology and product mix, very important in terms of being able to treat patients with purple artery disease."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Anthony Petrone with Jefferies is next.",6,"Anthony Petrone with Jefferies is next."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I'm going to stay on the topics of emerging markets and Lutonix. I guess, first, on emerging markets. You mentioned the PICC opportunity is quite large in the various markets you've invested in. Can you size what the opportunity is? And maybe how long it",54,"I'm going to stay on the topics of emerging markets and Lutonix. I guess, first, on emerging markets. You mentioned the PICC opportunity is quite large in the various markets you've invested in. Can you size what the opportunity is? And maybe how long it will take to maybe fully realize that opportunity?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think we're going to refrain talking about the size of the opportunity for competitive reasons. But it's, quite frankly, it's solely in our hands and that these markets don't exist for the most part today. We have to do the market building work, t",91,"Well, I think we're going to refrain talking about the size of the opportunity for competitive reasons. But it's, quite frankly, it's solely in our hands and that these markets don't exist for the most part today. We have to do the market building work, the education work and the training work in order to build these markets into substantial opportunity. So I mean, it's not as if we're just trying to convert out someone else's product. The reality is, we have to go in and create these markets from scratch."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we have said, it is our largest and fastest growing product in China, for example. So -- and to John's point, we're in the early stages, we believe, of really building that market. And I think the exciting thing about PICCs is that, it's not just",129,"I think we have said, it is our largest and fastest growing product in China, for example. So -- and to John's point, we're in the early stages, we believe, of really building that market. And I think the exciting thing about PICCs is that, it's not just an emerging market opportunity, there's lots of developed geographies where PICCs just have not penetrated the market yet. Frankly, some of the investments we started to make a couple of years ago were focused on those geographies and we're seeing strong double-digit in North of 20% growth in PICCs in developed markets as well. So this has a long, long way to play out and as we said in our prepared remarks, continues to be the largest global opportunity for us."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we have -- we've crossed the hour here. Let's just take one more and then we'll end it.",19,"And we have -- we've crossed the hour here. Let's just take one more and then we'll end it."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Okay. The final question is from Josh Jennings with Cowen and Company.",12,"Okay. The final question is from Josh Jennings with Cowen and Company."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a quick question on Lutonix. We talked with some clinicians that are using drug-coated balloons in cases of above the knew, in-stent restenosis, post atherectomy and just wanted to see if you could give us some anecdotal information around sort of ty",103,"Just a quick question on Lutonix. We talked with some clinicians that are using drug-coated balloons in cases of above the knew, in-stent restenosis, post atherectomy and just wanted to see if you could give us some anecdotal information around sort of types of cases that drug-coated balloons and Lutonix, specifically, are being used by your customer base. And just a follow-up for Chris, any update in terms of a longer-term tax rate target and my understanding is that you expect [indiscernible] basis points improvement in '15 and maybe that continue to trend down with some tax optimization strategies in the out years?"
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Josh, this is Tim. And then, I'll let John DeFord comment on Lutonix question. I think it's just too early for us to really be able to call out any trends of usage of Lutonix in either certain types of patient, regions or if other technologies are us",206,"Yes, Josh, this is Tim. And then, I'll let John DeFord comment on Lutonix question. I think it's just too early for us to really be able to call out any trends of usage of Lutonix in either certain types of patient, regions or if other technologies are used or not. I think what you're seeing and what you're hearing is what we -- frankly, we thought, when we bought the technology, that this is a huge unmet need and that I think, over a number of years, this is going to play out relative to all of the things that you pointed out and how well they work, either together or independently, what kind of regions, et cetera. And the data will tell us how that plays out but suffice it to say, that there's an awful lot of use in interest, various clinicians tend to focus in one of those areas more than another. And we're seeing those physicians have an interest in trying drug-coated balloon technology together with their techniques or technologies, depending how they look at treating the disease. So I think it's going to take a number of years for that to play out to be able to cite any trends."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think that's right, Tim. Anything that we shared today with sort of the anecdotes and really, probably wouldn't be that helpful. I think it will take a little while for some CMS data to come out, to see how the technology's being used and if it's b",99,"Yes, I think that's right, Tim. Anything that we shared today with sort of the anecdotes and really, probably wouldn't be that helpful. I think it will take a little while for some CMS data to come out, to see how the technology's being used and if it's being used. Certainly, we would expect that there'd be more use of provisional stenting than what we saw in our Levant 2 trial, for example. We saw that in the registry at sort of the 20-plus percent range. So other than that, it's all anecdotal at this point, just too early."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Josh, just on the tax question. We actually have, over the last couple of years, completed some meaningful projects. Ironically, the onset of the Gore royalty, which is tax at full U.S. rates, sort of hit some of the progress we've made on the tax ra",129,"Yes, Josh, just on the tax question. We actually have, over the last couple of years, completed some meaningful projects. Ironically, the onset of the Gore royalty, which is tax at full U.S. rates, sort of hit some of the progress we've made on the tax rate. We're certainly continuing to evaluate additional opportunities. They will occur over time and certainly, as we move year-to-year, we'll provide guidance to reflect that. They're not -- there are no easy, large, big wins, if you will, but we'll continue to tackle it over time. And certainly, one of our objectives is to move the tax rate down consistently over time. And we'll, again, on an annual basis, continue to give you guys insight on what kind of progress we're making there."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","This concludes our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments.",23,"This concludes our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments."
254131,305681277,837662,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much and I'd like to thank all of you for taking the time to join us today, as well as thanking Bard's employees around the world for their commitment to excellence and a very good execution quarter. We'll talk to you next quarter. Thanks.",48,"Thank you very much and I'd like to thank all of you for taking the time to join us today, as well as thanking Bard's employees around the world for their commitment to excellence and a very good execution quarter. We'll talk to you next quarter. Thanks."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc.'s Second Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand replay",274,"Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc.'s Second Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations. 
Today, Bard's management team will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statements regarding forward-looking information in Bard's March 31, 2015, Form 10-Q, and the information under the caption, Risk Factors, in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures which, management believes provide an additional meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 23, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. I'd like to welcome all of you to Bard's Second Quarter 2015 Earnings Call and thank all of you for taking the time to join us today. We would expect the presentation portion of the call to last about 25 minutes and the total call to last about",632,"Thank you. I'd like to welcome all of you to Bard's Second Quarter 2015 Earnings Call and thank all of you for taking the time to join us today. We would expect the presentation portion of the call to last about 25 minutes and the total call to last about an hour. The agenda today will go as follows: I'll begin with an overview of the results for the second quarter; John Weiland, our President and Chief Operating Officer, will review our second quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and Chief Financial Officer, will review the second quarter income statement and the balance sheet as well as our expectations for the third quarter and the remainder of the year. And then finally, we'll close with Q&A. 
Second quarter 2015 net sales totaled $859.8 million, that's up 4% over Q2 of last year and on an as-reported basis, and up 8% on a constant currency basis. Currency impact for the quarter was unfavorable by about 380 basis points. The royalty payment we received from Gore in the quarter was approximately $36.9 million, that's down 2% from a year ago. We believe the decline is due to FX headwinds, but we don't receive that level of detail from them. Our organic revenue growth was approximately 8.2% this quarter, which exceeded our expectations. That does include a little more than 250 basis points of benefit from drug-coated balloon sales in the U.S. alone. 
Net loss for the second quarter of 2015 was $54.7 million and diluted loss per share was $0.74, which included a net charge from product liability. Excluding this and other items that affected the comparability of results between periods, which Chris will cover later, adjusted second quarter 2015 net income and diluted earnings per share were $154.3 million and $2.27, that's up 8% and 10%, respectively. These adjusted results exceeded the guidance we provided for the quarter, and the first half of the year is coming little bit better than we projected. 
Looking at the revenue growth geographically compared to the second quarter of 2014. Net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%, Japan was up 2% and our other international businesses grew 20%. We continue to be very pleased with the acceleration we're seeing in emerging markets, which represented 10% of our total sales in the second quarter, with all of our major geographic categories contributing strong double-digit growth. We're seeing good returns from our increased investments over the last couple of years.
As we told you, a key objective of our investment plan was to accelerate the growth rates of the company. In Q2, every business performed either at the top or above our stated guidance range for each category. And each of the major growth drivers that we've been highlighting, mainly emerging markets, drug-coated balloons, BioSurgery, homecare and Targeted Temperature Management, all grew in the healthy double digits this quarter. We continue to believe that executing our investment plan will allow us to provide a sustainable, above market revenue growth rate for the overall portfolio in the mid- to high single digits for the track of returns for shareholders. 
On the business development front, in early July, we acquired Vascular Pathways and this is a technology to enhance our wider assisted Vascular Access devices for approximately $90 million, plus milestones. While the existing revenue is very small, we believe this strengthens our future pipeline and revenue opportunity long term in a very large and important market for us. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth dated in comparison to prior year period on a constant currency basis, unless noted otherwise. So let's begin with Vascular. Total net sales were $248",734,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth dated in comparison to prior year period on a constant currency basis, unless noted otherwise. 
So let's begin with Vascular. Total net sales were $248.6 million, up 7% over last year on an as-reported basis and 12% on a constant currency basis. Excluding the royalty payment and transition agreement related to the divestiture of electrophysiology products, total Vascular sales were up 15% in Q2, with the United States business up 18% and international up 11%. Sales in our Surgical Graft target category were down 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 17% in the second quarter, excluding the Gore royalty. The key driver of this growth was strong Lutonix sales globally, which drove our peripheral PTA line to increase 45%. Our Stent business declined 3% in Q2, consistent with recent trends. Sales in our Vena Cava Filter line were up 8% in Q2. And as disclosed previously, we recently had FDA inspections that resulted in a warning letter, and we are working closely with the agency to resolve the issues identified. And to complete the Vascular category, our biopsy family of products grew 11% this quarter, driven by over 40% growth in emerging markets. Biopsy is one of our more global product lines in the portfolio, with approximately 60% of our sales coming from outside the United States. 
Let's go to Urology. Total net sales were $209.2 million, up 1% on an as-reported basis and up 4% on a constant currency basis compared to the second quarter of 2014. The United States business was up 4%, while internationally, we grew 6%. Our basic drainage business was up 3%, both globally and in the United States, with our I.C. Foley business down 2% globally and 4% in the United States. Our Targeted Temperature Management products grew in the healthy double-digits again this quarter. Our continence business was up 4% in Q2 compared to a year ago. Sales in Urological Specialties were up 3% this quarter, including our brachytherapy business, which grew at 1%. And finally, in this category, standalone sales of our StatLock catheter stabilization line increased 2% in the second quarter. 
So let's move on to Oncology. Total net sales in this category were $235.2 million, an increase of 5% on an as-reported basis and 8% on a constant currency basis over Q2 last year. Geographically, net sales in the United States were up 5% and international sales were up 17%. Our fourth business was up 1% versus Q2 of last year. Our PICC revenue was up 11% this quarter, with each of our major geographical regions performing well. As we've said before, we believe PICCs represent our largest single, outside of the United States revenue growth opportunity and we are focused on developing the international markets and advancing lives in the delivery of health care across the globe. Our Vascular Access Ultrasound product line grew 20% this quarter, with significant growth coming from both the United States and internationally. And to close out this category, our Dialysis Access product line was up 7% this quarter. 
Let's conclude with our Surgical Specialties business. Total net sales in this category were $143.8 million, up 3% as reported and up 6% on a constant currency basis. United States sales were up 6% and international sales were up 9% this quarter. We are pleased with the continued momentum from our BioSurgery business, which grew in the healthy double digits again this quarter. Our soft tissue repair business grew 8% in the second quarter, which is the best result since the first quarter of 2011. Our synthetic hernia products grew 9% this quarter and our natural tissue products grew 8%, driven by our new XenMatrix antibacterial porcine match or Xen AB. And our hernia fixation business, which is included in the soft tissue repair subtotal, declined 5% this quarter. John DeFord will tell you about a couple of launches that we hope can change the trajectory here. 
Closing out the surgical category in Q2, our Performance Irrigation business was down 35%, similar to last quarter, as we told you that we discontinued certain product lines in this category at the beginning of 2015. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for our pipeline update."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Q2 is a pretty busy quarter for our R&D teams and for the sake of time, I'll just hit some of the highlights today. I'll start with drug-coated balloons, where we're excited to report publication of the Levant",1043,"Thanks, John, and good afternoon, everyone. Q2 is a pretty busy quarter for our R&D teams and for the sake of time, I'll just hit some of the highlights today. 
I'll start with drug-coated balloons, where we're excited to report publication of the Levant 2 study in the New England Journal of Medicine on July 9. We also released the a first look at the 24-month results from the Levant 2 study and data from our global registry at the Society of Vascular Surgery meeting in mid-June. While those are important events, we're continuing to push forward with additional configuration, sizes and indications worldwide. Our PMA supplement for 120- and 150-millimeter balloon links was recently approved, and the rollout of these sizes is underway for use in the SFA and popliteal arteries. Enrollment continues in our Bellow the Knee, IDE and in-stent restenosis studies and we received IDE approval and enrolled the first few patients in our AV Access drug-coated balloons study. We're also on track to start our Levant China clinical trial and enroll our first patient before the end of the year. 
Also in Vascular, the LifeStream Balloon Expandable Covered Stent IDE continues to enroll very rapidly and I'm pleased to announce that we've completed enrollment of the initial cohort required for analysis of our primary endpoint. We're continuing to enroll a larger cohort and anticipate completing recruitment by the end of the year. This clinical study is evaluating the technology for the treatment of iliac artery disease with a 9-month followup. 
In other Stent Graft news, our next-generation device for using AV Access is in final internal testing and we anticipate launching in Europe in Q4. This product will require a clinical study for U.S. approval and we anticipate filing the IDE and initiating a study in the first half of 2016. Our venous stent project is on a similar development pathway and we anticipate launching in Europe in Q4 and initiating an IDE study around the end of the year. 
Next, moving to Urology and home care. We're anticipating the launch of a new intermittent self catheterization product, the Magic 3 touchless, later this quarter. Magic 3 touchless combines the comfort and insertion benefits of the Magic 3 platform with our touchless closed system to reduce the risk of contamination and infection due to catheter insertion in more challenging environments outside of the hospital. In June, we launched our new Hydrosil Rose 2 intermittent catheter designed specifically for the female patient. Hydrosil Rose 2 incorporates a new handle design to further ease insertion with the technology of our Magic 3 silicone catheter and very low friction coating. The new handle is also designed to simplify the interface of the catheter with the drainage bag for enhanced patient control. 
Closing this category, I'm happy to tell you about our new self lubricating catheterization product, the Magic 3 Go. This new family of catheters anticipated to begin rollout around the end of the year, incorporates our new and proprietary coating technology that provides a hydrophilic low-friction insertion without the mess and inconvenience of a water sachet. This new coating provides a sterile and wetted catheter surface straight from the package without excess moisture and is designed specifically to address the needs of users outside the acute setting that may have limited dexterity. 
Moving to Oncology. Earlier this month, we launched the new Site-Rite 8 ultrasound system, with integrated 3CG Diamond in Europe. This Site-Rite 8 with Pinpoint GT technology and 3CG Diamond is slated for U.S. launch in Q4. We believe the combination of ultrasounds, needle guidance and catheter tip confirmation in an integrated system will provide a full-featured, user-friendly and intuitive solution for vascular catheter placement. 
In PICCs, we submitted for U.S. regulatory clearance a new catheter line that's highly resistant to the chemicals used in chemotherapy as well as cleaning and disinfecting agents. This new and proprietary material is designed for extended exposure to these various solutions while maintaining the catheter characteristics that have made our PICCs the market leader. We anticipate product launch in Q4. 
As Tim announced, we've recently closed the acquisition of Vascular Pathways and have begun selling the AccuCath product. We believe the combination of our PICCs, PowerGlide Midline family and AccuCath will help us bring the best guidewire assisted peripheral devices to a broad spectrum of patients with Vascular Access needs. 
We're also working toward the launch in the first half of 2016 of a next-generation of both the PowerGlide and AccuCath products. 
For the acute hemodialysis patient, we've recently launched our new Trialysis Slim catheter. Trialysis Slim incorporates superior flexibility and kink resistance, with flow rates in excess of 400 milliliters per minute in a small 12 French triple lumen catheter configuration. 
I'll close my portion of the discussion today with surgery, and I'm pleased to present a series of launches ongoing or anticipated this quarter. First, in hernia repair, our new Phasix ST is expected to launch in just a couple of weeks. Phasix ST incorporates our proven separate barrier technology with our bioresorbable Phasix mesh to provide a fully resorbable ventral hernia repair solution. This new offering supplements XenMatrix AB, XenMatrix and Phasix and allows us to offer proprietary and differentiated products that address the spectrum of complex abdominal wall repairs. 
Moving on to our BioSurgery product family. In Q2, we filed our PMA supplement, seeking approval for our new Tridyne vascular sealant and continue to anticipate approval and launch in mid-2016. And finally, in fixation, we're in the early launch phase of our OPTIFIX spring-loaded resorbable tack device. OPTIFIX has been designed to employ stored energy for ease and efficiency of tack delivery while reducing tissue trauma that's been associated with some other fixation devices. We're also in the early rollout of our new permanent fixation device named Capsure. Capsure is designed to reduce the risk of tissue injury due to exposed sharps seen on some other permanent fixation devices and incorporate to small cap on the tack to reduce the risk of adhesions, also seen with some other products. With these 2 fixation launches, we're excited to move back to playing offense in this highly competitive space. 
Thanks for your attention. Let me now hand it over to Chris."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's first start with the items that affect the comparability of our results between periods. First quarter, we received $210.5 million related to the willfulness ruling in the Gore litigation. In product liability matters, based on re",952,"Thank you, John. Let's first start with the items that affect the comparability of our results between periods. 
First quarter, we received $210.5 million related to the willfulness ruling in the Gore litigation. In product liability matters, based on recent developments, including progress on several large settlements, in Q2, we've recorded a net charge of $343.7 million, primarily related to pelvic health product litigation. We also had acquisition-related items of $4.5 million in the quarter and charges of $8.5 million related to restructuring and productivity initiatives. The P&L impact for these items is detailed in the notes for the financial statements and the reconciliation accompanying our Q2 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $526.1 million or 61.2% of sales for Q2. On an adjusted basis, GP was 61.4% of sales, up 10 basis points from the prior year quarter, a little better than we expected. New amortization of intangibles relating to activity in the last 12 months cost us about 30 basis points year-over-year this quarter. Price was unfavorable at 120 basis points on the revenue line and 40 basis points in gross profit, consistent with expectations. And foreign exchange was about a 50 basis point headwind to gross margin in the quarter. Mix was favorable by 40 basis points and our cost improvements and the timing of manufacturing variances drove approximately 90 basis points of favorability in GP in Q2.
As we've described in the past, manufacturing variances can be somewhat lumpy from quarter-to-quarter and in comparison to prior year, causing some ebbs and flows in GP. So in Q3, we expect the gross margin of about 61% even. Our cost savings and margin improvement programs are on track and we remain comfortable with our full year guidance of GPs of between 61.4% and 61.8%.
SG&A expenses were $250 million for the quarter or 29.1% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29% even or 60 basis points lower than Q2 of 2014, consistent with our full year guidance. R&D expenditures totaled $64 million for the second quarter or 7.4% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.3%, again, consistent with our full year guidance. I'll remind you that a couple of years ago, we significantly increased the level of R&D investment and we are now seeing leverage from that higher investment level as sales increased. We remain on offense from an investment standpoint, and based on what we've seen in the results in the first half of the year on sales and income, we intend to increase funding towards certain projects in both SG&A and R&D that we believe drive long-term shareholder value. Interest expense was $11.2 million for the second quarter and other income and expense was $141.7 million of expense for the second quarter as reported or zero on an adjusted basis. 
The effective tax rate for the quarter was 24.9%, down 80 basis points from the prior year. We continue to expect the effective tax rate for the full year to improve between zero and 50 basis points when compared to the full year 2014. As a reminder, our full year EPS guidance continues to assume the renewal of the R&D tax credit in Q4. 
Diluted shares for the period were $75.5 million and we repurchased approximately 194,000 shares in the second quarter. The net result is adjusted EPS of $2.27, well above the range we provided for the quarter, driven primarily by the over achievement in sales.
The balance sheet as of June 30 reflects cash, restricted cash and short-term investments of $1.1 billion compared to $1.03 billion at March 31. For the quarter, accounts receivables days were down 0.4 days and inventory days were up 0.6 days. Capital expenditures totaled $28.4 million in the quarter.
On the liability side, total debt was $1.4 billion as of June 30 compared to $1.6 billion at March 31. Debt-to-total capital at the end of the second quarter was about 46% and total shareholder investment was $1.7 billion as of June 30.
Now moving to financial guidance. For Q3, we are expecting constant currency sales growth between 6% and 7% and organic sales growth between 6.5% and 7.5%. We expect the Gore royalty to decline compared to the prior year due to foreign exchange. With regard to the full year, we now expect constant currency sales growth to be between 5% and 6% and organic sales growth to be between 5.5% and 6.5%, which is a full 150 basis point improvement from our original guidance in January. And we now expect foreign exchange to reduce sales for both Q3 and the full year by about 350 basis points. From an EPS standpoint, excluding items affecting comparability, we expect the third quarter in the range of $2.21 to $2.25 per share, reflecting a somewhat lower gross margin and the higher R&D spend compared to Q2 in the prior year. For the full year, we're increasing our adjusted EPS guidance by $0.05 to a range of $9 to $9.10. This higher range reflects modest dilution from a recent acquisition and the increased investments we expect to make in SG&A and R&D during the second half of 2015. 
In summary, the first half of the year has gone quite well from both a sales and profitability perspective. As we now move to the second half, we remain focused on executing our investment plan and pursuing strategic opportunities, with the clear objective of driving attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn you back to Tim."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. Due to the number of investors on the call, I'd ask that you please limit yourself to one question and one f",47,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. Due to the number of investors on the call, I'd ask that you please limit yourself to one question and one follow-up."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Bob.",2,"Sure, Bob."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Given the outperformance in revenues, I wanted to focus my questions there. So I guess from a top-down perspective, as you look at the composition of the growth drivers, is there anything in this quarter that you think was maybe one time in nature? And al",75,"Given the outperformance in revenues, I wanted to focus my questions there. So I guess from a top-down perspective, as you look at the composition of the growth drivers, is there anything in this quarter that you think was maybe one time in nature? And also, Tim, for you. Do you think this has anything to do with kind of a pickup in markets? Or is this really more Bard-specific innovation that's driving the growth?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. With respect to the first question, Bob, and I think we've tried to capture it in our guidance, organic revenue growth guidance for Q3. Of course, Q2 was the first quarter in which Boston Scientific was distributing the Lutonix balloon as well.",128,"Yes, sure. With respect to the first question, Bob, and I think we've tried to capture it in our guidance, organic revenue growth guidance for Q3. Of course, Q2 was the first quarter in which Boston Scientific was distributing the Lutonix balloon as well. As we have talked about, we certainly expected some of those initial orders to be stocking orders. It's difficult to be at all precise in terms of what portion of it were, but certainly, that probably would be the one item and we had signaled that clearly, coming in to the quarter. That is relatively one time in nature. Obviously, we'll need a couple of quarters to cycle through that. Otherwise, I think everything else is really part of the core at this point."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, as it relates, Bob, to the underlying market, it still is hard to say exactly. I mean, things feel a little bit better. It's hard to hang your hat on a lot of specifics. Clearly, we watch other competitors and companies in our space as close to it, a",125,"Yes, as it relates, Bob, to the underlying market, it still is hard to say exactly. I mean, things feel a little bit better. It's hard to hang your hat on a lot of specifics. Clearly, we watch other competitors and companies in our space as close to it, and ancillary spaces and try to get a feel for their trends. I'd say, for the first half year, it's been somewhat positive, although we did see some mix when you look at some of the larger companies there. So it's hard to say. I would say, we're pleased with our emerging market growth, and that's a lot of moving parts, but everything seems to be moving in the right direction and it works for us."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes, that was -- so my second question, one of the things that I thought was impressive is that in addition to drug-coated balloons, it looks like the underlying core business also accelerated here. So was -- as emerging markets kind of in that 20% thresh",127,"Yes, that was -- so my second question, one of the things that I thought was impressive is that in addition to drug-coated balloons, it looks like the underlying core business also accelerated here. So was -- as emerging markets kind of in that 20% threshold, like you've been seeing or did that accelerate? And then maybe lastly, if you could just comment a little bit on hernia because you've got some product momentum going there, which I know is a very high-margin business. So if you can just talk about, maybe in a little more detail, some of these launches that you've recently had and have coming in your future. And just put those in perspective for us about how big an opportunity those might be."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the quarter could be summed up as that we had really very consistent growth through all of different businesses and geographies. I mean, it was hard to go through our entire portfolio and find the weakness in it this quarter. As it relates to emer",85,"I think the quarter could be summed up as that we had really very consistent growth through all of different businesses and geographies. I mean, it was hard to go through our entire portfolio and find the weakness in it this quarter. As it relates to emerging markets and we actually, without giving out any numbers of what our actual growth was, we did see an uptick in growth and it really was across-the-board on emerging markets, again, the consistency theme that we started with."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And Bob, just jumping in on the pipeline and some of the launches. I think we have had a pretty good string here of some good launches around the company. Xen AB, for example, that John talked about, the Phasix product and the synthetics seems to be doing",128,"And Bob, just jumping in on the pipeline and some of the launches. I think we have had a pretty good string here of some good launches around the company. Xen AB, for example, that John talked about, the Phasix product and the synthetics seems to be doing well. We've talked about Phasix ST as upcoming launch here in the next few weeks and then obviously, OPTIFIX and Capsure, really too new to have changed the trajectory yet. But we think that all of those, and you talked about hernia in particular, are, I think a pretty reasonable bag that we've got right now of new technology, a lot of stuff for the rest to talk about and I think a lot of good products to help patients."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Larry Kuesch with Raymond James is next.",7,"Larry Kuesch with Raymond James is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","For Tim and Chris, I wanted to touch on the capital allocation. Obviously, Tim, you've stated in the past that you're a little disappointed with the cadence of M&A last year and kind of here we are, sitting in July with not much done yet, so I'm wondering",108,"For Tim and Chris, I wanted to touch on the capital allocation. Obviously, Tim, you've stated in the past that you're a little disappointed with the cadence of M&A last year and kind of here we are, sitting in July with not much done yet, so I'm wondering if you can talk a little bit about the environment. And do you still think you have some opportunities there? And then obviously, not a whole lot of the stock repurchase during the quarter, so really just trying to understand, you guys have a lot of cash, a lot of cash flow generation, kind of what the plans there are."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll cover that broadly and if Chris wants to comment relative and specific, I'll let him jump in. Our strategic use of cash has not changed. Strategic first, but we continue to be extremely active in the business, the development front, that it's a",98,"Sure. I'll cover that broadly and if Chris wants to comment relative and specific, I'll let him jump in. Our strategic use of cash has not changed. Strategic first, but we continue to be extremely active in the business, the development front, that it's a bit opportunistic and timing to bring things along, but we're as activist as we've been and hopefully, we'll be able to focus more things on core. But certainly, that's more timing-related than effort or focus related. And the share buyback would be the effective use of cash and dividend. But beyond that, Chris..."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we'll continue to do both. Obviously, we knew we'll be closing the acquisition in early July, so obviously, we had a use of cash coming into Q3. And as we move forward through Q3 and Q4, I would expect us to continue to be active on the repurch",145,"And Larry, we'll continue to do both. Obviously, we knew we'll be closing the acquisition in early July, so obviously, we had a use of cash coming into Q3. And as we move forward through Q3 and Q4, I would expect us to continue to be active on the repurchase side, always with a view to what the pipeline looks like. And as Tim said, and as you guys all well know, it ebbs and flows and you can't exactly predict which ones you're going to get over the finish line despite the, I think, very high level of activity that we have. So the priorities are clear. We love to be closing more. We're certainly trying. And absent that and in conjunction with that, we'll continue to return cash to shareholders in a pretty consistent basis between buybacks and obviously, the slightly increased dividend."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Mike Weinstein with JPMorgan is next.",6,"Mike Weinstein with JPMorgan is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","So Tim, this is your best quarter since, I think, the fourth quarter of 2008. What do you think, besides Lutonix in the launch, which we're all aware of, what do you think kicked in this quarter on the base business? And it looks like you had some U.S. bu",104,"So Tim, this is your best quarter since, I think, the fourth quarter of 2008. What do you think, besides Lutonix in the launch, which we're all aware of, what do you think kicked in this quarter on the base business? And it looks like you had some U.S. businesses that did a lot better than they've been doing, trend wise. But you also had -- surgery had a really big business outside the U.S., so it's kind of all over the map. What was special this quarter that kicked in? And obviously, based on your guidance, you're assuming a high level of sustainability."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Really, there wasn't any magic formula. We've been making a number of different investments, as you know, for several years across the board, both in SG&A and sales force expansion and R&D, and a lot of those just happen to come together from an exec",96,"Yes. Really, there wasn't any magic formula. We've been making a number of different investments, as you know, for several years across the board, both in SG&A and sales force expansion and R&D, and a lot of those just happen to come together from an execution point of view in the quarter. As John said, it was very consistent across the board, both from a product and geographic standpoint. And I give a lot of credit to the management teams and the employees around the world for a very high level of execution in the quarter."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So like, if I look at some of the different businesses, so surgery outside the U.S., as I mentioned, was up 9% this quarter versus down 4% last quarter. Part of that was because the product lines you discontinued in irrigation. But like that high si",74,"Okay. So like, if I look at some of the different businesses, so surgery outside the U.S., as I mentioned, was up 9% this quarter versus down 4% last quarter. Part of that was because the product lines you discontinued in irrigation. But like that high single-digit performance in the surgery outside the U.S., that's sustainable. Obviously, the Oncology performance outside the U.S, which has been fantastic, in the mid-teens or better, that's sustainable?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I would disagree with your viewpoint on that, Mike.",9,"I would disagree with your viewpoint on that, Mike."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I mean, we've talked for a while, getting productivity in the sales force is that we've expanded. We talked a lot about the pipeline of registrations in markets around the world. All of that's been happening. And you've got now larger, more productiv",74,"Yes, I mean, we've talked for a while, getting productivity in the sales force is that we've expanded. We talked a lot about the pipeline of registrations in markets around the world. All of that's been happening. And you've got now larger, more productive salesforces with more products in their bag. And again, it's 2-plus years into the investment plan, I think you're seeing again, Mike, a lot of the results of those investments."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Dave Lewis with Morgan Stanley is next.",7,"Dave Lewis with Morgan Stanley is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 quick questions. Chris, just first for you on the reinvestment. Obviously, dramatic opportunity in the top line, you're reinvesting some of that away. But given the prior investment in the last 18 months, can you give us a sense of where you these",92,"Just 2 quick questions. Chris, just first for you on the reinvestment. Obviously, dramatic opportunity in the top line, you're reinvesting some of that away. But given the prior investment in the last 18 months, can you give us a sense of where you these investments in the second of the year are going relative to where the prior investments were in the last 15 or 18 months? And what does this tell us about the abilities to drive leverage as we look forward into '16? And I have a quick follow-up."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, clearly, even with these investments, David, over the coming years, we certainly intend to believe we can continue to drive leverage. I think the balance we're trying to strike is the sustainability question, to take advantage of strength, t",223,"Yes, I think, clearly, even with these investments, David, over the coming years, we certainly intend to believe we can continue to drive leverage. I think the balance we're trying to strike is the sustainability question, to take advantage of strength, to make sure that we're doing everything we can with the pipeline and with the emerging geographies to continue to strengthen them over time. And again, I think this quarter, and how we've done in the first half, gives us some of that luxury. We're frankly looking at some additional opportunities in emerging markets on the salesforce side with a couple of product categories, including in China. We're ramping up some of the clinical trial work in a number of places, and John DeFord mentioned the trial in China. And there are a couple of other projects that, frankly, we're able to turn on as we move in to the back half of the year than we've probably wouldn't have been able to, if we haven't performed quite as well as we have through the first half. So we're trying to strike a balance with delivering strong returns in the near term, but also continuing to set the portfolio up to drive attractive organic growth rates for the long term, and that's the challenge and that's how we're trying to manage it."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's fair enough. And then John, you spent a fair amount of time in the call talking about intermittent catheters and that doesn't happen that often. So I wonder if you can talk about the -- how you're seeing your portfolio and you could exploit t",58,"Okay, that's fair enough. And then John, you spent a fair amount of time in the call talking about intermittent catheters and that doesn't happen that often. So I wonder if you can talk about the -- how you're seeing your portfolio and you could exploit that opportunity in light of patent expiry coming up for Coloplast SpeediCath?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, I think, again, just as Chris said and as Tim said, we've had a lot of focus on execution and getting products through our development pipeline. And so you see, we're in the position to talk about some of these products that have been in the d",126,"Sure. Well, I think, again, just as Chris said and as Tim said, we've had a lot of focus on execution and getting products through our development pipeline. And so you see, we're in the position to talk about some of these products that have been in the development pipeline and we're either launching or very near launch. So it is a pretty exciting time for us. I think, as far as the intellectual property goes, look, you were certainly aware of all of that. We already had internal developments of our own. We think they were in good shape and obviously, on a go-forward basis, we'll continue to look at ways that we can expand and develop products to meet the needs of our patients."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Kristen Stewart with Deutsche Bank is next.",7,"Kristen Stewart with Deutsche Bank is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to, I guess, address a couple of things. First, with respect for the willfulness, how should we think about the cash that you're going to be receiving? Should we think about it in the same context with respect to the lump sum that you receiv",106,"I just wanted to, I guess, address a couple of things. First, with respect for the willfulness, how should we think about the cash that you're going to be receiving? Should we think about it in the same context with respect to the lump sum that you received in terms of reinvestment, in the context of giving back half to shareholders and reinvesting the rest back into the business? Or should we just think about that in terms of going to offset maybe some of the increased product liability claims that you have? How should we think about that offsetting sort of from a P&L perspective?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure Kristen. Actually, the cash -- the cash actually was received in Q2, so it will be reflected in the balance sheet for the quarter. It's about $150 million after tax, and I think we've been pretty consistent. And if it sort of goes into the caveat, ob",137,"Sure Kristen. Actually, the cash -- the cash actually was received in Q2, so it will be reflected in the balance sheet for the quarter. It's about $150 million after tax, and I think we've been pretty consistent. And if it sort of goes into the caveat, obviously, it gives us some increased flexibility. But it's not like we're going to do an incremental $75 million buyback on the back of the receipt of that cash. So we'll, as I said, continue to be active from a buyback standpoint. The money is already in the bank and again, as Tim said, we're also actively looking at opportunities on the business development side. And again, just a reminder, with respect to the product liability, those cash needs, yes, we'll be able to be service with our U.S. cash."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And you also have like half of it, do you have -- it's offset by -- you can claim, I guess it's now Medtronic, or your other partner -- the main original manufacturer as well, right?",36,"And you also have like half of it, do you have -- it's offset by -- you can claim, I guess it's now Medtronic, or your other partner -- the main original manufacturer as well, right?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. As we said, the Q will be out tomorrow and actually, obviously, there's been a lot of activity the quarter, vis--vis product liability and so there'll be a lot of good disclosure for you. But about half the claims, as we've talked about, relate to",89,"Yes. As we said, the Q will be out tomorrow and actually, obviously, there's been a lot of activity the quarter, vis--vis product liability and so there'll be a lot of good disclosure for you. But about half the claims, as we've talked about, relate to Medtronic and there's been good progress there as well with respect to settlement. So I think a lot of, frankly, productive activity, as it relates to the product liability exposure, and I think we feel good about where we are now exiting Q2."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then just walking to the guidance, it looks like your -- just, can you help me understand just the underlying changes within the sales growth rate? It looks like Gore is expected to decline due to FX and then you have the base, organic sales gro",85,"Okay. And then just walking to the guidance, it looks like your -- just, can you help me understand just the underlying changes within the sales growth rate? It looks like Gore is expected to decline due to FX and then you have the base, organic sales growth change, which is an improvement from January, but then you're raising full year EPS by just $0.05. Just kind of the moving parts, maybe bridging the EPS, reflecting the change in Gore, relative to acquisitions and investments?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And it's a little unusual because organic growth is higher than constant currency, and so that's why we're calling it out. But so for Q3, organic of 6.5% to 7.5%, we're saying, a negative 50 basis points related to a decline in Gore, so constan",224,"Yes, sure. And it's a little unusual because organic growth is higher than constant currency, and so that's why we're calling it out. But so for Q3, organic of 6.5% to 7.5%, we're saying, a negative 50 basis points related to a decline in Gore, so constant currency of 6% to 7% and FX impact of 3.5%. So again, a strong quarter. And again, the difference between Q3 and Q2 is Boston stocking orders in Q2. For the full year, the other impact, organic at 5.5% to 6.5%, there -- you'll also see in Q4 a decline in our sales to Boston Scientific related to the electrophysiology products, and that's actually material. So that's why we've got this difference in for the full year, from a constant currency basis, to the organic number. And again, currency impacting it negatively by about 3.5%. So a nice, strong improvement in organic. From an earnings standpoint, we've talked about some dilution from the acquisition of $0.02 to $0.03, and you'll see some stepped up investment in R&D and SG&A, relative to what we would've done frankly, otherwise, given the strength in the top line. So I think that kind of organic growth commitment for the full year, moving earnings higher but still being able to maintain a high level of investment, I think, strikes the right balance."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","David Roman with Goldman Sachs is next.",7,"David Roman with Goldman Sachs is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted just to start with the Surgical Specialties business, which, as a number of others have commented, had a very nice pick-up here. And I think in your prepared remarks, John, you talked about the soft tissue repair franchise seeing its best grown s",94,"I wanted just to start with the Surgical Specialties business, which, as a number of others have commented, had a very nice pick-up here. And I think in your prepared remarks, John, you talked about the soft tissue repair franchise seeing its best grown since 2011. Can you maybe just elaborate on that in a little bit more detail? Are we seeing sort of a bottoming out of utilization in that category and some of the concerns that had driven those declines, in 2011, are behind us, or is it more new product related?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No, David, I'd say it's all new products related. We launched Phasix the year before last. We have had great momentum building that business and continue to have strong momentum with Phasix. The uptick of XenMatrix AB -- having an antibiotic coating in ch",140,"No, David, I'd say it's all new products related. We launched Phasix the year before last. We have had great momentum building that business and continue to have strong momentum with Phasix. The uptick of XenMatrix AB -- having an antibiotic coating in challenged cases in ventral is a big deal, and we saw outstanding uptake in Xen AB in its first full quarter out there and we don't have any reason to believe we're not going to continue to be very successful in converting biological accounts to Xen AB for those challenged cases. So the pipeline is what's driving it. We're delighted to say that with the 2 new fixation launches that we have over the next few quarters, we expect the momentum that we started, both in biologics, to continue and build on that with the fixation launches."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then maybe just a follow-up on the M&A topic. Tim, on the last call, I had asked about kind of your view on looking at ROIC/cash growth versus just cash EPS accretion. I mean, over the past 90 days, we've seen, obviously, continued M&A activity",130,"Okay. And then maybe just a follow-up on the M&A topic. Tim, on the last call, I had asked about kind of your view on looking at ROIC/cash growth versus just cash EPS accretion. I mean, over the past 90 days, we've seen, obviously, continued M&A activity across the landscape and valuation continue to move high year but somewhat more mixed equity market reaction to deals they announced. Is there any sort of update on your thinking as you see the landscape unfold in front of you and the activity that's taken place over the past couple of months and how you're sort of sizing up your parameters for thinking about M&A at this point? And how does the target environment maybe changed as you put it into that context?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, no, we haven't changed our focus at all relative to the way we look at things. And I think if you were to go back and look at a lot of the growth or some of the growth from this quarter over the last several years, a lot of it are platforms that we'v",136,"Yes, no, we haven't changed our focus at all relative to the way we look at things. And I think if you were to go back and look at a lot of the growth or some of the growth from this quarter over the last several years, a lot of it are platforms that we've invested in internally, like in the surgical area. You've got bio resorbables, big investment in that whole BioSurgical area, both with acquisitions and internally, and you're starting to see those pay off with the increased revenue growth at a very nice margin. So that's kind of a the that we have. And frankly, the external environment of diluting revenue growth for more accretion, we watch that. It hasn't changed our thinking at all in terms of how we look at acquisition."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And Richard Newitter with Leerink Partners is next.",8,"And Richard Newitter with Leerink Partners is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's Ravi, here for Rich. Can you hear me?",10,"It's Ravi, here for Rich. Can you hear me?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we can, Ravi.",4,"Yes, we can, Ravi."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple of questions, one on the acquisition and one, maybe a longer-term question on the Gore royalty. So I was hoping you could help me understand the, sort of a little bit around the dilution around the Vascular Pathways. Is that going to be just a po",142,"A couple of questions, one on the acquisition and one, maybe a longer-term question on the Gore royalty. So I was hoping you could help me understand the, sort of a little bit around the dilution around the Vascular Pathways. Is that going to be just a portion on your gross margins? Or SG&A going forward, or how should we think about that as we model going forward? And then with Gore, I think the royalty comes off in 2019. And just trying to figure out, at this point, since it's a while away, what are you thinking about in terms of how do you replace it? Is it mostly new indications really sort of organic, organic  growth, other segments of the business step up, inorganic acquisitions? Or how should we think about what's going to replace that in the long run?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","So first, on the acquisition, Ravi, there are really no material sales at all in '15. We'll be looking to really launch it more broadly in '16. So I said it's $0.02 to $0.03 dilutive in '15. We're obviously covering that while still increasing our guidanc",319,"So first, on the acquisition, Ravi, there are really no material sales at all in '15. We'll be looking to really launch it more broadly in '16. So I said it's $0.02 to $0.03 dilutive in '15. We're obviously covering that while still increasing our guidance for the year. It'll be relatively limited sales and breakeven on a cash EPS standpoint in '16 and then, it'll become accretive in '17 beyond. As John DeFord said, it's a really interesting technology addition to the Vascular Access product portfolio for us, and we think it will be an excellent long-term value creating investment for us. But again, I mean, I think it's too small at this stage for you to worry too much about, and from a near term standpoint, we've covered the dilution. I think the Gore royalty in 2019, we've talked about for a number of quarters now, the objective of everything we're doing is frankly, by 2019, to make that royalty a smaller and smaller and less significant portion of the P&L. Obviously, this quarter helps in that regard. We're looking, internally and externally, to find things that will provide good organic growth and then good drop-throughs, so as we get to 2019, again, our portfolio is performing in a way that helps to overcome some of that. And I think we've been pretty frank about continuing to have a lot of balance sheet flexibility to help mitigate that impact as you jump from '19 to '20 through utilizing the balance sheet through increased share repurchase activity. So we've spent a lot of time planning and thinking about it and obviously, as we get to 2019, there'll be an opportunity for us to give you more visibility. But we're certainly thinking about it in a way that it's -- it will be manageable and we'll make sure we do everything we can to mitigate the impact for investors."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Dave Turkaly with JMP Securities is next.",7,"Dave Turkaly with JMP Securities is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is John, on for Dave, can you hear me okay?",11,"This is John, on for Dave, can you hear me okay?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, John.",2,"Sure, John."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","So first, I just wanted to follow-up on the question Bob asked earlier on Lutonix. Granted it's a different ballgame now, with Boston on board and strong registry data out there, but given the stocking orders that have taken place, make it a little bit tr",79,"So first, I just wanted to follow-up on the question Bob asked earlier on Lutonix. Granted it's a different ballgame now, with Boston on board and strong registry data out there, but given the stocking orders that have taken place, make it a little bit tricky to evaluate what's going on, I think it might be helpful to get a sense of any trends you're seeing in reorder rates. Any color you can give us there would be helpful."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I would say that consistent with last quarter, we're seeing uptick and uptake that has b-ball of our internal projections, which we're delighted with. This quarter is no different than last quarter. We like the momentum that we're building ourselves. We h",170,"I would say that consistent with last quarter, we're seeing uptick and uptake that has b-ball of our internal projections, which we're delighted with. This quarter is no different than last quarter. We like the momentum that we're building ourselves. We have great expectations with the momentum Boston will bring to it. In addition, one of the areas that I would not discount is the additional reimbursement that was given to Lutonix during the quarter. And I think a good way to look at that is that in essence, there's full reimbursement now for Lutonix in all of these cases. And the question would be, based on the efficacy that you'll see in all the data sets, registry data, et cetera, why wouldn't you use Lutonix in a purple case? So I think that the momentum we're building at a field-selling standpoint, the momentum that the full reimbursement will give us and the fact that our own internal results are beating our expectations, we like where we are right now."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","All right, that's helpful. And then I know a couple of people have hit on it already, but I just wanted to dig a little bit more into the uses of cash. So if we look back historically at the M&A, there was a period of pretty significant activity from sort",149,"All right, that's helpful. And then I know a couple of people have hit on it already, but I just wanted to dig a little bit more into the uses of cash. So if we look back historically at the M&A, there was a period of pretty significant activity from sort of late 2011 to late 2013, a number of acquisitions, divestiture of the EP business. And then it kind of dropped off and during that time, across life sciences, there was obviously a lot of activity, there's been an enormous amount in the first half of 2015. And it's great to see the Vascular Pathways deal. Is that a signal that you're refocusing on that in any way? Or is it just that the targets have been harder to find, sellers' expectations have been too lofty? Maybe if you can just comment on that, that will be helpful."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take a stab at the broader kind of environment comment. There's a lot of things that go when looking at deals and including our high filters. There've been some assets that have trended over the last couple of years and frankly, we've taken a l",168,"Sure. I'll take a stab at the broader kind of environment comment. There's a lot of things that go when looking at deals and including our high filters. There've been some assets that have trended over the last couple of years and frankly, we've taken a look at it and passed on. Other companies have gotten forward and acquired those. They didn't meet our expectations on what our filters are, which are focused primarily on being a market leader, number one, and number two, product leadership, the sustainability of that and the revenue growth profile projected on a sustainable basis. So it just takes time and we're turning over a lot of rocks. And all I can tell you is we haven't changed our strategy or mindset relative to doing those things. We look at those as adding platforms to do more investment with going forward as just buying revenue. So I wouldn't read anything into one deal changing our outlook, one way or the other, from quarter-to-quarter."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add to that is that if we look back at the transactions that we made the decision on, we wanted to complete. Our success rate is very, very, very high, and I'd use Lutonix as a good example today.",45,"And the only thing I'd add to that is that if we look back at the transactions that we made the decision on, we wanted to complete. Our success rate is very, very, very high, and I'd use Lutonix as a good example today."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] The next question is coming from the line of Matt Taylor with Barclays.",15,"[Operator Instructions] The next question is coming from the line of Matt Taylor with Barclays."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just drill down a little bit more on the emerging market growth and if you can provide some details, but I was wondering if this quarter, there was more of a step up and sometimes, I don't like this analogy, but what inning of your investment",62,"I wanted to just drill down a little bit more on the emerging market growth and if you can provide some details, but I was wondering if this quarter, there was more of a step up and sometimes, I don't like this analogy, but what inning of your investment are you in there? And how long of a runway do you have?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, the best way I can describe that is, we think we're kind of in the second inning. And I'd say that for this reason. 35% of our worldwide sales force is in emerging markets. Yet, it represents only 10% of our revenue today. We've made the investments",92,"Well, the best way I can describe that is, we think we're kind of in the second inning. And I'd say that for this reason. 35% of our worldwide sales force is in emerging markets. Yet, it represents only 10% of our revenue today. We've made the investments and we'll continue to make investments in those geographies. But I would say, we're very early in the cycle. And that adds tremendously to the accretive nature of those investments that are already made as it relates to future revenues that come from them."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And one follow-up on Lutonix. I guess, just given the strength, are you willing to give any kind of update in terms of your thoughts on market size or market share or the, I guess, kind of future applications?",40,"And one follow-up on Lutonix. I guess, just given the strength, are you willing to give any kind of update in terms of your thoughts on market size or market share or the, I guess, kind of future applications?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I'll take that. We are #1 or # 2. [indiscernible] Market share hasn't come up for a while. We're pleased with the momentum and the build in the market. I think if you -- a lot of analysts have written that they look at the size of the U.S. market bei",127,"Yes. I'll take that. We are #1 or # 2. [indiscernible] Market share hasn't come up for a while. We're pleased with the momentum and the build in the market. I think if you -- a lot of analysts have written that they look at the size of the U.S. market being closer to the $140 million to $160 million size on an annualized basis. It's hard for us to project that, but that's probably close to being right, I think. We initially thought it was going to be closer to $100 million. So all that's indicative of a lot of excitement and uptake in the market for technology and our product mix, very important in terms of being able to treat patients with purple artery disease."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Anthony Petrone with Jefferies is next.",6,"Anthony Petrone with Jefferies is next."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. I'm going to stay on the topics of emerging markets and Lutonix. I guess, first, on emerging markets, you mentioned the PICC opportunity is quite large in the various markets that you've invested in. Can you size what the opportunity is, and maybe",55,"Great. I'm going to stay on the topics of emerging markets and Lutonix. I guess, first, on emerging markets, you mentioned the PICC opportunity is quite large in the various markets that you've invested in. Can you size what the opportunity is, and maybe how long it will take to maybe fully realize that opportunity?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think we're going to refrain talking about the size of the opportunity for competitive reasons. But it's -- quite frankly, it's solely in our hands and that these markets don't exist for the most part today. We have to do the market building work,",92,"Well, I think we're going to refrain talking about the size of the opportunity for competitive reasons. But it's -- quite frankly, it's solely in our hands and that these markets don't exist for the most part today. We have to do the market building work, the education work and the training work in order to build these markets into substantial opportunity. So I mean, it's not as if we're just trying to convert out someone else's product. The reality is, we have to go on and create these markets from scratch."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we have said, it is our largest and fastest-growing product in China, for example. So -- and to John's point, we're in the early stages, we believe, of really building that market. I mean, I think the exciting thing about PICCs is that, it's not j",131,"I think we have said, it is our largest and fastest-growing product in China, for example. So -- and to John's point, we're in the early stages, we believe, of really building that market. I mean, I think the exciting thing about PICCs is that, it's not just an emerging market opportunity, there's lots of developed geographies where PICCs just have not penetrated the market yet. Frankly, some of the investments we started to make a couple of years ago were focused on those geographies and we're seeing strong double-digit in the north of 20% growth in PICCs in developed markets as well. So this has a long, long way to play out and as we said in our prepared remarks, it continues to be the largest global opportunity for us."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we have -- we've crossed the hour here. Let's just take one more and then we'll end it.",19,"And we have -- we've crossed the hour here. Let's just take one more and then we'll end it."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Okay. And the final question is from Josh Jennings with Cowen and Company.",13,"Okay. And the final question is from Josh Jennings with Cowen and Company."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a quick question on Lutonix. We talked with some clinicians that are using drug-coated balloons in cases of all variety of Above the Knee, in-stent restenosis, post atherectomy, and I just wanted to see if you could give us some anecdotal information",110,"Just a quick question on Lutonix. We talked with some clinicians that are using drug-coated balloons in cases of all variety of Above the Knee, in-stent restenosis, post atherectomy, and I just wanted to see if you could give us some anecdotal information around types of cases that drug-coated balloons and Lutonix, specifically, are being used in by your customer base. And then just a follow-up for Chris. Any update in terms of the longer-term tax rate targets? And my understanding is that you expect zero to 50 basis points improvement in '15, and maybe can that continue to trend down with some tax optimization strategies in the out years?"
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Josh, this is Tim. And then, I'll let John DeFord comment on the Lutonix question. I think it's just too early for us to really be able to call out any trends of usage of Lutonix in either certain types of patient, lesions or if other technologies ar",207,"Yes, Josh, this is Tim. And then, I'll let John DeFord comment on the Lutonix question. I think it's just too early for us to really be able to call out any trends of usage of Lutonix in either certain types of patient, lesions or if other technologies are used or not. I think what you're seeing and what you're hearing is what we -- frankly, we thought, when we bought the technology, that this is a huge unmet need and that I think, over a number of years, this is going to play out relative to all of the things that you pointed out and how well they work, either together or independently, what kind of lesions, et cetera. And the data will tell us how that plays out. But suffice it to say that there's an awful lot of use and interest, various clinicians tend to focus in one of those areas more than another and we're seeing those physicians have an interest in trying drug-coated balloon technology together with their techniques or technologies, depending how they look at treating the disease. So I think it's going to take a number of years for that to play out to be able to cite any trends."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think that's right, Tim. Anything that we've shared today with sort of the anecdotes and really, probably wouldn't be that helpful. I think it'll take a little while for some CMS data to come out to see how the technology is being used and if it's",99,"Yes, I think that's right, Tim. Anything that we've shared today with sort of the anecdotes and really, probably wouldn't be that helpful. I think it'll take a little while for some CMS data to come out to see how the technology is being used and if it's being used. Certainly, we would expect that there'd be more use of provisional stenting than what we saw in our Levant 2 trial, for example. We saw that in the registry at sort of the 20-plus percent range. So other than that, it's all anecdote at this point, just too early."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Josh, just on the tax question. We actually have, over the last couple of years, completed some meaningful projects. Ironically, the onset of the Gore royalty, which is tax at full U.S. rates, sort of hit some of the progress we've made on the tax ra",129,"Yes, Josh, just on the tax question. We actually have, over the last couple of years, completed some meaningful projects. Ironically, the onset of the Gore royalty, which is tax at full U.S. rates, sort of hit some of the progress we've made on the tax rate. We're certainly continuing to evaluate additional opportunities. They will occur, over time, and certainly, as we move year-to-year, we'll provide guidance to reflect that. They're not -- there are no easy, large, big wins, if you will, but we'll continue to tackle it over time. And certainly, one of our objectives is to move the tax rate down consistently over time. And we'll, again, on an annual basis, continue to give you guys insight on what kind of progress we're making there."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","This concludes our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments.",23,"This concludes our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments."
254131,305681277,837909,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much, and I'd like to thank all of you for taking the time to join us today, as well as thanking Bard's employees around the world for their commitment to excellence and a very good execution quarter. We'll talk to you next quarter. Thanks.",47,"Thank you very much, and I'd like to thank all of you for taking the time to join us today, as well as thanking Bard's employees around the world for their commitment to excellence and a very good execution quarter. We'll talk to you next quarter. Thanks."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc.'s Second Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand replay",274,"Ladies and gentlemen, thank you for standing by. Welcome to the CR Bard Inc.'s Second Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded and will be available for future on-demand replay through the Bard website. 
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations. 
Today, Bard's management team will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statements regarding forward-looking information in Bard's March 31, 2015, Form 10-Q, and the information under the caption, Risk Factors, in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures which, management believes provide an additional meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of July 23, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to the prior year period. 
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. I'd like to welcome all of you to Bard's Second Quarter 2015 Earnings Call and thank all of you for taking the time to join us today. We would expect the presentation portion of the call to last about 25 minutes and the total call to last about",628,"Thank you. I'd like to welcome all of you to Bard's Second Quarter 2015 Earnings Call and thank all of you for taking the time to join us today. We would expect the presentation portion of the call to last about 25 minutes and the total call to last about an hour. The agenda today will go as follows: I'll begin with an overview of the results for the second quarter; John Weiland, our President and Chief Operating Officer, will review our second quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you a brief update on our product pipeline; and then, Chris Holland, our Senior VP and Chief Financial Officer, will review the second quarter income statement and the balance sheet as well as our expectations for the third quarter and the remainder of the year. And then finally, we'll close with Q&A. 
Second quarter 2015 net sales totaled $859.8 million, that's up 4% over Q2 of last year on an as-reported basis, and up 8% on a constant currency basis. Currency impact for the quarter was unfavorable by about 380 basis points. The royalty payment we received from Gore in the quarter was approximately $36.9 million, that's down 2% from a year ago. We believe the decline is due to FX headwinds, but we don't receive that level of detail from them. Our organic revenue growth was approximately 8.2% this quarter, which exceeded our expectations. That does include a little more than 250 basis points of benefit from drug-coated balloon sales in the U.S. alone. 
Net loss for the second quarter of 2015 was $54.7 million and diluted loss per share was $0.74, which included a net charge from product liability. Excluding this and other items that affected the comparability of results between periods, which Chris will cover later, adjusted second quarter 2015 net income and diluted earnings per share were $154.3 million and $2.27, that's up 8% and 10%, respectively. These adjusted results exceeded the guidance we provided for the quarter, and the first half of the year is coming a little bit better than we projected. 
Looking at the revenue growth geographically compared to the second quarter of 2014. Net sales in the U.S. increased 7%. On a constant currency basis, Europe grew 5%, Japan was up 2% and our other international businesses grew 20%. We continue to be very pleased with the acceleration we're seeing in emerging markets, which represented 10% of our total sales in the second quarter, with all of our major geographic categories contributing strong double-digit growth. We're seeing good returns from our increased investments over the last couple of years.
As we told you, a key objective of our investment plan was to accelerate the growth rate of the company. In Q2, every business performed either at the top or above our stated guidance range for each category. And each of the major growth drivers that we've been highlighting, mainly emerging markets, drug-coated balloons, BioSurgery, homecare and Targeted Temperature Management, all grew in the healthy double digits this quarter. We continue to believe that executing our investment plan will allow us to provide a sustainable, above market revenue growth rate for the overall portfolio in the mid- to high single digits with attractive returns for shareholders. 
On the business development front, in early July, we acquired Vascular Pathways and its technology to enhance our wider assisted Vascular Access devices for approximately $90 million, plus milestones. While the existing revenue is very small, we believe this strengthens our future pipeline and revenue opportunity long term in a very large and important market for us. 
With that, let me turn you over to John Weiland for a review of our product line revenue."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to prior year period on a constant currency basis, unless noted otherwise. So let's begin with Vascular. Total net sales were $248.",734,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to prior year period on a constant currency basis, unless noted otherwise. 
So let's begin with Vascular. Total net sales were $248.6 million, up 7% over last year on an as-reported basis and 12% on a constant currency basis. Excluding the royalty payment and transition agreement related to the divestiture of electrophysiology products, total Vascular sales were up 15% in Q2, with the United States business up 18% and international up 11%. Sales in our Surgical Graft target category were down 5% in the second quarter, within the range of recent experience. Our Endovascular business grew 17% in the second quarter, excluding the Gore royalty. The key driver of this growth was strong Lutonix sales globally, which drove our peripheral PTA line to increase 45%. Our Stent business declined 3% in Q2, consistent with recent trends. Sales in our Vena Cava Filter line were up 8% in Q2. And as disclosed previously, we recently had FDA inspections that resulted in a warning letter, and we are working closely with the agency to resolve the issues identified. And to complete the Vascular category, our biopsy family of products grew 11% this quarter, driven by over 40% growth in emerging markets. Biopsy is one of our more global product lines in the portfolio, with approximately 60% of our sales coming from outside the United States. 
Let's go to Urology. Total net sales were $209.2 million, up 1% on an as-reported basis and up 4% on a constant currency basis compared to the second quarter of 2014. The United States business was up 4%, while internationally, we grew 6%. Our basic drainage business was up 3%, both globally and in the United States, with our I.C. Foley business down 2% globally and 4% in the United States. Our Targeted Temperature Management products grew in the healthy double-digits again this quarter. Our continence business was up 4% in Q2 compared to a year ago. Sales in Urological Specialties were up 3% this quarter, including our brachytherapy business, which grew at 1%. And finally, in this category, standalone sales of our StatLock catheter stabilization line increased 2% in the second quarter. 
So let's move on to Oncology. Total net sales in this category were $235.2 million, an increase of 5% on an as-reported basis and 8% on a constant currency basis over Q2 last year. Geographically, net sales in the United States were up 5% and international sales were up 17%. Our port business was up 1% versus Q2 of last year. Our PICC revenue was up 11% this quarter, with each of our major geographical regions performing well. As we've said before, we believe PICCs represent our largest single, outside of the United States revenue growth opportunity and we are focused on developing the international markets and advancing lives in the delivery of health care across the globe. Our Vascular Access Ultrasound product line grew 20% this quarter, with significant growth coming from both the United States and internationally. And to close out this category, our Dialysis Access product line was up 7% this quarter. 
Let's conclude with our Surgical Specialties business. Total net sales in this category were $143.8 million, up 3% as reported and up 6% on a constant currency basis. United States sales were up 6% and international sales were up 9% this quarter. We are pleased with the continued momentum from our BioSurgery business, which grew in the healthy double digits again this quarter. Our soft tissue repair business grew 8% in the second quarter, which is the best result since the first quarter of 2011. Our synthetic hernia products grew 9% this quarter and our natural tissue products grew 8%, driven by our new XenMatrix antibacterial porcine mesh or Xen AB. And our hernia fixation business, which is included in the soft tissue repair subtotal, declined 5% this quarter. John DeFord will tell you about a couple of launches that we hope can change the trajectory here. 
Closing out the surgical category in Q2, our Performance Irrigation business was down 35%, similar to last quarter, as we told you that we discontinued certain product lines in this category at the beginning of 2015. 
This concludes our product line revenue discussion. I'll now turn you over to John DeFord for our pipeline update."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon, everyone. Q2 is a pretty busy quarter for our R&D teams and for the sake of time, I'll just hit some of the highlights today. I'll start with drug-coated balloons, where we're excited to report publication of the Levant",1044,"Thanks, John, and good afternoon, everyone. Q2 is a pretty busy quarter for our R&D teams and for the sake of time, I'll just hit some of the highlights today. 
I'll start with drug-coated balloons, where we're excited to report publication of the Levant 2 study in the New England Journal of Medicine on July 9. We also released the a first look at the 24-month results from the Levant 2 study and data from our global registry at the Society of Vascular Surgery meeting in mid-June. While those are important events, we're continuing to push forward with additional configuration, sizes and indications worldwide. Our PMA supplement for 120- and 150-millimeter balloon links was recently approved, and the rollout of these sizes is underway for use in the SFA and popliteal arteries. Enrollment continues in our Bellow the Knee, IDE and in-stent restenosis studies and we received IDE approval and enrolled the first few patients in our AV Access drug-coated balloons study. We're also on track to start our Levant China clinical trial and enroll our first patient before the end of the year. 
Also in Vascular, the LifeStream Balloon Expandable Covered Stent IDE continues to enroll very rapidly and I'm pleased to announce that we've completed enrollment of the initial cohort required for analysis of our primary endpoint. We're continuing to enroll a larger cohort and anticipate completing recruitment by the end of the year. This clinical study is evaluating the technology for the treatment of iliac artery disease with a 9-month followup. 
In other Stent Graft news, our next-generation device for using AV Access is in final internal testing and we anticipate launching in Europe in Q4. This product will require a clinical study for U.S. approval and we anticipate filing the IDE and initiating a study in the first half of 2016. Our venous stent project is on a similar development pathway and we anticipate launching in Europe in Q4 and initiating an IDE study around the end of the year. 
Next, moving to Urology and home care. We're anticipating the launch of a new intermittent self catheterization product, the Magic 3 touchless, later this quarter. Magic 3 touchless combines the comfort and insertion benefits of the Magic 3 platform with our touchless closed system to reduce the risk of contamination and infection due to catheter insertion in more challenging environments outside of the hospital. In June, we launched our new Hydrosil Rose 2 intermittent catheter designed specifically for the female patient. Hydrosil Rose 2 incorporates a new handle design to further ease insertion with the technology of our Magic 3 silicone catheter and very low friction coating. The new handle is also designed to simplify the interface of the catheter with the drainage bag for enhanced patient control. 
Closing this category, I'm happy to tell you about our new self lubricating catheterization product, the Magic 3 Go. This new family of catheters anticipated to begin rollout around the end of the year, incorporates our new and proprietary coating technology that provides a hydrophilic low-friction insertion without the mess and inconvenience of a water sachet. This new coating provides a sterile and wetted catheter surface straight from the package without excess moisture and is designed specifically to address the needs of users outside the acute setting that may have limited dexterity. 
Moving to Oncology. Earlier this month, we launched the new Site-Rite 8 ultrasound system, with integrated 3CG Diamond in Europe. This Site-Rite 8 with Pinpoint GT technology and 3CG Diamond is slated for U.S. launch in Q4. We believe the combination of ultrasounds, needle guidance and catheter tip confirmation in an integrated system will provide a full-featured, user-friendly and intuitive solution for vascular catheter placement. 
In PICCs, we submitted for U.S. regulatory clearance a new catheter line that's highly resistant to the chemicals used in chemotherapy as well as cleaning and disinfecting agents. This new and proprietary material is designed for extended exposure to these various solutions while maintaining the catheter characteristics that have made our PICCs the market leader. We anticipate product launch in Q4. 
As Tim announced, we've recently closed the acquisition of Vascular Pathways and have begun selling the AccuCath product. We believe the combination of our PICCs, PowerGlide Midline family and AccuCath will help us bring the best guidewire assisted peripheral devices to a broad spectrum of patients with Vascular Access needs. 
We're also working toward the launch in the first half of 2016 of a next-generation of both the PowerGlide and AccuCath products. 
For the acute hemodialysis patient, we've recently launched our new Trialysis Slim catheter. Trialysis Slim incorporates superior flexibility and kink resistance, with flow rates in excess of 400 milliliters per minute in a small 12 French triple lumen catheter configuration. 
I'll close my portion of the discussion today with surgery, and I'm pleased to present a series of launches ongoing or anticipated this quarter. First, in hernia repair, our new Phasix ST is expected to launch in just a couple of weeks. Phasix ST incorporates our proven separate barrier technology with our bioresorbable Phasix mesh to provide a fully resorbable ventral hernia repair solution. This new offering supplements XenMatrix AB, XenMatrix and Phasix and allows us to offer proprietary and differentiated products that address the spectrum of complex abdominal wall repairs. 
Moving on to our BioSurgery product family. In Q2, we filed our PMA supplement, seeking approval for our new Tridyne vascular sealant and continue to anticipate approval and launch in mid-2016. And finally, in mesh fixation, we're in the early launch phase of our OPTIFIX spring-loaded resorbable tack device. OPTIFIX has been designed to employ stored energy for ease and efficiency of tack delivery while reducing tissue trauma that's been associated with some other fixation devices. We're also in the early rollout of our new permanent fixation device named Capsure. Capsure is designed to reduce the risk of tissue injury due to exposed sharps seen on some other permanent fixation devices and incorporate to small cap on the tack to reduce the risk of adhesions, also seen with some other products. With these 2 fixation launches, we're excited to move back to playing offense in this highly competitive space. 
Thanks for your attention. Let me now hand it over to Chris."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's first start with the items that affect the comparability of our results between periods. First quarter, we received $210.5 million related to the willfulness ruling in the Gore litigation. In product liability matters, based on re",952,"Thank you, John. Let's first start with the items that affect the comparability of our results between periods. 
First quarter, we received $210.5 million related to the willfulness ruling in the Gore litigation. In product liability matters, based on recent developments, including progress on several large settlements, in Q2, we've recorded a net charge of $343.7 million, primarily related to pelvic health product litigation. We also had acquisition-related items of $4.5 million in the quarter and charges of $8.5 million related to restructuring and productivity initiatives. The P&L impact for these items is detailed in the notes for the financial statements and the reconciliation accompanying our Q2 earnings press release. 
Now let's go to the statement of income for the quarter. Gross profit was $526.1 million or 61.2% of sales for Q2. On an adjusted basis, GP was 61.4% of sales, up 10 basis points from the prior year quarter, a little better than we expected. New amortization of intangibles relating to activity in the last 12 months cost us about 30 basis points year-over-year this quarter. Price was unfavorable at 120 basis points on the revenue line and 40 basis points in gross profit, consistent with expectations. And foreign exchange was about a 50 basis point headwind to gross margin in the quarter. Mix was favorable by 40 basis points and our cost improvements and the timing of manufacturing variances drove approximately 90 basis points of favorability in GP in Q2.
As we've described in the past, manufacturing variances can be somewhat lumpy from quarter-to-quarter and in comparison to prior year, causing some ebbs and flows in GP. So in Q3, we expect the gross margin of about 61% even. Our cost savings and margin improvement programs are on track and we remain comfortable with our full year guidance of GPs of between 61.4% and 61.8%.
SG&A expenses were $250 million for the quarter or 29.1% of sales. On an adjusted basis, SG&A as a percentage of net sales was 29% even or 60 basis points lower than Q2 of 2014, consistent with our full year guidance. R&D expenditures totaled $64 million for the second quarter or 7.4% of sales on a reported basis. On an adjusted basis, R&D expense as a percentage of sales was 7.3%, again, consistent with our full year guidance. I'll remind you that a couple of years ago, we significantly increased the level of R&D investment and we are now seeing leverage from that higher investment level as sales increased. We remain on offense from an investment standpoint, and based on what we've seen in the results in the first half of the year on sales and income, we intend to increase funding towards certain projects in both SG&A and R&D that we believe drive long-term shareholder value. Interest expense was $11.2 million for the second quarter and other income and expense was $141.7 million of expense for the second quarter as reported or zero on an adjusted basis. 
The effective tax rate for the quarter was 24.9%, down 80 basis points from the prior year. We continue to expect the effective tax rate for the full year to improve between 0 and 50 basis points when compared to the full year 2014. As a reminder, our full year EPS guidance continues to assume the renewal of the R&D tax credit in Q4. 
Diluted shares for the period were $75.5 million and we repurchased approximately 194,000 shares in the second quarter. The net result is adjusted EPS of $2.27, well above the range we provided for the quarter, driven primarily by the over achievement in sales.
The balance sheet as of June 30 reflects cash, restricted cash and short-term investments of $1.1 billion compared to $1.03 billion at March 31. For the quarter, accounts receivables days were down 0.4 days and inventory days were up 0.6 days. Capital expenditures totaled $28.4 million in the quarter.
On the liability side, total debt was $1.4 billion as of June 30 compared to $1.6 billion at March 31. Debt-to-total capital at the end of the second quarter was about 46% and total shareholder investment was $1.7 billion as of June 30.
Now moving to financial guidance. For Q3, we are expecting constant currency sales growth between 6% and 7% and organic sales growth between 6.5% and 7.5%. We expect the Gore royalty to decline compared to the prior year due to foreign exchange. With regard to the full year, we now expect constant currency sales growth to be between 5% and 6% and organic sales growth to be between 5.5% and 6.5%, which is a full 150 basis point improvement from our original guidance in January. And we now expect foreign exchange to reduce sales for both Q3 and the full year by about 350 basis points. From an EPS standpoint, excluding items affecting comparability, we expect the third quarter in the range of $2.21 to $2.25 per share, reflecting a somewhat lower gross margin and the higher R&D spend compared to Q2 in the prior year. For the full year, we're increasing our adjusted EPS guidance by $0.05 to a range of $9 to $9.10. This higher range reflects modest dilution from a recent acquisition and the increased investments we expect to make in SG&A and R&D during the second half of 2015. 
In summary, the first half of the year has gone quite well from both a sales and profitability perspective. As we now move to the second half, we remain focused on executing our investment plan and pursuing strategic opportunities, with the clear objective of driving attractive and sustainable revenue growth, profitability and shareholder returns over the long term. 
I'll now turn you back to Tim."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. Due to the number of investors on the call, I'd ask that you please limit yourself to one question and one f",47,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now turn the call back to the moderator to facilitate the Q&A session. Due to the number of investors on the call, I'd ask that you please limit yourself to one question and one follow-up."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Can you hear me okay?",5,"Can you hear me okay?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Bob.",2,"Sure, Bob."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Given the outperformance in revenues, I wanted to focus my questions there. So I guess from a top-down perspective, as you look at the composition of the growth drivers, is there anything in this quarter that you think was maybe one time in nature? And al",75,"Given the outperformance in revenues, I wanted to focus my questions there. So I guess from a top-down perspective, as you look at the composition of the growth drivers, is there anything in this quarter that you think was maybe one time in nature? And also, Tim, for you. Do you think this has anything to do with kind of a pickup in markets? Or is this really more Bard-specific innovation that's driving the growth?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. With respect to the first question, Bob, and I think we've tried to capture it in our guidance, organic revenue growth guidance for Q3. Of course, Q2 was the first quarter in which Boston Scientific was distributing the Lutonix balloon as well.",128,"Yes, sure. With respect to the first question, Bob, and I think we've tried to capture it in our guidance, organic revenue growth guidance for Q3. Of course, Q2 was the first quarter in which Boston Scientific was distributing the Lutonix balloon as well. As we have talked about, we certainly expected some of those initial orders to be stocking orders. It's difficult to be at all precise in terms of what portion of it were, but certainly, that probably would be the one item and we had signaled that clearly, coming in to the quarter. That is relatively one time in nature. Obviously, we'll need a couple of quarters to cycle through that. Otherwise, I think everything else is really part of the core at this point."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, as it relates, Bob, to the underlying market, it still is hard to say exactly. I mean, things feel a little bit better. It's hard to hang your hat on a lot of specifics. Clearly, we watch other competitors and companies in our space as close to it, a",123,"Yes, as it relates, Bob, to the underlying market, it still is hard to say exactly. I mean, things feel a little bit better. It's hard to hang your hat on a lot of specifics. Clearly, we watch other competitors and companies in our space as close to it, and ancillary spaces and try to get a feel for their trends. I'd say, for the first half year, it's been somewhat positive, although it is mixed when you look at some of the larger companies there. So it's hard to say. I would say, we're pleased with our emerging market growth, and that's a lot of moving parts, but everything seems to be moving in the right direction and it works for us."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Yes, that was -- so my second question, one of the things that I thought was impressive is that in addition to drug-coated balloons, it looks like the underlying core business also accelerated here. So was -- as emerging markets kind of in that 20% thresh",127,"Yes, that was -- so my second question, one of the things that I thought was impressive is that in addition to drug-coated balloons, it looks like the underlying core business also accelerated here. So was -- as emerging markets kind of in that 20% threshold, like you've been seeing or did that accelerate? And then maybe lastly, if you could just comment a little bit on hernia because you've got some product momentum going there, which I know is a very high-margin business. So if you can just talk about, maybe in a little more detail, some of these launches that you've recently had and have coming in your future. And just put those in perspective for us about how big an opportunity those might be."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think the quarter could be summed up as that we had really very consistent growth through all of different businesses and geographies. I mean, it was hard to go through our entire portfolio and find the weakness in it this quarter. As it relates to emer",85,"I think the quarter could be summed up as that we had really very consistent growth through all of different businesses and geographies. I mean, it was hard to go through our entire portfolio and find the weakness in it this quarter. As it relates to emerging markets and we actually, without giving out any numbers of what our actual growth was, we did see an uptick in growth and it really was across-the-board on emerging markets, again, the consistency theme that we started with."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And Bob, just jumping in on the pipeline and some of the launches. I think we have had a pretty good string here of some good launches around the company. Xen AB, for example, that John talked about, the Phasix product and the synthetics seems to be doing",128,"And Bob, just jumping in on the pipeline and some of the launches. I think we have had a pretty good string here of some good launches around the company. Xen AB, for example, that John talked about, the Phasix product and the synthetics seems to be doing well. We've talked about Phasix ST as upcoming launch here in the next few weeks and then obviously, OPTIFIX and Capsure, really too new to have changed the trajectory yet. But we think that all of those, and you talked about hernia in particular, are, I think a pretty reasonable bag that we've got right now of new technology, a lot of stuff for the reps to talk about and I think a lot of good products to help patients."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Larry Keusch with Raymond James is next.",7,"Larry Keusch with Raymond James is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","For Tim and Chris, I wanted to touch on the capital allocation. Obviously, Tim, you've stated in the past that you're a little disappointed with the cadence of M&A last year and kind of here we are, sitting in July with not much done yet, so I'm wondering",108,"For Tim and Chris, I wanted to touch on the capital allocation. Obviously, Tim, you've stated in the past that you're a little disappointed with the cadence of M&A last year and kind of here we are, sitting in July with not much done yet, so I'm wondering if you can talk a little bit about the environment. And do you still think you have some opportunities there? And then obviously, not a whole lot of the stock repurchase during the quarter, so really just trying to understand, you guys have a lot of cash, a lot of cash flow generation, kind of what the plans there are."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll cover that broadly and if Chris wants to comment relative and specific, I'll let him jump in. Our strategic use of cash has not changed. Strategic first, but we continue to be extremely active in the business, the development front, that it's a",98,"Sure. I'll cover that broadly and if Chris wants to comment relative and specific, I'll let him jump in. Our strategic use of cash has not changed. Strategic first, but we continue to be extremely active in the business, the development front, that it's a bit opportunistic and timing to bring things along, but we're as active as we've been and hopefully, we'll be able to focus more things on core. But certainly, that's more timing-related than effort or focus related. And the share buyback would be the effective use of cash and dividend. But beyond that, Chris..."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And Larry, we'll continue to do both. Obviously, we knew we'll be closing the acquisition in early July, so obviously, we had a use of cash coming into Q3. And as we move forward through Q3 and Q4, I would expect us to continue to be active on the repurch",145,"And Larry, we'll continue to do both. Obviously, we knew we'll be closing the acquisition in early July, so obviously, we had a use of cash coming into Q3. And as we move forward through Q3 and Q4, I would expect us to continue to be active on the repurchase side, always with a view to what the pipeline looks like. And as Tim said, and as you guys all well know, it ebbs and flows and you can't exactly predict which ones you're going to get over the finish line despite the, I think, very high level of activity that we have. So the priorities are clear. We'd love to be closing more. We're certainly trying. And absent that and in conjunction with that, we'll continue to return cash to shareholders in a pretty consistent basis between buybacks and obviously, the slightly increased dividend."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Mike Weinstein with JPMorgan is next.",6,"Mike Weinstein with JPMorgan is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","So Tim, this is your best quarter since, I think, the fourth quarter of 2008. What do you think, besides Lutonix in the launch, which we're all aware of, what do you think kicked in this quarter on the base business? And it looks like you had some U.S. bu",104,"So Tim, this is your best quarter since, I think, the fourth quarter of 2008. What do you think, besides Lutonix in the launch, which we're all aware of, what do you think kicked in this quarter on the base business? And it looks like you had some U.S. businesses that did a lot better than they've been doing, trend wise. But you also had -- surgery had a really big business outside the U.S., so it's kind of all over the map. What was special this quarter that kicked in? And obviously, based on your guidance, you're assuming a high level of sustainability."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Really, there wasn't any magic formula. We've been making a number of different investments, as you know, for several years across the board, both in SG&A and sales force expansion and R&D, and a lot of those just happen to come together from an exec",96,"Yes. Really, there wasn't any magic formula. We've been making a number of different investments, as you know, for several years across the board, both in SG&A and sales force expansion and R&D, and a lot of those just happen to come together from an execution point of view in the quarter. As John said, it was very consistent across the board, both from a product and geographic standpoint. And I give a lot of credit to the management teams and the employees around the world for a very high level of execution in the quarter."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So like, if I look at some of the different businesses, so surgery outside the U.S., as I mentioned, was up 9% this quarter versus down 4% last quarter. Part of that was because the product lines you discontinued in irrigation. But like that high si",74,"Okay. So like, if I look at some of the different businesses, so surgery outside the U.S., as I mentioned, was up 9% this quarter versus down 4% last quarter. Part of that was because the product lines you discontinued in irrigation. But like that high single-digit performance in the surgery outside the U.S., that's sustainable. Obviously, the Oncology performance outside the U.S, which has been fantastic, in the mid-teens or better, that's sustainable?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I would disagree with your viewpoint on that, Mike.",9,"I would disagree with your viewpoint on that, Mike."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I mean, we've talked for a while, getting productivity in the sales force is that we've expanded. We talked a lot about the pipeline of registrations in markets around the world. All of that's been happening. And you've got now larger, more productiv",75,"Yes, I mean, we've talked for a while, getting productivity in the sales force is that we've expanded. We talked a lot about the pipeline of registrations in markets around the world. All of that's been happening. And you've got now larger, more productive sales forces with more products in their bag. And again, it's 2-plus years into the investment plan, I think you're seeing again, Mike, a lot of the results of those investments."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Dave Lewis with Morgan Stanley is next.",7,"Dave Lewis with Morgan Stanley is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just 2 quick questions. Chris, just first for you on the reinvestment. Obviously, dramatic opportunity in the top line, you're reinvesting some of that away. But given the prior investment in the last 18 months, can you give us a sense of where these inve",91,"Just 2 quick questions. Chris, just first for you on the reinvestment. Obviously, dramatic opportunity in the top line, you're reinvesting some of that away. But given the prior investment in the last 18 months, can you give us a sense of where these investments in the second of the year are going relative to where the prior investments were in the last 15 or 18 months? And what does this tell us about the abilities to drive leverage as we look forward into '16? And I have a quick follow-up."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, clearly, even with these investments, David, over the coming years, we certainly intend to and believe we can continue to drive leverage. I think the balance we're trying to strike is the sustainability question, to take advantage of strengt",225,"Yes, I think, clearly, even with these investments, David, over the coming years, we certainly intend to and believe we can continue to drive leverage. I think the balance we're trying to strike is the sustainability question, to take advantage of strength, to make sure that we're doing everything we can with the pipeline and with the emerging geographies to continue to strengthen them over time. And again, I think this quarter, and how we've done in the first half, gives us some of that luxury. We're frankly looking at some additional opportunities in emerging markets on the sales force side with a couple of product categories, including in China. We're ramping up some of the clinical trial work in a number of places, and John DeFord mentioned the trial in China. And there are a couple of other projects that, frankly, we're able to turn on as we move in to the back half of the year than we probably wouldn't have been able to, if we haven't performed quite as well as we have through the first half. So we're trying to strike a balance with delivering strong returns in the near term, but also continuing to set the portfolio up to drive attractive organic growth rates for the long term, and that's the challenge and that's how we're trying to manage it."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay, that's fair enough. And then John, you spent a fair amount of time in the call talking about intermittent [ph] and catheters and that doesn't happen that often. So I wonder if you can talk about the -- how you're seeing your portfolio and how you co",61,"Okay, that's fair enough. And then John, you spent a fair amount of time in the call talking about intermittent [ph] and catheters and that doesn't happen that often. So I wonder if you can talk about the -- how you're seeing your portfolio and how you could exploit that opportunity in light of patent expiry coming up for Coloplast SpeediCath?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. Well, I think, again, just as Chris said and as Tim said, we've had a lot of focus on execution and getting products through our development pipeline. And so you see, we're in the position to talk about some of these products that have been in the d",125,"Sure. Well, I think, again, just as Chris said and as Tim said, we've had a lot of focus on execution and getting products through our development pipeline. And so you see, we're in the position to talk about some of these products that have been in the development pipeline and we're either launching or very near launch. So it is a pretty exciting time for us. I think, as far as the intellectual property goes, look, we're certainly aware of all of that. We already had internal developments of our own. We think they were in good shape and obviously, on a go-forward basis, we'll continue to look at ways that we can expand and develop products to meet the needs of our patients."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Kristen Stewart with Deutsche Bank is next.",7,"Kristen Stewart with Deutsche Bank is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just wanted to, I guess, address a couple of things. First, with respect for the willfulness, how should we think about the cash that you're going to be receiving? Should we think about it in the same context with respect to the lump sum that you receiv",106,"I just wanted to, I guess, address a couple of things. First, with respect for the willfulness, how should we think about the cash that you're going to be receiving? Should we think about it in the same context with respect to the lump sum that you received in terms of reinvestment, in the context of giving back half to shareholders and reinvesting the rest back into the business? Or should we just think about that in terms of going to offset maybe some of the increased product liability claims that you have? How should we think about that offsetting sort of from a P&L perspective?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure Kristen. Actually, the cash -- the cash actually was received in Q2, so it will be reflected in the balance sheet for the quarter. It's about $150 million after tax, and I think we've been pretty consistent. And it sort of goes into the caveat, obvio",136,"Sure Kristen. Actually, the cash -- the cash actually was received in Q2, so it will be reflected in the balance sheet for the quarter. It's about $150 million after tax, and I think we've been pretty consistent. And it sort of goes into the caveat, obviously, it gives us some increased flexibility. But it's not like we're going to do an incremental $75 million buyback on the back of the receipt of that cash. So we'll, as I said, continue to be active from a buyback standpoint. The money is already in the bank and again, as Tim said, we're also actively looking at opportunities on the business development side. And again, just a reminder, with respect to the product liability, those cash needs, yes, we'll be able to be service with our U.S. cash."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And you also have like half of it, do you have -- it's offset by -- you can claim, I guess it's now Medtronic, or your other partner -- the main original manufacturer as well, right?",36,"And you also have like half of it, do you have -- it's offset by -- you can claim, I guess it's now Medtronic, or your other partner -- the main original manufacturer as well, right?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. As we said, the Q will be out tomorrow and actually, obviously, there's been a lot of activity the quarter, vis--vis product liability and so there'll be a lot of good disclosure for you. But about half the claims, as we've talked about, relate to",89,"Yes. As we said, the Q will be out tomorrow and actually, obviously, there's been a lot of activity the quarter, vis--vis product liability and so there'll be a lot of good disclosure for you. But about half the claims, as we've talked about, relate to Medtronic and there's been good progress there as well with respect to settlement. So I think a lot of, frankly, productive activity, as it relates to the product liability exposure, and I think we feel good about where we are now exiting Q2."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then just walking through the guidance, it looks like your -- just, can you help me understand just the underlying changes within the sales growth rate? It looks like Gore is expected to decline due to FX and then you have the base, organic sale",85,"Okay. And then just walking through the guidance, it looks like your -- just, can you help me understand just the underlying changes within the sales growth rate? It looks like Gore is expected to decline due to FX and then you have the base, organic sales growth change, which is an improvement from January, but then you're raising full year EPS by just $0.05. Just kind of the moving parts, maybe bridging the EPS, reflecting the change in Gore, relative to acquisitions and investments?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And it's a little unusual because organic growth is higher than constant currency, and so that's why we're calling it out. But so for Q3, organic of 6.5% to 7.5%, we're saying, a negative 50 basis points related to a decline in Gore, so constan",224,"Yes, sure. And it's a little unusual because organic growth is higher than constant currency, and so that's why we're calling it out. But so for Q3, organic of 6.5% to 7.5%, we're saying, a negative 50 basis points related to a decline in Gore, so constant currency of 6% to 7% and FX impact of 3.5%. So again, a strong quarter. And again, the difference between Q3 and Q2 is Boston stocking orders in Q2. For the full year, the other impact, organic at 5.5% to 6.5%, there -- you'll also see in Q4 a decline in our sales to Boston Scientific related to the electrophysiology products, and that's actually material. So that's why we've got this difference in for the full year, from a constant currency basis, to the organic number. And again, currency impacting it negatively by about 3.5%. So a nice, strong improvement in organic. From an earnings standpoint, we've talked about some dilution from the acquisition of $0.02 to $0.03, and you'll see some stepped up investment in R&D and SG&A, relative to what we would've done frankly, otherwise, given the strength in the top line. So I think that kind of organic growth commitment for the full year, moving earnings higher but still being able to maintain a high level of investment, I think, strikes the right balance."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","David Roman with Goldman Sachs is next.",7,"David Roman with Goldman Sachs is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted just to start with the Surgical Specialties business, which, as a number of others have commented, had a very nice pick-up here. And I think in your prepared remarks, John, you talked about the soft tissue repair franchise seeing its best grown s",94,"I wanted just to start with the Surgical Specialties business, which, as a number of others have commented, had a very nice pick-up here. And I think in your prepared remarks, John, you talked about the soft tissue repair franchise seeing its best grown since 2011. Can you maybe just elaborate on that in a little bit more detail? Are we seeing sort of a bottoming out of utilization in that category and some of the concerns that had driven those declines, in 2011, are behind us, or is it more new product related?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","No, David, I'd say it's all new products related. We launched Phasix the year before last. We have had great momentum building that business and continue to have strong momentum with Phasix. The uptick of XenMatrix AB -- having an antibiotic coating in ch",140,"No, David, I'd say it's all new products related. We launched Phasix the year before last. We have had great momentum building that business and continue to have strong momentum with Phasix. The uptick of XenMatrix AB -- having an antibiotic coating in challenged cases in ventral is a big deal, and we saw outstanding uptake in Xen AB in its first full quarter out there and we don't have any reason to believe we're not going to continue to be very successful in converting biological accounts to Xen AB for those challenged cases. So the pipeline is what's driving it. We're delighted to say that with the 2 new fixation launches that we have over the next few quarters, we expect the momentum that we started, both in biologics, to continue and build on that with the fixation launches."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then maybe just a follow-up on the M&A topic. Tim, on the last call, I had asked about kind of your view on looking at ROIC/cash growth versus just cash EPS accretion. I mean, over the past 90 days, we've seen, obviously, continued M&A activity",129,"Okay. And then maybe just a follow-up on the M&A topic. Tim, on the last call, I had asked about kind of your view on looking at ROIC/cash growth versus just cash EPS accretion. I mean, over the past 90 days, we've seen, obviously, continued M&A activity across the landscape and valuation continue to move higher but somewhat more mixed equity market reaction to deals they announced. Is there any sort of update on your thinking as you see the landscape unfold in front of you and the activity that's taken place over the past couple of months and how you're sort of sizing up your parameters for thinking about M&A at this point? And how does the target environment maybe changed as you put it into that context?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, no, we haven't changed our filters at all relative to the way we look at things. And I think if you were to go back and look at a lot of the growth or some of the growth from this quarter over the last several years, a lot of it are platforms that we",136,"Yes, no, we haven't changed our filters at all relative to the way we look at things. And I think if you were to go back and look at a lot of the growth or some of the growth from this quarter over the last several years, a lot of it are platforms that we've either invested internally, like in the surgical area. You've got bio resorbables, big investment in that whole BioSurgical area, both with acquisitions and internally, and you're starting to see those pay off with the increased revenue growth at a very nice margin. So that's kind of the discipline that we have. And frankly, the external environment of diluting revenue growth for more accretion, we watch that. It hasn't changed our thinking at all in terms of how we look at acquisition."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","And Richard Newitter with Leerink Partners is next.",8,"And Richard Newitter with Leerink Partners is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's Ravi, here for Rich. Can you hear me?",10,"It's Ravi, here for Rich. Can you hear me?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we can, Ravi.",4,"Yes, we can, Ravi."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","A couple of questions, one on the acquisition and one, maybe a longer-term question on the Gore royalty. So I was hoping you could help me understand the, sort of a little bit around the dilution around the Vascular Pathways. Is that going to be just a po",142,"A couple of questions, one on the acquisition and one, maybe a longer-term question on the Gore royalty. So I was hoping you could help me understand the, sort of a little bit around the dilution around the Vascular Pathways. Is that going to be just a portion on your gross margins? Or SG&A going forward, or how should we think about that as we model going forward? And then with Gore, I think the royalty comes off in 2019. And just trying to figure out, at this point, since it's a while away, what are you thinking about in terms of how do you replace it? Is it mostly new indications really sort of organic, organic growth, other segments of the business step up, inorganic acquisitions? Or how should we think about what's going to replace that in the long run?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","So first, on the acquisition, Ravi, there are really no material sales at all in '15. We'll be looking to really launch it more broadly in '16. So I said it's $0.02 to $0.03 dilutive in '15. We're obviously covering that while still increasing our guidanc",319,"So first, on the acquisition, Ravi, there are really no material sales at all in '15. We'll be looking to really launch it more broadly in '16. So I said it's $0.02 to $0.03 dilutive in '15. We're obviously covering that while still increasing our guidance for the year. It'll be relatively limited sales and breakeven on a cash EPS standpoint in '16 and then, it'll become accretive in '17 beyond. As John DeFord said, it's a really interesting technology addition to the Vascular Access product portfolio for us, and we think it will be an excellent long-term value creating investment for us. But again, I mean, I think it's too small at this stage for you to worry too much about, and from a near term standpoint, we've covered the dilution. I think the Gore royalty in 2019, we've talked about for a number of quarters now, the objective of everything we're doing is frankly, by 2019, to make that royalty a smaller and smaller and less significant portion of the P&L. Obviously, this quarter helps in that regard. We're looking, internally and externally, to find things that will provide good organic growth and then good drop-throughs, so as we get to 2019, again, our portfolio is performing in a way that helps to overcome some of that. And I think we've been pretty frank about continuing to have a lot of balance sheet flexibility to help mitigate that impact as you jump from '19 to '20 through utilizing the balance sheet through increased share repurchase activity. So we've spent a lot of time planning and thinking about it and obviously, as we get to 2019, there'll be an opportunity for us to give you more visibility. But we're certainly thinking about it in a way that it's -- it will be manageable and we'll make sure we do everything we can to mitigate the impact for investors."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Dave Turkaly with JMP Securities is next.",7,"Dave Turkaly with JMP Securities is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is John, on for Dave, can you hear me okay?",11,"This is John, on for Dave, can you hear me okay?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, John.",2,"Sure, John."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","So first, I just wanted to follow-up on the question Bob asked earlier on Lutonix. Granted it's a different ballgame now, with Boston on board and strong registry data out there, but given the stocking orders that have taken place, make it a little bit tr",79,"So first, I just wanted to follow-up on the question Bob asked earlier on Lutonix. Granted it's a different ballgame now, with Boston on board and strong registry data out there, but given the stocking orders that have taken place, make it a little bit tricky to evaluate what's going on, I think it might be helpful to get a sense of any trends you're seeing in reorder rates. Any color you can give us there would be helpful."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I would say that consistent with last quarter, we're seeing uptick and uptake that has beat all of our internal projections, which we're delighted with. This quarter is no different than last quarter. We like the momentum that we're building ourselves. We",171,"I would say that consistent with last quarter, we're seeing uptick and uptake that has beat all of our internal projections, which we're delighted with. This quarter is no different than last quarter. We like the momentum that we're building ourselves. We have great expectations with the momentum Boston will bring to it. In addition, one of the areas that I would not discount is the additional reimbursement that was given to Lutonix during the quarter. And I think a good way to look at that is that in essence, there's full reimbursement now for Lutonix in all of these cases. And the question would be, based on the efficacy that you'll see in all the data sets, registry data, et cetera, why wouldn't you use Lutonix in a purple case? So I think that the momentum we're building at a field-selling standpoint, the momentum that the full reimbursement will give us and the fact that our own internal results are beating our expectations, we like where we are right now."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","All right, that's helpful. And then I know a couple of people have hit on it already, but I just wanted to dig a little bit more into the uses of cash. So if we look back historically at the M&A, there was a period of pretty significant activity from sort",149,"All right, that's helpful. And then I know a couple of people have hit on it already, but I just wanted to dig a little bit more into the uses of cash. So if we look back historically at the M&A, there was a period of pretty significant activity from sort of late 2011 to late 2013, a number of acquisitions, divestiture of the EP business. And then it kind of dropped off and during that time, across life sciences, there was obviously a lot of activity, there's been an enormous amount in the first half of 2015. And it's great to see the Vascular Pathways deal. Is that a signal that you're refocusing on that in any way? Or is it just that the targets have been harder to find, sellers' expectations have been too lofty? Maybe if you can just comment on that, that will be helpful."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I'll take a stab at the broader kind of environment comment. There's a lot of things that go when looking at deals and including our high filters. There've been some assets that have trended over the last couple of years and frankly, we've taken a l",169,"Sure. I'll take a stab at the broader kind of environment comment. There's a lot of things that go when looking at deals and including our high filters. There've been some assets that have trended over the last couple of years and frankly, we've taken a look at it and passed on. Other companies have gotten forward and acquired those. They didn't meet our expectations on what our filters are, which are focused primarily on being a market leader, number one, and number two, product leadership, the sustainability of that and the revenue growth profile projected on a sustainable basis. So it just takes time and we're turning over a lot of rocks. And all I can tell you is we haven't changed our strategy or mindset relative to doing those things. We look at those as adding platforms to do more investment with going forward as to just buying revenue. So I wouldn't read anything into one deal changing our outlook, one way or the other, from quarter-to-quarter."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And the only thing I'd add to that is that if we look back at the transactions that we made the decision on, we wanted to complete. Our success rate is very, very, very high, and I'd use Lutonix as a good example today.",45,"And the only thing I'd add to that is that if we look back at the transactions that we made the decision on, we wanted to complete. Our success rate is very, very, very high, and I'd use Lutonix as a good example today."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] The next question is coming from the line of Matt Taylor with Barclays.",15,"[Operator Instructions] The next question is coming from the line of Matt Taylor with Barclays."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to just drill down a little bit more on the emerging market growth and you did provide some details, but I was wondering if this quarter, there was more of a step up and sometimes, I don't like this analogy, but what inning of your investment are",61,"I wanted to just drill down a little bit more on the emerging market growth and you did provide some details, but I was wondering if this quarter, there was more of a step up and sometimes, I don't like this analogy, but what inning of your investment are you in there? And how long of a runway do you have?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, the best way I can describe that is, we think we're kind of in the second inning. And I'd say that for this reason. 35% of our worldwide sales force is in emerging markets. Yet, it represents only 10% of our revenue to date. We've made the investmen",93,"Well, the best way I can describe that is, we think we're kind of in the second inning. And I'd say that for this reason. 35% of our worldwide sales force is in emerging markets. Yet, it represents only 10% of our revenue to date. We've made the investments and we'll continue to make investments in those geographies. But I would say, we're very early in the cycle. And that adds tremendously to the accretive nature of those investments that are already made as it relates to future revenues that come from them."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","And one follow-up on Lutonix. I guess, just given the strength, are you willing to give any kind of update in terms of your thoughts on market size or market share or the, I guess, kind of future applications?",40,"And one follow-up on Lutonix. I guess, just given the strength, are you willing to give any kind of update in terms of your thoughts on market size or market share or the, I guess, kind of future applications?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I'll take that. We're either #1 or # 2. [indiscernible] Market share hasn't come up for a while. We're pleased with the momentum and the build in the market. I think if you -- a lot of analysts have written that they look at the size of the U.S. mark",127,"Yes. I'll take that. We're either #1 or # 2. [indiscernible] Market share hasn't come up for a while. We're pleased with the momentum and the build in the market. I think if you -- a lot of analysts have written that they look at the size of the U.S. market being closer to the $140 million to $160 million size on an annualized basis. It's hard for us to project that, but that's probably close to being right, I think. We initially thought it was going to be closer to $100 million. So all that's indicative of a lot of excitement and uptake in the market for technology and a product that's very important in terms of being able to treat patients with purple artery disease."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Anthony Petrone with Jefferies is next.",6,"Anthony Petrone with Jefferies is next."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. I'm going to stay on the topics of emerging markets and Lutonix. I guess, first, on emerging markets, you mentioned the PICC opportunity is quite large in the various markets that you've invested in. Can you size what the opportunity is, and maybe",55,"Great. I'm going to stay on the topics of emerging markets and Lutonix. I guess, first, on emerging markets, you mentioned the PICC opportunity is quite large in the various markets that you've invested in. Can you size what the opportunity is, and maybe how long it will take to maybe fully realize that opportunity?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I think we're going to refrain talking about the size of the opportunity for competitive reasons. But it's -- quite frankly, it's solely in our hands and that these markets don't exist for the most part today. We have to do the market building work,",92,"Well, I think we're going to refrain talking about the size of the opportunity for competitive reasons. But it's -- quite frankly, it's solely in our hands and that these markets don't exist for the most part today. We have to do the market building work, the education work and the training work in order to build these markets into substantial opportunity. So I mean, it's not as if we're just trying to convert out someone else's product. The reality is, we have to go in and create these markets from scratch."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","I think we have said, it is our largest and fastest-growing product in China, for example. So -- and to John's point, we're in the early stages, we believe, of really building that market. I mean, I think the exciting thing about PICCs is that, it's not j",131,"I think we have said, it is our largest and fastest-growing product in China, for example. So -- and to John's point, we're in the early stages, we believe, of really building that market. I mean, I think the exciting thing about PICCs is that, it's not just an emerging market opportunity, there's lots of developed geographies where PICCs just have not penetrated the market yet. Frankly, some of the investments we started to make a couple of years ago were focused on those geographies and we're seeing strong double-digit in the north of 20% growth in PICCs in developed markets as well. So this has a long, long way to play out and as we said in our prepared remarks, it continues to be the largest global opportunity for us."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","And we have -- we've crossed the hour here. Let's just take one more and then we'll end it.",19,"And we have -- we've crossed the hour here. Let's just take one more and then we'll end it."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","Okay. And the final question is from Josh Jennings with Cowen and Company.",13,"Okay. And the final question is from Josh Jennings with Cowen and Company."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Analysts","Just a quick question on Lutonix. We talked with some clinicians that are using drug-coated balloons in cases of all variety of Above the Knee, in-stent restenosis, post atherectomy, and I just wanted to see if you could give us some anecdotal information",110,"Just a quick question on Lutonix. We talked with some clinicians that are using drug-coated balloons in cases of all variety of Above the Knee, in-stent restenosis, post atherectomy, and I just wanted to see if you could give us some anecdotal information around types of cases that drug-coated balloons and Lutonix, specifically, are being used in by your customer base. And then just a follow-up for Chris. Any update in terms of the longer-term tax rate targets? And my understanding is that you expect 0 to 50 basis points improvement in '15, and maybe can that continue to trend down with some tax optimization strategies in the out years?"
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Josh, this is Tim. And then, I'll let John DeFord comment on the Lutonix question. I think it's just too early for us to really be able to call out any trends of usage of Lutonix in either certain types of patient, lesions or if other technologies ar",207,"Yes, Josh, this is Tim. And then, I'll let John DeFord comment on the Lutonix question. I think it's just too early for us to really be able to call out any trends of usage of Lutonix in either certain types of patient, lesions or if other technologies are used or not. I think what you're seeing and what you're hearing is what we -- frankly, we thought, when we bought the technology, that this is a huge unmet need and that I think, over a number of years, this is going to play out relative to all of the things that you pointed out and how well they work, either together or independently, what kind of lesions, et cetera. And the data will tell us how that plays out. But suffice it to say that there's an awful lot of use and interest, various clinicians tend to focus in one of those areas more than another and we're seeing those physicians have an interest in trying drug-coated balloon technology together with their techniques or technologies, depending how they look at treating the disease. So I think it's going to take a number of years for that to play out to be able to cite any trends."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think that's right, Tim. Anything that we'd share today would sort of the anecdotes and really, probably wouldn't be that helpful. I think it'll take a little while for some CMS data to come out to see how the technology is being used and if it's b",99,"Yes, I think that's right, Tim. Anything that we'd share today would sort of the anecdotes and really, probably wouldn't be that helpful. I think it'll take a little while for some CMS data to come out to see how the technology is being used and if it's being used. Certainly, we would expect that there'd be more use of provisional stenting than what we saw in our Levant 2 trial, for example. We saw that in the registry at sort of the 20-plus percent range. So other than that, it's all anecdote at this point, just too early."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, Josh, just on the tax question. We actually have, over the last couple of years, completed some meaningful projects. Ironically, the onset of the Gore royalty, which is tax at full U.S. rates, sort of hit some of the progress we've made on the tax ra",129,"Yes, Josh, just on the tax question. We actually have, over the last couple of years, completed some meaningful projects. Ironically, the onset of the Gore royalty, which is tax at full U.S. rates, sort of hit some of the progress we've made on the tax rate. We're certainly continuing to evaluate additional opportunities. They will occur, over time, and certainly, as we move year-to-year, we'll provide guidance to reflect that. They're not -- there are no easy, large, big wins, if you will, but we'll continue to tackle it over time. And certainly, one of our objectives is to move the tax rate down consistently over time. And we'll, again, on an annual basis, continue to give you guys insight on what kind of progress we're making there."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Operator","This concludes our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments.",23,"This concludes our Q&A session. I would like to turn the call back over to Bard's management for closing or additional comments."
254131,305681277,837975,"CR Bard Inc., Q2 2015 Earnings Call, Jul 23, 2015",2015-07-23,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much, and I'd like to thank all of you for taking the time to join us today, as well as thanking Bard's employees around the world for their commitment to excellence and a very good execution quarter. We'll talk to you next quarter. Thanks.",47,"Thank you very much, and I'd like to thank all of you for taking the time to join us today, as well as thanking Bard's employees around the world for their commitment to excellence and a very good execution quarter. We'll talk to you next quarter. Thanks."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to CR Bard Inc. Third Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand repl",275,"Ladies and gentlemen, thank you for standing by, and welcome to CR Bard Inc. Third Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2015, Form 10-Q, and the information under the caption Risk Factors in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 22, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to the prior year period.
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. And I'd like to welcome everyone to Bard's Third Quarter 2015 Earnings Call, and thank all of you for taking the time to join with us today. We expect the presentation portion of the call to last about 30 minutes and the total call to last abou",615,"Thank you. And I'd like to welcome everyone to Bard's Third Quarter 2015 Earnings Call, and thank all of you for taking the time to join with us today. We expect the presentation portion of the call to last about 30 minutes and the total call to last about an hour. The agenda today will be as follows: I'll begin with an overview of the results for the quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; and Chris Holland, our Senior VP and CFO, will review the third quarter income statement, balance sheet as well as our expectations for the fourth quarter, and then finally, we'll close with Q&A.
Third quarter 2015 net sales totaled $865.7 million, that's up 4% over Q3 of last year on as-reported basis and up 8% on a constant-currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable, about 370 basis points. Excluding the Gore royalty of $38.4 million in sales related to recent acquisitions and divestitures, our organic growth rate was approximately 8.3% for the quarter. That's above our expectations. The U.S. sales of the Lutonix drug-coated balloon contributed a little less than 300 basis points of growth in Q3.
Net loss for the quarter of 2015 was $86 million and diluted loss per share was $1.16. Excluding these items that affected the comparability of results between periods, which Chris will cover later, third quarter 2015 net income was $154.5 million and diluted earnings per share, which excludes amortization of intangibles, were $2.28. That's up 4% and 6%, respectively.
Looking at revenue growth geographically compared to the same quarter last year. Third quarter net sales in the U.S. were up 7%. Internationally, we grew 10% on a constant-currency basis with Europe growing 7%, Japan declining 1% and our other international businesses growing 18% this quarter. Strong quarter in Europe was driven by Endovascular radiology infix, and the slight decline in Japan was due to inventory fluctuations at our joint venture.
You may have noticed a few weeks ago, we announced the acquisition of the remaining 50% ownership of our Japanese joint venture. We expect this transaction to be completed in the coming weeks. While it comes with some near-term dilution driven by exchange, we believe this is strategically important for us. Increased investment for market development and clinical trials in Japan was difficult with the structure of the joint venture when you combine that with foreign exchange pressure. So we decided this was a timely opportunity to take full ownership and advance our product leadership strategy in the world's third-largest health care market.
Our emerging markets business continues to grow into healthy double digits, following our significant investments there over the last couple of years. So as we look at our overall results for the quarter and the first 9 months of 2015, we said at the beginning of the year that it was an important year of execution for us. And so far, we're pleased with the results. As we projected at the announcement of our strategic investment plan nearly 3 years ago now, we are back at the top end of the sector from a revenue growth perspective, and we remain convinced that above-market revenue growth is a key to a premium multiple. We remain focused on making investments in areas of faster growth in a profitable manner to enhance shareholder value over the long term.
So with that, let me turn over to John Weiland for a review of our product line revenue."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be getting all percentage growth data in comparison to the prior year period on a constant-currency basis, unless otherwise noted.So let's begin with Vascular. Growth in this categor",871,"Good afternoon, everyone. Before I start, let me point out that I will be getting all percentage growth data in comparison to the prior year period on a constant-currency basis, unless otherwise noted.
So let's begin with Vascular. Growth in this category was 13% for the quarter or 8% as reported, with total net sales of $250.5 million. Excluding the Gore royalty and the divested EP sales, total Vascular grew -- sales grew 16% globally, with the United States business up 18% and the international business growing 14% in the quarter.
Sales in our Surgical Graft category were up 4% in Q3. Excluding the Gore royalty, our Endovascular business increased 18% in the third quarter. Within Endovascular, our biopsy products had another strong quarter with 14% growth, with nice performance in the United States and even better performance outside of the United States.
Sales in our peripheral PTA line increased 48%, driven by global sales of our Lutonix drug-coated balloon. We are very pleased with the performance of this important product, which had anniversary-ed its FDA approval and the U.S. launch on October 10. It has been a good first 12 months in the United States, and we're pleased with the results from our real-world registry study. John DeFord will tell you more about this in a few minutes.
As we seek to expand the indications and reach of this compelling technology platform, we expect to see long-term global growth from Lutonix. Our Stent business declined 3% again this quarter, consistent with recent experience. And finally, net sales in our Vena Cava Filter line declined 3% in Q3.
So let's go to Urology. Total net sales were $212.3 million, up 5% versus Q3 of last year on a constant-currency basis and 1% on an as-reported basis. The United States business grew 5%, while internationally, we grew 4%. Our Targeted Temperature Management products grew into healthy double digits again this quarter. Our basic drainage business was up 6% globally in Q3, with the United States business up 7%. Our IC Foley business was up 3% globally and up 1% in the United States. We believe that Foley's this quarter benefited from subduer stocking, but we don't know the precise impact. So we've been cautioned against reading too much into these improved growth rates at a single quarter.
Our continence business decreased 3% in the third quarter. Sales in Urological Specialties grew 1% with our brachytherapy business down 1%. And finally, in this category, standalone sales of our StatLock catheter stabilization product line declined 4% in Q3.
Now let's go to Oncology. Total net sales in this category were $239.3 million, an increase of 8% on a constant-currency basis and 4% on an as-reported basis over the third quarter last year. Geographically, net sales in the United States were 5% and international sales were up 15%. Our port business decreased 1% this quarter due to the price reductions in the United States that we talked about at the beginning of the year. Our PICC revenue was up 13% in the third quarter, including strong results in the United States, Europe and emerging markets again this quarter. We're very pleased with the clinical adoption of our advanced technology, which helps patients and can save time and cost for the hospital.
Despite the competitive noise on single features here and there, we believe that the quality and performance of our broad product offering is why we continue to grow faster than the market. And as the competition tries to catch up to our older products, we continue to advance the technology and solve unmet needs for our customers and our patients. John DeFord will tell you more about this.
Our Vascular Access ultrasound product line was up 1% this quarter. The growth rates for this system can be a little lumpy around new product launches, and that's what we're seeing due to the vision to [ph] launch in the prior year and the pending Site-Rite 8 launch later this year. And to complete Oncology, our Dialysis Access product line was up 12% over Q3 of last year.
so let's conclude with our Surgical Specialties business. Total net sales in this category were $139.8 million, up 6% on a constant-currency basis and up 3% as reported. United States sales were up 6% and international sales grew 4% this quarter. 2 years after the acquisition of the Arista Hemostat and 3 years after the acquisition of the Progel sealant technology, our combined biosurgical product portfolio continues to grow double digits.
Our soft tissue repair business grew 7% in Q3, with our synthetic ventral hernia repair products growing 6%, while our natural tissue products grew 14%, driven by our new XenMatrix AB coated porcine mesh. Our hernia fixation business grew 2% this quarter, which was the first quarter in positive territory since the second quarter of 2011. We are hopeful that our new product launches here can reverse the trend of declines in recent years.
In closing out the surgical category, our performance irrigation business was down 20% in Q3. As we told you, we discontinued some products earlier in the year.
This concludes our product line revenue discussion, and now I'll turn you over to John DeFord."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon or maybe it's evening for everyone. Thanks for taking time to join us today. For the sake of time, I'll jump right into some highlights, starting with drug-coated balloons. About 2 weeks ago with TCT, we released full 12-m",1202,"Thanks, John, and good afternoon or maybe it's evening for everyone. Thanks for taking time to join us today. For the sake of time, I'll jump right into some highlights, starting with drug-coated balloons. About 2 weeks ago with TCT, we released full 12-month results from our almost 700-patient global SFA and public registry. Lesion lengths were over 100 millimeters, about half the patients had significant calcification and over 30% of the lesions treated were chronic total occlusions. The study found over 94% of patients were free from TLR through the 12-month follow-up, with primary patency in almost 90% of patients. Interim 24-month results demonstrated 93% freedom from TLR and primary patency in excess of 80%. We believe the learnings from the Levant 2 study on keys to a successful procedure are working their way into real world practice, and we're very pleased with the results.
In our Below the Knee IDE enrollment continues, though, recruitment remains slower than planned due to the complex nature of these patients and their disease. We're working with FDA to find ways to speed up enrollment and analysis in this important study. At current recruitment weight rates, we like -- we'll likely to enroll patients through much of 2016, putting PMA submission in the second half of 2017.
On the other hand, our AB Access DCB IDE study that began enrollment last quarter is recruiting very quickly, and we anticipate enrollment could be complete as early as Q1 of 2016, which could put PMA submission ahead of schedule in the first half of 2017. The in-stent restenosis IDE study is ongoing, and we're currently planning a second half 2016 PMA submission, seeking this expanded indication. We have a host of other DCB studies ongoing or in start-up around the world, and we plan to begin enrollment in our Levant China study in Q1 of 2016.
Also in Vascular, the LifeStream balloon expandable covered stent IDE completed enrollment in Q3. This clinical study is evaluating the technology for the treatment of iliac artery disease with a 9-month follow-up. We anticipate PMA submission in the second half of 2016.
Our Covera next-generation stent graft designed for use in the AV Access circuit is planned for launch in Europe this quarter, and we're working with FDA to commence our U.S. IDE study in the first half of 2016. Our new de novo veno stent recently gained a CE Mark. As with Covera, we're working closely with FDA to initiate an IDE study seeking U.S. approval with enrollment planned to begin in the first half of next year.
Next, moving to Urology and home care, we're pleased to announce the release of the new Magic 3 Go self-lubricated catheter for female patients. This product's designed for enhanced comfort and ease of use for patients that often have limited dexterity. We plan to roll out this product selectively during Q4 as we ramp manufacturing. We also anticipate the launch of our Magic 3 touchless catheter in early 2016. Both of these products employ our latest silicone technology designed to enhance patient use and comfort.
We've got some other impactful products in this portfolio for launch later in 2016. But I'll hold off sharing the details until we get closer to those launches.
Now moving to Oncology. The new Site-Rite 8 ultrasound system with integrated 3 CG Diamond is rolling out in Europe. The Site-Rite 8 with Pinpoint GT and 3 CG Diamond is on track for U.S. launch in Q4, as John alluded to. We believe the combination of ultrasound, needle guidance and catheter tip confirmation in an integrated system will provide a full-featured user-friendly and intuitive solution for vascular catheter placement.
In PICCs, we've submitted the 510(k) and a way FDA clearance to launch a new and proprietary catheter family. These PICCs have been designed to resist common chemicals used in chemotherapy solutions as well as cleaning and disinfection agents. While these solutions are known to degrade standard PICC materials, this new catheter can maintain the same high-performance standards available in our current PICCs, even after long-term exposure. We're also expanding our development efforts toward technologies we believe can further reduce the risk of thrombosis.
While we prefer to keep our development plans confidential, I will say we have a new product family under development that's based on a new high-performance material. We expect to begin launching products using this new material in the back half of next year. Our current plans also anticipate commencement of studies to provide further clinical evidence to support the benefits of these new designs.
In concert with these efforts, we've also recently launched a training program and some associated products designed to reduce infections and promote the safe and effective use of our PICCs. With this change in near-term focus, we've reduced the priority we placed on our antimicrobial and thrombo-resistant coating technologies. The developments are ongoing, but we don't believe they'll have a major revenue contribution compared to these other opportunities.
For the difficult stick IB catheter patients, we announced on the last call the acquisition of the AccuCath guide wire-assisted PIV products. We've taken that technology into our development engine and anticipate the launch of an improved family of AccuCath products in the first half of 2016. These products are anticipated to launch alongside our new midline catheter, the Powered Like Pro, also planned for launch in that same time period. We believe the combination of our PICCs, the PowerGlide midline family and AccuCath IV product line will help us bring important guide wire-assisted devices to a broad spectrum of patients with Vascular Access needs.
Lastly, for the acute hemodialysis patient, we're expanding our family of catheters with the expected launch of a new dual lumen powers Genesys catheter in Q1 of next year. Genesys is designed for superior flexibility and kink resistance, along with flow rates in excess of 400 mils [ph] per minute in a small 11 per inch catheter configuration.
I'll close my portion of the discussion today with surgery. Just a few weeks ago, we launched our new Phasix ST resorbable synthetic mesh. This launch as another differentiated product to our complex abdominal wall portfolio that includes XenMatrix, XenMatrix AB and the Phasix mesh technology. We're continuing our efforts to expand our product offerings based on the Phasix platform, and we expect to begin launching those new products over the next several quarters. We're also making good progress on our development of additional sizes of our one-of-a-kind antibiotic-coated XenMatrix AB family, with launches expected throughout 2016 and into 2017. In our BioSurgery product offering, on our last call, I told you we'd filed our PMA supplement, seeking approval of our new triadine Vascular sealant, and we continue to anticipate approval and launch in the back half of next year.
And finally, in mesh fixation, we recently launched both the OPTIFIX spring-loaded resorbable tack device and the capture permanent fixation product. We're working to build upon that momentum through the launch of 2 additional fixation devices, but due to the competitive nature of this market, I'll hold back the details for a later call.
Thanks for your time and attention tonight. Let me now hand you over to Chris."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start with the items that affect the comparability of our results between periods.In Q3, we had acquisition-related items of $2.5 million and a $14.6 million charge for restructuring and productivity initiatives. This quarter, we",1135,"Thank you, John. Let's start with the items that affect the comparability of our results between periods.
In Q3, we had acquisition-related items of $2.5 million and a $14.6 million charge for restructuring and productivity initiatives. This quarter, we had made significant additional progress in settlement activity related to our women's health product liability. Driven by this settlement progress and additional information learned from it as well as recent activity in other product liability matters, we took an additional combined charge of $241.1 million this quarter. The final impact for these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $529.4 million or 61.2% of sales for Q3. On an adjusted basis, gross profit was $530.3 million or 61.3% of sales, a little better than we projected and down 120 basis points from the prior year. New amortization of intangibles relating to transactions closed in the last 12 months was about 50 basis points this quarter, and foreign exchange drove approximately 30 basis points of headwind for us in Q3. Price was unfavorable by 90 basis points on the revenue line and approximately 30 basis points in gross profit, and our mix was favorable by about 40 basis points this quarter. As we forecasted last quarter, the manufacturing variances in our plans from year-to-year can be a little lumpy, and Q3 is an example of that. In Q2, cost savings drove 90 basis points of improvement but in Q3, it was 50 basis points negative. In Q4, we look for Q4 to look more like Q2 with strong favorability. So we expect gross profit in Q4 on an adjusted basis to be a meaningful improvement over Q3 and back to the Q4 2014 level or maybe even a little better, which would put us in the high end of the original guidance we gave you for gross margins for the full year. So it's been a year of solid organic improvement for us on the gross margin line.
SG&A expenses were $247.1 million for the quarter or 28.5% of sales. On an adjusted basis, SG&A was also 28.5% of sales, down 60 basis points from Q3 of last year. I'll remind you that we typically see an uptick in SG&A as a percent of sales in Q4 sequentially, but we expect to still see good leverage compared to the prior year and expect to be within our full year guidance for 2015.
R&D expenditures totaled $65.2 million or 7.5% of sales on a reported basis for the third quarter, which was the same on an adjusted basis, down 40 basis points from the prior year and right on our full year guidance. We feel good about the level of investment in innovation and continue to drive an active new product pipeline towards faster revenue growth opportunities as you could probably tell from John DeFord's update.
Interest expense was $11.2 million for the third quarter, no change from the prior year. Other income expense was $258.3 million of expense for the third quarter as reported and $1.8 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.9%, which is the same for the 9 months year-to-date, where we were down 50 basis points compared to the prior year, consistent with our original guidance. We do expect the renewal of the R&D tax credit before the end of the year, which would lower the rate in Q4.
Diluted shares on adjusted earnings for the period were $75.4 million, and we repurchased 767,000 shares during the third quarter. The net result is adjusted cash APS for Q3 of $2.28, above the guidance range we provided for the quarter, driven by the higher sales.
The balance sheet as of September 30 reflects cash, restricted cash and short-term investments of $1.1 billion, no change from June 30. For the quarter, accounts receivable to days were down 1.6 days and inventory days were down 3 days. Capital expenditures totaled $21.7 million for the quarter.
On the liability side, total debt was $1.4 billion as of September 30, no change from June 30. Debt to total cap at the end of the third quarter was about 49%, and total shareholder investment was $1.5 billion at September 30.
Now moving to financial guidance. At the beginning of this year, we guided organic revenue growth to be between 4% and 5% for the full year, and we're now expecting to be closer to 6.5%. That includes lapping the anniversary of the U.S. launch of Lutonix in Q4 of 2014, which included significant initial stocking orders. Excluding those initial stocking orders from last year, which we estimate represent about 1% of sales to the quarter, we project Q4 organic sales growth between 5% and 6%, with about 300 basis points of headwind from FX and an additional 200 basis points of headwind from other sales reductions on a reported basis. The biggest of these reductions relates to the pending acquisition of the Japanese joint venture, which would add about $40 million to operating revenue on an annual basis. However, the joint venture is holding inventory we have already recorded as sales to them. So we expect to have a negative impact to reported revenue in Q4 and Q1 until we work through that inventory.
We also, as we've discussed in prior calls, expect the sales of EP products to Boston Scientific to decline in Q4, as they have now started manufacturing some of those product lines themselves. So we are projecting reported revenue to be flat to down 1% in Q4, even though the organic momentum in the business is expected to remain quite strong.
Now to update our expectations for adjusted cash EPS. Following our announcement of the acquisition of our Japanese JV, our latest forecast was $8.95 to $9.05 for the full year. Today, we are raising that guidance to be between $9.03 and $9.07. At the midpoint, this also represents a $0.05 increase to our original full year guidance provided in January despite absorbing approximately $0.15 of expected combined dilution from acquisitions and worsening FX during the year. Specific to Q4, this means we expect adjusted cash EPS to be between $2.38 and $2.42, which includes about $0.06 for the renewal of the R&D tax credit. This performance speaks to the strength of our execution in 2015. We've been able to increase investments in the business with the objective of sustaining above-market revenue growth while absorbing dilution along the way, and yet we still expect to increase the EPS delivered on the bottom line in 2015 above our initial expectation.
Thank you for your attention. I'll now turn you back to Tim."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now hand the call out to the moderator to facilitate the Q&A session. [Operator Instructions]",27,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now hand the call out to the moderator to facilitate the Q&A session. [Operator Instructions]"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] We have our first question that will come from Bob Hopkins with Bank of America.",17,"[Operator Instructions] We have our first question that will come from Bob Hopkins with Bank of America."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","So 2 things. One for Chris and one for Tim. First, Chris, I was just wondering if you could go over the thoughts on Q4, especially as it relates to the EP business in Japan. So that 5% to 6% revenue growth, does that exclude those 2 things? And can you ju",73,"So 2 things. One for Chris and one for Tim. First, Chris, I was just wondering if you could go over the thoughts on Q4, especially as it relates to the EP business in Japan. So that 5% to 6% revenue growth, does that exclude those 2 things? And can you just go into a little more detail on how those 2 things impact the guidance you've given in top and bottom line?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So what we're saying for Q4 organic, excluding the stocking impact from last year's Q4 is 5% to 6%. So about a point from Lutonix stocking last year gets you to 4% to 5% organic. There's been about 2% that relate specifically to the decline in Bosto",134,"Sure. So what we're saying for Q4 organic, excluding the stocking impact from last year's Q4 is 5% to 6%. So about a point from Lutonix stocking last year gets you to 4% to 5% organic. There's been about 2% that relate specifically to the decline in Boston sales expected in the quarter and the impact of lower sales into Japan results expecting to close the acquisition in a couple of weeks here. So the combination of those and a flat core royalty reduced sales by 2%. So you get the constant currency, if you will, Bob, of 2% to 3% for the quarter. And then the FX impact, as we said, is going to reduce sales by 3%. So that then gets us to the negative 1% to 0% on a reported basis."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","All right. I'm sure there'll be some follow-up on that. But I wanted to ask one [ph] for Tim for my second question your so Tim, could you just give us your sense as to the broader utilization environment that you saw in the quarter? And if you wouldn't m",119,"All right. I'm sure there'll be some follow-up on that. But I wanted to ask one [ph] for Tim for my second question your so Tim, could you just give us your sense as to the broader utilization environment that you saw in the quarter? And if you wouldn't mind breaking it out by the U.S. and then separately, emerging markets. And I ask it that way because it looks like you guys are seeing really good growth in emerging markets. Some of the orthopedic players like J&J and Stryker have reported a slowdown and implant rates in Brazil and China. And I just wanted to get again your broader comments on utilization broken down U.S. and emerging markets."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Again, Bob, I hesitate to call trends out on a quarter-to-quarter kind of a swing just because there's so much uncertainty going on all the time. But I would have to say that our utilization was pretty strong or our volume was strong everywhere. Ther",109,"Yes. Again, Bob, I hesitate to call trends out on a quarter-to-quarter kind of a swing just because there's so much uncertainty going on all the time. But I would have to say that our utilization was pretty strong or our volume was strong everywhere. There wasn't any weakness other than kind of the one you've cited in Japan. Geographically and emerging markets remain very strong for us. We watch it here and before and we keep looking for that, both in the projections we get from the businesses and our actuals we just haven't seen it. So I would say similar to what we saw last quarter overall."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question on queue will come from Mike Weinstein from JPMorgan.",12,"The next question on queue will come from Mike Weinstein from JPMorgan."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, I think I need your help. I'm still struggling a little bit with the fourth quarter guidance as well. So first part of it so why I don't understand Lutonix stocking in the fourth quarter last year but Lutonix revenues should year-over-year be up? W",121,"Chris, I think I need your help. I'm still struggling a little bit with the fourth quarter guidance as well. So first part of it so why I don't understand Lutonix stocking in the fourth quarter last year but Lutonix revenues should year-over-year be up? Why are you describing there's 100 basis point headwind? And then second, just want to make sure I understand impact of both top line and on the gross margin of the Japanese joint venture by in the fourth quarter. That almost 200 basis point reduction you're saying is coming from Japan. Was there stocking of products into Japan over the last couple of quarters that would have benefited those quarters relative to kind of underlying trends?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Mike. I think when we think -- when we talk about Lutonix, we talked about Q2 and Q3 with sales to Boston, right? As Boston stepped up sales and we talked about stocking in Q2 with Boston. We think we've actually seen some stocking in Q3 as well. We",165,"Sure, Mike. I think when we think -- when we talk about Lutonix, we talked about Q2 and Q3 with sales to Boston, right? As Boston stepped up sales and we talked about stocking in Q2 with Boston. We think we've actually seen some stocking in Q3 as well. We actually launched a couple of additional links in the quarter as well. So I think certainly as we look in Q4 as it relates to Boston's order pattern, we would certainly expect to see a sequential decline as they begin to now work through that initial inventory. So that's certainly impacting the overall growth rate for Lutonix as we look at Q4. We're seeing continued very strong organic growth in Lutonix. Relative to last Q4, though, we had a large stocking order in our own business, right? And so that's -- it's that lapping of that as well as the sequential sales into Boston that are just driving some of the sequential moves for Lutonix."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","How are you coming up with 100 basis point, just so we can understand what that is.",17,"How are you coming up with 100 basis point, just so we can understand what that is."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","That's our -- as we evaluated last year's Q4 sales of Lutonix, that's our estimate of what the stocking component of those sales were.",25,"That's our -- as we evaluated last year's Q4 sales of Lutonix, that's our estimate of what the stocking component of those sales were."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So you're basically taking out the stocking, but you're not giving yourselves credit for the underlying sales?",18,"Okay. So you're basically taking out the stocking, but you're not giving yourselves credit for the underlying sales?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. We've not projected a number for Lutonix for Q4 in the analysis that Chris gave.",16,"Yes. We've not projected a number for Lutonix for Q4 in the analysis that Chris gave."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. You're getting yourself the penalty but not the benefit?",10,"Okay. You're getting yourself the penalty but not the benefit?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. But I think the other sequential impact is sales -- our expected sales in the Boston.",17,"Yes. But I think the other sequential impact is sales -- our expected sales in the Boston."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Understood. Understood. I'm sorry. And then just Japan piece, Chris.",10,"Understood. Understood. I'm sorry. And then just Japan piece, Chris."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only impact there it's about $11 million, Mike. And the way -- so last year, we would, in the ordinary course, be selling product into the JV as their obviously been selling out. They maintain levels of inventory that are similar to us and similar to",145,"The only impact there it's about $11 million, Mike. And the way -- so last year, we would, in the ordinary course, be selling product into the JV as their obviously been selling out. They maintain levels of inventory that are similar to us and similar to the sector. The sales that we make to them, once we close the transaction, we will not record until they're sold out the door. And so they're sitting on inventory today. We haven't closed the transaction. We've already recorded sales for as they then sell those products out the door in November, December, we can't record the sale again. In the ordinary course, we'll continue to ship products to them, which is what we did last year. But there's a delay now as that inventory needs to get sold once we have full ownership of the JV."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","And is that -- before distributors usually bought they have an incentive to stock up on extra product. And just making sure that the Japanese distributor wasn't buying in excess product to have as much on their shelves before the conversion.",41,"And is that -- before distributors usually bought they have an incentive to stock up on extra product. And just making sure that the Japanese distributor wasn't buying in excess product to have as much on their shelves before the conversion."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","No. To be very clear, nothing about the order patterns last year and the order patterns this year are different at all. So it's purely the mechanism that once we have ownership, we just have to wait for the inventory to clear before we record additional s",47,"No. To be very clear, nothing about the order patterns last year and the order patterns this year are different at all. So it's purely the mechanism that once we have ownership, we just have to wait for the inventory to clear before we record additional sales."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question in queue will come from Brooks West with Piper Jaffray.",13,"The next question in queue will come from Brooks West with Piper Jaffray."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","One more just on that last topic. Chris, you said $11 million impact from Japan in Q4. You said there's going to be a little bit into Q1. What is the impact in Q1?",34,"One more just on that last topic. Chris, you said $11 million impact from Japan in Q4. You said there's going to be a little bit into Q1. What is the impact in Q1?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. It's about the same impact.",6,"Yes. It's about the same impact."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then the last part of that is just some declines in EP sales to Boston Scientific. Is that a surprise that that's dropping off? Or was that part of the forecast and again could you quantify that?",39,"Okay. And then the last part of that is just some declines in EP sales to Boston Scientific. Is that a surprise that that's dropping off? Or was that part of the forecast and again could you quantify that?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Sure. Actually, you go back this quarter, we've actually talked about it, both coming into the year and in every quarter because actually, what they did prior to this quarter, we actually were seeing growth in sales to them as they were actually buil",126,"Yes. Sure. Actually, you go back this quarter, we've actually talked about it, both coming into the year and in every quarter because actually, what they did prior to this quarter, we actually were seeing growth in sales to them as they were actually building inventory in anticipation of the shift to self-manufacturing. We've taken those sales out of organic growth obviously the entire year. And so we talked about Q4 being the first big quarter where we would see step-down because they now have actually stood up the manufacturing plant in Costa Rica. So that impact in the quarter is round numbers about $5 million. So between that and Japan, you're talking about $16 million, $17 million of negative impact as compared to prior year."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then, I guess, one big picture for me, guys. It looks like now you're going to have the Gore royalty through '19 based on the, I guess, the decision not to hear the case. You've executed well against the investment plan you laid out. Believe the",108,"Okay. And then, I guess, one big picture for me, guys. It looks like now you're going to have the Gore royalty through '19 based on the, I guess, the decision not to hear the case. You've executed well against the investment plan you laid out. Believe the only thing you haven't done is a big acquisition. So I guess, 2-part question for Tim, how are you thinking about mitigating that the falloff in the Gore royalty? And can you just update us on what you're seeing out in the market? And are you starting to get more aggressive given some of the declines in multiples we're seeing?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think it's a little early to comment specifically in 2019 right now. I can tell you, though, that clearly, it's very visible in front of us and clearly a noble event for us. And we're obviously planning or what will become over time, obviously, we",114,"Sure. I think it's a little early to comment specifically in 2019 right now. I can tell you, though, that clearly, it's very visible in front of us and clearly a noble event for us. And we're obviously planning or what will become over time, obviously, we've been planning and anticipating that. So that's the comment generally about the Gore royalties. And relative to our business development activity, we remain extremely active going through a number of things in our, what we call funnel, if you will. And I remain optimistic that, that landscape continues to look robust for us. And as we go ahead and close, then we'll announce them when they occur."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go to our next question in queue. That will gone to come from David Roman from Goldman Sachs.",20,"We'll go to our next question in queue. That will gone to come from David Roman from Goldman Sachs."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted to come back to Lutonix and go into the utilization in a little bit more detail. Can you maybe talk to us about how you're seeing this being used in a real-world setting because our understanding and feedback from TCT is that technology that is g",93,"I wanted to come back to Lutonix and go into the utilization in a little bit more detail. Can you maybe talk to us about how you're seeing this being used in a real-world setting because our understanding and feedback from TCT is that technology that is getting used in a broad number of cases. And it's not so much proven to be replacement for things like stent therapy or atherectomy more used as an adjunct. Can you maybe give us your perspective on that and how you're seeing the adoption curve rollout?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. John DeFord here. Let me talk about a utilization. I think what you heard the TCT is fairly consistent. We're beginning to see drug-coated balloons used as sort of an initial therapy, not necessarily the destination therapy, but an initial therapy. A",182,"Yes. John DeFord here. Let me talk about a utilization. I think what you heard the TCT is fairly consistent. We're beginning to see drug-coated balloons used as sort of an initial therapy, not necessarily the destination therapy, but an initial therapy. And then depending on the outcome of that initial therapy, making other decisions. Now obviously, atherectomy or things like that might come into play prior to using any kind of other technology. But by and large, we're seeing drug-coated balloons be used first. And then as you would expect, if there's provisional stenting required and stents are used. If there are other technologies or other pieces needed, then they get included. So I don't think we ever expected DCB to replace some of these other technologies. But we are seeing it move exactly as we expected to be the first line of therapy. We think there's still a long way to go as far as growth and penetration. But this is -- it's still early days. But that's what we're seeing. I think that's fairly consistent with what you've heard."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then maybe just sort of a broader question as you think about the growth rate, 2015 has obviously proven to be a very strong period of organic growth for the company. And I think when you laid out the investment plan earlier about in early 2013,",104,"Okay. And then maybe just sort of a broader question as you think about the growth rate, 2015 has obviously proven to be a very strong period of organic growth for the company. And I think when you laid out the investment plan earlier about in early 2013, this is the year you're envisioning growing above market growth. But maybe you can talk to us about where we are in the realization of the benefits from that investment plan and to what extent you think the trends we've seen over the past 9 months and what you're guiding for the full year are sustainable."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we haven't given guidance nor will be on this call for 2016. I think if you go back and look at what we said in 2013, is we expected to be above-market revenue growth about this point in time. And that our expectation, both with not only the investm",91,"Well, we haven't given guidance nor will be on this call for 2016. I think if you go back and look at what we said in 2013, is we expected to be above-market revenue growth about this point in time. And that our expectation, both with not only the investments that we made then, but with the investments ongoing, is that, that would be sustainable. So that's what we said a few years ago and that's kind of what the plan was. That will give you guidance for 2016 in January."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And maybe one other different way think about the momentum in the business that you're seeing today, is there any part of it you'd ascribe to macro-related factors that in the call versus Bard-related factors?",36,"Okay. And maybe one other different way think about the momentum in the business that you're seeing today, is there any part of it you'd ascribe to macro-related factors that in the call versus Bard-related factors?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","In any given quarter, and I obviously, I said earlier we watch it is and everybody. It's very difficult for any company I don't care how big your gain share, loss share on, the markets increase or stay flat or decline from quarter-to-quarter. I wouldn't s",185,"In any given quarter, and I obviously, I said earlier we watch it is and everybody. It's very difficult for any company I don't care how big your gain share, loss share on, the markets increase or stay flat or decline from quarter-to-quarter. I wouldn't say virtually impossible over that short period of time. So we said in the past be kind of felt like things were getting a little bit better. I think that some of the old metrics we used to use like hospital admissions, especially when you're involved with procedures, maybe the weather signs necessarily that they were a few years ago. So some of the dynamics as you know in health care utilization generally are changing. So it's kind of difficult to say when you look at hospital admission metrics maybe going down, and yet our continues to grow. What does that all mean? It's very difficult to say. We said earlier in the last call it feels a little bit better. I would say that still holds true for this quarter. Just hard to put any fine points on it."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add and obviously we track the sector and when we look at organic growth rates across the sector, actually, over the last 4 or 5 quarters, they're frankly pretty flat relative sequentially. And obviously, we've moved over that period of",126,"The only thing I'd add and obviously we track the sector and when we look at organic growth rates across the sector, actually, over the last 4 or 5 quarters, they're frankly pretty flat relative sequentially. And obviously, we've moved over that period of time. So at least the things that are growing for us in both emerging markets and in the product portfolio and Lutonix being part of that, are related to things that we've invested in over the last couple of years. And so we haven't seen material moves stent point in volumes or utilization. And as we look at the sector, it certainly would appear to be that proven organic growth that we've experienced is directly related to investments that we made."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question in queue will come from David Lewis from Morgan Stanley.",13,"Our next question in queue will come from David Lewis from Morgan Stanley."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just a quick follow-up on the Japanese distributor. So the EPS dilution that you had previously described obviously appears like it's dropping through and full in the fourth quarter. Should we expect the same to hold true in '16 the full $0.20 drop",57,"Chris, just a quick follow-up on the Japanese distributor. So the EPS dilution that you had previously described obviously appears like it's dropping through and full in the fourth quarter. Should we expect the same to hold true in '16 the full $0.20 drop straight through? Or should we expect it to be offset in some way?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. I think certainly it's a $0.20 whole, right? And it's purely related to the yen, just to be clear. So it's a whole and obviously, we haven't given guidance, David, for 2016. But because of a transaction, we're facing much more significant yen headwin",122,"Yes. I think certainly it's a $0.20 whole, right? And it's purely related to the yen, just to be clear. So it's a whole and obviously, we haven't given guidance, David, for 2016. But because of a transaction, we're facing much more significant yen headwind than we would've been otherwise. So will obviously as we roll up our budget and decide what we're ready to commit to for 2016. We are starting with a big yen headwind that we wouldn't have had. Now having said that, it's a very interesting strategic move for us, and we believe it will pay nice dividends long term for the company. But it'll -- it's a headwind that we'll deal with as we go into 2016."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just as a follow-up maybe Tim or Chris, could can you give us a sense of what that accretion or return looks like in '17 and beyond? And then, I guess, just for John DeFord, as it relates to Lutonix, I guess, if you give us a sense for in the fe",99,"Okay. And just as a follow-up maybe Tim or Chris, could can you give us a sense of what that accretion or return looks like in '17 and beyond? And then, I guess, just for John DeFord, as it relates to Lutonix, I guess, if you give us a sense for in the feel what do you think is resonating with clinicians more the trial data or the registry data. And I guess, more directly what I'm trying to get at is would you expect any impact on your business based on the impact one [ph] results post TCT."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I wonn't be specific, David, but assuming the yen stays roughly where it is and we execute, which includes some interesting product launches for us into Japan, including Life stent and Lutonix overtime here, the business for us will return nicely accretiv",61,"I wonn't be specific, David, but assuming the yen stays roughly where it is and we execute, which includes some interesting product launches for us into Japan, including Life stent and Lutonix overtime here, the business for us will return nicely accretive beginning in '17 and beyond. But I'm not going to put a fine point on it for you."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And then just jumping in to talk about the data. We think that clinicians are really interested in looking at both pivotal and randomized studies and registries. I think the Levant 2 study as published in New England Journal Medicine and also very unique",290,"And then just jumping in to talk about the data. We think that clinicians are really interested in looking at both pivotal and randomized studies and registries. I think the Levant 2 study as published in New England Journal Medicine and also very unique study design. Also, we've also found in that study that procedure really matters. And that was something that came out. The panel came out and some of the post discussions that the way the device was used compared to PTA was different. And actually, in our study, the drug-coated balloon was used what you could call had a less effective treatment at the end of the procedure compared to PTA. Again, I think that attribute is attributed to some of the results that we see in our randomized study. Certainly, I understand our competitor wanting to try to shift the discussion back to theirs. It's kind of interesting they haven't updated their registry data yet. But our registry data real world is in much -- more difficult patients that we saw in Levant 2. We think it's really demonstrating the real-world usage of the technology. And of course, those clinicians were educated on the things that we've learned in the Levant 2 study on the importance of fully inflating the balloons, getting good expansion, appropriate access to the vessel and the lesion quickly and other things that were discussed by Dr. Schmidt at TCT. And so we think that these results are pretty indicative of real-world usage based on that new knowledge. Now what clinicians are going to do? So far, I think it's resonated pretty well that drug-coated balloons work. And at least the 2 technologies on the market today seem to work pretty similarly."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","It'll come from David Turkaly from GMP Securities.",9,"It'll come from David Turkaly from GMP Securities."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Do you guys give the percentage emerging markets was in the quarter?",12,"Do you guys give the percentage emerging markets was in the quarter?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","It's about 9.5% of total sales, David. It's up about 120 basis points year-over-year. Very strong double-digit growth and obviously, continuing to move in the right direction overall. There is some seasonality to the different geographies, but we had anot",57,"It's about 9.5% of total sales, David. It's up about 120 basis points year-over-year. Very strong double-digit growth and obviously, continuing to move in the right direction overall. There is some seasonality to the different geographies, but we had another great quarter. And again, it's actually across all the geographies, just like we saw in Q2."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then obviously, everyone's aware that you hired a bunch of folks there. I was just curious as you look at their productivity, now what will that look like versus some of your U.S. or European perhaps over time and how long do you think it takes",60,"Great. And then obviously, everyone's aware that you hired a bunch of folks there. I was just curious as you look at their productivity, now what will that look like versus some of your U.S. or European perhaps over time and how long do you think it takes some of these guys to get fully ramped and up to speed?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I would say that we're delighted with the ground game of our team in emerging markets. We've been very aggressive in terms of adding to that field sales force around the world. And as we've talked continually, that sales force represents about 34% o",154,"Well, I would say that we're delighted with the ground game of our team in emerging markets. We've been very aggressive in terms of adding to that field sales force around the world. And as we've talked continually, that sales force represents about 34% of our reps around the world. It's the fastest area of investments for us in field sales reps. it was a little bit less than 10% of our sales. So we think we've made the right investments for the long term. we lacked the uptick that our people are giving us in the field as they get seasoned, takes on average 9 months to 12 months for a person to really be productive no matter what geography that you're working in. And I would say that we're delighted with the execution and the ground game that our team is putting on, not only in emerging markets, but around the world."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question onto, that'll come from Kristen Stewart from Deutsche Bank.",12,"The next question onto, that'll come from Kristen Stewart from Deutsche Bank."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Anyway, I was just wondering if you could expand a little bit more. I think you mentioned their dealer stocking with fully catheters because that seem to be up quite a lot. I don't remember basic genetics has been up actually like 6% and 7% in the U.S. so",76,"Anyway, I was just wondering if you could expand a little bit more. I think you mentioned their dealer stocking with fully catheters because that seem to be up quite a lot. I don't remember basic genetics has been up actually like 6% and 7% in the U.S. so how big of a stocking or was there in the quarter and will that just pull, I guess, from the fourth quarter? Or is that shift from?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And frankly, Kristin, we don't know for sure as we get additional tracing data. We're just speculating there was some in the quarter, and so we just wanted to caution you against it. It could possibly pull a bit from Q4. And that's certainly factored into",80,"And frankly, Kristin, we don't know for sure as we get additional tracing data. We're just speculating there was some in the quarter, and so we just wanted to caution you against it. It could possibly pull a bit from Q4. And that's certainly factored into our overall sales guidance. So I don't want to make too much of it. And we can't say for certain yet. We'll know more in the coming weeks as we get additional tracing data."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Actually, in the grand scheme of things it's a really small point for us across the board.",17,"Actually, in the grand scheme of things it's a really small point for us across the board."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Yes.",2,"Yes. Yes."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Right. And I guess, just in general, just in terms of, I guess, going back just to the M&A side, Tim, is there anything in terms of the landscape that you're seeing that makes you more or less likely to go often to any additional areas, whether it be pref",118,"Right. And I guess, just in general, just in terms of, I guess, going back just to the M&A side, Tim, is there anything in terms of the landscape that you're seeing that makes you more or less likely to go often to any additional areas, whether it be preference to do more smaller tuck-in deals or product portfolio in the U.S? Or are you seeing or thinking about doing more deals that might give you greater exposure into international markets at this point? Or do you feel comfortable with the investments that you made in emerging markets say that you have the right investments there and you're capable growth given just the investments that you have already?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, in terms of our lenses and our filters, the answer is yes, to all of the above. We're looking at everything. So relative to the landscape, we've kind of like what we see. And in terms of what's out there, our filters, our hurdles have not changed re",232,"Well, in terms of our lenses and our filters, the answer is yes, to all of the above. We're looking at everything. So relative to the landscape, we've kind of like what we see. And in terms of what's out there, our filters, our hurdles have not changed relative to our priorities. We don't start with size as one of the first questions. In fact, probably, it's couple of reviews through every before I even start to focus on that. We focused more on strategic intent. Some of the examples of things we've done over the last couple of years, and talking temperature management is one Rochester whatever. We're focused on revenue growth because we think revenue growth provides a better shareholder return than slower revenue growth than on earnings. So we look at revenue growth upside, sustainability of that. We actually look at each investment is it a platform to invest further in? Whether that be both with technology. And clearly, we've given a size of the transactions we've done. They've had limited capabilities outside the United States, just from an expense affordability standpoint. And we already have that footprint. So we look at all of those things. But I'm optimistic about what the landscape looks like. And we'll see how many of those actually clear our filters, but we haven't changed our standards at all in the last several years."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And I'd add, Kristin, obviously we're focused on finding good targets internationally as well that fits all the same criteria. And frankly, within emerging markets, we continue to struggle to find good targets that meet the criteria that we have. And so o",91,"And I'd add, Kristin, obviously we're focused on finding good targets internationally as well that fits all the same criteria. And frankly, within emerging markets, we continue to struggle to find good targets that meet the criteria that we have. And so obviously, we now have a really nice track record of executing organic growth-driven strategies in a lot of those markets continue to do that well we still look. But we're looking, to Tim's point, really around the world for opportunities that are, first and foremost, product leadership opportunities."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","And the buying into the JV over in Japan, was that just because of the pressure of failing in dollars and the JV just taking a hit with currency or just benefits of going direct?",35,"And the buying into the JV over in Japan, was that just because of the pressure of failing in dollars and the JV just taking a hit with currency or just benefits of going direct?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Let me a little background history here just for those of you that may not know this. So if you go back into the 90s, we actually had a Bard Japan limited business and Medtronic joint venture with Kobayashi. That was primarily responsible for our Urology",202,"Let me a little background history here just for those of you that may not know this. So if you go back into the 90s, we actually had a Bard Japan limited business and Medtronic joint venture with Kobayashi. That was primarily responsible for our Urology product line. In 1998, we sold off the cardiology business as part of that transaction because entity in Japan went with that transactions. We have to make a decision back then that we put of Bard's product into the joint venture or do we start our own business there. That then we made the decision. We had a lot of confidence and faith in Medicon and obviously the fact that we just the other halfway more so now move entire product line that JV. Given the structure of the JV, as we've invested more heavily internally in R&D, in new product launches, which require also clinical trials and just put pressure on business model in Japan. And strategically, it made all the sense in the world for us to own the thing in its entirety so that we can make all the investment decisions we need to make to grow the business over the long term."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","That makes sense. And that fund is because every other health care companies coming out today you have ownership stake in any pharmacy company? I'm just curious...",27,"That makes sense. And that fund is because every other health care companies coming out today you have ownership stake in any pharmacy company? I'm just curious..."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question in queue will come from from Cowen and Company.",12,"Our next question in queue will come from from Cowen and Company."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is on Josh Jennings. So you've highlighted in the past Targeted Temperature Management and BioSurgery segments with significant market opportunity expansion. And those are seeing double-digit growth. Can you give us more color on how those lines are",51,"This is on Josh Jennings. So you've highlighted in the past Targeted Temperature Management and BioSurgery segments with significant market opportunity expansion. And those are seeing double-digit growth. Can you give us more color on how those lines are tracking relative to that and when you might see some significant ramp?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we've been seeing a significant ramp in those product lines since day 1 of the acquisitions. We've been taking share annually in both of those major product lines that we acquired. We really build out a very successful independent sales force pretty",86,"Well, we've been seeing a significant ramp in those product lines since day 1 of the acquisitions. We've been taking share annually in both of those major product lines that we acquired. We really build out a very successful independent sales force pretty large by U.S. standards in that business. And I think they're executing extremely well. So we have been growing substantially in that space. We would expect we will continue to. And we're always looking for opportunities to be adjunctive to those product launches."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add meal is that both of those opportunities play out over a number of years because there's a number of additional indications that our technologies are going to be effective with both on the Targeted Temperature Management side as wel",104,"The only thing I'd add meal is that both of those opportunities play out over a number of years because there's a number of additional indications that our technologies are going to be effective with both on the Targeted Temperature Management side as well as within BioSurgery. So to Tim's point about having acquired platforms that have an investment opportunity beyond the initial product set that we acquired, we've got a long runway we think in both of those categories to grow them for many years. And again both of them are growing nicely in the double digits as we sit here today."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just one quick follow-up. So I believe you saw some softness in Europe earlier in the year. But then recover in the second quarter and then even more so in the third quarter here. How are the reimbursement issues shaking out in Europe, particula",48,"Okay. And just one quick follow-up. So I believe you saw some softness in Europe earlier in the year. But then recover in the second quarter and then even more so in the third quarter here. How are the reimbursement issues shaking out in Europe, particularly in France?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me deal with the macro issue first. I think that's the important one. And that is that we did have a slow first quarter. And I think as we predicted, we thought the year would pick up and it certainly has. Our team over there is executing extrem",97,"Well, let me deal with the macro issue first. I think that's the important one. And that is that we did have a slow first quarter. And I think as we predicted, we thought the year would pick up and it certainly has. Our team over there is executing extremely well. There's nothing from a major pricing standpoint going on in our business in Europe. And in fact, our Europe team was positive price for the quarter. So we don't see a big issue right now looming in front of us in terms of reimbursement in France."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I would add because I know there were some comments made perhaps by other in the market regarding specifically reimbursement for drug-coated balloons in Europe. And I would just tell you, that is a category reimbursement and not kind",61,"The only other thing I would add because I know there were some comments made perhaps by other in the market regarding specifically reimbursement for drug-coated balloons in Europe. And I would just tell you, that is a category reimbursement and not kind of an individual brand reimbursement. We're working very hard to expand that as well throughout Europe. So..."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And that's New England Journal of Medicine publication frankly helps having that kind of publication is required in certain geographies to help achieve reimbursement.",25,"And that's New England Journal of Medicine publication frankly helps having that kind of publication is required in certain geographies to help achieve reimbursement."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Hey, Tony, we have crossed the top of the hour. we're going to me take 2 more questions and apologize to anyone in the queue after that.",27,"Hey, Tony, we have crossed the top of the hour. we're going to me take 2 more questions and apologize to anyone in the queue after that."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll take our next question in from Matt Taylor from Barclays.",12,"We'll take our next question in from Matt Taylor from Barclays."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just had a follow-up on some of the Lutonix commentary. I guess, I just wanted to ask maybe more straightforwardly. If you could just talk about the underlying trends and what you're seeing there is sequentially versus the stocking comments. And then co",107,"I just had a follow-up on some of the Lutonix commentary. I guess, I just wanted to ask maybe more straightforwardly. If you could just talk about the underlying trends and what you're seeing there is sequentially versus the stocking comments. And then conceptually, the partnership with Boston Scientific has been interesting. Curious to know if you look out longer term, do you think that they're going to be selling a meaningful chunk of your overall Lutonix sales? If you could give us any sense of what the state would be there and then is there any opportunity to expand that partnership into other product areas?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So I think just the sequential kind of Q2, Q3 Q4 and the first thing I'd say is we need as we've said, it'll be nice to have this all settled out. But it's going to take a few quarters for this to settle out. So Boston ramped up in Q2. Certainly had",192,"Yes. So I think just the sequential kind of Q2, Q3 Q4 and the first thing I'd say is we need as we've said, it'll be nice to have this all settled out. But it's going to take a few quarters for this to settle out. So Boston ramped up in Q2. Certainly had some stocking in Q2. As I said, we launched a couple of additional sizes in Q3, which drove, we think, some additional stocking in Q3. And so certainly, we would expect a sequential decline in Q4 for Boston as they begin to work through that initial stocking inventory. So when you then adjust for our stick stocking order last year in Q4, we're seeing really terrific, both sequential and year-over-year growth, in our base organic Lutonix business and feel really good about our competitive position and John DeFord talked about the real-world registry data, which is, frankly, outstanding. So we need to get through these couple of quarters here and get to a steady state next year. Where Boston's been business now with us for a while. And we've been moved beyond our initial launch in the U.S."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I take to the longer-term issue on Boston, we think the strategy was sound that we entered into. Your question was will they -- what kind of a position will they have Lutonix. I mean, as we set out on this, Boston had the rights to sell the product at a s",138,"I take to the longer-term issue on Boston, we think the strategy was sound that we entered into. Your question was will they -- what kind of a position will they have Lutonix. I mean, as we set out on this, Boston had the rights to sell the product at a small subset of customers. And based on where they have good relationships or position in a certain therapy that we're not involved in. We have no plans to expand that to other product lines today or circumstances. I think this was a unique opportunity for us to be complementary with Boston in a small segment of customers. And I think that we like that positioning. But Bard will be possible for the greatest majority of sales and the greatest majority of customers obviously, around the world."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","All right. That's helpful. And one follow-up on Lutonix. I guess, broadly just from the good data, both out of your registry and the Medtronic data from TCT, do you expect that or any other clinical or, I guess, market expansion to change the growth rate",67,"All right. That's helpful. And one follow-up on Lutonix. I guess, broadly just from the good data, both out of your registry and the Medtronic data from TCT, do you expect that or any other clinical or, I guess, market expansion to change the growth rate in the near term of the market? Or do you think we're just going to kind of see continued good growth?"
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I'll jump in here. I think we expect continued good growth. But we also think that additional indications are really important. So we talked about these studies, the AV Access study, Below the Knee, in-stent restenosis, other indications we think ar",61,"Well, I'll jump in here. I think we expect continued good growth. But we also think that additional indications are really important. So we talked about these studies, the AV Access study, Below the Knee, in-stent restenosis, other indications we think are additional catalysts for growth. So we're strictly and specifically focused on those areas, and we'll continue to be so."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from Anthony Petrone from Jefferies.",10,"Our next question will come from Anthony Petrone from Jefferies."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","One on Lutonix. Just wondering if you can provide an update on utilization per case, how many balloons are actually used per case? And then one is a broader question community health reported lower revenue per admission today is now lower negotiated rates",75,"One on Lutonix. Just wondering if you can provide an update on utilization per case, how many balloons are actually used per case? And then one is a broader question community health reported lower revenue per admission today is now lower negotiated rates from Medicare. And then in addition, we're seeing consolidation of private managed care companies. I'm just wondering how you think this plays out ultimately in price for medical device companies over time."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I'm happy to jump in on the Lutonix side. I can tell you that I'm not sure we have specific data to share on number of devices used per case just because we don't really have insight into that. And as we haven't to have somebody standing in the room, we w",87,"I'm happy to jump in on the Lutonix side. I can tell you that I'm not sure we have specific data to share on number of devices used per case just because we don't really have insight into that. And as we haven't to have somebody standing in the room, we wouldn't necessarily know. I can tell you by the lesion lengths that we see and we do expect this sort of be in that 1.3 to 1.5 devices potentially per case kind of averaged out."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Pricing scenario consolidation clearance. It's a very dynamic environment going on right now. Pricing pressure has always been on us and other companies in the space. I think specifically, as you -- I think the pricing dynamics is taking on a little bit l",97,"Pricing scenario consolidation clearance. It's a very dynamic environment going on right now. Pricing pressure has always been on us and other companies in the space. I think specifically, as you -- I think the pricing dynamics is taking on a little bit larger or maybe a little bit of a larger impression in the investment community mainly because some of the biotech and the pharma pressing issues that have been in the media recently. A very large percentage, I think it's 50% of our revenue, has some ASP of less than $500 probably close to $400."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","75%.",2,"75%."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","75% of our revenue actually so we're not exactly on the high end of the radar screen here when they get to that. Nonetheless, the procedures under pressure and what we're trying to do is demonstrate the value and the quality and the outcomes in doing that",77,"75% of our revenue actually so we're not exactly on the high end of the radar screen here when they get to that. Nonetheless, the procedures under pressure and what we're trying to do is demonstrate the value and the quality and the outcomes in doing that with the data, which are getting a lot of traction and uptake from our customers as they move or to in the U.S. in a ACO kind of organization structure."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think those data sets are certainly very helpful in driving reimbursement evidence to full reimbursement for Lutonix as a result of that value analysis that we work with CMS on.",32,"And I think those data sets are certainly very helpful in driving reimbursement evidence to full reimbursement for Lutonix as a result of that value analysis that we work with CMS on."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, this does conclude our Q&A session. I would now like to turn the call back over to Bard's management for closing or additional comments.",27,"Ladies and gentlemen, this does conclude our Q&A session. I would now like to turn the call back over to Bard's management for closing or additional comments."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much, and I'd like to thank all of you for joining us today. And also close by thanking Bard employees globally for a strong year of execution so far. So we'll update you again in our progress in January. Thanks, everybody.",44,"Thank you very much, and I'd like to thank all of you for joining us today. And also close by thanking Bard employees globally for a strong year of execution so far. So we'll update you again in our progress in January. Thanks, everybody."
254131,312630689,880436,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. Ladies and gentlemen, that does conclude our conference call for today. We do thank you for your participation, and using AT&T Executive TeleConference. You may now disconnect.",29,"Thank you. Ladies and gentlemen, that does conclude our conference call for today. We do thank you for your participation, and using AT&T Executive TeleConference. You may now disconnect."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. And welcome to the C.R. Bard, Inc. Third Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-dema",276,"Ladies and gentlemen, thank you for standing by. And welcome to the C.R. Bard, Inc. Third Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2015, Form 10-Q, and the information under the caption Risk Factors in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 22, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to the prior year period.
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. And I'd like to welcome everyone to Bard's Third Quarter 2015 Earnings Call, and thank all of you for taking the time to join with us today. We expect the presentation portion of the call to last about 30 minutes and the total call to last abou",618,"Thank you. And I'd like to welcome everyone to Bard's Third Quarter 2015 Earnings Call, and thank all of you for taking the time to join with us today. We expect the presentation portion of the call to last about 30 minutes and the total call to last about an hour. The agenda today will be as follows: I'll begin with an overview of the results for the quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; and Chris Holland, our Senior VP and CFO, will review the third quarter income statement, balance sheet as well as our expectations for the fourth quarter, and then finally, we'll close with Q&A.
Third quarter 2015 net sales totaled $865.7 million. That's up 4% over Q3 of last year on as-reported basis and up 8% on a constant currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable, about 370 basis points. Excluding the Gore royalty of $38.4 million in sales related to recent acquisitions and divestitures, our organic growth rate was approximately 8.3% for the quarter. That's above our expectations. The U.S. sales of the Lutonix drug-coated balloon contributed a little less than 300 basis points of growth in Q3.
Net loss for the quarter of 2015 was $86 million and diluted loss per share was $1.16. Excluding these items that affected the comparability of results between periods, which Chris will cover later, third quarter 2015 net income was $154.5 million and diluted earnings per share, which excludes amortization of intangibles, were $2.28. That's up 4% and 6%, respectively.
Looking at revenue growth geographically, compared to the same quarter last year, third quarter net sales in the U.S. were up 7%. Internationally, we grew 10% on a constant currency basis, with Europe growing 7%, Japan declining 1% and our other international businesses growing 18% this quarter. Strong quarter in Europe was driven by Endovascular radiology infix, and the slight decline in Japan was due to inventory fluctuations at our joint venture.
You may have noticed a few weeks ago, we announced the acquisition of the remaining 50% ownership of our Japanese joint venture. We expect this transaction to be completed in the coming weeks. While it comes with some near-term dilution driven by exchange, we believe this is strategically important for us. Increased investment for market development and clinical trials in Japan was difficult with the structure of the joint venture when you combine that with foreign exchange pressure. So we decided this was a timely opportunity to take full ownership and advance our product leadership strategy in the world's third-largest health care market.
Our emerging markets business continues to grow into healthy double digits, following our significant investments there over the last couple of years. So as we look at our overall results for the quarter and the first 9 months of 2015, we said at the beginning of the year that it was an important year of execution for us. And so far, we're pleased with the results. As we projected at the announcement of our strategic investment plan nearly 3 years ago now, we are back at the top end of the sector from a revenue growth perspective, and we remain convinced that above-market revenue growth is a key to a premium multiple. We remain focused on making investments in areas of faster growth in a profitable manner to enhance shareholder value over the long term.
So with that, let me turn you over to John Weiland for a review of our product line revenue."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted.So let's begin with Vascular. Growth in this category",873,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted.
So let's begin with Vascular. Growth in this category was 13% for the quarter or 8% as-reported, with total net sales of $250.5 million. Excluding the Gore royalty and the divested EP sales, total Vascular grew -- sales grew 16% globally, with the United States business up 18% and the international business growing 14% in the quarter.
Sales in our Surgical Graft category were up 4% in Q3. Excluding the Gore royalty, our Endovascular business increased 18% in the third quarter. Within Endovascular, our biopsy products had another strong quarter with 14% growth, with nice performance in the United States and even better performance outside of the United States.
Sales in our peripheral PTA line increased 48%, driven by global sales of our Lutonix drug-coated balloon. We are very pleased with the performance of this important product, which anniversary-ed its FDA approval and the U.S. launch on October 10. It has been a good first 12 months in the United States and we're pleased with the results from our real-world registry study. John DeFord will tell you more about this in a few minutes.
As we seek to expand the indications and reach of this compelling technology platform, we expect to see long-term global growth from Lutonix. Our Stent business declined 3% again this quarter, consistent with recent experience. And finally, net sales in our Vena Cava Filter line declined 3% in Q3.
So let's go to Urology. Total net sales were $212.3 million, up 5% versus Q3 of last year on a constant currency basis and 1% on an as-reported basis. The United States business grew 5% while internationally, we grew 4%. Our Targeted Temperature Management products grew into healthy double digits again this quarter. Our basic drainage business was up 6% globally in Q3, with the United States business up 7%. Our I.C. Foley business was up 3% globally and up 1% in the United States. We believe that Foleys this quarter benefited from some dealer stocking, but we don't know the precise impact. So we've been cautioned against reading too much into these improved growth rates in a single quarter.
Our continence business decreased 3% in the third quarter. Sales in urological specialties grew 1% with our brachytherapy business down 1%. And finally, in this category, standalone sales of our StatLock catheter stabilization product line declined 4% in Q3.
Now let's go to Oncology. Total net sales in this category were $239.3 million, an increase of 8% on a constant currency basis and 4% on an as-reported basis over the third quarter last year. Geographically, net sales in the United States were up 5% and international sales were up 15%. Our port business decreased 1% this quarter due to the price reductions in the United States that we talked about at the beginning of the year. Our PICC revenue was up 13% in the third quarter, including strong results in the United States, Europe and emerging markets again this quarter. We're very pleased with the clinical adoption of our advanced technology, which helps patients and can save time and cost for the hospital.
Despite the competitive noise on single features here and there, we believe that the quality and performance of our broad product offering is why we continue to grow faster than the market. And as the competition tries to catch up to our older products, we continue to advance the technology and solve unmet needs for our customers and our patients. John DeFord will tell you more about this.
Our vascular access ultrasound product line was up 1% this quarter. The growth rates for this system can be a little lumpy around new product launches, and that's what we're seeing due to the Vision II launch in the prior year and the pending Site-Rite 8 launch later this year. And to complete Oncology, our Dialysis Access product line was up 12% over Q3 of last year.
So let's conclude with our Surgical Specialties business. Total net sales in this category were $139.8 million, up 6% on a constant currency basis and up 3% as-reported. United States sales were up 6% and international sales grew 4% this quarter. Two years after the acquisition of the Arista Hemostat and 3 years after the acquisition of the Progel sealant technology, our combined biosurgical product portfolio continues to grow double digits.
Our soft tissue repair business grew 7% in Q3, with our synthetic ventral hernia repair products growing 6%, while our natural tissue products grew 14%, driven by our new XenMatrix AB coated porcine mesh. Our hernia fixation business grew 2% this quarter, which was the first quarter in positive territory since the second quarter of 2011. We are hopeful that our new product launches here can reverse the trend of declines in recent years.
In closing out the surgical category, our performance irrigation business was down 20% in Q3. As we told you, we discontinued some products earlier in the year.
This concludes our product line revenue discussion, and now I'll turn you over to John DeFord."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon or maybe it's evening for everyone. Thanks for taking time to join us today. For the sake of time, I'll jump right into some highlights, starting with drug-coated balloons. About 2 weeks ago with TCT, we released full 12-m",1197,"Thanks, John, and good afternoon or maybe it's evening for everyone. Thanks for taking time to join us today. For the sake of time, I'll jump right into some highlights, starting with drug-coated balloons. About 2 weeks ago with TCT, we released full 12-month results from our almost 700-patient global SFA and popliteal registry. Lesion lengths were over 100 millimeters. About half the patients had significant calcification and over 30% of the lesions treated were chronic total occlusions. The study found over 94% of patients were free from TLR through the 12-month follow-up, with primary patency in almost 90% of patients. Interim 24-month results demonstrated 93% freedom from TLR and primary patency in excess of 80%. We believe the learnings from the Levant 2 study on keys to a successful procedure are working their way into real world practice, and we're very pleased with the results.
In our Below the Knee IDE, enrollment continues, though, recruitment remained slower than planned due to the complex nature of these patients and their disease. We're working with FDA to find ways to speed up enrollment and analysis in this important study. At current recruitment weight -- rates, we like -- we'll likely to enroll patients through much of 2016, putting PMA submission in the second half of 2017.
On the other hand, our AV access DCB IDE study that began enrollment last quarter is recruiting very quickly, and we anticipate enrollment could be complete as early as Q1 of 2016, which could put PMA submission ahead of schedule in the first half of 2017. The in-stent restenosis IDE study is ongoing, and we're currently planning a second half 2016 PMA submission, seeking this expanded indication. We have a host of other DCB studies ongoing or in start-up around the world, and we plan to begin enrollment in our Levant China study in Q1 of 2016.
Also in Vascular, the LifeStream balloon expandable covered stent IDE completed enrollment in Q3. This clinical study is evaluating the technology for the treatment of iliac artery disease with a 9-month follow-up. We anticipate PMA submission in the second half of 2016.
Our Covera [ph] next-generation stent graft, designed for use in the AV access circuit, is planned for launch in Europe this quarter, and we're working with FDA to commence our U.S. IDE study in the first half of 2016. Our new de-novo veno stent recently gained the CE mark. As with Covera [ph], we're working closely with FDA to initiate an IDE study seeking U.S. approval with enrollment planned to begin in the first half of next year.
Next, moving to Urology and home care, we're pleased to announce the release of the new Magic3 Go self-lubricated catheter for female patients. This product's designed for enhanced comfort and ease-of-use for patients that often have limited dexterity. We plan to roll out this product selectively during Q4 as we ramp manufacturing. We also anticipate the launch of our Magic3 touchless catheter in early 2016. Both of these products employ our latest silicone technology designed to enhance patient use and comfort.
We've got some other impactful products in this portfolio for launch later in 2016. But I'll hold off sharing the details until we get closer to those launches.
Now moving to Oncology. The new Site-Rite 8 ultrasound system with integrated 3CG Diamond is rolling out in Europe. The Site-Rite 8 with Pinpoint GT and 3CG Diamond is on track for U.S. launch in Q4, as John alluded to. We believe the combination of ultrasound, needle guidance and catheter tip confirmation in an integrated system will provide a full-featured, user-friendly and intuitive solution for vascular catheter placement.
In PICCs, we've submitted the 510(k) and await FDA clearance to launch a new and proprietary catheter family. These PICCs have been designed to resist common chemicals used in chemotherapy solutions as well as cleaning and disinfection agents. While these solutions are known to degrade standard PICC materials, this new catheter can maintain the same high-performance standards available in our current PICCs, even after long-term exposure. We're also expanding our development efforts toward technologies we believe can further reduce the risk of thrombosis.
While we prefer to keep our development plans confidential, I will say we have a new product family under development that's based on a new high-performance material. We expect to begin launching products using this new material in the back half of next year. Our current plans also anticipate commencement of studies to provide further clinical evidence to support the benefits of these new designs.
In concert with these efforts, we've also recently launched a training program and some associated products designed to reduce infections and promote the safe and effective use of our PICCs. With this change in near-term focus, we've reduced the priority we placed on our antimicrobial and thrombo-resistant coating technologies. The developments are ongoing, but we don't believe they'll have a major revenue contribution compared to these other opportunities.
For the difficult stick IV catheter patients, we announced on the last call the acquisition of the AccuCath guide wire-assisted PIV products. We've taken that technology into our development engine and anticipate the launch of an improved family of AccuCath products in the first half of 2016. These products are anticipated to launch alongside our new midline catheter, the PowerGlide Pro, also planned for launch in that same time period. We believe the combination of our PICCs, the PowerGlide midline family and AccuCath IV product line will help us bring important guide wire-assisted devices to a broad spectrum of patients with Vascular Access needs.
Lastly, for the acute hemodialysis patient, we're expanding our family of catheters with the expected launch of a new dual lumen powers Xenesys [ph] catheter in Q1 of next year. Xenesys [ph] is designed for superior flexibility and kink resistance, along with flow rates in excess of 400 ml per minute in a small 11 per inch catheter configuration.
I'll close my portion of the discussion today with surgery. Just a few weeks ago, we launched our new Phasix ST resorbable synthetic mesh. This launch adds another differentiated product to our complex abdominal wall portfolio that includes XenMatrix, XenMatrix AB and the Phasix mesh technology. We're continuing our efforts to expand our product offerings based on the Phasix platform, and we expect to begin launching those new products over the next several quarters. We're also making good progress on our development of additional sizes of our one-of-a-kind antibiotic-coated XenMatrix AB family, with launches expected throughout 2016 and into 2017. In our BioSurgery product offering, on our last call, I told you we'd filed our PMA supplement, seeking approval of our new TRIDYNE vascular sealant. And we continue to anticipate approval and launch in the back half of next year.
And finally, in mesh fixation, we recently launched both the OPTIFIX spring-loaded resorbable tack device and the Capsure permanent fixation product. We're working to build upon that momentum through the launch of 2 additional fixation devices. But due to the competitive nature of this market, I'll hold back the details for a later call.
Thanks for your time and attention tonight. Let me now hand you over to Chris."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start with the items that affect the comparability of our results between periods.In Q3, we had acquisition-related items of $2.5 million and a $14.6 million charge for restructuring and productivity initiatives. This quarter, we",1136,"Thank you, John. Let's start with the items that affect the comparability of our results between periods.
In Q3, we had acquisition-related items of $2.5 million and a $14.6 million charge for restructuring and productivity initiatives. This quarter, we had made significant additional progress in settlement activity related to our women's health product liability. Driven by this settlement progress and additional information learned from it as well as recent activity in other product liability matters, we took an additional combined charge of $241.1 million this quarter. The P&L impact for these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $529.4 million or 61.2% of sales for Q3. On an adjusted basis, gross profit was $530.3 million or 61.3% of sales, a little better than we projected and down 120 basis points from the prior year. New amortization of intangibles relating to transactions closed in the last 12 months was about 50 basis points this quarter, and foreign exchange drove approximately 30 basis points of headwind for us in Q3. 
Price was unfavorable by 90 basis points on the revenue line and approximately 30 basis points in gross profit, and our mix was favorable by about 40 basis points this quarter. As we forecasted last quarter, the manufacturing variances in our plants from year-to-year can be a little lumpy, and Q3 is an example of that. In Q2, cost savings drove 90 basis points of improvement but in Q3, it was 50 basis points negative. In Q4, we look for Q4 to look more like Q2 with strong favorability. So we expect gross profit in Q4 on an adjusted basis to be a meaningful improvement over Q3 and back to the Q4 2014 level or maybe even a little bit better, which would put us near the high end of the original guidance we gave you for gross margins for the full year. So it's been a year of solid organic improvement for us on the gross margin line.
SG&A expenses were $247.1 million for the quarter or 28.5% of sales. On an adjusted basis, SG&A was also 28.5% of sales, down 60 basis points from Q3 of last year. I'll remind you that we typically see an uptick in SG&A as a percent of sales in Q4 sequentially, but we expect to still see good leverage compared to the prior year and expect to be within our full year guidance for 2015.
R&D expenditures totaled $65.2 million or 7.5% of sales on a reported basis for the third quarter, which was the same on an adjusted basis, down 40 basis points from the prior year and right on our full year guidance. We feel good about the level of investment in innovation and continue to drive an active new product pipeline towards faster revenue growth opportunities as you could probably tell from John DeFord's update.
Interest expense was $11.2 million for the third quarter, no change from the prior year. Other income and expense was $258.3 million of expense for the third quarter as-reported and $1.8 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.9%, which is the same for the 9 months year-to-date, where we are down 50 basis points compared to the prior year, consistent with our original guidance. We do expect the renewal of the R&D tax credit before the end of the year, which would lower the rate in Q4.
Diluted shares on adjusted earnings for the period were $75.4 million, and we repurchased 767,000 shares during the third quarter. The net result is adjusted cash EPS for Q3 of $2.28, above the guidance range we provided for the quarter, driven by the higher sales.
The balance sheet as of September 30 reflects cash, restricted cash and short-term investments of $1.1 billion, no change from June 30. For the quarter, accounts receivable days were down 1.6 days and inventory days were down 3 days. Capital expenditures totaled $21.7 million for the quarter.
On the liability side, total debt was $1.4 billion as of September 30, no change from June 30. Debt to total cap at the end of the third quarter was about 49%, and total shareholder investment was $1.5 billion at September 30.
Now moving to financial guidance. At the beginning of this year, we guided organic revenue growth to be between 4% and 5% for the full year, and we're now expecting to be closer to 6.5%. That includes lapping the anniversary of the U.S. launch of Lutonix in Q4 of 2014, which included significant initial stocking orders. Excluding those initial stocking orders from last year, which we estimate represent about 1% of sales to the quarter, we project Q4 organic sales growth between 5% and 6%, with about 300 basis points of headwind from FX and an additional 200 basis points of headwind from other sales reductions on a reported basis. The biggest of these reductions relates to the pending acquisition of the Japanese joint venture, which would add about $40 million to operating revenue on an annual basis. However, the joint venture is holding inventory we have already recorded as sales to them. So we expect to have a negative impact to reported revenue in Q4 and Q1 until we work through that inventory.
We also, as we've discussed in prior calls, expect the sales of EP products to Boston Scientific to decline in Q4, as they have now started manufacturing some of those product lines themselves. So we are projecting the reported revenue to be flat to down 1% in Q4, even though the organic momentum in the business is expected to remain quite strong.
Now to update our expectations for adjusted cash EPS. Following our announcement of the acquisition of our Japanese JV, our latest forecast was $8.95 to $9.05 for the full year. Today, we are raising that guidance to be between $9.03 and $9.07. At the midpoint, this also represents a $0.05 increase to our original full year guidance provided in January despite absorbing approximately $0.15 of expected combined dilution from acquisitions and worsening FX during the year. Specific to Q4, this means we expect adjusted cash EPS to be between $2.38 and $2.42, which includes about $0.06 for the renewal of the R&D tax credit. This performance speaks to the strength of our execution in 2015. We've been able to increase investments in the business with the objective of sustaining above-market revenue growth while absorbing dilution along the way, and yet we still expect to increase the EPS delivered on the bottom line in 2015 above our initial expectation.
Thank you for your attention. I'll now turn you back to Tim."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now hand the call out to the moderator to facilitate the Q&A session. [Operator Instructions]",27,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now hand the call out to the moderator to facilitate the Q&A session. [Operator Instructions]"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] At this time, we go to our first question that will come from Bob Hopkins with Bank of America.",21,"[Operator Instructions] At this time, we go to our first question that will come from Bob Hopkins with Bank of America."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","So 2 things. One for Chris and one for Tim. First, Chris, I was just wondering if you could go over to some of the thoughts on Q4, especially as it relates to the EP business in Japan. So that 5% to 6% revenue growth, does that exclude those 2 things? And",76,"So 2 things. One for Chris and one for Tim. First, Chris, I was just wondering if you could go over to some of the thoughts on Q4, especially as it relates to the EP business in Japan. So that 5% to 6% revenue growth, does that exclude those 2 things? And can you just go into a little more detail on how those 2 things impact the guidance you've given on top and bottom line?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So what we're saying for Q4 organic, excluding the stocking impact from last year's Q4 is 5% to 6%. So about a point from Lutonix stocking last year gets you to 4% to 5% organic. There's been about 2% that relate specifically to the decline in Bosto",136,"Sure. So what we're saying for Q4 organic, excluding the stocking impact from last year's Q4 is 5% to 6%. So about a point from Lutonix stocking last year gets you to 4% to 5% organic. There's been about 2% that relate specifically to the decline in Boston sales expected in the quarter and the impact of lower sales into Japan results. I was expecting to close the acquisition in a couple of weeks here. So the combination of those and a flat Gore royalty reduced sales by 2%. So you get the constant currency, if you will, Bob, of 2% to 3% for the quarter. And then the FX impact, as we said, is going to reduce sales by 3%. So that then gets us to the negative 1% to 0% on a reported basis."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","All right. I'm sure there'll be some follow-up on that. But I wanted to ask one of Tim for my second question. So Tim, could you just give us your sense as to the broader utilization environment that you saw in the quarter? And if you wouldn't mind breaki",119,"All right. I'm sure there'll be some follow-up on that. But I wanted to ask one of Tim for my second question. So Tim, could you just give us your sense as to the broader utilization environment that you saw in the quarter? And if you wouldn't mind breaking it out by the U.S. and then separately, emerging markets. And I ask it that way because it looks like you guys are seeing really good growth in emerging markets. Some of the orthopedic players like J&J and Stryker have reported a slowdown in implant rates in Brazil and China. And I just wanted to get your -- again, your broader comments on utilization, broken down U.S. and emerging markets."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Again, Bob, I hesitate to call trends out on a quarter-to-quarter kind of a swing just because there's so much uncertainty going on all the time. But I would have to say that our utilization was pretty strong or our volume was strong everywhere. Ther",115,"Yes. Again, Bob, I hesitate to call trends out on a quarter-to-quarter kind of a swing just because there's so much uncertainty going on all the time. But I would have to say that our utilization was pretty strong or our volume was strong everywhere. There wasn't any weakness other than kind of the one that we've cited in Japan geographically and emerging markets remain very strong for us. We watch and hear and read what everybody else reports and we keep looking for that, both in the projections we get from the businesses and our actuals, but we just haven't seen it. So I would say similar to what we saw last quarter overall."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question on queue will come from Mike Weinstein with JPMorgan.",12,"The next question on queue will come from Mike Weinstein with JPMorgan."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, I think I need your help. I'm still struggling a little bit with the fourth quarter guidance as well. So first part of it is, so why is -- I understand Lutonix had stocking in the fourth quarter last year, but Lutonix revenues should year-over-year",119,"Chris, I think I need your help. I'm still struggling a little bit with the fourth quarter guidance as well. So first part of it is, so why is -- I understand Lutonix had stocking in the fourth quarter last year, but Lutonix revenues should year-over-year be up. Why are you describing this 100-basis-point headwind? And then second, just want to make sure I understand impact, both top line and on the gross margin of the Japanese joint venture buy-in in the fourth quarter. That almost 200-basis-point reduction you're saying is coming from Japan. Was there stocking of products into Japan over the last couple of quarters that would have benefited those quarters relative to kind of underlying trends?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Mike. I think when we think -- when we talk about Lutonix, we -- and we talked about Q2 and Q3 with sales to Boston, right, as Boston stepped up sales, and we talked about stocking in Q2 with Boston, we think we've actually seen some stocking in Q3",168,"Sure, Mike. I think when we think -- when we talk about Lutonix, we -- and we talked about Q2 and Q3 with sales to Boston, right, as Boston stepped up sales, and we talked about stocking in Q2 with Boston, we think we've actually seen some stocking in Q3 as well. We actually launched a couple of additional lengths in the quarter as well. So I think, certainly, as we look at Q4, as it relates to Boston's order pattern, we would certainly expect to see a sequential decline as they begin to now work through that initial inventory. So that's certainly impacting the overall growth rate for Lutonix as we look at Q4. We're seeing continued very strong organic growth in Lutonix. Relative to last Q4, though, we had a large stocking order in our own business, right? And so that's -- it's that lapping of that as well as the sequential sales into Boston that are just driving some of the sequential moves for Lutonix."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","How are you coming up within 100 basis point, just so we can understand what that is?",17,"How are you coming up within 100 basis point, just so we can understand what that is?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, that's our -- as we evaluated last year's Q4 sales of Lutonix, that's our estimate of what the stocking component of those sales were.",25,"Yes, that's our -- as we evaluated last year's Q4 sales of Lutonix, that's our estimate of what the stocking component of those sales were."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So you're basically taking out the stocking, but you're not giving yourselves credit for the underlying sales.",18,"Okay. So you're basically taking out the stocking, but you're not giving yourselves credit for the underlying sales."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we've not projected a number for Lutonix for Q4 in the analysis that Chris gave.",16,"Yes, we've not projected a number for Lutonix for Q4 in the analysis that Chris gave."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So you're giving yourself the penalty but not the benefit?",11,"Okay. So you're giving yourself the penalty but not the benefit?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. But I think the other sequential impact is sales -- our expected sales into Boston.",16,"Yes. But I think the other sequential impact is sales -- our expected sales into Boston."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Understood. Understood. Okay. I'm sorry. And then just the Japan piece, Chris?",12,"Understood. Understood. Okay. I'm sorry. And then just the Japan piece, Chris?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the only -- the impact there, it's about $11 million, Mike. And the way -- so last year, we would, in the ordinary course, be selling product into the JV, as they are obviously then selling out. They maintain levels of inventory that are similar to u",148,"Yes, the only -- the impact there, it's about $11 million, Mike. And the way -- so last year, we would, in the ordinary course, be selling product into the JV, as they are obviously then selling out. They maintain levels of inventory that are similar to us and similar to the sector. The sales that we make to them, once we close the transaction, we will not record until they're sold out the door. And so they're sitting on inventory today. We haven't closed the transaction. We've already recorded sales for, as they then sell those products out the door in November, December, we can't record the sale again. In the ordinary course, we'll continue to ship product to them, which is what we did last year. But there's a delay now as that inventory needs to get sold once we have full ownership of the JV."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","And my question, Chris, is that -- before distributors usually bought, they have an incentive to stock up on extra product. And I'm just making sure that the Japanese distributor wasn't buying in excess product to have as much on their shelf before the co",45,"And my question, Chris, is that -- before distributors usually bought, they have an incentive to stock up on extra product. And I'm just making sure that the Japanese distributor wasn't buying in excess product to have as much on their shelf before the conversion."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","No. To be very clear, nothing about the order patterns last year and the order patterns this year are different at all. So it's purely the mechanism that once we have ownership, right, we just have to wait for the inventory to clear before we record addit",48,"No. To be very clear, nothing about the order patterns last year and the order patterns this year are different at all. So it's purely the mechanism that once we have ownership, right, we just have to wait for the inventory to clear before we record additional sales."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question in queue will come from Brooks West with Piper Jaffray.",13,"The next question in queue will come from Brooks West with Piper Jaffray."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","One more just on that last topic. Chris, you said $11 million impact from Japan in Q4. You said there's going to be a little bit into Q1. What is the impact in Q1?",34,"One more just on that last topic. Chris, you said $11 million impact from Japan in Q4. You said there's going to be a little bit into Q1. What is the impact in Q1?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, it's about the same impact.",6,"Yes, it's about the same impact."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then the last part of that is just some declines in EP sales to Boston Scientific. Is that a surprise that, that's dropping off? Or was that part of the forecast? And again, could you quantify that?",39,"Okay. And then the last part of that is just some declines in EP sales to Boston Scientific. Is that a surprise that, that's dropping off? Or was that part of the forecast? And again, could you quantify that?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And actually, you go back to each quarter, we've actually talked about it, both coming into the year and then every quarter, because actually, what they did prior to this quarter, we actually were seeing growth in sales to them as they were act",130,"Yes, sure. And actually, you go back to each quarter, we've actually talked about it, both coming into the year and then every quarter, because actually, what they did prior to this quarter, we actually were seeing growth in sales to them as they were actually building the inventory in anticipation of the shift to self-manufacturing. We've taken those sales out of organic growth, obviously, the entire year. And so we talked about Q4 being the first big quarter where we would see step-down because they now have actually stood up the manufacturing plant in Costa Rica. So that impact in the quarter is round numbers, about $5 million. So between that and Japan, you're talking about $16 million, $17 million of negative impact as it compares to prior year."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then, I guess, one big picture for me, guys. It looks like now you're going to have the Gore royalty through '19 based on, I guess, the decision not to hear the case. You've executed well against the investment plan you laid out. I believe the o",107,"Okay. And then, I guess, one big picture for me, guys. It looks like now you're going to have the Gore royalty through '19 based on, I guess, the decision not to hear the case. You've executed well against the investment plan you laid out. I believe the only thing you haven't done is a big acquisition. So, I guess, 2-part question for Tim. How are you thinking about mitigating the falloff in the Gore royalty? And can you just update us on what you're seeing out in the market? And are you starting to get more aggressive given some of the declines and multiples we're seeing?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think it's a little early to comment specifically on 2019 right now. I can tell you, though, that, clearly, it's very visible in front of us. It's clearly a noble event for us. And we're obviously planning or what will become over time, obviously,",115,"Sure. I think it's a little early to comment specifically on 2019 right now. I can tell you, though, that, clearly, it's very visible in front of us. It's clearly a noble event for us. And we're obviously planning or what will become over time, obviously, that we've been planning and anticipating that. So that's the comment generally about the Gore royalties. And relative to our business development activity, we remain extremely active, going through a number of things in our, what we call, funnel, if you will. And I remain optimistic that, that landscape continues to look robust for us. And as we go ahead and close things, we'll announce them when they occur."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go to our next question in queue. That will come from David Roman with Goldman Sachs.",18,"We'll go to our next question in queue. That will come from David Roman with Goldman Sachs."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted us to come back to Lutonix and go into the utilization in a little bit more detail. Can you maybe talk to us about how you're seeing this being used in a real world setting? Because our understanding and feedback from TCT is that this is the tech",101,"I wanted us to come back to Lutonix and go into the utilization in a little bit more detail. Can you maybe talk to us about how you're seeing this being used in a real world setting? Because our understanding and feedback from TCT is that this is the technology that's getting used in a broad number of cases. And it's not so much proven to be a replacement for things like stent therapy or atherectomy, it's being more used as an adjunct. Can you maybe give us your perspective on that and how you're seeing the adoption curve roll out?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. John DeFord here. Let me talk a little bit about the utilization. I think what you heard at TCT is fairly consistent. We're beginning to see drug-coated balloons used as sort of an initial therapy, not necessarily the destination therapy, but an init",185,"Yes. John DeFord here. Let me talk a little bit about the utilization. I think what you heard at TCT is fairly consistent. We're beginning to see drug-coated balloons used as sort of an initial therapy, not necessarily the destination therapy, but an initial therapy. And then depending on the outcome of that initial therapy, making other decisions. Now obviously, atherectomy or things like that might come into play prior to using any kind of other technology. But by and large, we're seeing drug-coated balloons be used first. And then as you would expect, if there's provisional stenting required, then stents are used. If there are other technologies or other pieces needed, then they get included. So I don't think we ever expected DCB to replace some of these other technologies. But we are seeing it move exactly as we expected to be the first line of therapy. We think there's still a long way to go as far as growth and penetration. But this is -- it's still early days. But that's what we're seeing. I think that's fairly consistent with what you've heard."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then maybe just sort of a broader question as you think about the growth rate. 2015 has obviously proven to be a very strong period of organic growth for the company. And I think when you had laid out the investment plan earlier about -- in earl",110,"Okay. And then maybe just sort of a broader question as you think about the growth rate. 2015 has obviously proven to be a very strong period of organic growth for the company. And I think when you had laid out the investment plan earlier about -- in early 2013, this is the year you're envisioning growing above market growth. But maybe you can talk to us a little bit about where we are in the realization of the benefits from that investment plan and to what extent do you think the trends we've seen over the past 9 months and what you're guiding for the full year are sustainable."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, we haven't given guidance nor will we on this call for 2016. I think if you go back and look at what we said in 2013 is we expected to be above market revenue growth occurring about this point in time. And that our expectation, both with not on",94,"Yes. Well, we haven't given guidance nor will we on this call for 2016. I think if you go back and look at what we said in 2013 is we expected to be above market revenue growth occurring about this point in time. And that our expectation, both with not only the investments that we made then, but with the investments ongoing, is that, that would be sustainable. So that's what we said a few years ago, and that's kind of what the plan was. And we'll give you guidance for 2016 in January."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And maybe just again one other different way. So if you think about the momentum in the business that you're seeing today, is there any part of it you describe to macro-related factors that others can't [indiscernible] in their call versus Bard-rela",44,"Okay. And maybe just again one other different way. So if you think about the momentum in the business that you're seeing today, is there any part of it you describe to macro-related factors that others can't [indiscernible] in their call versus Bard-related factors?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","That's -- in any given quarter, and I -- obviously, I said earlier, we watch and listen to everybody. It's very difficult for any company, I don't care how big you are, to know if you gain share or loss share on, the markets increase or stay flat or decli",203,"That's -- in any given quarter, and I -- obviously, I said earlier, we watch and listen to everybody. It's very difficult for any company, I don't care how big you are, to know if you gain share or loss share on, the markets increase or stay flat or decline from quarter-to-quarter. I wouldn't say virtually impossible to know that over that short period of time. So we said in the past, it kind of felt like things were getting a little bit better. I think that some of the old metrics we used to use, like hospital admissions, especially when you're involved in procedures, maybe aren't the bellwether signs necessarily that they were a few years ago. So some of the dynamics, as you know, with health care, utilization, generally, are changing. So it's kind of difficult to say when you look at hospital admission metrics maybe going down, and yet our revenue continues to grow. What does all that mean? It's just very difficult to say. And we said earlier at the last call, it feels a little bit better. I would say that still holds true for this quarter. It's just hard to put any fine points on it."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think the only thing I'd add, Dave, and obviously, we track the sector, and when we look at organic growth rates across the sector, actually, over the last 4 or 5 quarters, they're frankly pretty flat sequentially. And obviously, we've moved higher",132,"Yes, I think the only thing I'd add, Dave, and obviously, we track the sector, and when we look at organic growth rates across the sector, actually, over the last 4 or 5 quarters, they're frankly pretty flat sequentially. And obviously, we've moved higher over that period of time. So at least the things that are growing for us in both emerging markets and in the product portfolio, and Lutonix being part of that, are related to things that we've invested in over the last couple of years. And so we haven't seen material moves stent [ph] point in volumes or utilization. And as we look at the sector, it certainly would appear to be that improvement in organic growth that we've experienced is directly related to the investments that we made."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question in queue will come from David Lewis with Morgan Stanley.",13,"Our next question in queue will come from David Lewis with Morgan Stanley."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just a quick follow-up on the Japanese distributor. So the EPS dilution that you had previously described, obviously, it appears like it's dropping through and full in the fourth quarter. Should we expect the same to hold true in '16, the full $0.2",58,"Chris, just a quick follow-up on the Japanese distributor. So the EPS dilution that you had previously described, obviously, it appears like it's dropping through and full in the fourth quarter. Should we expect the same to hold true in '16, the full $0.20 drop straight through? Or should we expect it to be offset in some way?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, certainly, it's a $0.20 whole, right? And it's purely related to the yen, just to be clear. So it's a whole. And obviously, we haven't given guidance, David, for 2016. But because of a transaction, we're facing much more significant yen head",121,"Yes, I think, certainly, it's a $0.20 whole, right? And it's purely related to the yen, just to be clear. So it's a whole. And obviously, we haven't given guidance, David, for 2016. But because of a transaction, we're facing much more significant yen headwind than we would have been otherwise. So obviously, as we roll up our budget and decide what we're ready to commit to for 2016, we are starting with a big yen headwind that we wouldn't have had. Now having said that, it's a very interesting strategic move for us, and we believe it will pay nice dividends long-term for the company. But it'll -- it's a headwind that we'll deal with as we go in 2016."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just as a follow-up, maybe quickly for Chris. Can you give us a sense of what that accretion or return looks like in '17 and beyond? And then, I guess, just for John DeFord. As it relates to Lutonix, I guess, if you give us a sense for, in the f",97,"Okay. And just as a follow-up, maybe quickly for Chris. Can you give us a sense of what that accretion or return looks like in '17 and beyond? And then, I guess, just for John DeFord. As it relates to Lutonix, I guess, if you give us a sense for, in the field, what do you think is resonating with clinicians more, the trial data or the registry data? And, I guess, more directly what I'm trying to get at is, would you expect any impact on your business based on the impact one results post TCT?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I won't be specific, David, but assuming the yen stays roughly where it is and we execute, which includes some interesting product launches for us into Japan, including LifeStent and Lutonix over time here, the business for us will return nicely accr",61,"Yes, I won't be specific, David, but assuming the yen stays roughly where it is and we execute, which includes some interesting product launches for us into Japan, including LifeStent and Lutonix over time here, the business for us will return nicely accretive beginning in '17 and beyond. But I'm not going to put a fine point on it for you."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. And then just jumping in to talk about the data. We think that clinicians are really interested in looking at both pivotal and randomized studies and registries. I think the Levant 2 study, as published in New England Journal of Medicine, is a very",294,"Okay. And then just jumping in to talk about the data. We think that clinicians are really interested in looking at both pivotal and randomized studies and registries. I think the Levant 2 study, as published in New England Journal of Medicine, is a very unique study design. Also, we've also found in that study that procedure really matters. And that was something that came out at panel, came out in some of the post discussions, that the way the device was used compared to PTA was different. And actually, in our study, the drug-coated balloon was used what you could call had a less effective treatment at the end of the procedure compared to PTA. Again, I think that is attributed to some of the results that we see in our randomized study. Certainly, I understand our competitor wanting to try to shift the discussion back to theirs. It's kind of interesting they haven't updated their registry data yet. But our registry data real world is in much -- more difficult patients than we saw in Levant 2. We think it's really demonstrating the real world usage of the technology. And of course, those clinicians were educated on the things that we've learned in the Levant 2 study on the importance of fully inflating the balloons, getting good expansion, appropriate access to the vessel and the lesion quickly and other things that were discussed by Dr. Schmidt [ph] at TCT. And so we think that these results are pretty indicative of real world usage based on that new knowledge. Now what clinicians are going to do? So far, I think it's resonated pretty well that drug-coated balloons work. And at least the 2 technologies on the market today seem to work pretty similarly."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","It will come from David Turkaly with JMP Securities.",9,"It will come from David Turkaly with JMP Securities."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Did you guys give the percentage at emerging markets was in the quarter?",13,"Did you guys give the percentage at emerging markets was in the quarter?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","It's about 9.5% of total sales, David. It's up about 120 basis points year-over-year. Very strong double-digit growth and, obviously, continuing to move in the right direction overall. There is some seasonality to the different geographies, but we had ano",57,"It's about 9.5% of total sales, David. It's up about 120 basis points year-over-year. Very strong double-digit growth and, obviously, continuing to move in the right direction overall. There is some seasonality to the different geographies, but we had another great quarter. And again, it's actually across all the geographies, just like we saw in Q2."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then, obviously, everyone's aware that you've hired a bunch of folks there. I was just curious, as you look at their productivity, now what will that look like versus some of your U.S. or European perhaps over time? And then how long do you thi",61,"Great. And then, obviously, everyone's aware that you've hired a bunch of folks there. I was just curious, as you look at their productivity, now what will that look like versus some of your U.S. or European perhaps over time? And then how long do you think it takes some of these guys to get fully ramped and up to speed?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I would say that we're delighted with the ground game of our team in emerging markets. We've been very aggressive in terms of adding to that field sales force around the world. And as we've talked continually, that sales force represents about 34% o",158,"Well, I would say that we're delighted with the ground game of our team in emerging markets. We've been very aggressive in terms of adding to that field sales force around the world. And as we've talked continually, that sales force represents about 34% of our reps around the world. It's the fastest area of investments for us in field sales reps, yet it only equals a little bit less than 10% of our sales. So we think we've made the right investments for the long term. We like the uptick that our people are giving us in the field, but as they get seasoned, it takes, on average, 9 months to 12 months for a person to really be productive no matter what geography that you're working in. And I would say that we're delighted with the execution and the ground game that our team is putting on, not only in emerging markets, but around the world."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question in queue, that will come from Kristen Stewart with Deutsche Bank.",14,"The next question in queue, that will come from Kristen Stewart with Deutsche Bank."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Anyway, I was just wondering if you could expand a little bit more. I think you had mentioned there was dealer stocking with Foley catheters because that seemed to be up quite a lot. I don't remember when they could -- basic drainage has been up, actually",85,"Anyway, I was just wondering if you could expand a little bit more. I think you had mentioned there was dealer stocking with Foley catheters because that seemed to be up quite a lot. I don't remember when they could -- basic drainage has been up, actually, like 6%, 7% in the U.S. So how big of a stocking or was there in the quarter? And will that just pull, I guess, from the fourth quarter? Or is that -- where did that shift from?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think -- and frankly, Kristen, we don't know for sure as we get additional tracing data. We're just -- we're speculating there was some in the quarter, and so we just wanted to caution you against it. It could possibly pull a bit from Q4, and that'",87,"Yes, I think -- and frankly, Kristen, we don't know for sure as we get additional tracing data. We're just -- we're speculating there was some in the quarter, and so we just wanted to caution you against it. It could possibly pull a bit from Q4, and that's certainly factored into our overall sales guidance. So I don't want to make too much of it. And we can't say for certain yet. And we'll know more in the coming weeks as we get additional tracing data."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd say in the grand scheme of things, it's a really small point for us across the board.",19,"I'd say in the grand scheme of things, it's a really small point for us across the board."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Right. And then, I guess, just in general, just in terms of, I guess, going back just to the M&A side, Tim, is there anything in terms of the landscape that you're seeing that makes you more or less likely to go often to any additional areas, whether it b",121,"Right. And then, I guess, just in general, just in terms of, I guess, going back just to the M&A side, Tim, is there anything in terms of the landscape that you're seeing that makes you more or less likely to go often to any additional areas, whether it be preference to do more smaller tuck-in deals for a product portfolio in the U.S.? Or are you seeing or thinking about doing more deals that might give you greater exposure into international markets at this point? Or do you feel comfortable with the investments that you made in emerging markets say that you have the right investments there and you're capable of growth given just the investments that you have already?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, in terms of our lenses and our filters, the answer is yes to all of the above. We're looking at everything. So relative to the landscape, we kind of like what we see. And in terms of what's out there, our filters or our hurdles have not changed",238,"Yes. Well, in terms of our lenses and our filters, the answer is yes to all of the above. We're looking at everything. So relative to the landscape, we kind of like what we see. And in terms of what's out there, our filters or our hurdles have not changed relative to our priorities. We don't start with the size as one of the first questions. In fact, probably, it's couple of reviews through [indiscernible] before I even start to focus on that. We're focused more on strategic intent. Some of the examples of things we've done over the last couple of years, I'm talking temperature management as one, Rochester, whatever, we're focused on revenue growth, because we think revenue growth provides a better shareholder return and slower revenue growth than grinding on earnings. So we look at revenue growth upside, sustainability of that. We actually look at each investment as, is it a platform to invest further in? Whether that be both with technology. And clearly, as we've given the size of the transactions we've done, they've had limited capabilities outside the United States, just from an expense affordability standpoint, and we already have that footprint. So we look at all of those things. But I'm optimistic about what the landscape looks like, and we'll see how many of those actually clear our filters. But we haven't changed our standards at all in the last several years."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I'd add, Kristen, obviously, we're focused on finding good targets internationally as well that fit all the same criteria. And frankly, within emerging markets, we've continued to struggle to find good targets that meet the criteria that we have. And",93,"Yes, I'd add, Kristen, obviously, we're focused on finding good targets internationally as well that fit all the same criteria. And frankly, within emerging markets, we've continued to struggle to find good targets that meet the criteria that we have. And so, obviously, we now have a really nice track record of executing organic growth-driven strategies in a lot of those markets. And so we'll continue to do that while we still look. But we're looking, to Tim's point, really, around the world for opportunities that are, first and foremost, product leadership opportunities."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","And the buying in of the JV over in Japan, was that just because of the pressure of selling in dollars and the JV just taking a hit with currency [indiscernible] or just benefits of going direct?",37,"And the buying in of the JV over in Japan, was that just because of the pressure of selling in dollars and the JV just taking a hit with currency [indiscernible] or just benefits of going direct?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, let me -- maybe a little background history here, just for those of you that may not know this. So if you go back into the '90s, we actually had a Bard Japan Limited business and Medicon has joint venture with Kobayashi that was primarily responsible",222,"Yes, let me -- maybe a little background history here, just for those of you that may not know this. So if you go back into the '90s, we actually had a Bard Japan Limited business and Medicon has joint venture with Kobayashi that was primarily responsible for our Urology product line. In 1998, we sold off the cardiology business as part of that transaction because of tax field. That entity in Japan went with this -- with that transactions. We had to make a decision back then, can we put the rest of Bard's products into the joint venture or do we start our own business there? That then we made the decision. We had a lot of confidence and faith in Medicon and, obviously, the fact that we just spot out [ph] the other halfway every -- more so now move the entire product line into that JV. Given the structure of the JV, as we've invested more heavily internally in R&D, new product launches, which require also clinical trials, it just put pressure on the business model in Japan. And strategically, it made all the sense in the world for us to own the thing in its entirety so that we can make all the investment decisions we need to make to grow the business over the long term."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","That makes sense. Okay. And last one, just because every other health care companies come out today, do you have an ownership stake in any pharmacy company? I'm just curious.",30,"That makes sense. Okay. And last one, just because every other health care companies come out today, do you have an ownership stake in any pharmacy company? I'm just curious."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","We do not.",3,"We do not."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Sorry, I can't resist.",4,"Sorry, I can't resist."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you for the question, Kristen.",6,"Thank you for the question, Kristen."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's probably not funny for a lot of people who have dealt with a lot of stocks today.",19,"It's probably not funny for a lot of people who have dealt with a lot of stocks today."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question in queue will come from Neil Chatterji with Cowen and Company.",14,"Our next question in queue will come from Neil Chatterji with Cowen and Company."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Neil on for Josh Jennings. So you've highlighted in the past Targeted Temperature Management and BioSurgery segments with significant market opportunity expansion, and those have seen double-digit growth. Can you give us some more color on how tho",54,"This is Neil on for Josh Jennings. So you've highlighted in the past Targeted Temperature Management and BioSurgery segments with significant market opportunity expansion, and those have seen double-digit growth. Can you give us some more color on how those lines are tracking relative to that and when you might see some significant ramp?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we've been seeing a significant ramp in those product lines since day 1 of the acquisitions. We've been taking share annually in both of those major product lines that we acquired. We really build out a very successful independent sales force pretty",86,"Well, we've been seeing a significant ramp in those product lines since day 1 of the acquisitions. We've been taking share annually in both of those major product lines that we acquired. We really build out a very successful independent sales force pretty large by U.S. standards in that business, and I think they're executing extremely well. So we have been growing substantially in that space. We would expect we will continue to. And we're always looking for opportunities to be adjunctive to those product launches."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, Neil, is that both of those opportunities play out over a number of years because there's a number of additional indications that our technologies are going to be effective with, both on the Targeted Temperature Management side as",104,"The only thing I'd add, Neil, is that both of those opportunities play out over a number of years because there's a number of additional indications that our technologies are going to be effective with, both on the Targeted Temperature Management side as well as within BioSurgery. So to Tim's point about having acquired platforms that have an investment opportunity beyond the initial product set that we acquired, we've got a long runway, we think, in both of those categories to grow them for many years. And, again, both of them are growing nicely in the double digits as we sit here today."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just 1 quick follow-up. So I believe you saw some softness in Europe earlier in the year, but then [indiscernible] recover in the second quarter and then even more so in the third quarter here. How are the reimbursement issues shaking out in Eur",49,"Okay. And just 1 quick follow-up. So I believe you saw some softness in Europe earlier in the year, but then [indiscernible] recover in the second quarter and then even more so in the third quarter here. How are the reimbursement issues shaking out in Europe, particularly in France?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me deal with the macro issue first. I think that's the important one. And that is that we did have a slow first quarter [indiscernible]. And I think as we predicted, we thought the year would pick up, and it certainly has. Our team over there is",100,"Well, let me deal with the macro issue first. I think that's the important one. And that is that we did have a slow first quarter [indiscernible]. And I think as we predicted, we thought the year would pick up, and it certainly has. Our team over there is executing extremely well. There is nothing from a major pricing standpoint going on in our business in Europe. And in fact, our Europe team was positive in price for the quarter. So we don't see a big issue right now looming in front of this in terms of reimbursement in France."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I would add, because I know there were some comments made perhaps by others in the market regarding specifically reimbursement for drug-coated balloons in Europe, and I would just tell you, that is a category reimbursement. That's kin",59,"The only other thing I would add, because I know there were some comments made perhaps by others in the market regarding specifically reimbursement for drug-coated balloons in Europe, and I would just tell you, that is a category reimbursement. That's kind of an individual brand reimbursement. We're working very hard to expand that as well throughout Europe. So..."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And then that's where the New England Journal of Medicine publication frankly helps. Having that kind of publication is required in certain geographies to help achieve reimbursement.",28,"And then that's where the New England Journal of Medicine publication frankly helps. Having that kind of publication is required in certain geographies to help achieve reimbursement."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Neil. Tony, we have crossed the top of the hour. We're going to take 2 more questions and then -- and I apologize to anyone in the queue after that.",31,"Thanks, Neil. Tony, we have crossed the top of the hour. We're going to take 2 more questions and then -- and I apologize to anyone in the queue after that."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll take that next question in from Matt Taylor with Barclays.",12,"We'll take that next question in from Matt Taylor with Barclays."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just had a follow-up on some of the Lutonix commentary. I guess, I just wanted to ask maybe more straightforwardly. If you could just talk about the underlying trends. And what you're seeing there is sequentially versus the stocking. There were a few st",111,"I just had a follow-up on some of the Lutonix commentary. I guess, I just wanted to ask maybe more straightforwardly. If you could just talk about the underlying trends. And what you're seeing there is sequentially versus the stocking. There were a few stocking comments. And then conceptually, the partnership with Boston Scientific has been interesting. Curious to know, if you look out longer-term, do you think that they're going to be selling a meaningful chunk of your overall Lutonix sales? If you could give us any sense of what the split would be there. And then is there any opportunity to expand that partnership into other product areas?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So I think, Matt, just the sequential kind of Q2, Q3, Q4, and the first thing I'd say is we need -- as we've said, it'll be nice to have this all settled out. But it's going to take a few quarters for this to settle out. So Boston ramped up in Q2, ce",196,"Yes. So I think, Matt, just the sequential kind of Q2, Q3, Q4, and the first thing I'd say is we need -- as we've said, it'll be nice to have this all settled out. But it's going to take a few quarters for this to settle out. So Boston ramped up in Q2, certainly had some stocking in Q2. As I said, we launched a couple of additional sizes in Q3, which drove, we think, some additional stocking in Q3. And so certainly, we would expect a sequential decline in Q4 for Boston as they begin to work through that initial stocking inventory. So when you then adjust for [indiscernible] stocking order last year in Q4, we're seeing really terrific, both sequential and year-over-year, growth in our base organic Lutonix business. And feel really good about our competitive position. And John DeFord talked about the real world registry data, which is, frankly, outstanding. So we'll need to get through these couple of quarters here and get to a steady state next year, where Boston's been in the business now with us for a while and we've been moved beyond our initial launch in the U.S."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I would say, to the longer-term issue on Boston, we think the strategy was sound that we entered into. Your question was, will they -- what kind of a position will they have with Lutonix? I mean, as we set out on this, Boston had the rights to sell the pr",138,"I would say, to the longer-term issue on Boston, we think the strategy was sound that we entered into. Your question was, will they -- what kind of a position will they have with Lutonix? I mean, as we set out on this, Boston had the rights to sell the product at a small subset of customers based on where they have good relationships or position in a certain therapy that we're not involved in. We have no plans to expand that to other product lines today or circumstances. I think this was a unique opportunity for us to be complementary with Boston in a small segment of customers, and I think that we like that positioning. But Bard will be responsible for the greatest majority of sales and the greatest majority of customers, obviously, around the world."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And then 1 follow-up on Lutonix. I guess, broadly, just from the good data, both out of your registry and the Medtronic data from TCT, do you expect that or any other clinical or, I guess, market expansion catalysts to change the gro",67,"Okay. That's helpful. And then 1 follow-up on Lutonix. I guess, broadly, just from the good data, both out of your registry and the Medtronic data from TCT, do you expect that or any other clinical or, I guess, market expansion catalysts to change the growth rate in the near term of the market or you think we're just going to kind of see continued good growth?"
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I'll jump in here. I think we expect continued good growth, but we also think that additional indications are really important. So we talked about the studies, the AV access study, Below the Knee, in-stent restenosis, other indications we think are",61,"Well, I'll jump in here. I think we expect continued good growth, but we also think that additional indications are really important. So we talked about the studies, the AV access study, Below the Knee, in-stent restenosis, other indications we think are additional catalysts for growth. So we're strictly and specifically focused on those areas, and we'll continue to be so."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from Anthony Petrone with Jefferies.",10,"Our next question will come from Anthony Petrone with Jefferies."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","One on Lutonix. Just wondering if you can provide an update on utilization per case, how many balloons are actually used per case. And then one is a broader question. Community health reported lower revenue per admission today, and that was from lower neg",77,"One on Lutonix. Just wondering if you can provide an update on utilization per case, how many balloons are actually used per case. And then one is a broader question. Community health reported lower revenue per admission today, and that was from lower negotiated rates from Medicare. And then in addition, we're seeing consolidation of private managed care companies. I'm just wondering how you think this plays out ultimately in price for medical device companies over time."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I'm happy to jump in on the Lutonix side. I could tell you that I'm not sure we have specific data to share on number of devices used per case just because we don't really have insight into that. Unless we happen to have somebody standing in the roo",84,"Well, I'm happy to jump in on the Lutonix side. I could tell you that I'm not sure we have specific data to share on number of devices used per case just because we don't really have insight into that. Unless we happen to have somebody standing in the room, we wouldn't necessarily know. I can tell you by the lesion lengths that we see, we'd expect this sort of be in that 1.3 to 1.5 devices potentially per case kind of averaged out."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Relative to the pricing scenario with consolidation [indiscernible], it's a very dynamic environment going on right now. Pricing pressure has always been on us and other companies in the space. I think, specifically, as you -- I think the pricing dynamic",103,"Relative to the pricing scenario with consolidation [indiscernible], it's a very dynamic environment going on right now. Pricing pressure has always been on us and other companies in the space. I think, specifically, as you -- I think the pricing dynamic is taking on a little bit larger or made a little bit of a larger impression in the investment community, mainly because of some of the biotech and the pharma pricing issues that have been in the media recently. A very large percentage, I think it's 50% of our revenue, has some ASP of less than $500, probably close to $400. So..."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","75% of our revenue, actually. So we're not exactly on the high end of the radar screen here when they get to that. Nonetheless, the procedures, they're under pressure. And what we're trying to do is demonstrate the value and the quality and the outcomes a",76,"75% of our revenue, actually. So we're not exactly on the high end of the radar screen here when they get to that. Nonetheless, the procedures, they're under pressure. And what we're trying to do is demonstrate the value and the quality and the outcomes and doing that with data, which we're getting a lot of traction and uptake from our customers as they move more to in the U.S. and ACO kind of organization structure."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think that the -- that those data sets are certainly very helpful in driving reimbursement, and I'd evidence to full reimbursement for Lutonix as a result of that value analysis that we work with CMS on.",38,"And I think that the -- that those data sets are certainly very helpful in driving reimbursement, and I'd evidence to full reimbursement for Lutonix as a result of that value analysis that we work with CMS on."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","And ladies and gentlemen, this does conclude our Q&A session. I would now like to turn the call back over to Bard's management for closing or additional comments.",28,"And ladies and gentlemen, this does conclude our Q&A session. I would now like to turn the call back over to Bard's management for closing or additional comments."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much. And I'd like to thank all of you for joining us today. And also, I'll close by thanking Bard employees globally for a strong year of execution so far. So we'll update you again on our progress in January. Thanks, everybody.",45,"Thank you very much. And I'd like to thank all of you for joining us today. And also, I'll close by thanking Bard employees globally for a strong year of execution so far. So we'll update you again on our progress in January. Thanks, everybody."
254131,312630689,880610,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference call for today. We do thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect.",31,"Thank you. And ladies and gentlemen, that does conclude our conference call for today. We do thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Ladies and gentlemen, thank you for standing by. And welcome to the C.R. Bard, Inc. Third Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-dema",276,"Ladies and gentlemen, thank you for standing by. And welcome to the C.R. Bard, Inc. Third Quarter 2015 Earnings Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for future on-demand replay through the Bard website.
Today's presentation will be hosted by Timothy M. Ring, Chairman and Chief Executive Officer; along with John H. Weiland, President and Chief Operating Officer; Christopher S. Holland, Senior Vice President and Chief Financial Officer; and John A. DeFord, Senior Vice President, Science, Technology and Clinical Affairs. Also in attendance today is Todd W. Garner, Vice President, Investor Relations.
Today, Bard's management will discuss some forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Please refer to the cautionary statement regarding forward-looking information in Bard's June 30, 2015, Form 10-Q, and the information under the caption Risk Factors in Bard's 2014 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.
During the call, references will be made to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product franchises. Reconciliations of non-GAAP measures to the most comparable GAAP measures are provided in Bard's earnings press release and on the company's website at www.crbard.com. All information that is not historical is given only as of October 22, 2015, and the company undertakes no responsibility to update any information, unless otherwise noted. All comparisons are to the prior year period.
At this time, I will turn the call over to Mr. Timothy Ring. Please go ahead."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you. And I'd like to welcome everyone to Bard's Third Quarter 2015 Earnings Call, and thank all of you for taking the time to join with us today. We expect the presentation portion of the call to last about 30 minutes and the total call to last abou",621,"Thank you. And I'd like to welcome everyone to Bard's Third Quarter 2015 Earnings Call, and thank all of you for taking the time to join with us today. We expect the presentation portion of the call to last about 30 minutes and the total call to last about an hour. The agenda today will be as follows: I'll begin with an overview of the results for the quarter; John Weiland, our President and COO, will review third quarter product line revenue; John DeFord, our Senior VP of Science, Technology and Clinical Affairs, will give you an update on our product development pipeline; and Chris Holland, our Senior VP and CFO, will review the third quarter income statement, balance sheet as well as our expectations for the fourth quarter. And then finally, we'll close with Q&A.
Third quarter 2015 net sales totaled $865.7 million. That's up 4% over Q3 of last year on an as-reported basis and up 8% on a constant currency basis. The currency impact for the quarter versus the same quarter last year was unfavorable, about 370 basis points. Excluding the Gore royalty of $38.4 million and sales related to recent acquisitions and divestitures, our organic growth rate was approximately 8.3% for the quarter. That's above our expectations. The U.S. sales of the Lutonix drug-coated balloon contributed a little less than 300 basis points of growth in Q3.
Net loss for the quarter of 2015 was $86 million and diluted loss per share was $1.16. Excluding these items that affected the comparability of results between periods, which Chris will cover later, third quarter 2015 net income was $154.5 million and diluted earnings per share, which excludes amortization of intangibles, were $2.28. That's up 4% and 6%, respectively.
Looking at revenue growth geographically, compared to the same quarter last year, third quarter net sales in the U.S. were up 7%. Internationally, we grew 10% on a constant currency basis, with Europe growing 7%, Japan declining 1% and our other international businesses growing 18% this quarter. Strong quarter in Europe was driven by Endovascular, radiology and PICCs, and the slight decline in Japan was due to inventory fluctuations at our joint venture.
You may have noticed a few weeks ago, we announced the acquisition of the remaining 50% ownership of our Japanese joint venture. We expect this transaction to be completed in the coming weeks. While it comes with some near-term dilution driven by exchange, we believe this is strategically important for us. Increased investment for market development and clinical trials in Japan was difficult with the structure of the joint venture when you combine that with foreign exchange pressure. So we decided this was a timely opportunity to take full ownership and advance our product leadership strategy in the world's third-largest health care market.
Our emerging markets business continues to grow in the healthy double digits, following our significant investments there over the last couple of years. So as we look at our overall results for the quarter and the first 9 months of 2015, we said at the beginning of the year that it was an important year of execution for us. And so far, we're pleased with the results. As we projected at the announcement of our strategic investment plan nearly 3 years ago now, we are back at the top end of the sector from a revenue growth perspective, and we remain convinced that above-market revenue growth is a key to a premium multiple. We remain focused on making investments in areas of faster growth in a profitable manner to enhance shareholder value over the long term.
So with that, let me turn you over to John Weiland for a review of our product line revenue."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted.So let's begin with Vascular. Growth in this category",874,"Good afternoon, everyone. Before I start, let me point out that I will be giving all percentage growth data in comparison to the prior year period on a constant currency basis, unless otherwise noted.
So let's begin with Vascular. Growth in this category was 13% for the quarter, or 8% as-reported, with total net sales of $250.5 million. Excluding the Gore royalty and the divested EP sales, total Vascular grew -- sales grew 16% globally, with the United States business up 18% and the international business growing 14% in the quarter.
Sales in our Surgical Graft category were up 4% in Q3. Excluding the Gore royalty, our Endovascular business increased 18% in the third quarter. Within Endovascular, our biopsy products had another strong quarter with 14% growth, with nice performance in the United States and even better performance outside of the United States.
Sales in our peripheral PTA line increased 48%, driven by global sales of our Lutonix drug-coated balloon. We are very pleased with the performance of this important product, which anniversary-ed its FDA approval and the U.S. launch on October 10. It has been a good first 12 months in the United States, and we're pleased with the results from our real-world registry study. John DeFord will tell you more about this in a few minutes.
As we seek to expand the indications and reach of this compelling technology platform, we expect to see long-term global growth from Lutonix. Our Stent business declined 3% again this quarter, consistent with recent experience. And finally, net sales in our Vena Cava Filter line declined 3% in Q3.
So let's go to Urology. Total net sales were $212.3 million, up 5% versus Q3 of last year on a constant currency basis and 1% on an as-reported basis. The United States business grew 5% while internationally, we grew 4%. Our Targeted Temperature Management products grew in the healthy double digits again this quarter. Our basic drainage business was up 6% globally in Q3, with the United States business up 7%. Our I.C. Foley business was up 3% globally and up 1% in the United States. We believe that Foleys this quarter benefited from some dealer stocking, but we don't know the precise impact. So we've been cautioned against reading too much into these improved growth rates in a single quarter.
Our continence business decreased 3% in the third quarter. Sales in urological specialties grew 1% with our brachytherapy business down 1%. And finally, in this category, standalone sales of our StatLock catheter stabilization product line declined 4% in Q3.
Now let's go to Oncology. Total net sales in this category were $239.3 million, an increase of 8% on a constant currency basis and 4% on an as-reported basis over the third quarter last year. Geographically, net sales in the United States were up 5% and international sales were up 15%. Our port business decreased 1% this quarter due to the price reductions in the United States that we talked about at the beginning of the year. Our PICC revenue was up 13% in the third quarter, including strong results in the United States, Europe and emerging markets again this quarter. We're very pleased with the clinical adoption of our advanced technology, which helps patients and can save time and cost for the hospital.
Despite the competitive noise on single features here and there, we believe that the quality and performance of our broad product offering is why we continue to grow faster than the market. And as the competition tries to catch up to our older products, we continue to advance the technology and solve unmet needs for our customers and our patients. John DeFord will tell you more about this.
Our vascular access ultrasound product line was up 1% this quarter. The growth rates for this system can be a little lumpy around new product launches, and that's what we're seeing due to the Vision II launch in the prior year and the pending Site-Rite 8 launch later this year. And to complete Oncology, our Dialysis Access product line was up 12% over Q3 of last year.
So let's conclude with our Surgical Specialties business. Total net sales in this category were $139.8 million, up 6% on a constant currency basis and up 3% as-reported. United States sales were up 6% and international sales grew 4% this quarter. Two years after the acquisition of the Arista Hemostat and 3 years after the acquisition of the Progel sealant technology, our combined biosurgical product portfolio continues to grow double digits.
Our soft tissue repair business grew 7% in Q3, with our synthetic ventral hernia repair products growing 6%, while our natural tissue products grew 14%, driven by our new XenMatrix AB coated porcine mesh. Our hernia fixation business grew 2% this quarter, which was the first quarter in positive territory since the second quarter of 2011. We are hopeful that our new product launches here can reverse the trend of declines in recent years.
In closing out the surgical category, our performance irrigation business was down 20% in Q3. As we told you, we discontinued some products earlier in the year.
This concludes our product line revenue discussion, and now I'll turn you over to John DeFord."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, John, and good afternoon -- or maybe it's evening for everyone. Thanks for taking time to join us today. For the sake of time, I'll jump right into some highlights, starting with drug-coated balloons. About 2 weeks ago at TCT, we released full 12-",1197,"Thanks, John, and good afternoon -- or maybe it's evening for everyone. Thanks for taking time to join us today. For the sake of time, I'll jump right into some highlights, starting with drug-coated balloons. About 2 weeks ago at TCT, we released full 12-month results from our almost 700-patient global SFA and popliteal registry. Lesion lengths were over 100 millimeters. About half the patients had significant calcification and over 30% of the lesions treated were chronic total occlusions. The study found over 94% of patients were free from TLR through the 12-month follow-up, with primary patency in almost 90% of patients. Interim 24-month results demonstrated 93% freedom from TLR and primary patency in excess of 80%. We believe the learnings from the Levant 2 study on keys to a successful procedure are working their way into real-world practice, and we're very pleased with the results.
In our Below the Knee IDE, enrollment continues, though recruitment remains slower than planned due to the complex nature of these patients and their disease. We're working with FDA to find ways to speed up enrollment and analysis in this important study. At current recruitment weight -- rates, we like -- we'll likely continue to enroll patients through much of 2016, putting PMA submission in the second half of 2017.
On the other hand, our AV access DCB IDE study that began enrollment last quarter is recruiting very quickly, and we anticipate enrollment could be complete as early as Q1 of 2016, which could put PMA submission ahead of schedule in the first half of 2017. The in-stent restenosis IDE study is ongoing, and we're currently planning a second half 2016 PMA submission, seeking this expanded indication. We have a host of other DCB studies ongoing or in start-up around the world, and we plan to begin enrollment in our Levant China study in Q1 of 2016.
Also in Vascular, the LifeStream Balloon Expandable Covered Stent IDE completed enrollment in Q3. This clinical study is evaluating the technology for the treatment of iliac artery disease with a 9-month follow-up. We anticipate PMA submission in the second half of 2016.
Our COVERA next-generation stent graft, designed for use in the AV access circuit, is planned for launch in Europe this quarter, and we're working with FDA to commence our U.S. IDE study in the first half of 2016. Our new de-novo [ph]  Venous stent recently gained a CE mark. As with COVERA, we're working closely with FDA to initiate an IDE study seeking U.S. approval, with enrollment planned to begin in the first half of next year.
Next, moving to Urology and home care, we're pleased to announce the release of the new Magic3 Go self-lubricated catheter for female patients. This product's designed for enhanced comfort and ease-of-use for patients that often have limited dexterity. We plan to roll out this product selectively during Q4 as we ramp manufacturing. We also anticipate the launch of our Magic3 touchless catheter in early 2016. Both of these products employ our latest silicone technology designed to enhance patient use and comfort.
We've got some other impactful products in this portfolio for launch later in 2016. But I'll hold off sharing the details until we get closer to those launches.
Now moving to Oncology. The new Site-Rite 8 ultrasound system with integrated 3CG Diamond is rolling out in Europe. The Site-Rite 8 with Pinpoint GT and 3CG Diamond is on track for U.S. launch in Q4, as John alluded to. We believe the combination of ultrasound, needle guidance and catheter tip confirmation in an integrated system will provide a full-featured, user-friendly and intuitive solution for vascular catheter placement.
In PICCs, we've submitted the 510(k) and await FDA clearance to launch a new and proprietary catheter family. These PICCs have been designed to resist common chemicals used in chemotherapy solutions as well as cleaning and disinfection agents. While these solutions are known to degrade standard PICC materials, this new catheter can maintain the same high-performance standards available in our current PICCs, even after long-term exposure. We're also expanding our development efforts toward technologies we believe can further reduce the risk of thrombosis.
While we prefer to keep our development plans confidential, I will say we have a new product family under development that's based on a new high-performance material. We expect to begin launching products using this new material in the back half of next year. Our current plans also anticipate commencement of studies to provide further clinical evidence to support the benefits of these new designs.
In concert with these efforts, we've also recently launched a training program and some associated products designed to reduce infections and promote the safe and effective use of our PICCs. With this change in near-term focus, we've reduced the priority we placed on our antimicrobial and thrombo-resistant coating technologies. The developments are ongoing, but we don't believe they'll have a major revenue contribution compared to these other opportunities.
For the difficult stick IV catheter patients, we announced on the last call the acquisition of the AccuCath guide wire-assisted PIV products. We've taken that technology into our development engine and anticipate the launch of an improved family of AccuCath products in the first half of 2016. These products are anticipated to launch alongside our new midline catheter, the PowerGlide Pro, also planned for launch in that same time period. We believe the combination of our PICCs, the PowerGlide midline family and AccuCath IV product line will help us bring important guide wire-assisted devices to a broad spectrum of patients with Vascular Access needs.
Lastly, for the acute hemodialysis patient, we're expanding our family of catheters with the expected launch of a new dual lumen power Xenesys [ph] catheter in Q1 of next year. Xenesys [ph] is designed for superior flexibility and kink resistance, along with flow rates in excess of 400 ml per minute in a small 11 per inch catheter configuration.
I'll close my portion of the discussion today with surgery. Just a few weeks ago, we launched our new Phasix ST resorbable synthetic mesh. This launch adds another differentiated product to our complex abdominal wall portfolio that includes XenMatrix, XenMatrix AB and the Phasix mesh technology. We're continuing our efforts to expand our product offerings based on the Phasix platform, and we expect to begin launching those new products over the next several quarters. We're also making good progress on our development of additional sizes of our one-of-a-kind antibiotic-coated XenMatrix AB family, with launches expected throughout 2016 and into 2017. In our BioSurgery product offering, on our last call, I told you we'd filed our PMA supplement, seeking approval of our new TRIDYNE vascular sealant. And we continue to anticipate approval and launch in the back half of next year.
And finally, in mesh fixation, we recently launched both the OPTIFIX spring-loaded resorbable tack device and the Capsure permanent fixation product. We're working to build upon that momentum through the launch of 2 additional fixation devices. But due to the competitive nature of this market, I'll hold back the details for a later call.
Thanks for your time and attention tonight. Let me now hand you over to Chris."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you, John. Let's start with the items that affect the comparability of our results between periods.In Q3, we had acquisition-related items of $2.5 million and a $14.6 million charge for restructuring and productivity initiatives. This quarter, we",1136,"Thank you, John. Let's start with the items that affect the comparability of our results between periods.
In Q3, we had acquisition-related items of $2.5 million and a $14.6 million charge for restructuring and productivity initiatives. This quarter, we had made significant additional progress in settlement activity related to our women's health product liability. Driven by this settlement progress and additional information learned from it as well as recent activity in other product liability matters, we took an additional combined charge of $241.1 million this quarter. The P&L impact for these items is detailed in the notes to the financial statements and the reconciliation accompanying our Q3 earnings press release.
Now let's go through the statement of income for the quarter. Gross profit was $529.4 million or 61.2% of sales for Q3. On an adjusted basis, gross profit was $530.3 million or 61.3% of sales, a little better than we projected and down 120 basis points from the prior year. New amortization of intangibles relating to transactions closed in the last 12 months was about 50 basis points this quarter, and foreign exchange drove approximately 30 basis points of headwind for us in Q3. 
Price was unfavorable by 90 basis points on the revenue line and approximately 30 basis points in gross profit, and our mix was favorable by about 40 basis points this quarter. As we forecasted last quarter, the manufacturing variances in our plants from year-to-year can be a little lumpy, and Q3 is an example of that. In Q2, cost savings drove 90 basis points of improvement; but in Q3, it was 50 basis points negative. In Q4 -- we look for Q4 to look more like Q2 with strong favorability. So we expect gross profit in Q4 on an adjusted basis to be a meaningful improvement over Q3 and back to the Q4 2014 level or maybe even a little bit better, which would put us near the high end of the original guidance we gave you for gross margins for the full year. So it's been a year of solid organic improvement for us on the gross margin line.
SG&A expenses were $247.1 million for the quarter or 28.5% of sales. On an adjusted basis, SG&A was also 28.5% of sales, down 60 basis points from Q3 of last year. I'll remind you that we typically see an uptick in SG&A as a percent of sales in Q4 sequentially, but we expect to still see good leverage compared to the prior year and expect to be within our full year guidance for 2015.
R&D expenditures totaled $65.2 million or 7.5% of sales on a reported basis for the third quarter, which was the same on an adjusted basis, down 40 basis points from the prior year and right on our full year guidance. We feel good about the level of investment in innovation and continue to drive an active new product pipeline towards faster revenue growth opportunities as you could probably tell from John DeFord's update.
Interest expense was $11.2 million for the third quarter, no change from the prior year. Other income and expense was $258.3 million of expense for the third quarter as-reported and $1.8 million of expense on an adjusted basis. The effective tax rate for the quarter was 24.9%, which is the same for the 9 months year-to-date, where we are down 50 basis points compared to the prior year, consistent with our original guidance. We do expect the renewal of the R&D tax credit before the end of the year, which would lower the rate in Q4.
Diluted shares on adjusted earnings for the period were $75.4 million, and we repurchased 767,000 shares during the third quarter. The net result is adjusted cash EPS for Q3 of $2.28, above the guidance range we provided for the quarter, driven by the higher sales.
The balance sheet as of September 30 reflects cash, restricted cash and short-term investments of $1.1 billion, no change from June 30. For the quarter, accounts receivable days were down 1.6 days and inventory days were down 3 days. Capital expenditures totaled $21.7 million for the quarter.
On the liability side, total debt was $1.4 billion as of September 30, no change from June 30. Debt to total cap at the end of the third quarter was about 49%, and total shareholder investment was $1.5 billion at September 30.
Now moving to financial guidance. At the beginning of this year, we guided organic revenue growth to be between 4% and 5% for the full year, and we're now expecting to be closer to 6.5%. That includes lapping the anniversary of the U.S. launch of Lutonix in Q4 of 2014, which included significant initial stocking orders. Excluding those initial stocking orders from last year, which we estimate represent about 1% of sales to the quarter, we project Q4 organic sales growth between 5% and 6%, with about 300 basis points of headwind from FX and an additional 200 basis points of headwind from other sales reductions on a reported basis. The biggest of these reductions relates to the pending acquisition of the Japanese joint venture, which would add about $40 million to operating revenue on an annual basis. However, the joint venture is holding inventory we have already recorded as sales to them. So we expect to have a negative impact to reported revenue in Q4 and Q1 until we work through that inventory.
We also, as we've discussed in prior calls, expect the sales of EP products to Boston Scientific to decline in Q4, as they have now started manufacturing some of those product lines themselves. So we are projecting reported revenue to be flat to down 1% in Q4, even though the organic momentum in the business is expected to remain quite strong.
Now to update our expectations for adjusted cash EPS. Following our announcement of the acquisition of our Japanese JV, our latest forecast was $8.95 to $9.05 for the full year. Today, we are raising that guidance to be between $9.03 and $9.07. At the midpoint, this also represents a $0.05 increase to our original full year guidance provided in January despite absorbing approximately $0.15 of expected combined dilution from acquisitions and worsening FX during the year. Specific to Q4, this means we expect adjusted cash EPS to be between $2.38 and $2.42, which includes about $0.06 for the renewal of the R&D tax credit. This performance speaks to the strength of our execution in 2015. We've been able to increase investments in the business with the objective of sustaining above-market revenue growth while absorbing dilution along the way, and yet we still expect to increase the EPS delivered on the bottom line in 2015 above our initial expectation.
Thank you for your attention. I'll now turn you back to Tim."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Chris. That does conclude the formal part of the presentation. I'll now hand the call out to the moderator to facilitate the Q&A session. [Operator Instructions]",27,"Thanks, Chris. That does conclude the formal part of the presentation. I'll now hand the call out to the moderator to facilitate the Q&A session. [Operator Instructions]"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","[Operator Instructions] At this time, we go to our first question. That will come from Bob Hopkins with Bank of America.",21,"[Operator Instructions] At this time, we go to our first question. That will come from Bob Hopkins with Bank of America."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","So 2 things. One for Chris and one for Tim. First, Chris, I was just wondering if you could go over some of the thoughts on Q4, especially as it relates to the EP business and Japan. So that 5% to 6% revenue growth, does that exclude those 2 things? And c",75,"So 2 things. One for Chris and one for Tim. First, Chris, I was just wondering if you could go over some of the thoughts on Q4, especially as it relates to the EP business and Japan. So that 5% to 6% revenue growth, does that exclude those 2 things? And can you just go into a little more detail on how those 2 things impact the guidance you've given on top and bottom line?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. So what we're saying for Q4 organic, excluding the stocking impact from last year's Q4, is 5% to 6%. So about a point from Lutonix stocking last year gets you to 4% to 5% organic. There's been about 2% that relates specifically to the decline in Bos",138,"Sure. So what we're saying for Q4 organic, excluding the stocking impact from last year's Q4, is 5% to 6%. So about a point from Lutonix stocking last year gets you to 4% to 5% organic. There's been about 2% that relates specifically to the decline in Boston sales expected in the quarter and the impact of lower sales into Japan -- a result of us expecting to close the acquisition in a couple of weeks here. So the combination of those and a flat Gore royalty reduced sales by 2%. So you get the constant currency, if you will, Bob, of 2% to 3% for the quarter. And then the FX impact, as we said, is going to reduce sales by 3%. So that then gets us to the negative 1% to 0% on a reported basis."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","All right. I'm sure there'll be some follow-up on that. But I wanted to ask one of Tim for my second question. So Tim, could you just give us your sense as to the broader utilization environment that you saw in the quarter? And if you wouldn't mind breaki",119,"All right. I'm sure there'll be some follow-up on that. But I wanted to ask one of Tim for my second question. So Tim, could you just give us your sense as to the broader utilization environment that you saw in the quarter? And if you wouldn't mind breaking it out by the U.S. and then separately, emerging markets? And I ask it that way because it looks like you guys are seeing really good growth in emerging markets. Some of the orthopedic players like J&J and Stryker have reported a slowdown in implant rates in Brazil and China. And I just wanted to get your -- again, your broader comments on utilization, broken down U.S. and emerging markets."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Again, Bob, I hesitate to call trends out of a quarter-to-quarter kind of a swing, just because there's so much uncertainty going on all the time. But I would have to say that our utilization was pretty strong, and our volume was strong everywhere. T",115,"Yes. Again, Bob, I hesitate to call trends out of a quarter-to-quarter kind of a swing, just because there's so much uncertainty going on all the time. But I would have to say that our utilization was pretty strong, and our volume was strong everywhere. There wasn't any weakness other than kind of the one that we've cited in Japan geographically. And emerging markets remain very strong for us. We watch and hear and read what everybody else reports, and we keep looking for that, both in the projections we get from the businesses and our actuals, but we just haven't seen it. So I would say similar to what we saw last quarter overall."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question on queue will come from Mike Weinstein with JPMorgan.",12,"The next question on queue will come from Mike Weinstein with JPMorgan."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, I think I need your help. I'm still struggling a little bit with the fourth quarter guidance as well. So first part of it is, so why is -- I understand Lutonix had stocking in the fourth quarter last year, but Lutonix revenues should year-over-year",121,"Chris, I think I need your help. I'm still struggling a little bit with the fourth quarter guidance as well. So first part of it is, so why is -- I understand Lutonix had stocking in the fourth quarter last year, but Lutonix revenues should year-over-year be up. Why are you describing it as a 100-basis-point headwind? 
And then second, just want to make sure I understand impact, both top line and on the gross margin of the Japanese joint venture buy-in in the fourth quarter. That almost 200-basis-point reduction you're saying is coming from Japan. Was there stocking of products into Japan over the last couple of quarters that would have benefited those quarters relative to kind of underlying trends?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure, Mike. I think when we think -- when we talk about Lutonix, we -- and we talked about Q2 and Q3 with sales to Boston, right, as Boston stepped up sales. And we talked about stocking in Q2 with Boston. We think we've actually seen some stocking in Q3",168,"Sure, Mike. I think when we think -- when we talk about Lutonix, we -- and we talked about Q2 and Q3 with sales to Boston, right, as Boston stepped up sales. And we talked about stocking in Q2 with Boston. We think we've actually seen some stocking in Q3 as well. We actually launched a couple of additional lengths in the quarter as well. So I think, certainly, as we look at Q4, as it relates to Boston's order pattern, we would certainly expect to see a sequential decline as they begin to now work through that initial inventory. So that's certainly impacting the overall growth rate for Lutonix as we look at Q4. We're seeing continued very strong organic growth in Lutonix. Relative to last Q4, though, we had a large stocking order in our own business, right? And so that's -- it's that lapping of that as well as the sequential sales into Boston that are just driving some of the sequential moves for Lutonix."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","How are you coming up within 100 basis point? Just so we can understand what that is.",17,"How are you coming up within 100 basis point? Just so we can understand what that is."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, that's our -- as we evaluated last year's Q4 sales of Lutonix, that's our estimate of what the stocking component of those sales were.",25,"Yes, that's our -- as we evaluated last year's Q4 sales of Lutonix, that's our estimate of what the stocking component of those sales were."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So you're basically taking out the stocking, but you're not giving yourselves credit for the underlying sales?",18,"Okay. So you're basically taking out the stocking, but you're not giving yourselves credit for the underlying sales?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, we've not projected a number for Lutonix for Q4 in the analysis that Chris gave.",16,"Yes, we've not projected a number for Lutonix for Q4 in the analysis that Chris gave."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. So you're not giving -- you're giving yourselves the penalty but not the benefit?",15,"Okay. So you're not giving -- you're giving yourselves the penalty but not the benefit?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. But I think the other sequential impact is sales -- our expected sales into Boston.",16,"Yes. But I think the other sequential impact is sales -- our expected sales into Boston."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Understood. Understood. Okay. I'm sorry. And then just the Japan piece, Chris?",12,"Understood. Understood. Okay. I'm sorry. And then just the Japan piece, Chris?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, the only -- the impact there, and it's about $11 million, Mike. And the way -- so last year, we would, in the ordinary course, be selling product into the JV, as they are obviously then selling out. They maintain levels of inventory that are similar",151,"Yes, the only -- the impact there, and it's about $11 million, Mike. And the way -- so last year, we would, in the ordinary course, be selling product into the JV, as they are obviously then selling out. They maintain levels of inventory that are similar to us and similar to the sector. The sales that we make to them, once we close the transaction, we will not record until they're sold out the door. And so they're sitting on inventory today -- we haven't closed the transaction -- we've already recorded sales for. As they then sell those products out the door in November, December, we can't record the sale again. In the ordinary course, we'll continue to ship product to them, which is what we did last year. But there's a delay now as that inventory needs to get sold once we have full ownership of the JV."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","And my question, Chris, is that -- before a distributor is usually bought, they have an incentive to stock up on extra product. And I'm just making sure that the Japanese distributor wasn't buying in excess product to have as much on their shelves before",47,"And my question, Chris, is that -- before a distributor is usually bought, they have an incentive to stock up on extra product. And I'm just making sure that the Japanese distributor wasn't buying in excess product to have as much on their shelves before the conversion."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","No. To be very clear, nothing about their order patterns last year and their order patterns this year are different at all. So it's purely the mechanism that once we have ownership, right, we just have to wait for the inventory to clear before we record a",48,"No. To be very clear, nothing about their order patterns last year and their order patterns this year are different at all. So it's purely the mechanism that once we have ownership, right, we just have to wait for the inventory to clear before we record additional sales."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question in queue will come from Brooks West with Piper Jaffray.",13,"The next question in queue will come from Brooks West with Piper Jaffray."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","One more just on that last topic. Chris, you said $11 million impact from Japan in Q4. You said there's going to be a little bit into Q1. What is the impact in Q1?",34,"One more just on that last topic. Chris, you said $11 million impact from Japan in Q4. You said there's going to be a little bit into Q1. What is the impact in Q1?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, it's about the same impact.",6,"Yes, it's about the same impact."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then the last part of that is just some declines in EP sales to Boston Scientific. Is that a surprise that, that's dropping off? Or was that part of the forecast? And again, could you quantify that?",39,"Okay. And then the last part of that is just some declines in EP sales to Boston Scientific. Is that a surprise that, that's dropping off? Or was that part of the forecast? And again, could you quantify that?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, sure. And actually, you go back to each quarter, we've actually talked about it, both coming into the year and then every quarter, because actually, what they did prior to this quarter, we actually were seeing growth in sales to them as they were act",129,"Yes, sure. And actually, you go back to each quarter, we've actually talked about it, both coming into the year and then every quarter, because actually, what they did prior to this quarter, we actually were seeing growth in sales to them as they were actually building inventory in anticipation of the shift to self-manufacturing. We've taken those sales out of organic growth, obviously, the entire year. And so we talked about Q4 being the first big quarter where we would see step-down, because they now have actually stood up the manufacturing plant in Costa Rica. So that impact in the quarter is, round numbers, about $5 million. So between that and Japan, you're talking about $16 million, $17 million of negative impact as it compares to prior year."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then, I guess, one big picture for me, guys. It looks like now you're going to have the Gore royalty through '19 based on, I guess, the decision not to hear the case. You've executed well against the investment plan you laid out. I believe the o",107,"Okay. And then, I guess, one big picture for me, guys. It looks like now you're going to have the Gore royalty through '19 based on, I guess, the decision not to hear the case. You've executed well against the investment plan you laid out. I believe the only thing you haven't done is a big acquisition. So, I guess, 2-part question for Tim. How are you thinking about mitigating the falloff in the Gore royalty? And can you just update us on what you're seeing out in the market? And are you starting to get more aggressive given some of the declines and multiples we're seeing?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Sure. I think it's a little early to comment specifically on 2019 right now. I can tell you, though, that, clearly, it's very visible in front of us. It's clearly a knowable event for us. And we're obviously planning -- or what will become over time, obvi",116,"Sure. I think it's a little early to comment specifically on 2019 right now. I can tell you, though, that, clearly, it's very visible in front of us. It's clearly a knowable event for us. And we're obviously planning -- or what will become over time, obviously, that we've been planning and anticipating that. So that's the comment generally about the Gore royalties. 
And relative to our business development activity, we remain extremely active, going through a number of things in our, what we call, funnel, if you will. And I remain optimistic that, that landscape continues to look robust for us. And as we go ahead and close things, we'll announce them when they occur."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll go to our next question in queue. That will come from David Roman with Goldman Sachs.",18,"We'll go to our next question in queue. That will come from David Roman with Goldman Sachs."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","I wanted us to come back to Lutonix and go into the utilization in a little bit more detail. Can you maybe talk to us about how you're seeing this being used in a real-world setting? Because our understanding and feedback from TCT is that this is a techno",100,"I wanted us to come back to Lutonix and go into the utilization in a little bit more detail. Can you maybe talk to us about how you're seeing this being used in a real-world setting? Because our understanding and feedback from TCT is that this is a technology that's getting used in a broad number of cases. And it's not so much proving to be a replacement for things like stent therapy or atherectomy, it's being more used as an adjunct. Can you maybe give us your perspective on that and how you're seeing the adoption curve roll out?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. John DeFord here. Let me talk a little bit about the utilization. I think what you heard at TCT is fairly consistent. We're beginning to see drug-coated balloons used as sort of an initial therapy, not necessarily the destination therapy, but an init",185,"Yes. John DeFord here. Let me talk a little bit about the utilization. I think what you heard at TCT is fairly consistent. We're beginning to see drug-coated balloons used as sort of an initial therapy, not necessarily the destination therapy, but an initial therapy. And then depending on the outcome of that initial therapy, making other decisions. Now obviously, atherectomy or things like that might come into play prior to using any kind of other technology. But by and large, we're seeing drug-coated balloons be used first. And then as you would expect, if there's provisional stenting required, then stents are used. If there are other technologies or other pieces needed, then they get included. So I don't think we ever expected DCB to replace some of these other technologies. But we are seeing it move exactly as we expected to be the first line of therapy. We think there's still a long way to go as far as growth and penetration. But this is -- it's still early days. But that's what we're seeing. I think that's fairly consistent with what you've heard."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And then maybe just sort of a broader question as you think about the growth rate. 2015 has obviously proven to be a very strong period of organic growth for the company. And I think when you had laid out the investment plan earlier about -- in earl",110,"Okay. And then maybe just sort of a broader question as you think about the growth rate. 2015 has obviously proven to be a very strong period of organic growth for the company. And I think when you had laid out the investment plan earlier about -- in early 2013, this is the year you're envisioning growing above market growth. But maybe you can talk to us a little bit about where we are in the realization of the benefits from that investment plan, and to what extent do you think the trends we've seen over the past 9 months and what you're guiding for the full year are sustainable?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, we haven't given guidance, nor will we, on this call for 2016. I think if you go back and look at what we said in 2013 is we expected to be above-market revenue growth occurring about this point in time. And that our expectation, both with not",93,"Yes. Well, we haven't given guidance, nor will we, on this call for 2016. I think if you go back and look at what we said in 2013 is we expected to be above-market revenue growth occurring about this point in time. And that our expectation, both with not only the investments that we made then, but with the investments ongoing, is that, that would be sustainable. So that's what we said a few years ago, and that's kind of what the plan was. And we'll give you guidance for 2016 in January."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And maybe just looking at it one other different way. So if you think about the momentum in the business that you're seeing today, is there any part of it you'd ascribe to macro-related factors that others [ph] came up earlier in the call versus Bar",48,"Okay. And maybe just looking at it one other different way. So if you think about the momentum in the business that you're seeing today, is there any part of it you'd ascribe to macro-related factors that others [ph] came up earlier in the call versus Bard-related factors?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","That's -- in any given quarter, and I -- obviously, I said earlier, we watch and listen to everybody. It's very difficult for any company, I don't care how big you are, to know if you gained share, or lost share, the market's increased or stayed flat or d",203,"That's -- in any given quarter, and I -- obviously, I said earlier, we watch and listen to everybody. It's very difficult for any company, I don't care how big you are, to know if you gained share, or lost share, the market's increased or stayed flat or declined from quarter-to-quarter. I would say it's virtually impossible to know that over that short period of time. So we said in the past, it kind of felt like things were getting a little bit better. I think that some of the old metrics we used to use, like hospital admissions, especially when you're involved in procedures, maybe aren't the bellwether signs necessarily that they were a few years ago. So some of the dynamics, as you know, in health care utilization generally are changing. So it's kind of difficult to say when you look at hospital admission metrics maybe going down, and yet our revenue continues to grow. What does all that mean? It's just very difficult to say. And we said earlier at the last call, it feels a little bit better. I would say that still holds true for this quarter. It's just hard to put any fine points on it."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think the only thing I'd add, Dave, and obviously, we track the sector. And when we look at organic growth rates across the sector, actually, over the last 4 or 5 quarters, they're frankly pretty flat sequentially. And obviously, we've moved higher",134,"Yes, I think the only thing I'd add, Dave, and obviously, we track the sector. And when we look at organic growth rates across the sector, actually, over the last 4 or 5 quarters, they're frankly pretty flat sequentially. And obviously, we've moved higher over that period of time. So at least the things that are growing for us in both emerging markets and in the product portfolio -- and Lutonix being part of that -- are related to things that we've invested in over the last couple of years. And so we haven't seen material moves, to Tim's point, in volumes or utilization. And as we look at the sector, it certainly would appear to be that improvement in organic growth that we've experienced is directly related to the investments that we made."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question in queue will come from David Lewis with Morgan Stanley.",13,"Our next question in queue will come from David Lewis with Morgan Stanley."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Chris, just a quick follow-up on the Japanese distributor. So the EPS dilution that you had previously described, obviously, it appears like it's dropping through and full in the fourth quarter. Should we expect the same to hold true in '16, the full $0.2",58,"Chris, just a quick follow-up on the Japanese distributor. So the EPS dilution that you had previously described, obviously, it appears like it's dropping through and full in the fourth quarter. Should we expect the same to hold true in '16, the full $0.20 drops straight through? Or should we expect it to be offset in some way?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think, certainly, it's a $0.20 hole, right? And it's purely related to the yen, just to be clear. So it's a hole. And obviously, we haven't given guidance, David, for 2016. But because of a transaction, we're facing much more significant yen headwi",121,"Yes, I think, certainly, it's a $0.20 hole, right? And it's purely related to the yen, just to be clear. So it's a hole. And obviously, we haven't given guidance, David, for 2016. But because of a transaction, we're facing much more significant yen headwind than we would have been otherwise. So obviously, as we roll up our budget and decide what we're ready to commit to for 2016, we are starting with a big yen headwind that we wouldn't have had. Now having said that, it's a very interesting strategic move for us, and we believe it will pay nice dividends long-term for the company. But it'll -- it's a headwind that we'll deal with as we go into 2016."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just as a follow-up, maybe quickly for Chris. Can you give us a sense of what that accretion or return looks like in '17 and beyond? And then, I guess, just for John DeFord. As it relates to Lutonix, I guess, if you can give us a sense for, in t",100,"Okay. And just as a follow-up, maybe quickly for Chris. Can you give us a sense of what that accretion or return looks like in '17 and beyond? And then, I guess, just for John DeFord. As it relates to Lutonix, I guess, if you can give us a sense for, in the field, what do you think has resonated with clinicians more, the trial data or the registry data? And, I guess, more directly what I'm trying to get at is, would you expect any impact on your business based on the impact [ph] one [ph] results post TCT?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I won't be specific, David, but assuming the yen stays roughly where it is, and we execute -- which includes some interesting product launches for us into Japan, including LifeStent and Lutonix over time here -- the business for us will return nicely",63,"Yes, I won't be specific, David, but assuming the yen stays roughly where it is, and we execute -- which includes some interesting product launches for us into Japan, including LifeStent and Lutonix over time here -- the business for us will return nicely accretive beginning in '17 and beyond. But I'm not going to put a fine point on it for you."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Okay. And then just jumping in to talk about the data. We think that clinicians are really interested in looking at both pivotal and randomized studies and registries. I think the Levant 2 study, as published in New England Journal of Medicine, it was a v",292,"Okay. And then just jumping in to talk about the data. We think that clinicians are really interested in looking at both pivotal and randomized studies and registries. I think the Levant 2 study, as published in New England Journal of Medicine, it was a very unique study design. Also, we've also found in that study that procedure really matters. And that was something that came out at panel, came out in some of the post discussions, that the way the device was used compared to PTA was different. And actually, in our study, the drug-coated balloon was used what you could call had a less-effective treatment at the end of the procedure compared to PTA. Again, I think that is attributed to some of the results that we see in our randomized study. 
Certainly, I understand our competitor wanting to try to shift the discussion back to theirs. It's kind of interesting they haven't updated their registry data yet. But our registry data real world is in much -- more difficult patients than we saw in Levant 2. We think it's really demonstrating the real-world usage of the technology. And of course, those clinicians were educated on the things that we've learned in the Levant 2 study on the importance of fully inflating the balloons, getting good expansion, appropriate access to the vessel and the lesion quickly and other things that were discussed by Dr. Schmidt at TCT. And so we think that these results are pretty indicative of real world usage based on that new knowledge. Now what clinicians are going to do? So far, I think it's resonated pretty well that drug-coated balloons work. And at least the 2 technologies on the market today seem to work pretty similarly."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","It will come from David Turkaly with JMP Securities.",9,"It will come from David Turkaly with JMP Securities."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Did you guys give the percentage that emerging markets was in the quarter?",13,"Did you guys give the percentage that emerging markets was in the quarter?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","It's about 9.5% of total sales, David. It's up about 120 basis points year-over-year. Very strong double-digit growth and, obviously, continuing to move in the right direction overall. There is some seasonality to the different geographies, but we had ano",57,"It's about 9.5% of total sales, David. It's up about 120 basis points year-over-year. Very strong double-digit growth and, obviously, continuing to move in the right direction overall. There is some seasonality to the different geographies, but we had another great quarter. And again, it's actually across all the geographies, just like we saw in Q2."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Great. And then, obviously, everyone's aware that you've hired a bunch of folks there. I was just curious, as you look at their productivity, now what will that look like versus some of your U.S. or European reps over time? And then how long do you think",61,"Great. And then, obviously, everyone's aware that you've hired a bunch of folks there. I was just curious, as you look at their productivity, now what will that look like versus some of your U.S. or European reps over time? And then how long do you think it takes some of these guys to get fully ramped and up to speed?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I would say that we're delighted with the ground game of our team in emerging markets. We've been very aggressive in terms of adding to that field sales force around the world. And as we've talked continually, that sales force represents about 34% o",157,"Well, I would say that we're delighted with the ground game of our team in emerging markets. We've been very aggressive in terms of adding to that field sales force around the world. And as we've talked continually, that sales force represents about 34% of our reps around the world. It's the fastest area of investments for us in field sales reps, yet it only equals a little bit less than 10% of our sales. So we think we've made the right investments for the long term. We like the uptick that our people are giving us in the field as they get seasoned. It takes, on average, 9 months to 12 months for a person to really be productive no matter what geography that you're working in. And I would say that we're delighted with the execution and the ground game that our team is putting on, not only in emerging markets, but around the world."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","The next question in queue, that will come from Kristen Stewart with Deutsche Bank.",14,"The next question in queue, that will come from Kristen Stewart with Deutsche Bank."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Anyway, I was just wondering if you could expand a little bit more. I think you had mentioned there was dealer stocking with Foley catheters because that seemed to be up quite a lot. I don't remember when they could -- basic drainage has been up, actually",85,"Anyway, I was just wondering if you could expand a little bit more. I think you had mentioned there was dealer stocking with Foley catheters because that seemed to be up quite a lot. I don't remember when they could -- basic drainage has been up, actually, like 6%, 7% in the U.S. So how big of a stocking or was there in the quarter? And will that just pull, I guess, from the fourth quarter? Or is that -- where did that shift from?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I think -- and frankly, Kristen, we don't know for sure. As we get additional tracing data, we're just -- we're speculating there was some in the quarter, and so we just wanted to caution you against it. It could possibly pull a bit from Q4, and that",87,"Yes, I think -- and frankly, Kristen, we don't know for sure. As we get additional tracing data, we're just -- we're speculating there was some in the quarter, and so we just wanted to caution you against it. It could possibly pull a bit from Q4, and that's certainly factored into our overall sales guidance. So I don't want to make too much of it. And we can't say for certain yet. And we'll know more in the coming weeks as we get additional tracing data."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I'd say in the grand scheme of things, it's a really small point for us across the board.",19,"I'd say in the grand scheme of things, it's a really small point for us across the board."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes.",1,"Yes."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Right. And then, I guess, just in general, just in terms of, I guess, going back just to the M&A side, Tim, is there anything in terms of the landscape that you're seeing that makes you more or less likely to go off into any additional areas, whether it b",120,"Right. And then, I guess, just in general, just in terms of, I guess, going back just to the M&A side, Tim, is there anything in terms of the landscape that you're seeing that makes you more or less likely to go off into any additional areas, whether it be preference to do more smaller tuck-in deals for a product portfolio in the U.S.? Or are you seeing or thinking about doing more deals that might give you greater exposure into international markets at this point? Or do you feel comfortable with the investments that you made in emerging markets that you have the right investments there, and you're capable of growth given just the investments that you have already?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. Well, in terms of our lenses and our filters, the answer is yes to all of the above. We're looking at everything. So relative to the landscape, we kind of like what we see in terms of what's out there. Our filters or our hurdles have not changed rela",238,"Yes. Well, in terms of our lenses and our filters, the answer is yes to all of the above. We're looking at everything. So relative to the landscape, we kind of like what we see in terms of what's out there. Our filters or our hurdles have not changed relative to our priorities. We don't start with size as one of the first questions. In fact, probably it's a couple of reviews through a read [ph] before I even start to focus on that. We're focused more on strategic intent. Some of the examples of things we've done over the last couple of years, target temperature management is one,  [indiscernible], whatever, we're focused on revenue growth. Because we think revenue growth provides a better shareholder return than slower revenue growth and grinding on earnings. So we look at revenue growth upside, sustainability of that. We actually look at each investment as, is it a platform to invest further in? Whether that be both with technology. And clearly, as we've given the size of the transactions we've done, they've had limited capabilities outside the United States, just from an expense affordability standpoint, and we already have that footprint. So we look at all of those things. But I'm optimistic about what the landscape looks like, and we'll see how many of those actually clear our filters. But we haven't changed our standards at all in the last several years."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, I'd add, Kristen, obviously, we're focused on finding good targets internationally as well that fit all the same criteria. And frankly, within emerging markets, we've continued to struggle to find good targets that meet the criteria that we have. And",93,"Yes, I'd add, Kristen, obviously, we're focused on finding good targets internationally as well that fit all the same criteria. And frankly, within emerging markets, we've continued to struggle to find good targets that meet the criteria that we have. And so, obviously, we now have a really nice track record of executing organic growth-driven strategies in a lot of those markets. And so we'll continue to do that while we still look. But we're looking, to Tim's point, really, around the world for opportunities that are, first and foremost, product leadership opportunities."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","And the buying in of the JV over in Japan, was that just because of the pressure of selling in dollars and the JV just taking a hit with currency [indiscernible] or just benefits of going direct?",37,"And the buying in of the JV over in Japan, was that just because of the pressure of selling in dollars and the JV just taking a hit with currency [indiscernible] or just benefits of going direct?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes, let me -- maybe a little background history here, just for those of you that may not know this. So if you go back into the '90s, we actually had a Bard Japan Limited business and Medicon, the joint venture with Kobayashi that was primarily responsibl",227,"Yes, let me -- maybe a little background history here, just for those of you that may not know this. So if you go back into the '90s, we actually had a Bard Japan Limited business and Medicon, the joint venture with Kobayashi that was primarily responsible for our Urology product line. In 1998, we sold off the cardiology business as part of that transaction because of tax  [ph]  [indiscernible]. That [ph] entity in Japan went with this -- with that transactions. So we had to make a decision back then, do we put the rest of Bard's products into the joint venture or do we start our own business there? Back then we made the decision, we had a lot of confidence and faith in Medicon -- and obviously, the fact that we just bought out the other halfway we have even more so now -- moved the entire product line into that JV. Given the structure of the JV, as we've invested more heavily internally in R&D, new product launches, which require also clinical trials, it just put pressure on the business model in Japan. And strategically, it made all the sense in the world for us to own the thing in its entirety so that we can make all the investment decisions we need to make to grow the business over the long term."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","That makes sense. Okay. And last one, just because every other health care company is coming out today, do you have an ownership stake in any pharmacy company? I'm just curious.",31,"That makes sense. Okay. And last one, just because every other health care company is coming out today, do you have an ownership stake in any pharmacy company? I'm just curious."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","We do not.",3,"We do not."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Sorry, I couldn't resist.",4,"Sorry, I couldn't resist."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you for the question, Kristen.",6,"Thank you for the question, Kristen."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","It's probably not funny for a lot of people who have dealt with a lot of stocks today.",19,"It's probably not funny for a lot of people who have dealt with a lot of stocks today."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question in queue will come from Neil Chatterji with Cowen and Company.",14,"Our next question in queue will come from Neil Chatterji with Cowen and Company."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","This is Neil on for Josh Jennings. So you've highlighted in the past Targeted Temperature Management and BioSurgery segments with significant market opportunity expansion, and those have seen double-digit growth. Can you give us some more color on how tho",54,"This is Neil on for Josh Jennings. So you've highlighted in the past Targeted Temperature Management and BioSurgery segments with significant market opportunity expansion, and those have seen double-digit growth. Can you give us some more color on how those lines are tracking relative to that and when you might see some significant ramp?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, we've been seeing a significant ramp in those product lines since day 1 of the acquisitions. We've been taking share annually in both of those major product lines that we acquired. We really built out a very successful independent sales force, prett",86,"Well, we've been seeing a significant ramp in those product lines since day 1 of the acquisitions. We've been taking share annually in both of those major product lines that we acquired. We really built out a very successful independent sales force, pretty large by U.S. standards in that business. And I think they're executing extremely well. So we have been growing substantially in that space. We would expect we will continue to. And we're always looking for opportunities to be adjunctive to those product lines."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only thing I'd add, Neil, is that both of those opportunities play out over a number of years, because there's a number of additional indications that our technologies are going to be effective with, both on the Targeted Temperature Management side as",104,"The only thing I'd add, Neil, is that both of those opportunities play out over a number of years, because there's a number of additional indications that our technologies are going to be effective with, both on the Targeted Temperature Management side as well as within BioSurgery. So to Tim's point about having acquired platforms that have an investment opportunity beyond the initial product set that we acquired, we've got a long runway, we think, in both of those categories to grow them for many years. And, again, both of them are growing nicely in the double digits as we sit here today."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. And just 1 quick follow-up. So I believe you saw some softness in Europe earlier in the year, but then volumes seemed to recover in the second quarter and then even more so in the third quarter here. How are the reimbursement issues shaking out in E",51,"Okay. And just 1 quick follow-up. So I believe you saw some softness in Europe earlier in the year, but then volumes seemed to recover in the second quarter and then even more so in the third quarter here. How are the reimbursement issues shaking out in Europe, particularly in France?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, let me deal with the macro issue first. I think that's the important one. And that is that we did have a slow first quarter [indiscernible]. And I think as we predicted, we thought the year would pick up, and it certainly has. Our team over there is",100,"Well, let me deal with the macro issue first. I think that's the important one. And that is that we did have a slow first quarter [indiscernible]. And I think as we predicted, we thought the year would pick up, and it certainly has. Our team over there is executing extremely well. There is nothing from a major pricing standpoint going on in our business in Europe. And in fact, our Europe team was positive at price for the quarter. So we don't see a big issue right now looming in front of us in terms of reimbursement in France."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","The only other thing I would add, because I know there were some comments made perhaps by others in the market regarding specifically reimbursement for drug-coated balloons in Europe, and I would just tell you, that is a category reimbursement, not kind o",59,"The only other thing I would add, because I know there were some comments made perhaps by others in the market regarding specifically reimbursement for drug-coated balloons in Europe, and I would just tell you, that is a category reimbursement, not kind of an individual brand reimbursement. We're working very hard to expand that as well throughout Europe. So..."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And then that's where the New England Journal of Medicine publication frankly helps. Having that kind of publication is required in certain geographies to help achieve reimbursement.",28,"And then that's where the New England Journal of Medicine publication frankly helps. Having that kind of publication is required in certain geographies to help achieve reimbursement."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thanks, Neil. Tony, we have crossed the top of the hour. We're going to take 2 more questions and then -- and I apologize to anyone in the queue after that.",31,"Thanks, Neil. Tony, we have crossed the top of the hour. We're going to take 2 more questions and then -- and I apologize to anyone in the queue after that."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","We'll take that next question in from Matt Taylor with Barclays.",12,"We'll take that next question in from Matt Taylor with Barclays."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","I just had a follow-up on some of the Lutonix commentary. I guess, I just wanted to ask maybe in a more straightforward way. If you could just talk about the underlying trends, and what you're seeing there as sequentially versus the stocking? There were a",114,"I just had a follow-up on some of the Lutonix commentary. I guess, I just wanted to ask maybe in a more straightforward way. If you could just talk about the underlying trends, and what you're seeing there as sequentially versus the stocking? There were a few stocking comments. 
And then conceptually, the partnership with Boston Scientific has been interesting. Curious to know, if you look out longer-term, do you think that they're going to be selling a meaningful chunk of your overall Lutonix sales? If you could give us any sense of what the split would be there. And then is there any opportunity to expand that partnership into other product areas?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Yes. So I think, Matt, just the sequential kind of Q2, Q3, Q4, and the first thing I'd say is we need -- as we've said, it'll be nice to have this all settle out. But it's going to take a few quarters for this to settle out. So Boston ramped up in Q2, cer",195,"Yes. So I think, Matt, just the sequential kind of Q2, Q3, Q4, and the first thing I'd say is we need -- as we've said, it'll be nice to have this all settle out. But it's going to take a few quarters for this to settle out. So Boston ramped up in Q2, certainly had some stocking in Q2. As I said, we launched a couple of additional sizes in Q3, which drove, we think, some additional stocking in Q3. And so certainly, we would expect a sequential decline in Q4 for Boston as they begin to work through that initial stocking inventory. So when you then adjust for our big stocking order last year in Q4, we're seeing really terrific, both sequential and year-over-year, growth in our base organic Lutonix business. And feel really good about our competitive position. And John DeFord talked about the real-world registry data, which is, frankly, outstanding. So we'll need to get through these couple of quarters here and get to a steady-state next year, where Boston's been in the business now with us for a while, and we've been moved beyond our initial launch in the U.S."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","I would say, to the longer-term issue on Boston, we think the strategy was sound that we entered into. Your question was, will they -- what kind of a position will they have with Lutonix? I mean, as we set out on this, Boston had the rights to sell the pr",138,"I would say, to the longer-term issue on Boston, we think the strategy was sound that we entered into. Your question was, will they -- what kind of a position will they have with Lutonix? I mean, as we set out on this, Boston had the rights to sell the product at a small subset of customers based on where they had good relationships or position in a certain therapy that we're not involved in. We have no plans to expand that to other product lines today or circumstances. I think this was a unique opportunity for us to be complementary with Boston in a small segment of customers, and I think that we like that positioning. But Bard will be responsible for the greatest majority of sales and the greatest majority of customers, obviously, around the world."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","Okay. That's helpful. And then 1 follow-up on Lutonix. I guess, broadly, just from the good data, both out of your registry and the Medtronic data from TCT, do you expect that or any other clinical or, I guess, market expansion catalysts to change the gro",67,"Okay. That's helpful. And then 1 follow-up on Lutonix. I guess, broadly, just from the good data, both out of your registry and the Medtronic data from TCT, do you expect that or any other clinical or, I guess, market expansion catalysts to change the growth rate in the near term of the market, or you think we're just going to kind of see continued good growth?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I'll jump in here. I think we expect continued good growth, but we also think that additional indications are really important. So we talked about the studies, the AV access study, Below the Knee, in-stent restenosis, other indications we think are",61,"Well, I'll jump in here. I think we expect continued good growth, but we also think that additional indications are really important. So we talked about the studies, the AV access study, Below the Knee, in-stent restenosis, other indications we think are additional catalysts for growth. So we're strictly and specifically focused on those areas, and we'll continue to be so."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Our next question will come from Anthony Petrone with Jefferies.",10,"Our next question will come from Anthony Petrone with Jefferies."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Analysts","One on Lutonix. Just wondering if you can provide an update on utilization per case, how many balloons are actually used per case? And then one is a broader question. Community Health reported lower revenue per admission today, and that was from lower neg",77,"One on Lutonix. Just wondering if you can provide an update on utilization per case, how many balloons are actually used per case? And then one is a broader question. Community Health reported lower revenue per admission today, and that was from lower negotiated rates from Medicare. And then in addition, we're seeing consolidation of private managed care companies. I'm just wondering how you think this plays out ultimately in price for medical device companies over time?"
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Well, I'm happy to jump in on the Lutonix side. I could tell you that I'm not sure we have specific data to share on number of devices used per case just because we don't really have insight into that. Unless we happen to have somebody standing in the roo",84,"Well, I'm happy to jump in on the Lutonix side. I could tell you that I'm not sure we have specific data to share on number of devices used per case just because we don't really have insight into that. Unless we happen to have somebody standing in the room, we wouldn't necessarily know. I can tell you by the lesion lengths that we see, we'd expect to sort of be in that 1.3 to 1.5 devices, potentially, per case kind of averaged out."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Relative to the pricing scenario with consolidation of payers, whatever, look, it's a very dynamic environment going on right now. Pricing pressure has always been on us and other companies in the space. I think, specifically, as you -- I think the pricin",106,"Relative to the pricing scenario with consolidation of payers, whatever, look, it's a very dynamic environment going on right now. Pricing pressure has always been on us and other companies in the space. I think, specifically, as you -- I think the pricing dynamic is taking on a little bit larger or made a little bit of a larger impression in the investment community, mainly because of some of the biotech and the pharma pricing issues that have been in the media recently. A very large percentage, I think it's 50% of our revenue, has an ASP of less than $500, probably closer to $400. So..."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","75%  [indiscernible] .",3,"75%  [indiscernible] ."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","75% of our revenue, actually. So we're not exactly on the high end of the radar screen here when they get to that. Nonetheless, the procedures, they're under pressure. And what we're trying to do is demonstrate the value and the quality in the outcomes an",77,"75% of our revenue, actually. So we're not exactly on the high end of the radar screen here when they get to that. Nonetheless, the procedures, they're under pressure. And what we're trying to do is demonstrate the value and the quality in the outcomes and doing that with data, which we're getting a lot of traction and uptake from our customers as they move more to -- in the U.S. an ACO kind of organization structure."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","And I think that the -- that those data sets are certainly very helpful in driving reimbursement. And I'd evidence the full reimbursement for Lutonix as a result of that value analysis that we worked with CMS on.",38,"And I think that the -- that those data sets are certainly very helpful in driving reimbursement. And I'd evidence the full reimbursement for Lutonix as a result of that value analysis that we worked with CMS on."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","And ladies and gentlemen, this does conclude our Q&A session. I would now like to turn the call back over to Bard's management for closing or additional comments.",28,"And ladies and gentlemen, this does conclude our Q&A session. I would now like to turn the call back over to Bard's management for closing or additional comments."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Executives","Thank you very much. And I'd like to thank all of you for joining us today. And also, I'll close by thanking Bard employees globally for a strong year of execution so far. So we'll update you again on our progress in January. Thanks, everybody.",45,"Thank you very much. And I'd like to thank all of you for joining us today. And also, I'll close by thanking Bard employees globally for a strong year of execution so far. So we'll update you again on our progress in January. Thanks, everybody."
254131,312630689,880656,"CR Bard Inc., Q3 2015 Earnings Call, Oct 22, 2015",2015-10-22,"Earnings Calls","C. R. Bard, Inc.","Operator","Thank you. And ladies and gentlemen, that does conclude our conference call for today. We do thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect.",31,"Thank you. And ladies and gentlemen, that does conclude our conference call for today. We do thank you for your participation and for using AT&T Executive TeleConference. You may now disconnect."
